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Although many studies have shown that pol III transcription is strongly 
regulated in higher eukaryotes, it is poorly understood how this regulation is 
achieved. The basal pol III factors TFIIIB and TFIIIC have been implicated as 
common targets for regulation. I have developed reproducible purification protocols 
for yielding partially purified active human TFIIIB and human TFIIIC. The purity of 
hTFIIIB and hTFIIIC obtained are a significant improvement upon that of hTFIIIB 
and hTFIIIC typically used in our laboratory, allowing regulatory studies to be 
conducted with a much higher level of confidence than previously.
One established repressor of pol III transcription is the tumour suppressor 
RB. Recently, the related proteins p i07 and p i30 have also been shown to inhibit 
pol III transcription. Here, I show that endogenous p i07 and p i30 coffactionate and 
coimmunoprecipitate with endogenous TFIIIB, suggesting that, like RB, p i07 and 
p i30 stably associate with TFIIIB under physiological conditions. I have also 
investigated why the binding of RB to TFIIIB inhibits pol III transcription. For 
several genes transcribed by pol II, RB represses transcription through the 
recruitment of the histone deacetylase HDAC1, which is thought to deacetylate 
histones at the promoter resulting in the formation of a more compact chromatin 
structure less accessible to transcription factors. However, the repression of pol III 
transcription in vitro by RB is unaffected by the presence of the histone deacetylase 
inhibitor trichostatin A. Using an immunoisolated pol III complex that contains pol 
III, TFIIIC and TFIIIB, I show that recombinant RB can specifically disrupt the 
interaction between TFIIIB and TFIIIC.
The serine/threonine kinase CKII is identified as a novel activator of 
mammalian pol III transcription and is shown to stably interact with endogenous 
hTFIIIB. Significantly, CKII kinase activity appears to promote the binding of 
TFIIIB to TFIIIC. The receptor tyrosine kinase neu (erbB2) is also implicated in the 
regulation of pol III transcription. A rodent ovarian epithelial cell line transformed 
by an activated neu oncogene is found to display elevated pol III activity. TFIIIC2
B-block binding activity is specifically elevated. Using the purified TFIIIB and
< .* •  •
TFIIIC fractions, I show that TFIIIC^s,limiting. in the untransformed control cell 
line, indicating that upregulation oi? iTIIIC2 activity in response to neu 
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1.1 Eukaryotic RNA polymerases
In prokaryotes, a single RNA polymerase is responsible for the production of 
all cellular RNA. This contrasts with the situation in eukaryotes in which there are 
multiple DNA-dependent RNA polymerases (80, 476). There are three distinct 
nuclear RNA polymerases and mitochondria and chloroplasts each have their own 
unique RNA polymerase (80, 476). The mitochondrial and chloroplast RNA 
polymerases reflect the partial maintenance by these organelles of their own genetic 
system derived from their endosymbiotic origin. The three nuclear RNA 
polymerases are thought to have evolved from a common ancestor. An initial 
fortuitous gene duplication event is likely to have first given rise to two RNA 
polymerases prior to the evolution of the present day tripartite system found in all 
eukaryotes (80).
The three nuclear RNA polymerases (pols) are not redundant activities as 
they are unable to functionally compensate for one another, as demonstrated by the 
lethality of separate mutations in each one of the pols. There is a precise division of 
labour; each of the three RNA polymerases is responsible for the transcription of a 
different set of genes. Thus, RNA polymerase I (pol I) synthesises the 45S 
ribosomal RNA (rRNA), RNA polymerase II (pol II) synthesises all messenger RNA 
(mRNA) and most small nuclear RNA (snRNA), and RNA polymerase III (pol III) 
synthesises 5S rRNA, transfer RNA (tRNA), U6 snRNA and a variety of other small 
RNAs. The evolution of three distinct nuclear RNA polymerases functionally 
specialised for the dedicated expression of different sets of genes may have been 
necessary to achieve the increased, more complex regulatory control upon gene 
expression required in eukaryotes.
1.2 Pol III transcripts
RNA polymerase II, being entirely responsible for the transcription of genes 
that encode proteins, transcribes by far the largest variety of different genes. In
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contrast, pol I is only responsible for the production of a single transcript, 45 S rRNA. 
Nonetheless, pol I transcription constitutes -70% of total nuclear transcription in an 
actively growing cell (410). Each 45 S rRNA molecule is cleaved to generate one 
molecule each of 5.8S rRNA, 18S rRNA and 28S rRNA, essential RNA components 
of the ribosome, the site of cellular protein synthesis. The gene encoding the 45 S 
rRNA is highly re-iterated in the eukaryotic genome, which may be necessary to 
ensure sufficient levels of 5.8S rRNA, 18S rRNA and 28S rRNA are produced to 
make enough ribosomes to support the biosynthetic requirements of the cell (410). It 
has been estimated that -10 million copies of each of these rRNA molecules must be 
synthesised each cell generation in an actively growing higher eukaryotic cell.
Approximately 10% of nuclear transcription is carried out by pol III (569). 
The genes transcribed by pol III, so-called class III genes, encode a variety of small 
stable RNAs, many of which have critical roles in cellular metabolism (568). The 
most abundantly expressed class III genes are those encoding 5S rRNA and tRNA 
molecules, highly conserved pol III transcripts, both of which have essential 
functions in the complex process of translation (568). 5S rRNA, the smallest of the 
ribosomal RNAs and the only one transcribed by pol III, is -120 nt in length and is 
found in all eukaryotes as part of the large subunit of ribosomes. As for the 45 S 
rRNA gene, the 5S rRNA gene is found in multiple copy number; there are -300-400 
5S rRNA genes in the haploid human genome (495). tRNAs, which are -70-90 nt 
long, act as translational adaptors serving to convert the genetic information 
contained within the nucleotide sequence of a messenger RNA into a particular order 
of amino acid residues in a protein, as specified by the genetic code. The fidelity of 
this process is dependent on the appropriate amino acid having been attached to each 
tRNA molecule in accordance with the anticodon sequence of the tRNA molecule. 
Base-pairing of the anticodon of a tRNA molecule with the complementary codon in 
the mRNA ensures that the correct amino acids are covalently linked, as dictated by 
the nucleotide sequence of the mRNA. The recently published draft of the human 
genome sequence contains 497 tRNA genes; these are thought to encode 
approximately 60-90 different tRNA species (199).
Other important class III genes include those encoding U6 snRNA, HI RNA 
and MRP RNA, each of which is involved in post-transcriptional processing (568, 
583). U6 snRNA functions in pre-mRNA splicing as part of the spliceosome, a large 
ribonucleoprotein (RNP) complex that catalyses the removal of introns and accurate
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splicing of exons (353). U6 snRNA is the most highly conserved of the spliceosomal 
RNAs and has been shown to be essential in yeast (56, 258). HI RNA is part of 
RNaseP, an endoribonuclease involved in the processing of the 5'-termini of pre- 
tRNA (26). MRP RNA, which is closely related to HI RNA and can fold into a 
similar secondary structure, is part of MRP RNase, another endoribonuclease, which 
has an important role in the endonucleolytic cleavage of the 45 S precursor rRNA 
(383). The influence of pol III transcription on protein synthesis may therefore 
extend beyond the production of 5S rRNA and tRNAs, indirectly through its effects 
on post-transcriptional processing.
Another essential class III gene is that encoding 7SL RNA, which is involved 
in the correct targeting of proteins to their appropriate intracellular location. 7SL, a 
highly conserved 300 nt transcript, forms the scaffold of the signal recognition 
particle (SRP), which is required for the cotranslational insertion of nascent 
polypeptides into the endoplasmic reticulum (547).
The VAi and VAn genes of adenovirus and the EBER1 and EBER2 genes of 
Epstein-Barr virus are also transcribed by pol III. The adenoviral VA RNAs, 
expressed at high levels during late stages of viral infection, are involved in 
subverting the translational machinery of the host cell towards the more effective 
production of viral proteins (519). A similar role is likely for the EBER RNAs as 
multiple copies of these short RNAs can substitute for VAi during adenovirus 
infection (35).
Other class III genes encode transcripts that are hitherto of unknown function 
(568, 583). These include 7SK and the various gene families of short interspersed 
nuclear elements (SINEs). SINEs are quantitatively the most important class III 
genes in higher organisms (250). Rodent species contain several SINE families; 
these include the ID gene family and the B1 and B2 gene families. The B2 family, 
which is rodent-specific, is represented by -80,000 copies of the B2 gene in the 
haploid mouse genome, constituting -0.7% of the total genomic DNA (29). 
Approximately 1% of the genome of Xenopus laevis is comprised of a SINE DNA 
called satellite 1 (309). The major SINE in primates is the Alu gene, of which there 
are about 500,000 to one million copies in the haploid human genome (251). This 
constitutes -5%  of the total human genomic DNA. Clearly, a significant proportion 
of the genome of a variety of eukaryotes consists of SINE DNA.
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The extraordinarily high copy numbers of the various SINEs are thought to 
have arisen by retrotransposition (558). This involves the reverse transcription of the 
SINE transcripts and integration of the resulting DNA into novel genomic sites. For 
some genes amplified by retrotransposition, the transcription of a gene copy requires 
its fortuitous insertion in the DNA adjacent to an active promoter. This dependency 
on external promoter elements for transcription severely limits the rate of 
transposition. However, SINEs, like the majority of class III genes, contain internal 
promoter elements. Therefore, each gene copy produced contains the necessary 
information for its own transcription and is not reliant on its site of integration in the 
DNA for expression and the generation of further copies. This may explain the very 
high rate of transposition of SINEs.
The major SINE families appear to be derived from class III genes of known 
physiological significance. Genes from the B2 and ID families share significant 
homology with tRNA genes and their transcripts can form similar secondary 
structures (110). In contrast, the B1 and Alu families are thought to have evolved 
from the 7SL gene (531). Such SINEs may therefore simply represent particularly 
mobile pseudogenes and may be totally devoid of function. Alternatively, perhaps 
certain of these SINEs have acquired functions during the course of evolution. 
Although a variety of functions have been proposed for particular SINEs (227), a 
functional role for a SINE family has yet to be convincingly demonstrated. Even if 
the individual SINE families have no specific function, the mobility of these short 
repetitive elements and their integration into novel genomic locations will inevitably 
have had major effects on the structure and evolution of the genome. The 
transposition of SINEs creates novel genetic combinations within the DNA. Such a 
large number of small homologous sequences are also likely to cause an increase in 
the levels of recombination, a major source of genetic variability.
These genetic changes induced by SINEs make a significant contribution to 
the fluidity and adaptability of the genome. However, such genetic change can also 
be highly detrimental; for example, essential genes may be disrupted. Clearly, 
SINEs have the potential to be potent mutagens and inflict serious genetic damage, 
which may partly explain why SINEs are only found to be expressed at extremely 
low levels in cells. Although there may be as many as one million Alu genes in the 
haploid human genome, a growing HeLa cell only contains about 100-1000 Alu 
transcripts (335). In contrast, approximately one million 7SL transcripts were
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detected per HeLa cell, yet there are only four 7SL genes in the entire genome. Alu 
genes are derived from 7SL; however, they lack the upstream promoter sequences of 
7SL and the internal promoter elements may also have acquired changes further 
reducing Alu expression (531).
1.3 Promoter structure of class III genes
Class III genes show a marked diversity of promoter organisation, consistent 
with the broad range of different genes that are transcribed by pol III. There are 
three basic classes of promoter recognised by pol III, type I, type II and type III (157, 
411, 583). Genes with a type I or type II promoter, which together constitute the 
majority of class III genes, are unusual in that they require intragenic sequences, so- 
called internal control regions (ICRs), for their expression. In contrast, transcription 
of genes with type III promoters is entirely determined by sequences that lie 
upstream of the start site (299). Type III promoters resemble those of genes 
transcribed by pol I or pol II in that they are completely independent of intragenic 
sequence elements.
1.3.1 Type I promoters
The type I promoter is unique to 5S rRNA genes. Extensive mutagenesis of a 
somatic 5S rRNA gene from Xenopus laevis defined three essential sequence blocks 
for transcription, each located in the coding region of the gene: the A-block (+50 to 
+64), the intermediate element (+67 to +72) and the C-block (+80 to +97) (39, 416, 
417). The identities of the bases in between these individual sequence elements have 
no effect on transcription efficiency; however, changes in the spacing of the elements 
were poorly tolerated (417). Linker scanning mutagenesis of the sequence between 
the A-block and the transcriptional start site suggests that this sequence can have a 
major influence on 5S rRNA production under conditions that are suboptimal for 
transcription (150, 270, 596). The 5'- and 3'- flanking regions can also affect 
transcription levels under less favourable conditions. These effects are purely
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modulatory, however; under optimal conditions the region from +50 to +97, 
encompassing the A-block, the intermediate element and the C-block, suffices for 
efficient transcription.
A synthetic 5S gene consisting solely of the coding region of a human 5S 
rRNA gene is transcribed in a HeLa extract (584). Clearly, the expression of 5S 
rRNA genes is possible in the absence of extragenic sequence. The 5' flanking 
region of the human 5S rRNA gene was capable of stimulating transcription ~10 
fold, however (495). Although the flanking sequences can clearly influence 
transcription, they are poorly conserved and can generally tolerate mutations 
reasonably well. In contrast, the A- and C- blocks and the intermediate element are 
strongly conserved between species and mutations in these regions abolish 
transcription.
1.3.2 Type II promoters
Most class III genes, including the tRNA, VA, Alu, B l, and B2 genes, have a 
type II promoter (568, 583). Transcription of these genes, like 5S rRNA genes, is 
dependent upon discontinuous intragenic sequence elements. The internal control 
region of type II promoters consists of two essential sequence elements, an A-block 
and a B-block, each ~10bp, optimally separated by ~30-60nt of non-essential DNA, 
although larger distances of up to 365bp can be tolerated (18, 138). The A-blocks of 
type I and type II promoters are homologous and sometimes interchangeable (94). 
However, the A-block of type II promoters are much closer to the start site (at ~+10- 
to +20) than the corresponding region of type I promoters, which tend to be found 
~40bp further upstream (158). This difference may reflect the dominant role of the 
A-block of type II promoters in start site selection (94, 138).
The tRNA genes and adenoviral VAi gene have been extensively studied as 
model templates for genes with a type II promoter. The A- and B- blocks of tRNA 
genes are remarkably well conserved, both between genes encoding different tRNA 
isoacceptors and between tRNA genes from different species (158). Even certain 
bacterial and chloroplast tRNA genes contain similar sequences and can therefore be 
transcribed by pol III (149, 176). Chimeras constructed from the 5' half of a tRNALeu
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gene and the 3' half of a tRNAMet gene, or vice-versa, were active for transcription, 
demonstrating the functional compatibility of the A- and B- blocks from different 
genes (158). The A- and B- blocks of tRNA genes encode the D- and T- loops 
respectively of tRNA molecules, both of which are absolutely essential for tRNA 
function. The high level of sequence conservation of the A- and B- blocks of tRNA 
genes is therefore likely to reflect selection both for tRNA and promoter function. 
Nevertheless, point mutations in the A- and B- blocks can severely affect 
transcription efficiency. Consensus sequences of TGGCNNAGTGG for the A-block 
and GGTTCGANNCC for the B-block have been derived (158). Mutational analysis 
of the yeast SUP4 tRNATyr gene suggests that the consensus sequences closely 
coincide, although not perfectly, with the sequences that give optimal promoter 
activity (8). The A- and B- blocks together constitute the minimal promoter 
requirements for accurate tRNA transcription. A chemically synthesised 
oligonucleotide corresponding to these two sequence elements separated by a 51 bp 
spacer was able to direct efficient transcription in a HeLa cell extract (389). As for 
5S rRNA genes, flanking regions are able to modulate transcription efficiency but are 
generally poorly conserved. The 5' flanking regions of tRNA genes show little or no 
homology even between different genes that encode the same tRNA isoacceptor 
(568). There is evidence to suggest that this sequence variation is involved in the 
differential regulation of tRNA genes, which is necessary for the tRNA population to 
be adapted to differing codon and amino acid usage in different cell types (568).
All type II promoters contain sequences highly homologous to the A- and B- 
blocks of tRNA genes. The promoter requirements are very similar for different 
genes with type II promoters; indeed, B2 promoter sequences have been shown to 
cross-compete with those of tRNA or VAi genes (182, 577). As for tRNA genes, the 
A- and B- blocks of the adenoviral VAi gene have been shown to be sufficient for its 
transcription in vitro (430, 444, 553, 599). Linker scanning mutagenesis has 
identified both positive and negative modulatory sequences upstream of the start site 
of the VAi gene, although the overall effect of surrounding sequences is stimulatory 
(430). The VAi gene is transcribed more strongly than tRNA genes; however, the 
sequences responsible for this difference in transcription efficiency have yet to be 
elucidated. Flanking sequences that are able to influence transcription levels are not 
conserved between different genes with type II promoters and are poorly
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characterised. These differences, as well as how closely the sequences of the A- and 
B- blocks match those that are optimal for transcription, are likely to be responsible 
for the differential promoter strength of different class III genes with type II 
promoters.
1.3.3 Type III promoters
A minority of pol III templates, such as the vertebrate U6 and 7SK genes and 
mammalian MRP genes, have a type III promoter (112, 281, 390, 610). The 
distinguishing feature of this type of class III promoter is the notable absence of 
intragenic promoter elements. The type III promoter resides exclusively in 
extragenic sequence, specifically in the 5' flanking region of the gene (157, 568, 
583). The entire coding sequence of human and mouse U6 genes can be replaced 
without any effect on transcription, either in vitro or in vivo (112, 301). The same 
has also been shown to be true of the human 7SK and MRP genes (281, 390, 610).
Whereas the U6 snRNA gene is transcribed by pol III, the other U snRNAs, 
U l, U2, U4 and U5, are products of pol II transcription (300, 379, 432). 
Nevertheless, despite being transcribed by different RNA polymerases, the promoters 
of vertebrate U6 snRNA genes are remarkably alike those of the U snRNA genes 
transcribed by pol II (302). Upstream sequences required for efficient transcription 
of human U6 genes are a TATA box between -30 and -25, a proximal sequence 
element (PSE) between -66 and -47 and a distal sequence element (DSE) between - 
244 and -214 (19, 72, 112, 302, 338). The human U6 PSE and DSE show 
substantial homology with elements found at comparable positions in the promoters 
of the class II U snRNA genes (19, 72, 111, 302, 338). Indeed, the PSEs of the 
human U2 and U6 promoters are identical at 13 out of 17 positions and are 
functionally interchangeable (338, 406). The DSEs of the human U2 and U6 
promoters are also interchangeable (19, 72, 302). However, a TATA box, a very 
common feature of class II genes, is absent from the promoters of U snRNA genes 
transcribed by pol II. Paradoxically, the TATA element is a major determinant of 
polymerase specificity (338, 339, 362). Inactivation of the TATA box allows the U6 
snRNA gene to be transcribed by pol II (362). Conversely, the insertion of a TATA
box into the corresponding position of a U2 promoter can convert the U2 gene into a 
pol III template (338). However, the U6 TATA box alone is insufficient to confer 
recognition by pol III upon the U1 gene (329). To switch the polymerase specificity 
of the U1 gene also requires that the PSE be moved 4 bp further upstream so that the 
distance between it and the TATA box is the same as in the U6 promoter (329). Pol 
III transcription of the U6 snRNA gene is severely impaired by changes in the 
separation of the PSE and TATA box (167, 339). The exact sequence requirements 
for a class III TATA box also differ slightly from those of a class II TATA box, as 
revealed by the differential sensitivity of pol II and pol III transcription to particular 
mutations of the Xenopus U6 TATA box (486). Clearly, the choice of polymerase 
for transcription of the individual U snRNA genes can be influenced by a number of 
factors.
The promoter structure of the human 7SK gene is very similar to that of 
vertebrate U6 genes with TATA, PSE and DSE sequences all located upstream of the 
coding region in almost identical positions to their U6 counterparts (568). In contrast 
to this similarity, the promoters of vertebrate and yeast U6 genes are vastly different 
from one another. The U6 promoter of the yeast Saccharomyces cerevisiae is 
tripartite, with upstream, intragenic and downstream promoter elements (56, 57, 
137). An A-block at +21 to +31 is essential for transcription, both in vitro and in 
vivo (67, 137). Efficient transcription of yeast U6 genes in vivo is also dependent 
upon a functional B-block sequence, unusually located 120bp downstream of the 
termination site in S. cerevisiae (57, 137). This novel positioning of the B-block may 
reflect an incompatibility of the B-block sequence with the function of the highly 
conserved U6 transcript. The upstream sequence of the gene contains a consensus 
TATA box at -30 to -25 . Although this sequence can influence start site selection 
and stimulates expression in vitro, it has little effect on transcription in vivo (67, 79, 
137, 357). Additionally, a sequence around -55 shows partial homology to PSEs of 
vertebrate U6 promoters but has little or no effect on the level of transcription (67, 
137).
Whereas the vertebrate U6 promoter resides entirely upstream of the coding 
sequence, transcription of the yeast U6 genes is dependent upon downstream A- and 
B- blocks. The yeast U6 promoters are therefore similar to the type II promoters of 
tRNA and VA genes (583). The totally extragenic promoter organisation of the U6 
genes has therefore evolved relatively recently, since the divergence of the metazoan
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and yeast lineages. The most obvious advantage of acquiring an extragenic promoter 
is that the promoter sequences are no longer constrained by serving a dual function 
and having to be compatible with transcript function. The promoter can evolve 
independently of the coding sequence, which may allow the evolution of a more 
complex promoter capable of more intricate control and fine-tuning of transcriptional 
output.
In contrast to the diversity of promoter organisation of the U6 snRNA genes, 
the promoters of most class III genes are quite well conserved between yeast and 
vertebrates (568).
1.3.4 Mixed promoters
A few class III genes have promoters that cannot be easily categorised into 
any of the aforementioned promoter types; these include the human 7SL and Epstein- 
Barr virus EBER2 genes (411). These genes rely on both internal and upstream 
sequences for their efficient expression. For example, the human 7SL gene has 
intragenic A- and B- blocks that are required for expression. However, these are 
fairly degenerate compared to the A- and B- blocks that are typical of type II 
promoters (8). Sequences upstream o f +1 are therefore also necessary for significant 
levels of transcription of the human 7SL gene (51, 532). Indeed, 5' deletion to -37 
reduces transcription more than 20-fold in transfected HeLa cells (51). A binding 
site for activating-transcription-factor (ATF) occurs at -51 to -44 (51). Point 
mutation of this binding site mimics the effect of 5' deletion to -37 (51). Moreover, 
extracts from cells pretreated with forskolin so as to induce the cAMP signal 
transduction pathway known to stimulate ATF activity support substantially 
enhanced levels of transcription of the human 7SL gene (51). In contrast, expression 
of the human 7SK gene, which has no ATF binding site, was unaffected by forskolin 
treatment demonstrating the specificity of this effect (51). Sequences downstream of 
-37 are also required for efficient transcription, which may include a putative TATA 
box at -28 to -24 (51).
The EBV EBER2 gene similarly requires a combination of internal and 
external promoter elements for its efficient expression (228). The EBER2 promoter
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has intragenic A- and B- blocks that are essential for transcription; these are less 
degenerate than are those of the human 7SL gene (228). Nevertheless, deletion of 
sequences upstream of -46 reduces EBER2 expression in transfected cells to -7%  of 
the wild-type level (228). This is thought to be due to the loss of upstream binding 
sites for ATF and Spl (228). In addition, a TATA box at -28 to -23 can stimulate 
transcription ~5-fold (228).
The EBV EBER2 and human 7SL promoters are examples of promoters with 
diverse combinations of sequence elements that can cooperate to direct efficient pol 
III transcription (583). Thus, A- and B- blocks, homologous to those of type II 
promoters, can be effectively combined with sequence elements such as ATF- and 
Spl- binding sites, which were originally defined as cis-acting regulatory elements of 
class II promoters (51, 228). The A- and B- blocks can also be combined with 
sequence elements from type III promoters, as the 5' flanking sequence of the human 
7SL gene can be efficiently substituted by that of the 7SK gene (282). The structure 
of these genes is analogous to the modality of class II promoters. It is also 
noteworthy that a few cis-acting elements are common to both class II and class III 
genes, including the TATA box, ATF- and Spl- binding sites, and octamer motifs 
found in DSEs.
1.4 RNA polymerase III
The existence of multiple forms of nuclear RNA polymerase was originally 
demonstrated by DEAE Sephadex chromatography of solubilised nuclei preparations 
(443). The polymerase activity of extracts from embryonic sea urchin nuclei could 
be resolved into three distinct peaks by gradient chromatography on DEAE Sephadex 
(443). Moreover, the chromatographic properties of the individual peaks of activity 
were maintained during their separate rechromatography, suggesting the resolved 
polymerase activities are not interconvertible but represent distinct entities (443). 
The three nuclear RNA polymerases, named according to their order of elution from 
DEAE Sephadex, have subsequently been shown to display differential 
chromatographic behaviour on a variety of columns (80, 440, 441, 467). They can 
also be distinguished by their sensitivity to the toxin a-amanitin, produced by the
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poisonous Amanita mushrooms (268). a-amanitin inhibits transcription elongation 
by interfering with polymerase translocation (116). In mammals, whereas pol I 
activity is highly resistant to a-amanitin toxicity, pol II is extremely susceptible with 
50% inhibition at 25ng/ml a-amanitin and pol III is moderately sensitive with 50% 
inhibition at 20pg/ml a-amanitin (467). These differential sensitivities to a-amanitin 
were used to determine which polymerase is responsible for transcribing particular 
genes.
The eukaryotic nuclear RNA polymerases are large multisubunit protein 
complexes made up of twelve or more different polypeptides. RNA polymerase III, 
the largest of the three nuclear pols, has been purified from a variety of organisms 
including human (247, 553, 554), mouse (490), frog (440, 441), silkworm (489), 
fruitfly (181), wheat (252, 516) and yeast (83, 184, 535). The polypeptide 
composition is quite well conserved between the different species. Saccharomyces 
cerevisiae pol III, which is the most extensively characterised, both biochemically 
and genetically, consists of seventeen subunits, ranging in size from 10 to 160 kD 
(83). The genes for sixteen of the seventeen subunits have now been cloned; all of 
them were found to be unique and essential for yeast cell viability (83). In contrast, 
several pol II subunits are dispensable for growth (598, 609).
The largest and second largest polypeptides of yeast pol III, C l60 and C l28, 
are structurally and immunologically related to the largest and second largest 
polypeptides of pols I and II (9, 49, 63, 368). Moreover, they display substantial 
homology to P' and P respectively of Escherichia coli RNA polymerase (9, 249, 368, 
506). The p' and p subunits together harbour the active site of the polymerase and 
are involved in basic pol functions, such as interactions with the DNA template and 
nascent RNA and the binding of nucleoside triphosphate substrates. The largest two 
subunits of pols I, II and III are thought to be functionally equivalent to p' and p 
(122, 368, 526). C l60 and C l28 of yeast pol III both have zinc finger motifs 
suggesting they may participate in DNA binding and the C l28 subunit is labelled by 
nucleotide analogues (438, 526). The phenotypic effects of mutations in C l60 and 
C l28 suggest that they are involved in similar core pol functions to the prokaryotic p 
and P' subunits (122, 436, 478). Two other subunits of yeast pol III, AC40 and 
AC 19, which are shared with pol I, show some sequence homology to the 
prokaryotic a  subunit, which functions in the assembly of the pol (120).
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Furthermore, a temperature-sensitive mutation in AC40 causes a defect in the in vivo 
assembly of pols I and III, suggesting functional equivalency with E.coli a  subunits 
(354). Together, C160, C128, AC40 and AC19 constitute the enzymatic core of 
yeast pol III.
Of the remaining thirteen subunits, five of these are also found in pols I and II 
(ABC 10a, ABC 1 Op, ABC14.5, ABC23, ABC27) (83). Although highly conserved, 
with 40-75% amino acid identity between the yeast and human homologues, the 
absence of homologous subunits in prokaryotic RNA polymerases suggests that they 
are probably not directly involved in the catalytic steps of transcription (483). At 
least one of the subunits, ABC23, is thought to be required for the structural and 
functional integrity of the pols (311). The other shared subunits may perform similar 
structural roles. They may also provide the opportunity for co-ordinate regulation of 
transcription by pols I, II and III. Yeast pol III also contains eight unique subunits 
(83). These pol Ill-specific subunits are required for specific transcription by pol III. 
Indeed, mutations in several of these subunits or antibodies raised against particular 
subunits, have been shown to have no effect on the efficiency of pol III transcription 
of non-specific templates, but the accurate transcription of pol III templates is 
substantially reduced (236, 244, 522). However, these pol Ill-specific subunits are 
insufficient for the accurate and specific recruitment of pol III to class III genes. 
This is also true of pols I and II. The purified nuclear pols have no sequence- 
specificity for DNA and thus are unable to specifically recognise the promoter 
elements of genes that together define the pol specificity of the gene and specify the 
site of transcription initiation. The assistance of additional proteins, so-called 
transcription factors, is required that serve to recruit the pol to the appropriate start 
sites of the appropriate sets of genes, thus ensuring accurate and specific initiation of 
transcription (405). Each of the nuclear pols utilises a different set of transcription 
factors (411, 613).
1.5 Transcription factors utilised by pol III
The transcription factor requirements for basal pol III transcription are not the 
same for every pol III template; this depends on the promoter structure of the gene
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(411, 568). Thus, genes with a type I promoter have different transcription factor 
requirements to genes with type II or type III promoters. For example, 5S rRNA 
genes are the only genes that require transcription factor IIIA (TFIIIA) (134, 473). 
TFIIIA is therefore a gene-specific transcription factor. However, although the exact 
requirements differ between genes of the different promoter types, there is also 
considerable overlap. Transcription factor IIIB (TFIIIB) and transcription factor IIIC 
(TFIIIC) are required for the transcription of all class III genes and may therefore be 
regarded as general pol III transcription factors (473, 568).
1.5.1 TATA-binding protein
The TATA-binding protein (TBP) is an essential component of TFIIIB. It 
was originally thought that its involvement in transcription was confined to TATA 
box-containing class II genes. The surprising discovery that a minority of class III 
genes, typified by the vertebrate U6 snRNA gene, also contain a TATA box as an 
essential component of their promoters raised the possibility that TBP may also be 
required for the transcription of a restricted set of pol III templates. It was first 
assumed that a TATA-binding factor distinct from TBP was involved, because the 
TATA box of class III genes has similar but distinct sequence requirements to the 
TATA boxes associated with class II genes (362, 391, 486). Moreover, the class III 
TATA box is a major determinant of the pol III specificity of these genes (338, 362). 
Subsequently, it was shown that TBP and the TATA-binding factor required for the 
transcription of TATA box-containing class III genes copurify and that cloned TBP 
can efficiently substitute for this factor in supporting U6 transcription (339, 356, 
485). It is now clear that the class III TATA-binding factor and TBP are the same.
Rather unexpectedly, it was found that the transcription of TATA-less class 
III genes also requires TBP (573, 575). This was first suggested by the observation 
by White et al. that transcription of TATA-less pol III templates is dramatically 
inhibited by the preincubation of cell extracts with short oligonucleotides containing 
TATA box sequences from class II promoters (575). This was shown for six 
different TATA-less pol III templates in all, 5S, tRNA, VA, Alu, B1 and B2, as well 
as the TATA-containing U6 and EBER2 genes (575). In contrast, oligonucleotides 
with mutated TATA boxes unable to bind TBP failed to inhibit transcription (575).
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The addition of pure recombinant TBP restored pol III transcription to extracts 
preincubated with TATA box oligonucleotide competitor, suggesting that the 
sequestered TATA-binding factor required for transcription is TBP (575). The 
specific inactivation of TBP by mild heat treatment or its removal from extracts by 
fractionation also abolished transcription of TATA-less pol III templates (237, 575). 
Addition of recombinant TBP to replace that depleted was able to restore 
transcription, providing further evidence of a role for TBP in the transcription of all 
class III genes (237, 575). Similar biochemical experiments suggested that TBP is 
also required for transcription of pol I templates and some TATA-less, as well as 
TATA-containing, pol II templates (213, 434, 479, 574). In recent years it has 
become clear that TBP is not required by all class II genes however.
In vivo evidence for the involvement of TBP in transcription by all three 
nuclear RNA polymerases was provided by genetic analyses in yeast (105). 
Expression of both TATA-less and TATA-containing class III genes was rapidly 
inhibited in yeast strains with a temperature-sensitive mutation in TBP upon 
incubation at the non-permissive temperature (105). The inhibitory effect on pol III 
transcription of an inactivating mutation in the largest subunit of pol II has much 
slower kinetics, suggesting that this inhibition due to loss of TBP function was not an 
indirect consequence of pol II transcription also being inhibited. Pol I transcription 
was also dramatically reduced, suggesting an in vivo role for TBP in transcription by 
all three nuclear pols (105). Extracts prepared from mutant TBP strains following 
incubation at the non-permissive temperature were unable to support pol I, II or III 
transcription (464). The addition of recombinant TBP restored transcription by each 
pol, demonstrating that the devastating effect of the TBP mutation on in vivo 
transcription by each of the pols is a direct one and independent of its effects on 
transcription by the other two nuclear pols (420, 464).
TBP is the only classless transcription factor identified to date and as such 
may be regarded as the most general. It also constitutes an obvious target for the co­
ordinated regulation of transcription by pols I, II and III. A general role for TBP in 
nuclear transcription has been shown both in yeast and human suggesting this is 
likely to be the case in many, if not all, eukaryotes. In support of this, TBP has been 
highly conserved through evolution (213). The N-terminal region of TBP is variable 
both in size and sequence, but the C-terminal region is extremely well conserved. 
The C-terminal 180 residues of TBP are 100% identical in human, mice and frogs
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and at least 80% identical between human and yeast (146, 198, 509). Moreover, in 
yeast the conserved C-terminal region is sufficient for cell viability and mutations in 
TBP that affect basal transcription by pols I, II and III all map to this region (105, 
420, 464). However, recent work from the Tjian laboratory suggests that TBP may 
not be required for pol III transcription or restricted cell-type specific pol II 
transcription in Drosophila (193, 508).
The Drosophila genome contains a single TBP gene but also has two distinct 
genes that encode proteins homologous to TBP (109, 429). One of these, TBP- 
related factor 1 (TRF1) binds specifically to TATA sequences and shows 
considerable sequence similarity to TBP, with -60% overall identity in the 
conserved C-terminal domain of TBP (109). The immunodepletion of TRF1 from 
Drosophila extracts was found to specifically inhibit pol III transcription of tRNA, 
5S and U6 genes (508). In contrast, depletion of TBP was observed to have no effect 
on the level of pol III transcription, suggesting that TRF1 and not TBP may be 
required for pol III transcription in Drosophila, at least in vitro (508). These results 
came as a surprise, as it had previously been shown that the overexpression of TBP 
in Drosophila tissue culture cells by transient transfection stimulates pol III 
transcription, both of TATA-less and TATA-containing class III genes, suggesting 
TBP is limiting for pol III transcription in these cells (527). One plausible 
explanation is that overexpressed TBP may be able to substitute for TRF1. However, 
it has yet to be demonstrated that in the context of a living cell, TRF1 has a role in 
pol III transcription in Drosophila. In support of this possibility, antibody staining of 
polytene chromosomes revealed that TRF1 colocalises at a number of sites that 
contain one or more tRNA genes (193). A subsequent immunolocalisation study 
using a different TRF1 antibody showed that TRF1 colocalises at the majority of 
sites at which the TFIIIB component BRF was detected (508). However, this TRF1 
antibody appeared to have lower specificity than that used in the previous study and 
TRF1 staining was very extensive, raising the possibility that the observed 
colocalisation was due to non-specific TRF1 antibody staining or was coincidental 
(508). There does not appear to be a mammalian homologue of Drosophila TRF1, 
however, several orthologs of a TBP-like protein have recently been identified in 
humans, which conceivably might perform analogous functions (32, 380, 429).
TBP fractionates extremely heterogenously during column chromatography 
of cell extracts, suggesting that it may be part of several different protein complexes,
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each with distinct chromatographic behaviour (33, 55, 91, 371, 421, 456, 507, 524). 
Indeed, gel filtration analysis of HeLa extract suggests that there is very little or no 
free TBP in the cell (524). TBP participates in transcription by the nuclear pols as 
part of three different pol-specific TBP-containing multisubunit protein complexes, 
SL1 (103, 133, 616), TFIID (130, 175, 425, 426, 524) and TFIIIB (237, 264, 340, 
484, 507, 573), that are required for transcription by pol I, pol II and pol III 
respectively. The polypeptides that interact with TBP in each of these complexes, 
so-called TBP-associated factors (TAFs) appear to be different, suggesting it is the 
TAFs that confer the class specificity upon the different complexes (91, 103, 507). 
The extent to which TBP is shared between pols I, II and III therefore seems to be 
dictated by the distinct sets of TAFs with which it associates. In HeLa cells there 
does not seem to be much, if any, free TBP in the cell suggesting that there may be 
competition between the different class-specific TAFs for binding to TBP (434, 524). 
Nevertheless, in most mammalian cells investigated, TBP is not normally limiting for 
pol III transcription. In yeast, there are significant amounts of free TBP in the cell.
1.5.2 TFIIIB
The accurate initiation of transcription requires the formation of a functional 
preinitiation complex at the promoter of the gene, a precisely ordered complex of 
transcription factors assembled on the DNA that accurately recruits and positions the 
pol over the start site for initiation (40, 405). For TATA-containing pol II templates, 
TFIID nucleates preinitiation complex formation, the TBP contained within this 
complex enabling it to specifically recognise and bind to the TATA sequence located 
upstream of the start site (442). Similarly, the TBP contained within TFIIIB is 
thought to enable TFIIIB, in co-operation with a PSE-binding factor 
(PBP/SNAPc/PTF) that binds sequence-specifically to the PSE, to nucleate complex 
formation at class III genes such as the vertebrate U6 and 7SK genes that also have a 
TATA box (376). However, for TATA-less class III genes, TFIIIB is recruited to the 
promoter by protein-protein interaction with other transcription factors such as 
TFIIIA and/or TFIIIC that are able to specifically bind to the promoters of these 
genes (36, 318, 472). In yeast, once TFIIIB has been recruited to the promoter and is 
stably bound, TFIIIC and TFIIIA can be stripped away by high salt or heparin and
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TFIIIB alone is able to support multiple rounds of accurate transcription by pol III
(263). Thus, clearly TFIIIB is the central class III initiation factor. The essential 
role of this factor in pol III transcription is reflected by the considerable effort that 
has been devoted to its purification and elucidation of its composition, both in yeast 
and in mammals (568).
An early attempt by Klekamp and Weil to purify TFIIIB from yeast by ion- 
exchange chromatography yielded weakly active fractions highly enriched in a 
60kDa polypeptide that constituted ~30% of the total protein in the most highly 
purified fraction (283). To investigate whether this abundant 60kDa polypeptide 
corresponds to TFIIIB, it was gel-purified and polyclonal antibodies were raised 
against it (283). The resulting antiserum inhibited tRNA and 5S transcription 
reconstituted either with yeast or human extracts, whereas the preimmune serum did 
not (283). Furthermore, preincubation of the antiserum with purified 60kDa protein 
used to raise it blocked its inhibitory effect on transcription. The authors thus 
concluded that this 60kDa polypeptide likely constitutes yeast TFIIIB (yTFIIIB) 
(283). However, whereas the partially purified TFIIIB fractions were capable of 
reconstituting tRNA transcription in the presence of partially purified TFIIIC and pol 
III, the gel-purified 60kDa polypeptide was unable to do so despite multiple attempts 
at renaturation (283), raising the possibility that additional proteins may be required 
for TFIIIB activity. In support of this, quantitative analyses of transcription 
reconstituted using the partially purified fractions estimated that 100-150 molecules 
of 60kDa polypeptide were required per template molecule (283). Although such a 
stoichiometry could simply reflect the inactivation of the 60kDa protein during 
purification, an equally plausible explanation is that other proteins are also required 
for TFIIIB activity that are present in much smaller quantities, the bulk of these 
having been removed during fractionation.
Kassavetis et al. later partially purified yeast TFIIIB by a fractionation 
scheme based on that of Klekamp and Weil but slightly modified (267). Their most 
highly purified TFIIIB fraction still contained at least 25 electrophoretically 
separable polypeptides after five chromatographic steps, but nevertheless had -60- 
fold higher specific activity than that of Klekamp and Weil (267). Notably, a 60kDa 
species was not a major constituent of this fraction (267).
Bartholomew et al. used this partially purified fraction and an ingenious 
photocrosslinking approach (23) to probe the polypeptide composition of yTFIIIB.
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DNase I footprinting analysis with crude extract had earlier shown that the assembly 
of active pol III transcription complexes on yeast 5S rRNA and tRNATyr genes 
caused protection of the entire transcription unit and -45 bp of 5' flanking sequence 
immediately upstream of the transcriptional start site (48). To dissect the interactions 
of the individual class III transcription factors with the DNA and their contributions 
to this extensive footprint, DNase I protection analyses with partially purified 
TFIIIA, TFIIIB and TFIIIC had then been performed (48). The activity providing 
protection of the upstream region of the tRNATyr gene was found to consistently 
copurify with TFIIIB activity (267). Furthermore, protection of this region was 
dependent on the prior interaction of TFIIIC with the B-block and was resistant to 
heparin, both properties of TFIIIB and its interactions with tRNA gene promoters 
(267). Together, these observations suggest that this upstream DNA-binding activity 
and TFIIIB are the same. Bartholomew et al. exploited this apparent ability of 
yTFIIIB to bind to the 5' flanking sequence of these genes to search for putative 
components of the factor using a novel photocrosslinking method (24). In this 
method, a photoactive nucleotide, 5-[N-(p-azidobenzoyl)-3-aminoallyl]-deoxyuridine 
(N3RdU), is incorporated into specific sites in the DNA, adjacent to radiolabelled 
nucleotides (23). The modified DNA is incubated with appropriate protein fractions 
for a short time to allow the assembly of proteins on the DNA probe and is then 
irradiated with ultraviolet light. Irradiation generates a reactive nitrene group from 
N3RdU that is able to rapidly form covalent bonds with polypeptides in very close 
proximity to the photoactive nucleotide, thus “tagging” them with radiolabelled 
DNA. The probe is then incubated with DNase I and micrococcal nuclease so that 
those regions of the DNA not bound by protein are destroyed. The size of the 
"tagged” proteins can then be determined by SDS-PAGE.
The structure of N3RdU places the reactive nitrene on a 0.9 to lnm tether, 
thus ensuring only proteins in the space just outside the DNA helix, within a distinct 
spatial region, will be detected (23). This approach, using photoactive nucleotides 
incorporated into the 45bp upstream region protected from DNase I digestion in a 
crude extract, detected two polypeptides, of 70 and 90kDa in size, within the 
partially purified TFIIIB fraction (24). The specificity of their crosslinking to this 
region of DNA was demonstrated by its dependence both upon a functional promoter 
and the presence of TFIIIC (24). The crosslinked 70 and 90kDa polypeptides are
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distinct and separate components of TFIIIB. In support of this, the two polypeptides 
were found to be preferentially crosslinked by photoactive nucleotides located on 
opposite sides of the DNA helix suggesting they have distinct spatial distributions 
within this upstream region (24). They also produce different V8 protease digestion 
patterns (24).
The 70 and 90kDa polypeptides are only minor components of the partially 
purified TFIIIB fraction of Kassavetis et al. used in these crosslinking experiments 
(267). Upon further purification of this fraction on Mono S, a cation exchanger, 
TFIIIB was split into two essential components, B' that eluted at ~275mM NaCl in a 
100mM-400mM NaCl gradient and B" that eluted in the subsequent 1M NaCl step 
(261). Together, the B' and B" fractions were able to reconstitute both the 
transcriptional and photocrosslinking properties of TFIIIB (261). Photocrosslinking 
associated the B' fraction with the 70kDa polypeptide of TFIIIB and the B" fraction 
with the 90kDa polypeptide of TFIIIB (261). Indeed, the B' fraction was found to be 
highly enriched in a 70kDa polypeptide that represented ~5% of the total protein, 
which was distributed among -10 polypeptides (261).
Three different groups independently cloned the BRF1 gene (TDS4/PSF4) 
that encodes the 70kDa polypeptide component of yeast TFIIIB (64, 101, 342). 
Database searches revealed that the N-terminal half of this protein shares extensive 
sequence homology with the pol II general transcription factor TFIIB, which is much 
smaller (64, 101, 342). The protein was therefore named yBRF, short for yeast 
TFIIB-related-factor (101). The sequence similarity between TFIIB and yBRF1 
suggested that yBRF may function in pol II transcription. However, despite this 
homology, in contrast to the rapid decline in tRNA synthesis observed, a reduction in 
the levels of yBRF was found to have no effect on the in vivo expression of either 
class II or class I genes (64, 342). Similarly, in vitro transcription of tRNA and 5S 
rRNA genes was found to be substantially diminished in extracts lacking functional 
yBRF, whereas transcription by pols I and II was as efficient as in wild type extracts 
(101). Recombinant yBRF was able to rescue transcription of tRNA and 5S rRNA 
genes in these BRF-deficient extracts and could also stimulate their expression in 
wild type extracts, but had no effect on transcription by pols I and II (101). These 
results demonstrate that yBRF is a pol Ill-specific factor and suggest that it is usually 
limiting for pol III transcription. Indeed, yeast strains with a dominant mutation in
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the BRF1 gene that specifically increases the in vivo expression levels of yBRF were 
found to have higher pol III transcriptional activity than wild-type strains (342).
The bulk of the homology between yBRF and the various TFIIB proteins that 
have been cloned is within three distinct regions, a putative zinc finger at the extreme 
N-terminus and two imperfect direct repeats (64, 101, 342). The direct repeat region 
of TFIIB has been shown to interact directly both with TBP and pol II, consistent 
with the proposed function of TFIIB as a bridging factor between promoter-bound 
TBP and pol II during preinitiation complex formation (183). Since this region is 
well conserved in yBRF it suggested that yBRF might also interact with TBP and, 
perhaps, pol III since several subunits are shared between pols II and III. In support 
of this, two of the groups that cloned the BRF1 gene isolated the gene as an allele 
specific multi-copy suppressor of TBP mutations (64, 101). The allelic specificity of 
the suppression is suggestive of a direct interaction between TBP and yBRF. A 
combination of in vitro and in vivo experiments showed TBP to be essential for yeast 
pol III transcription (105, 464). However, the crosslinking experiments of 
Bartholomew et al. that detected the 70 and 90kDa subunits of TFIIIB did not 
identify a polypeptide of ~27kDa corresponding to the size of yeast TBP (24). 
Nonetheless, TBP was detected in the partially purified TFIIIB fraction used for 
crosslinking and a significant amount was found in the B' fraction that is enriched in 
yBRF (264). In contrast, no TBP was detected by western blot analysis in highly 
purified fractions of TFIIIC and pol III (264). In addition, antibodies against TBP 
were found to specifically supershift a heparin-stripped TFIIIB-tDNA complex in an 
EMSA, demonstrating that TBP is part of this TFIIIB complex (264). Subsequently, 
it was shown that recombinant TBP and recombinant BRF directly interact (235, 
271). GST-BRF pulldown assays were used to map the regions of BRF to which 
TBP binds (271). As expected, the conserved direct repeat region of BRF was able 
to specifically bind TBP. Rather surprisingly, however, the C-terminal region alone 
was also shown to bind TBP with even higher affinity (271). Moreover, three 
separate point mutations in TBP that specifically inhibit pol III transcription in vivo 
were found to prevent TBP from interacting with the C-terminal half of BRF yet had 
no effect on its interaction with the direct repeats (271). This strongly suggests that 
the interaction between TBP and the C-terminal half of BRF is of physiological 
significance. The N-terminal direct repeat region was also found to interact with a
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subunit of pol III, consistent with the homologous region of TFIIB binding pol II 
(271). However, within this region the two pols interact with different repeats, 
moreover, the pol III subunit, C34, that directly binds to this region of BRF is unique 
to pol III (183, 271). In addition, the N-terminal half of BRF, but not the C-terminal 
half, was found to interact with the largest subunit of yeast TFIIIC (82). Thus, the N- 
terminal half of yBRF may perform an analogous function in pol III transcription to 
the highly homologous TFIIB since it participates in interactions both with the 
activity that recognises class III promoters (TFIIIC or TBP depending on promoter 
type) and the polymerase itself. Although there is significant conservation between 
TFIIB and the N-terminal half of BRF, these regions clearly actively participate in 
determining the differential pol specificity of TFIIB and BRF.
In contrast to the N-terminal region, the C-terminal half of yBRF has no 
obvious sequence similarity with any other known yeast protein. It is characterised 
by being highly charged, with 21% acidic residues (D or E), 17% basic residues (K 
or R) and 14% Ser and Thr residues (271). The high charge density of the C- 
terminal region of BRF has been well maintained through evolution (271). Sequence 
comparisons of yBRF cloned from three evolutionarily distant yeast species 
Saccharomyces cerevisiae, Kluveromyces lactis and Candida albicans, showed the 
N-terminal half of the protein to be highly conserved, especially the direct repeat 
region. The C-terminal half was found to be much less well conserved but it does 
contain three discreet areas of strong conservation that are likely to be essential for 
BRF function, yeast homology regions I, II and III (HI, HII and HIII) (271). In 
support of this, the deletion of the last 165 amino acid residues of yBRF, which 
includes the HII and HIII domain, prevented the binding of TBP (271). The HII 
domain is thought to mediate the interaction of TBP with the C-terminal half of BRF 
(11, 102, 262, 265, 271). The exact function of the other two homology domains 
have yet to be fully elucidated, but their high level of conservation suggests that they 
may mediate other important interactions of BRF.
The TFC5 gene encoding the 90kDa polypeptide of yTFIIIB has also been 
cloned (266, 439, 452). It actually encodes a 594 amino acid protein with a predicted 
molecular mass of ~68kDa that migrates anomalously as a ~90kDa protein on SDS 
PAGE (266, 439, 452). The protein, which has been called B", has little or no 
sequence similarity with other known proteins except for a putative SANT domain
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also found in N-CoR, SWI3 and ADA2 (1). This motif, which shares weak 
homology with the DNA-binding domain of the oncoprotein Myb, is implicated in 
protein-protein and protein-nucleic acid interactions (1).
TBP, BRF and B" are all essential for yeast cell viability and, specifically, 
pol III transcription. Despite its indispensability, however, B" is remarkably 
resistant to truncation (266, 297). Although B" is essential for U6 transcription, 
extensive deletion analysis has failed to identify a single amino acid that is absolutely 
required for transcription with only four isolated amino acids yet to be tested (297). 
A core B" protein of only 176 amino acids (out of 594) has been found to be 
sufficient for U6 transcription, although a larger domain is required for tRNA 
transcription (297). This is likely to reflect the TFIIIC dependency of tRNA 
synthesis. Two distinct domains (I and II), the first of which includes the SANT 
domain, that both seem to be necessary for tRNA transcription can function on an 
either-or basis for U6 snRNA synthesis (297). B" makes multiple contacts within 
the preinitiation complex (24, 253, 261, 264, 266, 439, 452), which may explain why 
it is so tolerant of deletion mutagenesis, the loss of any individual contact being 
compensated by other interactions made by the protein (266).
The recombinant B" protein is able to replace the Mono S B "  fraction in 
DNA binding and transcription of yeast tRNA and U6 genes, indicating that it is the 
sole essential component of the B" fraction (266). Similarly, recombinant TBP and 
recombinant BRF together are sufficient to reconstitute all the properties of B' 
TFIIIB activity (264). Indeed, it has been possible to reconstitute yTFIIIB from 
entirely recombinant components (266, 439, 452). However, although TFIIIB 
reconstituted from recombinant TBP, BRF and B" displayed identical DNA binding 
properties to native yTFIIIB, the factor was found to be less active for transcription 
(266, 452). This may be because the recombinant polypeptides are not folded 
correctly or lack important post-translational modifications. Alternatively, some 
component(s) may be missing from the transcriptional system reconstituted with 
recombinant TFIIIB components. Perhaps there are additional subunits of yTFIIIB 
that have yet to be identified that are nonessential but stimulatory, analogous to the 
TFIID TAFs that are dispensable for basal transcription of TATA-containing class II 
promoters but are required for activated transcription. It is also plausible that the 
component is an essential part of TFIIIB but present in residual amounts as a
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contaminant in the purified complementary fractions used to reconstitute 
transcription. Alternatively, the putative missing component may be distinct from 
TFIIIB. A prime candidate for such a component is TFIIIE, which has been detected 
in both native B' and B" fractions (121, 122). Ruth et al. found that transcription 
reconstituted with recombinant TBP, BRF, and B" is stimulated by TFIIIE (452). 
Thus, yeast TFIIIB consists minimally of BRF, TBP and B", but there may be 
additional, perhaps regulatory, subunits. However, the identification of any such 
subunits is made more difficult by its apparent lability (235, 261). Indeed, yTFIIIB 
has yet to be purified to anywhere near homogeneity without its resolution into at 
least two separate components. B" is easily dissociated from TFIIIB by a variety of 
mild chromatographic procedures (235, 261). It has been suggested that yTFIIIB is 
not a stable molecular entity, except when in a DNA-bound state (83, 235).
The composition of mammalian TFIIIB is much less well characterised than 
that of yeast. The mammalian factor was first identified as a single polypeptide of 
60kDa in size, as was originally reported for yeast TFIIIB by Klekamp and Weil 
(545). This followed chromatography of HeLa cell extracts on a series of ion- 
exchange columns in a fractionation scheme essentially the same as used by 
Klekamp and Weil. A 60kDa polypeptide was found to constitute -90% of the 
protein in the most highly purified fraction which was capable of supporting 
transcription of tRNA, 5S and VA genes in the presence of partially purified 
complementing fractions providing a source of TFIIIA, TFIIIC and pol III (545). 
Additional support for TFIIIB being a 60 kDa protein was provided by the 
sedimentation of TFIIIB activity at ~60kDa following glycerol gradient 
centrifugation of either crude or partially purified fractions (545). However, it was 
subsequently demonstrated that TBP is an essential component of human TFIIIB, as 
in yeast (340, 371, 484, 507, 573). Thus, antibodies raised against TBP were found 
to specifically immunoprecipitate TFIIIB activity (91, 340, 371, 507, 573). 
Furthermore, a subpopulation of TBP molecules were found to consistently 
cofractionate with TFIIIB during a variety of chromatographic procedures (340, 371, 
484, 507, 514, 573). The 60kDa protein reported by Seifart’s group is therefore 
likely at best to be only one component of a larger TFIIIB complex.
Gradient chromatography on Mono Q, a strong anionic exchanger, splits 
human TFIIIB (hTFIIIB) into two components raising the possibility that hTFIIIB,
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like yeast TFIIIB, might be labile (91, 340, 371). Lobo et al. found that these 
components eluted at 380mM and 480mM KC1 and named them 0.38M-TFIIIB and 
0.48M-TFIIIB, respectively (340). TBP was only found in the 0.38M-TFIIIB 
fraction (340). The active component of this fraction could be specifically 
immunodepleted using anti-TBP antibodies. Moreover, whereas recombinant TBP 
was unable to reconstitute transcription of 5S and VAi genes in a TBP- 
immunodepleted extract, the 0.38M-TFIIIB fraction was able to do so (340). This 
suggests that one or more TAF's exist in a complex with TBP in the 0.38M-TFIIIB 
fraction and that these are required for VAi and 5S transcription.
Using anti-TBP antibodies, a polypeptide of 88-90kDa was found to 
specifically coimmunoprecipitate with TBP and TFIIIB activity from 0.38M-TFIIIB 
fractions and other TFIIIB-containing fractions, suggesting that it might be a subunit 
of TFIIIB (374, 552). The cDNA for this protein was isolated and found to encode a 
677 amino acid protein (374, 552). The N-terminal 280 residues are 41% identical to 
S.cerevisiae BRF and 24% identical to human TFIIB (374). The protein is therefore 
referred to as human TFIIB-related factor (hBRF) (374). Regions of extensive 
homology shared by all three proteins include a zinc finger motif and two imperfect 
direct repeats (374). This is also true of BRF homologues cloned from 
Caenorhabditis elegans (CeBRF) and Drosophila melanogaster (DmBRF) (316, 508). 
The C-terminal half of hBRF is highly divergent with little homology to the yBRFs 
except for yeast homology regions II and III, which are conserved (374). The 
conservation of yeast HII and HIII domains between metazoan and lower eukaryotic 
BRF species suggests that these two domains are likely to be required for core BRF 
function. The C-terminal half of hBRF also has a region of low homology to chicken 
HMG2, including an acidic C-terminal tail typical of HMG2 proteins (552). 
However, CeBRF lacks an HMG2-like motif, suggesting such a motif is not essential 
for metazoan BRF function (316). Like the yeast BRFs, hBRF has two TBP-binding 
sites, a weak one in the N-terminal half and a strong one in the C-terminal half (552).
Immunodepletion of hBRF from HeLa nuclear extracts was found to severely 
inhibit transcription of VA and tRNA genes, demonstrating its essential role in 
human pol III transcription (374, 552). Transcription could be restored by the 
addition of recombinant BRF and TBP but not by rBRF alone, consistent with the 
stable association of TBP and BRF within hTFIIIB (374, 552). That rTBP and rBRF 
were sufficient to reconstitute transcription suggests that any other components of
25
hTFIIIB are either loosely associated, displaced by the antibodies, or not required for 
basal expression. Gel filtration of 0.38M-TFIIIB suggests that the complex has a 
molecular weight of 300kDa, so it is unlikely that TBP and BRF are its sole 
constituents (340).
In addition to hBRF, a variety of other polypeptides were also found to 
coprecipitate with TBP following the immunoprecipitation of partially purified 
TFIIIB fractions with anti-TBP antibodies (91, 340, 374, 507). Taggart et al. 
identified a tightly-associated polypeptide of 172kDa (TAFT 72) and another more 
loosely-associated polypeptide of unreported size (TAF-L) (507). Lobo et al. 
detected polypeptides of 54, 83 and 150kDa (340), Chiang et al. detected 
polypeptides of 60, 87, 96 and 190kDa (91), and Mital et al. detected polypeptides 
of 27, 45, 67 and 70 kDa, as well as a 90kDa polypeptide that corresponds to hBRF 
(374). At present, however, hBRF is the only polypeptide identified by this approach 
to be confirmed as a subunit of hTFIIIB. Some of the polypeptides detected 
appeared substoichiometric to TBP and BRF, suggesting they may only be loosely 
associated or may bind TBP indirectly. This may partly explain some of the 
differences in the polypeptides detected by the different groups, the relationships 
between which are presently unclear (434). Although it remains to be seen which, if 
any, of these polypeptides are actually subunits of hTFIIIB, the coprecipitation of so 
many polypeptides suggests that the polypeptide composition of hTFIIIB might be 
complex.
Although the exact composition of hTFIIIB remains uncertain, significant 
progress has recently been made with the cloning of a human homologue of yeast B" 
(463). Human B" (hB") is substantially larger than its yeast counterpart, with a 
predicted molecular mass of 156kDa (463). There are three major regions of 
sequence similarity, a putative SANT domain ( a a  415-472) that is 43% identical 
with that of yeast B", a 131-amino acid region immediately upstream of this domain 
of 21% identity and a 115-amino acid region immediately downstream of the SANT 
domain of 17% identity (463). In addition to human and Saccharomyces cerevisiae 
B", sequences coding for putative B" homologues have also been detected in mouse, 
Drosophila melanogaster, Caenorhabditis elegans, Schizosaccharomyces pombe and 
Arabidopsis thaliana genomes (463). In all of these organisms, the B" SANT 
domain is extremely well conserved, suggesting that it may be essential for B"
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function (463). The most notable feature of the large C-terminal extension of hB" 
that is missing from yB" is a stretch of 19 short repeats of 26-28 amino acids. These 
repeats are similar to sequences that form coiled-coil structures from proteins 
belonging to the myosin and intermediate filament families, but a similar structure is 
not predicted for this region of hB" (463). An essential role for hB" in human pol III 
transcription is suggested by its immunodepletion from cell extracts which was found 
to severely compromise class III gene expression but had no effect on pol II 
transcription from the adenovirus major late promoter or the human U1 snRNA 
promoter (463). Furthermore, the addition of bacterially expressed recombinant hB" 
to depleted extracts was able to restore pol III transcription (463). TFIIIB therefore 
seems to be strongly conserved between yeast and humans, all three core yeast 
subunits, TBP, BRF and B", having structural and functional homologues in human 
TFIIIB.
However, whereas in yeast there is a single form of TFIIIB that is necessary 
and sufficient for the transcription of all class III genes, in humans there appear to be 
multiple forms of TFIIIB that function at different class III promoters. There is now 
substantial evidence that the TFIIIB requirements for type III promoters are different 
to those of types I and II (340, 365, 374, 463, 514, 515, 552). There are several 
examples of the physical separation of these requirements by column 
chromatography (340, 514). Teichmann and Seifart separated two forms of hTFIIIB 
on EMD-DEAE-Fractogel (EDF) (514). One form, hTFIIIB-a, which eluted in 
200mM KC1, was active for U6 but not VAi transcription. Conversely, the other 
form, hTFIIIB-P, which eluted with TBP and BRF in 300mM KC1, was capable of 
supporting VAi but not U6 transcription (514). hTFIIIB-a and hTFIIIB-P were also 
found to behave differently on Cibacron blue and on a Sephacryl-S300 HR gel 
filtration column (514). It is well established that hBRF is necessary for the 
transcription of type I and type II genes, but its requirement for transcription of type 
III genes has been controversial (374, 552). Whereas Wang and Roeder observed 
inhibition of U6 and 7SK gene expression following immunodepletion of extracts 
with anti-BRF antibodies (552), Mital et al. found that immunodepletion of hBRF 
inhibited VAi but had no effect on U6 transcription (374). A possible explanation of 
this discrepancy is suggested by the recent cloning by two different groups of a novel 
gene that encodes a protein, BRFU (463) (or hTFIIIB50) (515), that is highly related
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to hBRF and hTFIIB. This protein is specifically required for transcription of human 
U6 and 7SK genes but not the adenoviral VAi gene (463, 515). It might be the anti- 
BRF antibodies of Wang and Roeder recognised both hBRF and BRFU, but those of 
Mital et al. only depleted extract of hBRF (374, 552). In addition to BRFU, several 
splice variants of hBRF (hBRFs 2, 3 and 4) have also recently been discovered (365). 
It is reported that the different splice variants function at different class III genes 
(365). Thus, hBRF, hereon referred to as hBRFl, is the most active variant in 
transcription of type I and II promoters whereas a different variant, hBRF2, a 139 
amino acid protein that completely lacks the first N-terminal direct repeat of hBRFl, 
is implicated in U6 gene expression. The form of TFIIIB required for U6 
transcription may therefore contain two distinct BRF species, BRFU and hBRF2. In 
contrast, BRF1 is required for the expression of genes with type I or type II 
promoters. The recently identified hB" is an essential component of TFIIIB for the 
transcription of both VAi and U6 genes, suggesting that, like TBP, it is a common 
factor of the different forms of TFIIIB utilised by different class III genes (463). At 
present it is unclear whether the identity of the BRF species within the TFIIIB 
complex represents the only difference in the composition of TFIIIB utilised by type 
III promoters versus types I and II, or whether there are additional protein 
components that may be involved in conferring promoter specificity. Possible 
candidates include proteins of 54, 48, 42 and 40kDa that were found to stably 
associate with BRFU (TFIIIB50) during its immunopurification (515). That these 
proteins might constitute active components of TFIIIB is suggested by the ability of 
this immunopurified complex to restore U6 transcription to extracts depleted of 
BRFU (TFIIIB50), whereas recombinant BRFU alone was unable to do so (515). 
The resistance of this immunopurified complex to stringent washing with 500mM 
KC1 provides support that these BRFU-associated proteins may be of physiological 
significance (515). A protein of similar size to BRF2 (365) was also observed in 
some preparations of the BRFU (TFIIIB50) complex (515).
1.5.3 TFIIIC
TFIIIB alone has little or no sequence-specific affinity for DNA. Its 
recruitment to class III genes with type I or type II promoters requires TFIIIC (318).
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TFIIIC specifically recognises and binds to the A- and B- block intragenic promoter 
elements of type II promoters. This sequence-specific DNA-binding activity of 
TFIIIC has greatly facilitated its purification (71, 118, 156, 267, 291, 331, 408, 505, 
608). The factor was first purified from yeast where it is also referred to as x factor. 
Yeast TFIIIC comprises of six polypeptides of 138 (325), 131 (355, 431), 95 (407, 
505), 91 (14), 60 (119) and 55 kDa (351) (referred to as xl38, xl31, x95, x91, x60 
and t55 respectively). These polypeptides were found to tightly associate and 
copurify as a single entity during ion-exchange chromatography and affinity 
chromatography on specific tDNA or B-block columns (71, 156, 267, 408, 505). 
Limited protease treatment of TFIIIC generated a smaller form of the factor that 
retained its DNA-binding affinity but was only able to bind the B-block (360). This 
suggested that the A-block and B-block binding domains of TFIIIC are separate. In 
support of this, visualisation of yeast TFIIIC-tDNA complexes by electron 
microscopy revealed TFIIIC to consist of two linked globular domains, each of -300 
kDa and -10 nm in diameter (465). The linker connecting the two DNA-binding 
domains appears flexible and able to stretch (67, 465), accounting for the remarkable 
feat of TFIIIC to bind to A- and B- blocks separated by a wide variety of distances 
(18, 138). All six polypeptides of TFIIIC have been cloned and have been shown to 
be essential for yeast cell viability (14, 119, 325, 351, 355, 407, 431, 505). Although 
several of the polypeptides contain sequences that closely resemble known DNA- 
binding motifs (326, 355, 505), none of the polypeptides seem to be able to bind 
specifically to DNA on their own, suggesting the A-block and B-block binding 
domains may be composite, involving more than one polypeptide. Photocrosslinking 
experiments showed xl31, x95 and x55 to be positioned in close vicinity to the A- 
block, suggesting that they may be involved in TFIIIC binding to the A-block (23, 
24). Only xl38 is accessible to photocrosslinking from the B-block, suggesting it is 
likely to be directly involved in B-block DNA binding (23). TFIIIC fractions 
consisting primarily of just xl38 and x95 retain a substantial proportion of TFIIIC 
DNA binding activity, suggesting that these polypeptides are the major quantitative 
determinants of tDNA recognition (155).
Human TFIIIC is less stable than the yeast factor (118, 607). It is resolved 
into two components, TFIIIC 1 and TFIIIC2, during ion exchange chromatography on 
Mono Q (607). Both of these components are required for transcription of tRNA, 5S
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and VA genes (118, 331, 553, 607) but only TFIIIC1 is required for U6 and 7SK 
transcription (307, 397, 604). The subunit composition of TFIIIC 1 has yet to be 
determined. Sedimentation analysis suggested a mass of up to 200kDa for TFIIIC 1, 
assuming that it is globular, however little further progress has been made towards its 
characterisation (607). TFIIIC2 has been highly purified and found to comprise of 5 
polypeptides of 220, 110, 102, 90 and 63 kDa (a, p, y, 5, 8, respectively) (291, 331, 
608). TFIIIC2 binds specifically and with high affinity to the B-block region of VAi 
and tRNA genes (44, 553, 607). TFIIIC 1 enhances the B-block footprint generated 
by TFIIIC2 and extends it both 3' and 5' to include the A-block (553, 607). 
However, it remains to be determined whether TFIIIC 1 binds directly to the A-block 
or induces rearrangements in TFIIIC2 allowing the latter to do so. All five subunits 
of TFIIIC2 have been cloned (230, 231, 307, 331, 488). In contrast to TFIIIB and 
pol III, TFIIIC seems to be very poorly conserved between yeast and humans. 
Human TFIIICa and TFIIICp, which together appear to be responsible for the 
specific B-block binding activity of TFIIIC2 (43, 44, 291, 481, 608), show no 
significant homology to any of the subunits of yeast TFIIIC. This is very surprising 
because the A- and B-block sequences are highly conserved between yeast and 
mammals. hTFIIICb also lacks significant sequence similarity with any of the yeast 
TFIIIC subunits (230). However, the remaining two components of TFIIIC2 display 
weak homology to particular subunits of yeast TFIIIC; hTFIIICe shares 22% identity 
with x95 and hTFIIICy is 31% identical to x l3 1, both of which contain 11 copies of a 
tetratricopeptide repeat (TPR) (231).
1.5.4 TFIIIA
TFIIIB, TFIIIC and pol III are sufficient for basal transcription of class III 
genes with type II promoters, however, 5S transcription requires an additional factor 
called TFIIIA (134, 473). Like TFIIIC, TFIIIA is poorly conserved between species, 
for example frog and yeast TFIIIA share only 20% overall sequence identity (13). 
Despite the sequence divergence of TFIIIAs from different species, in every species 
the factor is characterised by its possession of nine tandemly arranged, zinc- 
dependent DNA binding domains, commonly referred to as zinc fingers (13, 373,
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381). The TFIIIA zinc fingers have a single zinc ion coordinated by two cysteine 
and two histidine residues. The loop-like structure or “finger” created is thought to 
consist of an antiparallel P-sheet packed against an a-helix (31). The a-helix of such 
fingers typically make sequence-specific contacts in the major groove of DNA. 
TFIIIA is highly modular, with clusters of zinc fingers binding specifically to distinct 
regions of the 5S gene ICR. The N-terminal three fingers (fingers 1-3) bind the C- 
block, finger 5 binds the intermediate element, fingers 7-9 bind the A-block, whereas 
fingers 4 and 6 span these promoter regions, functioning primarily as spacer elements 
(98, 139, 200, 201). TFIIIA also specifically contacts TFIIIC, thus serving as a 
molecular adaptor between TFIIIC and the 5S gene promoter and allowing TFIIIC to 
recruit TFIIIB to 5S genes (318, 472).
1.5.5 PTF/SNAPc
Class III genes with a type III promoter such as 7SK and vertebrate U6 genes 
have distinct transcription factor requirements from genes with type I or II promoters 
(307, 365, 374, 432, 463, 514, 515, 546, 604). The lack of an internal control region 
(ICR) obviates the need for TFIIIA or TFIIIC2, however the poorly characterised 
TFIIIC 1 is required for transcription (307, 604). Since type III promoters contain a 
TATA box, TFIIIB can bind to such promoters independently of other factors. 
However, recruitment of TFIIIB to the TATA box is greatly enhanced by a factor 
called SNAPc/PTF that binds the PSE of these promoters (604). This factor is 
essential for transcription of 7SK and vertebrate U6 genes (604). It has five subunits, 
all of which have been cloned (17, 208-210, 455, 592, 605). The largest subunit, 
SNAP190 (PTFa), contains a Myb DNA-binding domain and can be crosslinked to 
the PSE (592). The U6 and U2 PSEs are functionally interchangeable suggesting 
that the same PSE-binding factor may be employed by class II and class III snRNA 
genes (334, 338). Indeed, immunodepletion of extracts of SNAPc/PTF was found to 
inhibit not only U6 and 7SK transcription but also pol II transcription of U1 and U2 
genes (17, 208, 210, 455, 605). Moreover, purified SNAPc/PTF was able to restore 
transcription of these genes; thus it seems that there is a single PSE-binding protein 
shared by pols II and III.
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The very strict PSE-TATA box spacing requirement of type III promoters 
suggests that TFIIIB and SNAPc/PTF interact (167, 329, 339, 543). Indeed, subunits 
of SNAPc/PTF have been shown to bind directly to TBP (17, 208, 210, 455, 605). 
This may explain how SNAPc/PTF stimulates TFIIIB recruitment to the U6 
promoter. Conversely, TBP enhances SNAPc/PTF binding to the PSE (376). It 
seems that SNAPc/PTF and TFIIIB cooperatively interact facilitating the recruitment 
of each other to the promoter. Despite this, their binding to the PSE and the TATA 
box respectively is relatively slow. SNAP 190 contains a C-terminal extension that 
inhibits it from interacting with the PSE, perhaps by masking its DNA-binding 
domain (377). However, interaction with a pol II- and pol III- transcriptional 
activator called Octl, which binds octamer motifs found in the DSE of these 
promoters and those of pol II-transcribed U snRNA genes, overcomes this 
autoinhibition (375). Thus, whereas the association of SNAPc with the PSE of the 
human U6 gene takes over one hour in the absence of Octl it is complete in 15-30 
minutes in its presence (375).
1.6 Preinitiation complex formation on class III genes and interactions 
between class III transcription factors and with pol III
The formation of active transcription complexes on the different class III 
genes was initially investigated by means of the template exclusion assay. This 
approach monitors the ability of a gene that is preincubated with limiting amounts of 
factor(s) to exclude transcription of a second gene added subsequently; preferential 
transcription of the first gene indicates the stable interaction of a limiting component 
during the preincubation, thereby precluding its association with the second gene. 
Using this assay, ordered stepwise assembly pathways for the formation of 
preinitiation complexes on type I and type II promoters have been defined (Fig. 1.1). 
Thus, TFIIIB was found only able to bind to VA and tRNA genes after TFIIIC had 
bound (318). In the case of a 5S gene, TFIIIC was found to bind after TFIIIA and 
before TFIIIB (318). Using separated TFIIIC 1 and TFIIIC2 it was found that 
TFIIIC2 is the first factor to bind to VAi or tRNA genes, consistent with its B-block 
binding activity (117). TFIIIC 1 and TFIIIB can then interact in either order to form 
a functional preinitiation complex (117).
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Figure 1.1
Stepwise assembly of class III preinitiation complexes in vitro
A)
Flow chart indicating the order of interaction of transcription factors and polymerase 
with a typical type II promoter such as that of a tRNA gene.
B)
Flow chart indicating the order of interaction of transcription factors and polymerase 



















Such assembly pathways defined in vitro with separated components clearly 
may differ from how functional preinitiation complexes are formed in vivo. Indeed, 
Wang et al. (551) recently reported the discovery of a human pol III holoenzyme, 
that is, a complex of the pol III machinery that is fully functional for accurate and 
specific pol III transcription that exists independently of DNA, suggesting that 
preinitiation complexes may be preassembled off the DNA. Nevertheless, these 
sequential assembly pathways are an indication of how transcription complex 
formation might occur in vivo and provide some information of interactions that 
likely occur between the transcription factors and with pol III that may be 
functionally important.
The current knowledge of the network of interactions between individual 
components of the pol III transcriptional machinery is most advanced in yeast where 
the majority of the components required for basal transcription have been cloned 
(83). Protein-DNA photocrosslinking has been used to map the positions of the 
various components of the pol III transcriptional machinery on a yeast tRNA 
promoter (23, 24). Thus, yBRF and B" can be specifically crosslinked to sequences 
located ~40bp upstream of the transcriptional start site in a TFIIIC-dependent 
manner (24). xl31 is the only subunit of TFIIIC accessible for crosslinking with 
photoactive nucleotides located upstream of the start site (24, 25). This subunit is 
therefore an excellent candidate for interacting with TFIIIB and correctly positioning 
it on the DNA. Moreover, x l3 1 contains 11 tetratricopeptide repeats (TPRs) which 
are known to mediate protein-protein interactions (355). Two-hybrid analysis 
showed that t131 interacts both with yBRF (82) and yB" (452). In addition, 
recombinant yBRF has been shown to bind directly to x 131 (271). Significantly, 
x l31 is one of the two subunits of yTFIIIC that has sequence similarity with a 
subunit of human TFIIIC suggesting that these interactions may be conserved. 
Indeed, the human homologue of x131, hTFIIICy, directly binds hBRF (231). It has 
also been shown to directly associate with TBP (231). In yeast, x60 interacts with 
TBP (119). In the vertebrate system interactions have also been described for 
hTFIIICe with hBRF and hTBP (231).
The assembly of TFIIIB on a yeast tRNA promoter can be reconstituted in 
vitro using isolated recombinant yeast TFIIIB subunits (266, 452). A precisely 
ordered series of interactions are required. yBRF is the first factor to associate with
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the TFIIIC/tDNA complex, followed by TBP and then B" (264). In the absence of 
BRF, TBP cannot be recruited, whereas recruitment of B" requires both TBP and 
BRF (264, 266, 452). Each step in the sequential assembly of TFIIIB on DNA is 
accompanied by changes in the photocrosslinking efficiency of xl31 and yBRF
(264). Such changes are suggestive of conformational rearrangements. This may 
explain the paradoxical ability of yeast TFIIIB, which alone has little or no affinity 
for DNA, to bind so tightly to DNA once fully assembled on the DNA by TFIIIC. It 
seems that yeast BRF contains a cryptic DNA-binding domain in its C-terminal half 
that becomes unmasked by the conformational changes that occur in the factor 
during the assembly of TFIIIB on the promoter (234). By hiding the DNA-binding 
domain, which is sequence independent, this prevents BRF from being randomly 
dispersed on irrelevant DNA sites through the genome.
In yeast, TFIIIA and TFIIIC are dispensable for transcription once they have 
recruited TFIIIB to the promoter (263). TFIIIB in turn is responsible for the 
recruitment of pol III to the promoter and correctly positioning it over the start site 
for transcription initiation. All three subunits of yeast TFIIIB are required for the 
stable recruitment of pol III however so far only yBRF has been shown to directly 
interact with the polymerase (22, 145, 271, 564). Prior to initiation, the C160, C128 
and C34 subunits of pol III are all accessible to crosslinking upstream of the start site 
and may therefore be in the close vicinity of promoter-bound TFIIIB (21, 22, 415). 
As such, these three pol III subunits constitute excellent candidates for interacting 
with TFIIIB. One of these, C34, has been shown to directly bind yBRF (271). The 
human homologue of C34, C39, interacts directly with both hBRF and TBP (554). 
The functional conservation of an interaction between TFIIIB and this subunit of pol 
III through evolution suggests that their interaction may be essential (554). In 
support of this, C34/C39 appear to play a crucial role in the recruitment of pol III to 
class III genes, which is also dependent upon interaction with TFIIIB (236, 554). 
Thus, antibodies against C34 were found to potently inhibit tRNA synthesis in vitro 
but had little effect upon nonspecific transcription of poly(dA.dT) by pol III (236). 
Furthermore, mutations in C34 that impair its interaction with yBRF also inhibited 
pol III recruitment (61). A similar role for C39 is suggested by its selective 
dissociation from human pol III by sucrose sedimentation in 0.5M KC1 or partially 
denaturing conditions as part of a stable subcomplex that also includes C62 and C32
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(554). Human pol III that has been depleted of this subcomplex is fully competent 
for transcription elongation and termination but has lost the ability to support 
promoter-directed initiation (554). Accurate initiation can be restored to the depleted 
polymerase by adding back recombinant or natural subcomplex (554). The 
homologous yeast proteins C34, C82 and C31 also form a subcomplex, which 
dissociates from yeast pol III during native gel electrophoresis (535, 565). 
Interactions between the human and yeast pol III subcomplexes and TFIIIB have 
only been detected for C34/C39 (554, 564). Recently, however, a direct interaction 
has been described between the newly identified yeast pol III subunit C17 and yBRF 
(145). C17 also interacts with C31 (145). Thus, at least two subunits of yeast pol III, 
C34 and C l7, may contribute to the specific recognition of TFIIIB by the enzyme. 
Both subunits are essential, suggesting that their roles in recruiting pol III to class III 
genes are not redundant.
The interaction site on yBRF for C34 has been mapped to the direct repeat 
region in the TFIIB-related N-terminal half of the protein (271). This region is 
highly conserved between BRF and TFIIB, raising the remote possibility that C34 
might also bind TFIIB. However, GST-pulldown assays have failed to detect an 
interaction between TFIIB and C34 (271). TFIIB performs an analogous role in pol 
II transcription to BRF in the pol III system since it is involved in the specific 
recruitment of pol II to class II promoters. Moreover, it is the direct repeat region of 
TFIIB that binds pol II (183). Importantly, C34 and C17 are both unique to pol III 
and have no similarity to any pol I or pol II subunit (145, 437, 499). This, and the 
selectivity of the interaction between BRF and C34 and that between BRF and C l7 
may be essential in defining the pol specificity of class III gene preinitiation 
complexes, although other interactions involving pol III may also be important.
Direct interactions have recently been detected between pol III and TFIIIC 
(129, 148, 230, 231). In yeast, two-hybrid screening detected an interaction between 
x l31 and the ABC 10a polymerase subunit that is found in all three nuclear pols 
(129). This has been confirmed in vitro using recombinant proteins (129). 
Additionally, a temperature sensitive mutation in ABC 10a has been shown to be 
specifically suppressed by the overexpression of a mutant form of xl31 (129). 
Furthermore, the mutation in ABC 10a was found to weaken the interaction with 
x l31 and the suppressive mutation in x l31 increased the interaction between the two
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proteins (129). Thus, the interaction between ABC 10a and xl31 appears to be 
functionally important. This is rather surprising because yeast TFIIIC is dispensable 
for transcription in vitro once TFIIIB has been recruited (263). Promoter-bound 
yTFIIIB is able to recruit pol III for multiple rounds of accurately initiated 
transcription with the same efficiency as a fully assembled transcription complex 
containing TFIIIC and, for 5S genes, TFIIIA (263). However, in a physiological 
context TFIIIB may not be sufficient and interactions between TFIIIC and pol III 
may be required. These may contribute to the recruitment of pol III or may be 
necessary for a post-recruitment function. Alternatively, in vivo, pol III may be 
recruited preassembled with TFIIIB and TFIIIC as part of a holoenzyme. The 
ABC10a-xl31 interaction may be involved in the formation and/or stability of such a 
complex. In support of the possible existence of a yeast pol III holoenzyme, Seifarf s 
group has immunopurified yeast pol III enzyme that contains immunologically 
detectable amounts of TBP, BRF and TFIIIC (83). Interestingly, this potential 
holoenzyme form contained functional amounts of TFIIIC but had to be 
supplemented with TFIIIB components for transcriptional activity (83). An 
interaction has also been detected by two-hybrid analysis between the yeast pol III 
subunit C53 and a fragment of xl31 (148), however this interaction could not be 
detected using the entire x 131 protein (129). In humans, interactions of TFIIIC8 with 
C39 and C62, and TFIIICe (homologous to x95) with C62 (homologous to yeast 
C82), have been reported (231).
The assembly of a functional preinitiation complex on class III genes is a 
slow process. Once formed however the complex is extremely stable with its 
constituent components all remaining associated after transcription initiation (40, 
154, 317, 318, 405). With pol III being the only factor that is recycled, once a 
preinitiation complex has formed on a class III gene the gene tends to be committed 
to multiple rounds of transcription (40, 154, 318). A very different situation exists 
for pol II, where most of the components of the transcription complex dissociate 
following initiation; only TFIID remains at the promoter, and the other factors must 
reassemble for each cycle (612). Clearly, the need of the class II factors to 
reassociate makes reinitiation slow and inefficient however it also provides 
considerable scope for regulating each round of transcription that is not available to 
pol III (123). The scope for regulation of transcription elongation and termination is
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also less for pol III. Whereas pol III appears to be able to carry out these two 
processes accurately and efficiently on its own, pol I and pol II both require the 
assistance of dedicated elongation and termination factors (411). After the formation 
of a stable preinitiation complex, the transcription of class III genes can proceed 
extremely rapidly. Even the recycling of pol III has been optimised such that after 
the initial round of transcription, cycles are 5- to 10- fold more rapid than the first 
(123). The polymerase is recycled without actually being released from the template; 
consequently the slow initial step of polymerase recruitment is avoided (123).
Pol III transcription is therefore notably more efficient than that of pol II and 
the level of basal pol III transcription is relatively high (568). Such transcriptional 
efficiency may be necessary to ensure that sufficiently large quantities of 5S rRNA 
and tRNA are produced to sustain adequate levels of cellular protein synthesis. 
Clearly, however, the translational requirements of a cell can vary considerably. For 
example, a cell that is actively proliferating will require substantially higher levels of 
protein synthesis than a cell that has withdrawn from the cycle and is in a state of 
quiescence. Although absolutely essential, the levels of 5S rRNA and tRNA needed 
by the cell can therefore also alter drastically. Rather than synthesise a vast excess of 
5S rRNA and tRNA to cater for variations in the amounts required of these two 
transcripts, it appears that their transcription by pol III is tightly regulated, thereby 
allowing their production to be tailored to the metabolic demands of the cell (568). 
This will reduce the energy load on the cell but also provides a potential point of 
control of the biosynthetic capacity of the cell. Pol III transcription of the other class 
III genes is also subject to regulation (568).
1.7 Regulation of RNA polymerase III transcription
A variety of proteins have been found to be able to modulate the rate of pol 
III transcription, either in a positive or a negative fashion (568). As such, these 
modulatory proteins are, potentially, regulators of pol III transcription. In support of 
this, pol III transcription has been shown to be regulated in response to changes in a 
number of different physiological conditions (569). The mechanisms which cells 
employ to regulate expression of class III genes under particular cellular and 
environmental conditions are slowly being elucidated. Many of the proteins shown
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to modulate the level of pol III transcription have been implicated. Changes in the 
chromatin structure of class III genes can also influence the level of transcription and 
may have a role in the physiological regulation of pol III transcription (569).
1.7.1 Activities that reduce pol III transcription 
Drl
Drl, a 19kDa nuclear phosphoprotein, was originally isolated from HeLa 
cells because of its ability to repress pol II transcription (242) but it has subsequently 
been shown to inhibit pol III transcription as well (576). The factor has been highly 
conserved through evolution, with 37% sequence identity between the human and 
yeast proteins, and is essential for yeast cell viability (276). Drl functions as a 
transcriptional repressor by directly binding TBP and blocking essential interactions 
made by the protein that are required for transcription (242, 276, 576, 602). For 
example, Drl inhibits pol II transcription by preventing promoter-bound TBP from 
interacting with the pol II-recruiting factor TFIIB (242). The exclusion of TFIIB 
binding to TBP is thought to result from conformational changes in the structure of 
TBP induced by the binding of Drl (370). Drl does not bind TFIIB (602) and 
contacts a surface of TBP that is spatially removed from the TFIIB-docking site 
(277). Using recombinant proteins, Drl has also been shown to interfere with the 
binding of TBP to the pol Ill-specific factor BRF (576). Thus, Drl appears to inhibit 
transcription by pols II and III by very similar mechanisms, in each case it prevents 
TBP from binding to a class-specific factor that is required for polymerase 
recruitment; TFIIB in the case of pol II and its homologue BRF in the case of pol III 
(242, 576). Unlike TFIIB though, two distinct regions of BRF contact TBP (82, 271, 
552). By analogy to its effects on TFIIB, Drl may disrupt binding to the N-terminal 
direct repeats of BRF through conformational changes in TBP. However, whereas 
TFIIB and this region of BRF interact with TBP at a site distinct from that bound by 
D rl, the C-terminal domain of BRF appears to make a pol Ill-specific high-affinity 
interaction with the basic repeat region of TBP, the very same region to which Drl 
binds (271). Point mutagenesis indicates that the binding sites of Drl and BRF in the
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basic repeat region of TBP extensively overlap (64, 271, 277). Thus, BRF and Drl 
are in direct competition for binding this region of TBP.
By targeting TBP and being able to repress both pol II- and pol III- 
transcription Drl has the potential to coordinately regulate the transcriptional 
activities of these two polymerases (576). TBP is also required for pol I transcription 
as part of the basal factor SL1 (103). However, whereas the addition of highly 
purified recombinant or native Drl to human extracts was found to potently repress 
the expression of a variety of different class III genes including tRNA, VA and U6, 
pol I transcription of rRNA under the same conditions was unaffected (576). 
Similarly, the overexpression of Drl in yeast was found to inhibit tRNA synthesis 
but had no discernible effect on pol I transcription (276). In contrast to pols II and 
III, pol I transcription is seemingly immune to the repressive effects of Drl. By 
selectively inhibiting pols II and III, Drl may be able to shift the balance of nuclear 
transcription in favour of pol I, which could be of considerable value when rRNA 
levels are limiting.
RB
The retinoblastoma protein, RB, a 105kDa nuclear phosphoprotein (324), was 
the first tumour suppressor to be identified, over a decade ago (153). The 
retinoblastoma susceptibility gene that encodes RB was initially cloned because of its 
association with an inherited predisposition to retinoblastoma, a rare paediatric 
tumour of the retina (153). Individuals who inherit a non-functional allele of the Rb 
gene have a roughly 90% chance of developing retinoblastoma at an early age (580). 
For retinoblastoma to actually arise, however, this requires the inactivation of the 
remaining allele of the Rb gene, since inactivating mutations in Rb are recessive 
(580). Loss of RB function appears to be a universal feature of both the familial and 
sporadic forms of this tumour and is likely to be the rate-limiting step in its initiation 
(226). Inactivating mutations in both alleles of the Rb gene have also been identified 
in a variety of other human cancers including many sarcomas, bladder and small cell 
lung carcinomas (226, 557, 580). In many other human malignancies a wild-type Rb 
allele is retained, but RB function is still disrupted, for example because of the
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association of RB with viral oncoproteins or the hyperactivity of cyclin-dependent 
kinases that switch off RB (557).
The ability of RB to function as a tumour suppressor can be explained by its 
normal roles in the cell. Thus, RB suppresses both the proliferation (increase in 
number) and the growth (increase in mass) of cells and is involved in ensuring that 
the cell does not divide and grow when conditions are unfavourable (557). When RB 
function is missing, the ability of cells to arrest proliferation and growth is severely 
compromised and the cell is less sensitive to normal regulatory signals; these 
changes constitute a major step towards carcinogenesis (482, 557, 580). RB is also 
implicated in promoting cell differentiation, which may also contribute to its tumour 
suppressor functions (95, 214, 245, 322). All of these functions of RB appear to be 
at least partly attributable to the effects of RB on gene expression (173, 214, 290). 
For example, RB is able to cooperate with certain transcription factors such as C- 
EBP family members and MyoD to activate the transcription of a number of pol II- 
transcribed genes involved in differentiation (179, 475).
RB is a highly abundant protein and can bind and regulate a variety of 
transcription factors (214, 290). One of the key targets of RB is the factor E2F (3, 
131, 305, 310, 556). E2F activates the expression of a range of pol II-transcribed 
genes that are important for cell cycle progression (3, 131). These include several 
genes that are required for DNA replication, such as those encoding DNA 
polymerase a  and the replication origin-binding protein HsOrcl, as well as genes 
that drive the cell cycle such as cdc2 and various cyclins. RB can bind to E2F, 
inactivating it, and can form a repressive complex that actively inhibits the 
transcription of these E2F-responsive genes that are required for passage through the 
cell cycle, thereby providing a possible explanation as to how RB is able to constrain 
cell proliferation (3, 131). The effects of RB on gene expression are not restricted to 
pol II-transcribed genes, however. RB can directly inhibit transcription by all three 
nuclear RNA polymerases (Fig. 1.2) (313, 566, 567). Whereas only a very restricted 
number of genes transcribed by pol II are inhibited by RB, it appears to be a general 
repressor of pol III transcription (314, 579). In a growing cell, pols I and III are 
responsible for -80% of total RNA synthesis (411). The bulk of this is devoted to 
the production of rRNA and tRNA, which are essential components of the 
translational machinery. By limiting the production of these, RB may be able to
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Figure 1.2
Suppression of cell growth and proliferation by RB
The pol II transcription factor E2F promotes the expression of a variety of genes 
required for cell cycle progression. These include the genes that encode for DNA 
polymerase a  (DNA pol a), dihydrofolate reductase (DHFR), thymidine kinase 
(TK), cdc2 and various cyclins. RB, by inhibiting E2F, can suppress transcription of 
these E2F-responsive genes thereby providing a brake on cellular proliferation. In 
addition, RB also represses the pol I factor UBF and the pol III factor TFIIIB thereby 
reducing the synthesis of rRNA and tRNA, important determinants of the 
biosynthetic capacity of the cell. By restraining protein synthesis, this may provide a 
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suppress the level of protein synthesis, which could provide a brake on cellular 
growth (313, 567). Careful measurements in animal cells have demonstrated that the 
rate of growth is directly proportional to the rate of protein accumulation, the main 
determinant of which is protein synthesis, although turnover also makes a 
contribution (27).
The ability of RB to repress pol III transcription was initially demonstrated in 
vivo by transient transfection experiments (579). The overexpression of RB was 
found to reduce transcription of the adenoviral VAi gene whereas transcription of a 
cotransfected CAT gene under the control of the pol II-transcribed human 
immunodeficiency virus promoter was unaffected (579). Clearly, however, this 
inhibitory effect of RB on pol III transcription observed in vivo could be very 
indirect, perhaps resulting from cell cycle changes. It was therefore tested whether 
RB could repress pol III transcription when reconstituted in vitro using partially 
purified fractions (579). This was indeed shown to be the case, suggesting that one 
or more components of the pol III transcriptional apparatus may be a direct target for 
regulation by RB.
These results showed for the first time that high levels of RB can inhibit pol 
III transcription. However, the possibility existed that the repression observed in 
vitro and in vivo is simply an artefact of overexpression. It was therefore very 
important to determine whether RB can influence pol III transcription when present 
at physiological concentrations within a cell. To address this, the pol III activity of 
two human osteosarcoma cell lines was compared; U20S, which contain functional 
wild-type RB, and SAOS2, which only express a truncated non-functional form of 
RB (579). SAOS2 cells were found to express a transfected VAi gene ~5-fold more 
actively than U20S (579). The higher pol III activity of the RB-deficient SAOS2 
cells was confirmed in vitro using cell extracts (579). In addition, primary 
fibroblasts from knockout mice in which the Rb gene had been inactivated by site- 
directed mutagenesis were shown by nuclear run-on assays to synthesise tRNA and 
5S rRNA at ~5-fold higher rates than equivalent cells from wild-type mice (579). In 
contrast, the overall level of pol II transcription was unchanged. Extracts prepared 
from the Rb-negative cells also displayed higher levels of pol III activity, providing 
independent confirmation that the pol III transcriptional apparatus is more active in 
the absence of RB (579). Since the only genetic difference between the Rb+/+ and 
Rb"/_ fibroblasts is the presence or absence of the Rb gene, it can be concluded from
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these results that endogenous RB plays a major role in suppressing pol III 
transcription in vivo. What is less clear is to what extent this may contribute to 
growth control by RB. However, multiple components of the translational apparatus 
are frequently deregulated in cancer cells, suggesting that regulation of protein 
synthesis is an important aspect of growth control (445, 494). There is also a 
correlation between the ability of RB to function as a tumour suppressor and its 
ability to affect pol III transcription (579). Thus, the minimal region of RB that is 
necessary to regulate cell growth and proliferation is also sufficient to repress pol III 
transcription (579). Moreover, four naturally occurring and highly localised 
mutations that inactivate RB in human cancers were each found to prevent RB from 
regulating pol III transcription (59, 579). However, it has yet to be demonstrated that 
tRNA and rRNA levels are ever limiting for protein synthesis in mammalian cells 
under normal physiological conditions. Nevertheless, the production of tRNA and 
rRNA does increase following mitogenic stimulation and decreases when cells 
quiesce, suggesting that their levels are closely regulated in accordance with the 
biosynthetic requirements of the cell (96, 255, 363, 445). In the yeast 
Saccharomyces cerevisiae, tRNA levels clearly can be limiting; a two-fold reduction 
in the level of initiator tRNA was found to result in a three-fold increase in cell 
doubling time (152). If similar is true of a mammalian cell, the 5-fold decrease in 
tRNA levels imposed by endogenous RB (579) could be a major constraint on 
cellular growth.
Apart from tRNA, 5S rRNA and VAi genes, RB has also been shown to 
inhibit transcription of B2, U6, EBER2, 7SK, and Alu genes (93, 215, 314, 503, 
579). In fact, every pol III template tested has been found to be inhibited by RB. 
Clearly, RB is effective in repressing transcription from all categories of pol III 
promoter, suggesting that it may target one of the general pol III transcription factors, 
or pol III itself, in order to achieve repression (314).
To try and determine which component(s) of the pol III transcriptional 
apparatus are targeted by RB, add-back experiments were performed to see if any of 
these could restore pol III transcription reconstituted in vitro in the presence of RB 
(314). Indeed, the addition of increasing amounts of a partially purified TFIIIB 
fraction was found to relieve inhibition of VAi transcription by recombinant RB in a 
dose-dependent manner (314). In contrast, the addition of partially purified pol III or 
TFIIIC, the latter of which is limiting in the absence of RB, had no effect (314).
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These results suggested that RB specifically targets TFIIIB for repression. In support 
of this, in pull-down assays GST-RB was shown to bind TBP and BRF (314). 
Furthermore, immunoprecipitation and cofractionation experiments have shown that 
endogenous RB and TFIIIB interact stably (314). This association is diminished or 
abolished in SAOS2 cells, which contain only a nonfunctional mutant form of RB 
(314). In addition, complementation assays have found that TFIIIB activity is 
significantly elevated in primary fibroblasts from Rb7' mice (314). In contrast, little 
or no difference is detected in TFIIIC2 B-block-binding activity between the Rb- 
positive and Rb-negative cells (314). Thus, endogenous RB also specifically inhibits 
TFIIIB. Since TFIIIB is required for the transcription of all class III genes, this 
provides a possible explanation as to how RB may act as a general repressor of pol 
III transcription, although the mechanism by which RB inactivates TFIIIB has yet to 
be determined (314). However, whereas the majority of class III genes utilise the 
same form of TFIIIB as VAi, recent data indicates that those templates with a type III 
promoter, such as the vertebrate U6 snRNA gene, utilise a different form of TFIIIB 
(365, 463, 515). At present it is unclear whether RB inhibits this form of TFIIIB as 
well. Alternatively, RB might repress transcription of these genes by targeting a 
different factor(s).
Hirsch et al. recently reported that RB and SNAPc physically interact (215). 
Moreover, they showed that TBP, or more effectively, a combination of TBP and 
SNAPc, is able to restore pol III transcription of the human U6 snRNA gene to RB- 
treated extracts (215). These results suggest that RB represses transcription of class 
III genes with external promoters, such as U6, by targeting TBP and/or SNAPc 
(215). However, the possibility remains that RB may also inhibit the form of TFIIIB 
utilised by type III promoters and that this also contributes to RB repression of these 
genes. Nevertheless, the fact that RB can inhibit SNAPc function, which is not 
required for transcription of pol III templates with type I or type II promoters, 
suggests that one or more class III genes with a type III promoter may be an 
important target for RB function. This is very unlikely to be true for all the different 
class III genes repressed by RB. Instead, this blanket repression of pol III 
transcription may simply be the indirect consequence of RB targeting a general 
component of the pol III transcriptional apparatus in order to repress functionally 
important targets such as 5S rRNA and tRNA genes.
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Recently, it has also been demonstrated that p i07 and p i30, which are 
structurally and functionally related to RB, also inhibit pol III transcription when 
overexpressed, both in vitro and in vivo (504). In addition, primary fibroblasts 
derived from p i07 p i30 double knockout mice were found to display elevated pol III 
transcriptional activity (504).
p53
Another important tumour suppressor, p53, which is unrelated to RB, also represses 
pol III transcription (70, 90). The gene that encodes p53 is highly conserved 
amongst vertebrate species; it also holds distinction as the most frequently mutated 
gene in human cancers (284). In fact, p53 is lost or mutated in over half of all human 
malignancies (222, 223). Like RB, wild-type p53 can arrest cell growth and 
proliferation (108, 358, 369, 372). However, whereas RB function is required every 
cell cycle as part of the normal proliferative and growth control, p53 function is more 
that of an emergency checkpoint control against aberrant growth and neoplastic 
transformation that is only occasionally needed (284). That p53 is not an essential 
cell cycle regulator is demonstrated by the viability and normal development of p53'A 
mice (127). However, these mice have a propensity to cancer, such that 74% 
develop tumours by the age of six months (127). Clearly, the inactivation of p53 can 
play a crucial role in carcinogenesis. Li-Fraumeni individuals, who carry a germ-line 
mutation in p53, are highly cancer-prone (284).
Under normal conditions, very little p53 protein is found in most of the cells 
of the body and much of it is in a latent form (332). However, on exposure of cells 
to certain stress stimuli such as DNA damage, cellular or viral oncogene activity, or 
hypoxia, active p53 protein rapidly accumulates and will either induce a growth 
arrest or apoptosis (284, 332). p53 is activated in response to such stimuli because 
cells that are exposed to these stresses commonly contain potentially carcinogenic 
mutations and exhibit abnormal cell behaviour, and are more likely to become 
cancerous. The ability of p53 to arrest cell growth or trigger apoptosis, by analogy to 
RB tumour suppressor functions, appears to be mediated, to a large extent, by 
changes in gene expression (284, 332).
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p53 is a transcription factor and can regulate the expression of a variety of 
genes (284, 332). It can bind DNA both in a sequence-specific manner and non- 
specifically, and is capable of both activating and repressing transcription depending 
on the gene (284, 332). Genes activated by p53 contain p53-binding sites in their 
promoters. These include pol II-transcribed genes encoding proteins that are 
involved in inhibiting cell cycle progression such as the cyclin-dependent kinase 
inhibitor p21/WAF1, which can block both the Gi/S and the G2/M cell cycle 
transitions, and pro-apoptotic genes such as Bax (284, 332). In addition, p53 can 
specifically repress a number of pol II-transcribed genes devoid of p53 recognition 
sequences, including those that encode c-fos, PCNA, and cyclin A, all of which are 
involved in promoting cell cycle progression (284). Both the transcriptional 
activation and transcriptional repression activities of p53 are therefore likely to 
contribute to the ability of p53 to function as a tumour suppressor. The vast majority 
of p53 mutations found in human cancers map to the sequence-specific DNA binding 
domain of p53 (284). The ability of these mutants to activate transcription is 
severely impaired (284). However, several tumour-derived mutants have also been 
found that can still stimulate transcription but are incapable of transcriptional 
repression (453). Furthermore, two oncoproteins have been shown to block p53- 
mediated transcriptional repression but have no effect on transcriptional activation by 
p53 (108). These results suggest that both transcriptional activities of p53 are 
targeted in carcinogenesis.
Transcriptional repression by p53 is not restricted to a few select genes 
transcribed by pol II however; p53 can also inhibit genes transcribed by pols I and III 
(62, 70, 90). The overexpression of p53 has been shown to repress transcription of a 
variety of class III genes both in vitro and in transfected cells (70, 90). Using gene 
knockout technology to disrupt the p53 gene, a physiological role for p53 in 
suppressing pol III transcription has also been demonstrated (70). Thus, a 
comparison of the rates of transcription in intact nuclei from p53+/+ and p53'/_ mouse 
embryonic fibroblasts revealed that the rate of synthesis of tRNA and 5S rRNA is 4- 
and 6- fold higher, respectively, in the p5 3-negative cells (70). Endogenous p53 has 
also been shown to inhibit transcription of various other pol III templates and appears 
to be a general repressor of pol III transcription (70). However, the class III genes 
display differential sensitivity to the repressive effects of p53 (70, 90). This has been 
observed both in vitro using recombinant p53 and when extracts from p53+/+ and
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p53"A cells are compared (70). There appears to be an inverse correlation between 
sensitivity to p53 and promoter strength. In vivo, this may enable p53 to 
differentially regulate pol III transcription, with genes such as Alu and U6 that have 
particularly weak promoters becoming inhibited at a lower p53 threshold than other 
genes.
Like RB, p53 appears to repress pol III transcription by binding and 
inactivating TFIIIB (70, 90). Thus, TFIIIB activity is specifically elevated in 
fibroblasts derived from p53 knockout mice (70). Moreover, add-back experiments 
revealed that TFIIIB is limiting in extracts from the equivalent wild-type cells so the 
rise in TFIIIB activity in response to disruption of the p53 gene should stimulate 
transcription (70). In addition, the inhibition of pol III transcription in vitro by 
recombinant p53 has been shown to be specifically relieved by the addition of excess 
TFIIIB (70). However, it remains possible that other components of the pol III 
transcriptional apparatus are additionally targeted and contribute to the repressive 
effects of p53. Endogenous TFIIIB and p53 have also been shown to stably 
associate, providing further support for regarding TFIIIB as a bona fide target of p53 
(70). Pull-down assays using GST-p53 fusion proteins have shown that the N- 
terminal 73 amino acids of p53 are sufficient to bind TFIIIB (90). This N-terminal 
region of p53 contains a TBP binding domain, suggesting that p53 directly binds 
TBP within TFIIIB (337, 528). In support of this, point mutations within this N- 
terminal region that abolish the binding of free TBP also abolish TFIIIB binding 
(90). Significantly, these same mutations also abrogate the ability of p53 to repress 
pol III transcription (90).
The inhibition of pol III transcription, by reducing the levels of tRNA and 5S 
rRNA, may contribute to growth suppression by p53 (70). However, although p53 is 
frequently mutated in human cancers, it remains to be determined whether or not the 
regulation of pol III transcription by p53 is compromised by these mutations and 
therefore the extent to which this control may contribute to the tumour suppressor 
function of p53. In addition, it is presently unknown how the regulation of pol III 




The cyclin-dependent kinase p34cdc2/cyclin B1 has been immuno- and 
affinity- purified from mitotic Xenopus extracts (169, 587). Both purified sources of 
p34cdc2 have been shown to potently inhibit 5S rRNA transcription (169, 587); in 
contrast, immunopurified MAP kinase had no discernible effect on transcription 
(587). In addition, the affinity-purified p34cdc2 has been shown to specifically 
inactivate TFIIIB when incubated with fractionated Xenopus pol III factors (169). 
This is dependent upon phosphorylation, since repression could be blocked by the 
general kinase inhibitor DMAP and reversed by alkaline phosphatase (169).
1.7.2 Activities that stimulate pol III transcription 
Staf
Staf, like Octl, can activate both pol II- and pol III transcription (375, 392, 
393, 458, 466). It contains seven tandemly repeated zinc fingers; these enable Staf to 
bind specifically to DNA (466). Staf recognition sites are found in the DSEs of 
vertebrate U snRNA and 7SK genes, commonly located close to an octamer motif, 
which binds Octl (458). It has been suggested that Staf may function co-operatively 
with Octl because their respective binding sites can activate transcription 
synergistically when appropriately spaced (458).
In addition to Staf and Octl, several other pol II factors that bind DNA in a 
sequence-specific manner have been implicated as potential regulators of pol III 
transcription on the basis of sequence motifs found in the promoters of class III 
genes. For example, GC boxes that resemble Spl binding sites are found in the 
promoters of the EBER2, mammalian 5S and Xenopus U6 genes (228, 330, 495). 
Spl is one member of a family of related factors that share similar DNA-binding 
specificities. It remains to be determined which, if any, of these factors can influence 
the expression of these genes with Spl-like binding sites. Nevertheless, two tandem 
copies of a Spl activation domain have been shown to activate U6 transcription 
when fused to a heterologous DNA-binding domain (113). In the pol II system, the
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response to upstream activators is commonly mediated by specific TAFs in the 
TFIID complex that are otherwise dispensable for transcription. For example, 
activation by VP 16 requires direct contact with TAFn40 (166); similarly, Spl 
activation is dependent upon a direct interaction with TAFullO (220). Perhaps 
TFIIIB contains a functional homologue of TAFullO; alternatively, the activation 
domain of Spl may contact different component(s) of the pol III transcriptional 
apparatus (568).
Another example of pol II factors that may be involved in pol III transcription 
are members of the ATF and CREB family that bind ATF sites (54). The promoters 
of EBER2 and 7SL genes contain several ATF sites, which are important for high 
levels of expression of these genes (51, 228). In support of this possibility, extracts 
from cells treated with forskolin, which can activate a subset of these factors through 
activation of the cAMP signal transduction pathway, were found to support increased 
levels of 7SL transcription, but to have no effect on 7SK, whose promoter is devoid 
of ATF sites (51).
Protein phosphatase 2A
The substrate specificity of protein phosphatase 2A (PP2A) is thought to be 
defined by its regulatory subunits (100). The TPD3 gene encodes the regulatory 
subunit A of PP2A (537). Strains of Saccharomyces cerevisiae that lack the TPD3 
gene are severely compromised for growth (537). A temperature sensitive tpd3 
strain (tpd3ts) was found to stop synthesising tRNA, an important determinant of the 
biosynthetic capacity of the cell, at the nonpermissive temperature; similarly, extracts 
prepared from these cells were also unable to transcribe tRNA (537). Extracts from 
tpd3ts cells grown at the permissive temperature were 2- to 4- fold less active for 
tRNA synthesis than wild-type cells. Transcription could be fully restored to wild- 
type levels in these extracts by the addition of partially purified TFIIIB, whereas pol 
III was partially stimulatory and TFIIIC had no effect (537). Mixing experiments 
indicate that the defect in tpd3ts cells is due to an inhibitory activity rather than the 
loss of a transcription component (537). These results suggest that PP2A positively 
regulates pol III transcription in yeast and that it does so by stimulating TFIIIB 
activity and, to a lesser extent, pol III (537). The inhibitory activity in the ts extracts
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is probably a kinase that phosphorylates and inactivates TFIIIB and perhaps pol III, 
whose repressive influence is normally antagonised by PP2A.
CKII
The highly conserved Ser/Thr protein kinase CKII has also been shown to 
stimulate pol III transcription in the yeast Saccharomyces cerevisiae (163, 164, 216). 
CKII functions primarily as a tetramer, consisting of two isozymic catalytic subunits 
(a  and/or a ')  and two regulatory subunits (P) (7, 419). The regulatory subunits of 
CKII are required for optimal kinase activity and also regulate substrate specificity. 
As for PP2A, a positive role for CKII in yeast pol III transcription was initially 
suggested by the phenotype of a yeast strain with a temperature sensitive lesion in 
one of the subunits of the protein (216). Thus, when a yeast mutant with a ts defect 
in the catalytic a ' subunit of CKII (cka2ts) was shifted to the nonpermissive 
temperature, tRNA synthesis and growth both declined, whereas production of large 
rRNA was unaffected (216). Similarly, extracts prepared from cka2ts cells were 
found to be severely compromised for transcription of tRNA and 5S rRNA genes, 
whereas pol I and basal pol II transcription was as efficient as in extracts from wild- 
type cells (216). Moreover, the addition of increasing amounts of purified wild-type 
CKII to cka2ts extracts stimulated tRNA and 5S rRNA transcription, providing direct 
evidence of a positive role for CKII in pol III transcription (216). Add-back 
experiments using purified pol III factors from wild-type cells showed that 
transcription could also be restored to cka2ts extracts by the addition of TFIIIB (163, 
164). However, pretreatment of TFIIIB with phosphatase abolished its ability to 
rescue transcription (164). These results suggest that CKII stimulates pol III 
transcription by phosphorylating TFIIIB. In vitro phosphorylation of a partially 
purified TFIIIB fraction with recombinant CKII suggested that the TBP subunit of 
TFIIIB is the preferred substrate of CKII (163, 164). CKII was also found to 
efficiently phosphorylate recombinant TBP (163, 164). Moreover, limiting amounts 
of CKII and recombinant TBP were found to synergistically increase pol III 
transcriptional activity in cka2ts extracts, suggesting that the stimulatory effect of 
CKII on yeast pol III transcription is mediated, at least in part, by the
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phosphorylation of the TBP subunit of TFIIIB (163, 164). However, the 
phosphorylation of other components of TFIIIB, or indeed other components of the 
pol III transcriptional apparatus, may also contribute to the stimulation of pol III 
transcription by CKII (163, 164).
1.7.3 Repression by chromatin
A human diploid cell contains ~6.4 x 109 base pairs of DNA. In a molecule 
of DNA adjacent base pairs are separated by 3.4A, so if all 6.4 x 109 bp were part of 
the same DNA molecule it would stretch a staggering 2.2 metres in length. Since the 
nucleus is only ~10pm in diameter, clearly the DNA must be highly compacted so as 
to actually physically fit it inside the nucleus! In order to stably bend the DNA, 
however, the negatively charged phosphates of the DNA phosphodiester backbone 
must be neutralised so as to overcome charge repulsion when different regions of the 
polyanionic DNA are brought close together. In the eukaryotic cell this is achieved 
by the association of the DNA with highly conserved, small basic proteins called 
histones. Histones are unique to eukaryotes and are amongst the most invariant 
proteins known. They bind DNA essentially without sequence specificity enabling 
the packaging of the entire genome into a highly condensed structure called 
chromatin.
The non-specific binding of histones to DNA is not random, as revealed by 
the ‘beads on a string’ chromatin structure observed by electron microscopy when 
chromatin is released from nuclei at low ionic strength (520). This is the first level 
of packing of DNA (~6-7 fold), the lOnm filament. The ‘beads’, which are regularly 
spaced, represent nucleosomes. The nucleosome is the basic unit of structure in 
chromatin (288). It consists of a wedge-shaped histone octamer around which two 
turns of DNA are organised. The crystal structure of the nucleosome has recently 
been determined at a resolution of 2.8A, revealing details of the histone-histone and 
histone-DNA interactions (345). The histone octamer consists of two molecules 
each of the four core histones, H2A, H2B, H3 and H4. A central (H3/H4)2 tetramer 
is flanked on either side by a H2A/H2B dimer (288, 520). Each of these histones has 
a very similar C-terminal domain structure, the “histone fold”, consisting of a long
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central a  helix that forms the dimerisation interface flanked by shorter helices and 
loops (345). Histone dimerisation creates the DNA-binding surfaces. The N- 
terminal “tails” protrude outside the nucleosome and interact with both nucleosomal 
and linker DNA, and adjacent nucleosomes (345). In addition, there is a fifth type of 
histone molecule associated with the nucleosome, the so-called linker histone, which 
is the least conserved of the histones (520). The majority of cells contain the histone 
HI. However, there are a number of HI variants which tend to be cell- or 
developmental stage-specific; these include H I0 found only in differentiating 
mammalian cells, sea urchin sperm-specific HI, and H5 which is unique to avian 
erythrocytes (520). All the variants share the same basic structure, consisting of a 
central globular domain flanked on either side by a highly basic tail. The central 
globular domain is thought to seal the two turns of DNA around the nucleosome, 
accounting for the protection of DNA at the dyad axis of the nucleosome from 
digestion by DNase I (520). Recently two DNA binding sites on the globular 
domain of H5 have been identified (172), this explains the preference of this linker 
histone for four-way junction DNA (520). The highly basic tails of the linker histone 
are thought to interact with the linker DNA between nucleosomes, thereby allowing 
the linker DNA to be easily bent.
The majority of interphase chromatin exists not as the lOnm filament but in a 
more condensed state, the so-called 30nm filament or solenoid (DNA packing ratio 
-40 fold) (520). There has been some controversy over the exact structure, but most 
of the evidence supports the coiling of the lOnm filament into a helix with -  6 
nucleosomes per turn (520). It has been demonstrated that HI or one of its variants 
is essential for the formation of the 30nm filament. Chemical cross-linking and 
neutron diffraction studies suggested formation of a HI ‘polymer’ within the 
solenoid (520). There is also evidence for several further levels of chromatin 
organisation above that of the 30nm filament, finally culminating in the structure of 
the metaphase chromosome, the most condensed state of chromatin (520).
The packaging of DNA into chromatin is a major obstacle to transcription, 
severely restricting the access of the transcriptional machinery to the DNA (568, 
588). Thus, class III genes assembled into solenoid-like structures in vitro are 
incapable of supporting significant levels of transcription. In vivo, both transcription 
and DNA replication are thought to require the decondensation of chromatin to the
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lOnm filament (520). At this level of chromatin organisation, the susceptibility of 
different genes to nucleosomal repression can vary considerably. To a large extent 
this depends on the positioning of nucleosomes over the gene (203, 588). Thus, a 
gene whose promoter is located within the centre of a nucleosome is more likely to 
be repressed than one whose promoter is located at the edge of a nucleosome or is 
nucleosome-free. Although histones bind DNA non-specifically and nucleosomes 
are regularly spaced along the DNA, there is considerable evidence for sequence- 
directed positioning of nucleosomes on DNA. This is related to the intrinsic 
bendability of the DNA sequence, that is the energy of bending DNA, which can 
vary substantially between different sequences (203). In addition, the locations of 
nucleosomes are sometimes constrained by “boundary” effects such as the binding of 
sequence-specific factors on the DNA that can compete effectively with histones 
(203). The extent to which the transcription factors of a gene can compete with 
histones is also a major determinant of susceptibility to chromatin repression.
5S rRNA genes
Transcription complex formation on a 5S rRNA gene is nucleated by the 
sequence-specific binding of TFIIIA (568). The surface of interaction between 
TFIIIA and the 5S rRNA gene is extensive. TFIIIA protects ~1 turn of DNA at each 
end of the 5S ICR, wrapping around all faces of the helix at the A- and C- block with 
the intervening 20 bp protected only on one face (203, 568). Clearly, this wrapping 
of TFIIIA around the DNA is incompatible with the simultaneous wrapping of the 
same region of DNA around a histone octamer. Significantly, however, the 
sequences of Xenopus 5S genes direct the positioning of nucleosomes on or near the 
ICR (202, 321). Thus, TFIIIA and histone octamers may directly compete for 
binding the ICR. The outcome of this competition will have a major effect on the 
potential transcriptional activity of these genes.
Once an active transcription complex or repressive chromatin structure has 
been established on a class III gene, either can be extremely stable. However, the 
passage of a replication fork displaces all bound factors (590). Therefore, at each 
cell cycle there is the opportunity to either reestablish or alter the set of genes that are 
actively expressed. Although the core histones have been shown to be sufficient to
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establish a repressed transcriptional state of 5S rRNA genes refractory to the 
subsequent addition of transcription factors in vitro, under certain circumstances 
stable repression may also require the linker histone (460). The linker histone 
inhibits nucleosome sliding, which can allow transcription factors to gain access to 
promoters (533). It can also repress transcription by directly occluding regions of 
DNA and promoting nucleosome compaction (591). For human 5S rRNA genes, 
binding of TFIIIA has been shown to be sufficient to prevent incorporation into a 
repressive chromatin state (501).
tRNA genes
The assembly of nucleosomes on tRNA genes in vitro has been shown to 
potently repress transcription (298). However, in vivo tRNA genes are highly 
resistant to repression by histones (45, 189, 384). For example, manipulating the 
level of histone HI in Xenopus embryos has no effect on tRNA expression (45). 
Similarly, a nucleosome deficiency in yeast that activates several class II genes does 
not affect tRNA synthesis (189). Moreover, a wild type yeast tRNA gene fused to 
nucleosome positioning signals capable of suppressing pol II transcription and the 
initiation of DNA replication was found to remain transcriptionally active in yeast 
cells (384). However, the ability of the gene to override these signals was lost on 
mutation of the B-block (384). This is highly significant in light of recent in vitro 
data from the human pol III system. Thus, Roeder and colleagues have shown that 
elevated amounts of highly purified hTFIIIC, the major B-block binding activity, can 
effectively overcome nucleosome-mediated repression of a human tRNAMet gene in 
vitro (298). Moreover, they also report that three subunits of hTFIIIC possess weak 
histone acetyltransferase (HAT) activity (231, 298). Histone acetyltransferases 
catalyse the acetylation of specific lysine residues in the N-terminal tails of the core 
histones (177). This reduces the positive charge of these highly basic tails and has 
been shown to weaken histone-DNA interactions and also interactions between 
nucleosomes (591). The acetylation of core histones assembled onto 5S rRNA genes 
in vitro overcomes the ability of these histones to exclude the binding of TFIIIA, 
thereby allowing transcription to proceed (321, 534). Thus, histone acetylation can 
facilitate the binding of transcription factors to their promoter elements in chromatin
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(321). However, it has yet to be demonstrated that the reported HAT activity of 
hTFIIIC contributes to its ability to relieve the chromatin-mediated repression of a 
human tRNAMet gene in vitro or has any role in vivo.
Yeast U6 genes
The Saccharomyces cerevisiae U6 gene is also highly resistant to the 
repressive effects of chromatin (357). Thus, the deletion of the histone H4 gene has 
no effect upon the level of U6 snRNA expression (357). However, mutant U6 genes 
with weakened promoters are susceptible to repression (357). The promoter of yeast 
U6 gene is highly unusual, with a TATA box at -30 and a B-block downstream of 
the transcription termination site (57). Significantly, a functional B-block and 
TFIIIC are only required for U6 transcription in the presence of histones, suggesting 
a dominant role of this interaction in protecting the U6 gene from chromatin- 
mediated repression (66). The assembly of nucleosomes on the yeast U6 gene in 
vitro by a Xenopus egg extract represses transcription (66). However, TFIIIC can 
compete effectively with histones even after the incorporation of the gene into 
chromatin and transcription is restored by the subsequent addition of affinity-purified 
TFIIIC (66). Thus, both human and yeast TFIIIC have major roles in relieving 
chromatin-mediated repression (66, 298). Preliminary investigations by Sentenac’s 
group have failed to detect any histone acetyltransferase activity associated with 
yeast TFIIIC (83). It may be that yeast TFIIIC and human TFIIIC counteract 
chromatin repression by different mechanisms. Alternatively, the reported HAT 
activity of hTFIIIC may not be involved in alleviating the repressive effects of 
chromatin.
5S rRNA genes also utilise TFIIIC; however, these genes are much more 
susceptible to nucleosomal repression than tRNA or yeast U6 genes. The addition of 
TFIIIA and TFIIIC makes no difference once a 5S rRNA gene has been incorporated 
into a chromatin structure (568). However, these genes lack a B-block and TFIIIC 
does not bind DNA directly, but depends on the prior binding of TFIIIA.
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SINEs
In chromatin isolated from interphase HeLa cells, the majority of tRNA and 
5S rRNA genes are accessible to transcription factors, whereas -99% of Alu genes 
with functional promoters are silenced and inaccessible to exogenous factors (451). 
The majority of potentially active copies of SINEs are thought to be constitutively 
masked by chromatin. This may be of considerable importance to the cell. The 
genomes of higher eukaryotes contain a vast number of SINEs. For example, there 
are -500,000 Alu elements in the haploid human genome, 5% of the total genetic 
material of the cell (251). Such a huge number of templates are potentially an 
enormous sink for transcription factors. Competition between the SINEs and 
essential class III genes for a limiting number of transcription factors might therefore 
be highly detrimental to the cell; hence the packaging of SINEs into repressive 
chromatin structures inaccessible to transcription factors. SINEs are extremely 
susceptible to nucleosomal repression. Silencing of Alu elements by histone 
octamers is so efficient that the depletion of HI from chromatin of HeLa cells raises 
Alu expression by only 2-fold (451). The Alu sequence directly positions a histone 
octamer over the start site and A-block, potently repressing transcription (135, 136).
DNA methylation may also be involved in chromatin-mediated repression of 
SINEs. Transcriptional repression by CpG methylation is closely correlated with 
alterations in chromatin structure (367, 510). Alu sequences contain an unusually 
high CpG density, and account for -  one-third of all potential methylation sites in 
human DNA (136). The methylation of Alu genes has been shown to repress their 
transcription in vitro (285). Most Alu genes are highly methylated in vivo (285, 
461). Moreover, a reduction in the methylation of Alu genes in HeLa cells, 
stimulated by the treatment of cells with 5-azacytidine which cannot be methylated, 
was accompanied by a 5- to 8- fold increase in the abundance of Alu transcripts 
(335). The mechanism by which methylation of Alu genes inhibits their transcription 
is poorly understood. However, repression in vitro can be relieved by the presence 
of methylated competitor DNA, suggesting that the inhibition is due to proteins that 
specifically bind to methylated DNA, such as MeCPl or MeCP2 (37, 336, 367, 510). 
It also involves changes in chromatin structure, causing a 20-fold increase in the 
efficiency with which a histone tetramer can block transcription factor access to an 
Alu promoter and repress transcription (136).
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Clearly, the chromatin structure of a gene can be a major determinant of its 
transcriptional activity and is therefore an obvious target for regulation. Although 
chromatin exerts a general repressive effect upon pol III transcription, the class III 
genes display differential sensitivity to these effects providing the opportunity for the 
differential regulation of class III genes by subtle changes in chromatin structure. 
The structure of chromatin in the cell is dynamic; moreover, it can be modified 
locally. A variety of chromatin remodelling factors have been identified. One major 
group is the ATP-dependent remodelling factors that include NURF, SWI-SNF, ACF 
and CHRAC (591). These are thought to facilitate transcription factor access by 
destabilising the nucleosome or altering its position. The other major group is the 
histone acetyltransferases (HATs) and their enzymatic antagonists the histone 
deacetylases (177, 500, 591). In recent years, a growing number of coactivators 
involved in pol II transcription have been found to possess HAT activity. Moreover, 
the HAT activity of two of these factors has been shown to be an essential part of 
their coactivator function (303, 357). Conversely, several transcriptional 
corepressors have been found to exist in complexes with histone deacetylases (5, 52, 
53, 144, 308, 349, 388). These findings suggest that the chromatin remodelling 
machinery can be targeted to particular genes and that alteration of chromatin 
structure has a major role in regulating pol II transcription. Interestingly, TFIIIC has 
recently been reported as a novel HAT, suggesting that similar chromatin 
remodelling activities may play an important part in the regulation of pol III 
transcription (230, 298).
1.8 Physiological regulation of pol III transcription
In higher eukaryotes, pol III transcription has been shown to be strongly 
regulated in response to a variety of important physiological stimuli such as growth 
and differentiation, the cell cycle, viral infection and transformation (568, 569). For 
some of the stimuli, in particular systems, the mechanisms responsible for regulating 
pol III transcription have been partially elucidated. However, invariably it has yet to 
be determined whether the mechanistic bases for regulation are peculiar to the 
system(s) in which it was examined or a general phenomenon for the particular 
physiological stimulus. In other cases it can be inferred that particular proteins
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previously shown to modulate pol III transcription might be involved based upon 
what is known regarding their physiological regulation.
1.8.1 Developmental regulation during Xenopus embryogenesis
There are two families of 5S genes in Xenopus laevis, the somatic 5S genes, 
of which there are ~ 400 copies per haploid genome, and the oocyte 5S genes, of 
which there are ~ 20,000 copies (568). During oogenesis, both somatic and oocyte 
5S genes are strongly expressed. However, transcription of both types of genes, and 
indeed transcription in general, is potently inhibited following meiosis. This 
repression continues post-fertilisation and through the first twelve cleavage divisions 
up until the mid-blastula transition (MBT). This blanket repression of transcription 
appears to be caused by the inaccessibility of genes to the transcriptional machinery 
resulting from the accumulation of a huge excess of core histones by the oocyte that 
gain access to the DNA when the nucleus breaks down during oocyte maturation 
(395, 595). At the MBT transcription resumes; equal amounts of somatic and oocyte 
5S RNA are produced indicating a 50-fold transcriptional preference for the somatic 
5S genes (544, 597). Several cell divisions later transcription ceases completely 
from the oocyte 5S genes, establishing the state found in all adult somatic cells in 
which 5S transcription proceeds solely from the less abundant somatic 5S genes 
(544, 597).
A variety of mechanisms appear to contribute to this developmental 
regulation of 5S transcription in Xenopus, which shall now be discussed. In the 
oocyte nucleus there are -70,000 molecules of TFIIIA per 5S gene, allowing high 
levels of transcription from both somatic and oocyte 5S genes (480). However, as 
development continues TFIIIA levels rapidly decline and become limiting; in adult 
somatic cells there are five 5S genes per molecule of TFIIIA (480). A difference in 
affinity for TFIIIA, or the stability of its association, between the somatic and oocyte 
5S genes might therefore contribute to the transcriptional bias towards the somatic 
5S genes after the MBT. In support of this, the injection of purified TFIIIA protein 
into Xenopus embryos resulted in a dramatic increase in 5S rRNA at the blastula 
stage and this was mostly due to transcription from oocyte 5S genes (58). However, 
this elevation in the expression of oocyte 5S genes relative to somatic 5S genes in
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response to artificially raised levels of TFIIIA is transient (12). By neurulation, the 
effect of increased levels of TFIIIA upon 5S transcription from the oocyte 5S genes 
is lost and replaced by the situation found in adult somatic cells in which these genes 
are transcriptionally inactive (12). This may be due to changes in chromatin 
structure that make oocyte 5S genes inaccessible or perhaps a different factor 
becomes limiting.
Footprinting and template challenge experiments have shown that 
transcription complexes formed on oocyte 5S genes are less stable than those 
assembled on somatic 5S genes (589). Significantly, transcription directed by 
unstable transcription complexes is more susceptible to changes in the concentration 
of limiting factors because factors in such complexes are in equilibrium with free 
factors (589). A difference of 3 nucleotides in the upstream part of the ICR results in 
TFIIIC having a 5-fold higher affinity for the TFIIIA/somatic 5S complex than for 
the TFIIIA/oocyte 5S complex (269). Moreover, the instability of the transcription 
complex formed on oocyte 5S genes provides more opportunity for the formation of 
a repressive chromatin structure that can exclude transcription factor binding. 
Indeed, clear differences are detected in the chromatin structure of somatic and 
oocyte 5S genes in adult somatic cells and oocyte 5S genes are found to be much less 
accessible to exogenous factors than somatic 5S genes (92). The removal of the 
linker histone HI by high salt or ion exchange chromatography restores accessibility 
to the oocyte 5S genes (92, 460). The readdition of HI represses transcription of 
oocyte 5S genes but has no effect on somatic 5S genes (460). HI has a preference 
for oocyte 5S genes; this is related to the spacer sequence, which has a higher A/T 
content than that of somatic 5S genes (287). A/T richness has been shown to 
strongly promote HI binding (433). Significantly, linker histone synthesis has also 
been shown to be developmentally regulated with the accumulation of HI correlating 
temporally with the decreased accessibility and transcription of oocyte 5S genes 
(125). In early stages of development HI is replaced by an embryonic variant, B4, 
which binds 6-fold less tightly to nucleosomes.
The developmental regulation of 5S transcription thus appears to be achieved 
by a multiplicity of effects. Factors contributing to the ~50-fold transcriptional 
preference towards somatic 5S genes that occurs shortly after the MBT likely include 
the lower stability of transcription complexes that form on oocyte 5S genes, 
decreased amounts of transcription factor(s) and increasing amounts of HI, which
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binds preferentially to oocyte 5S genes. In adult somatic cells, the somatic 5S genes 
are replicated earlier than the oocyte 5S genes and therefore have a competitive 
advantage in binding limiting amounts of transcription factors and forming an active 
transcription complex rather than a repressive chromatin structure (165, 180). This, 
and further reductions in the levels of TFIIIA, likely plays an important role in the 
complete repression of pol III transcription from the oocyte 5S genes (568).
1.8.2 Regulation in response to differentiation
RNA pol III transcription is also strongly regulated during early mouse 
development (538). In situ hybridisation has been used to follow changes in pol III 
transcript levels and reveal a dramatic decrease when cells differentiate into 
endoderm (538). High expression is maintained in ectoderm and mesoderm at this 
stage of development (7.5 days post coitum) (538). The decrease in pol III 
transcription during differentiation into endoderm can be accurately reproduced in 
culture using embryonal carcinoma (EC) cells (10, 577). The F9 EC cell line can be 
induced to differentiate into parietal endoderm (PE) by exposure to retinoic acid and 
cAMP, mimicking events in the early embryo (577). The rate of pol III transcription 
decreases ~9-fold when F9 cells differentiate (577). This was found to be 
accompanied by a specific decrease in TFIIIB activity (10). The abundance of BRF 
is substantially reduced in PE cells; furthermore, add-back experiments indicate that 
TFIIIB TAF activity is limiting in PE cells, suggesting that the decline in BRF levels 
may be sufficient to account for the decrease in pol III activity upon differentiation 
( 10).
1.8.3 Mitotic regulation
In higher eukaryotes all nuclear transcription is repressed during mitosis. 
RNA pol III transcription is inhibited by the phosphorylation and inactivation of 
TFIIIB (169, 327, 572). Thus, TFIIIB isolated from metaphase-arrested Xenopus 
eggs is unable to support transcription unless first treated with phosphatase (169). 
The predominant kinase at mitosis, cyclin B/cdc2, can inactivate affinity purified
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Xenopus TFIIIB (169). However, mitotic extracts depleted of cyclin B/cdc2 still 
repress pol III transcription (196). This inhibition is sensitive to the kinase inhibitor 
DMAP, suggesting there may be one or more additional kinases that can also inhibit 
pol III activity in metaphase-arrested frog eggs (196).
TFIIIB is also found to be specifically inhibited in mitotic extracts from HeLa 
cells (572). The TBP subunit of TFIIIB becomes hyperphosphorylated at mitosis, 
both in Xenopus and HeLa cells (327, 572). However, the consequences of this 
phosphorylation are unclear. Add-back experiments demonstrate that recombinant 
TBP is unable to restore expression to mitotic extracts (572). However, affinity- 
purified TFIIIB TAF fractions are able to reconstitute transcription (572). Thus, it 
appears that TFIIIB TAF activity is limiting in mitotic extracts. It may be the BRF 
subunit of TFIIIB is specifically inactivated since it is also found to be 
hyperphosphorylated in mitotic HeLa extracts (366).
Xenopus egg extracts can be shifted to the mitotic state by the addition of 
cyclin B (196). Preincubation of extracts with non-specific DNA to titrate out 
histones or a topoisomerase II inhibitor to block mitotic chromosome condensation 
made no difference to the extent of repression of pol III transcription (196). These 
results indicate that nucleosome formation or chromatin condensation is not required 
for the inhibition of pol III transcription by mitotic extracts, at least in Xenopus. 
However, in vivo the repression of TFIIIB by phosphorylation may not be sufficient 
to account for the complete silencing of pol III transcription that occurs during 
mitosis (572). The highly condensed state of the chromosomes that characterise 
mitosis are also likely to contribute to the inhibition of pol III transcription (572).
1.8.4 Regulation during interphase
On exit from mitosis, TFIIIB is rapidly dephosphorylated and pol III 
transcription resumes albeit at low levels (571). Transcription increases gradually as 
cells progress through G l, with a sharp rise in late G1 around the Gl/S transition, 
resulting in high levels of expression in S and G2 (571). Thus, the rate of pol III 
transcription is 2- to 3- fold higher in S and G2 than it is in early Gl (571). Extracts 
from cells synchronised in G l, S or G2 phase were analysed for changes in the 
activity of the different components of the general pol III transcriptional machinery.
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Whereas TFIIIC- and pol III- activity remain relatively constant, TFIIIB activity was 
found to be severely compromised in Gl phase extracts (571). Complementation 
assays revealed that the TAF component of TFIIIB is 6- to 8- fold less active in early 
Gl phase than it is in S or G2 (571). The addition of affinity-purified TFIIIB TAF 
fractions to early Gl phase extracts restored transcription to levels found in S and G2 
phase extracts, suggesting that the deficiency in TFIIIB TAF activity may be 
sufficient to account for the low pol III transcriptional activity in early Gl phase 
(571). In contrast, these TAFs have little or no effect when added to S or G2 phase 
extracts, indicating that TFIIIB TAF activity is no longer limiting in these phases of 
the cell cycle. Indeed, TFIIIB activity increases to such an extent in late Gl that by S 
phase it is in relative excess and TFIIIC is limiting for transcription in S and G2 
(571).
Detailed time courses have shown that the dramatic rise in pol III 
transcription and TFIIIB activity in late Gl phase closely corresponds to the time 
when RB is switched off by its hyperphosphorylation by the cyclin D- and cyclin E- 
dependent kinases around the restriction point (255, 363). Since RB is a potent 
repressor of pol III transcription and, moreover, is known to specifically inactivate 
TFIIIB, this suggests that the inactivation of RB by the cyclin-dependent kinases 
may be at least partly responsible for the increase in pol III transcription in late Gl 
phase (93, 314, 571, 579). In support of this, the hyperphosphorylation of RB 
appears to prevent it from binding to TFIIIB (471). Moreover, 
coimmunoprecipitation experiments show that RB dissociates from TFIIIB shortly 
before S phase entry (471). In addition, the overexpression of cyclin D/cdk4 and 
cyclin E/cdk2 in vivo by transient transfection is found to specifically stimulate pol 
III transcription (471). Together these data strongly suggest that the 
hyperphosphorylation of RB by the cyclin D- and cyclin E- dependent kinases 
prevents RB from inactivating TFIIIB and contributes to the rise in pol III 
transcription in late Gl phase. In early Gl phase RB is underphosphorylated and can 
bind and inactivate TFIIIB and is likely to be involved in maintaining a low level of 
pol III transcription during this part of the cell cycle (Fig. 1.3) (471). Thus, RB 
appears to have a major role in the cell cycle regulation of pol III transcription. 
However it is extremely likely that additional control mechanisms are also involved. 
Indeed, the gradual increase in pol III transcriptional activity through Gl prior to the
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Figure 1.3
Cell cycle regulation of pol III transcription
Schematic diagram illustrating some mechanisms that are thought to contribute to the 
cell cycle regulation of the mammalian pol III transcriptional apparatus. In Gl phase 
RB is in an active underphosphorylated form and can bind to and repress TFIIIB, 
resulting in only low levels of basal pol III transcription. However, in late Gl phase 
RB becomes inactivated due to its hyperphosphorylation by the cyclin D- and E- 
dependent kinases and TFIIIB is released enabling it to interact with TFIIIC at the 
class III promoter and recruit pol III into an active preinitiation complex. This is 
thought to account for the rapid rise in pol III transcription at the Gl/S transition. 
RB remains in a hyperphosphorylated state until the end of M phase when it is 
dephosphorylated by protein phosphatase 1, which may explain the high levels of pol 
III transcription observed during the S and G2 phases of the cell cycle. During 
mitosis, pol III transcription ceases completely. This results from the direct 
phosphorylation and inactivation of TFIIIB. The packaging of the DNA into a more 




abrupt rise at the R point cannot be readily explained by the cell cycle regulation of 
RB; however, it is presently unclear what may be responsible for this effect.
1.8.5 Regulation in response to quiescence
The principle determinant of proliferation rate in mammalian cells is the 
decision whether to quiesce; that is, to exit the cell cycle and growth arrest, or 
continue to cycle. The synthesis of tRNA and 5S rRNA is significantly reduced 
during quiescence (74, 96, 217, 255, 363, 471, 477, 525). This likely reflects the 
substantially diminished requirements for protein production in quiescent cells. Cells 
grown in culture can be induced to quiesce by serum withdrawal. The 
downregulation of pol III transcription in untransformed mouse fibroblasts in 
response to serum starvation has been studied in detail. Add-back and 
complementation experiments show that this is due to a specific reduction in TFIIIB 
activity (471). Analysis of the abundance of TBP and BRF by western blotting 
reveal little or no change in response to serum deprivation, suggesting that a decrease 
in the amount of TFIIIB is not responsible for the reduction in TFIIIB activity in 
these growth-arrested cells (471). However, the possibility cannot be excluded that 
unidentified components of TFIIIB become less abundant and contribute to the low 
TFIIIB activity of these cells. Significantly, quiescent cells express very little cyclin 
D or E, and RB is present in these cells in its active underphosphorylated form, 
raising the possibility that RB may contribute to the repression of TFIIIB during 
quiescence (173, 471). Indeed, fibroblasts derived from RB knockout mice are 
compromised in their ability to down-regulate pol III transcription in response to 
serum withdrawal relative to equivalent cells from wild type mice (471). Thus, 
Northern blot analysis revealed a 2.4-fold decrease in tRNA levels when RB+/+ cells 
were made quiescent, whereas RB'/_ cells show only a 1.3-fold decrease (471). In 
contrast, the levels of the pol II transcript ARPP PO did not change. Similar results 
were obtained when rates of pol III transcription were assayed directly by nuclear 
run-ons (471). Some decrease, albeit less substantial, was still observed in the RB'7' 
cells in response to quiescence, however, indicating that there are additional 
mechanisms that contribute to the downregulation of pol III transcription following 
exit from the cell cycle (471). The RB-related pocket proteins p i07 and p i30 have
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both recently been shown to repress pol III transcription both in vitro and in vivo 
(504). Moreover, p i07 p i30 double knockout fibroblasts showed much less of a 
decrease in pol III transcript levels in response to serum starvation than the 
corresponding wild-type cells, indicating that p i07 and/or p i30 are also part of the 
regulatory control by which pol III transcription is repressed during quiescence 
(504). Serum-starved mouse fibroblasts contain very little pl07, but pl30 is 
relatively abundant and in an active form (173).
1.8.6 Regulation in response to adenovirus infection
A variety of viruses have been shown to infect mammalian cells and stimulate 
pol III transcription; these include adenovirus, simian virus 40 (SV40), human T-cell 
leukaemia virus type 1 (HTLV-1), hepatitis B virus (HBV) and polyomavirus (143, 
569). Following infection, the viruses subvert the host cell’s translational and 
replication machinery towards mass production of viral proteins and the viral 
genome (569). The stimulation of pol III transcriptional activity therefore likely 
reflects a requirement for increased biosynthetic capacity. In addition, several viral 
genomes are found to contain class III genes, which are required for viral replication 
(568). Indeed, the adenovirus genome encodes two pol III products, VAi and VAn 
(492, 559); these small RNAs (~160nt) are synthesised at very high levels late in 
infection and are involved in the corruption of the host cell’s translational apparatus 
to ensure the synthesis of viral proteins (519).
The activation of pol III transcription in response to adenovirus infection 
appears to be achieved, to a large extent, by the activities of the El A oncoprotein of 
adenovirus (16, 341, 488, 569). Thus, a transfected E1A gene alone is sufficient to 
activate transcription of the VAi gene in human cells (16, 341). Furthermore, the 
addition of purified recombinant El A protein to HeLa cell extracts can stimulate VAi 
transcription up to 50-fold (114, 409). HeLa cells infected with wild-type adenovirus 
have elevated TFIIIC activity (217, 218, 488, 606). This appears to result from the 
conversion of a transcriptionally inactive form of TFIIIC2 (TFIIICb) that lacks the 
TFIIICp subunit into an active form (TFIIICa) that has the P subunit (114, 217, 488). 
El A induces an increase in TFIIICp mRNA and infected cells display a selective rise
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in the levels of TFIIICp protein (488). However, El A can also stimulate pol III 
transcription in vitro, suggesting that there are additional mechanisms by which 
adenovirus can activate pol III transcription that do not require de novo protein 
synthesis (114, 409). Indeed, E1A can bind and inactivate RB and has been shown 
to relieve repression of pol III transcription by RB, both in vitro and in transfected 
cells (579). In addition, E1A can disrupt the interaction of Drl with TBP, thereby 
releasing TFIIIB from Drl-mediated repression (293). Another transforming protein 
of adenovirus, E1B, can bind and inactivate p53, suggesting that adenovirus infection 
may also overcome the suppressive effects of p53 on pol III transcription (284). In 
support of this, full induction of Alu gene expression by adenovirus requires E1B 
(403). This also involves changes in the chromatin structure of Alu genes with an 
increase in the proportion of these templates that are accessible to transcription 
factors (451). Thus, multiple mechanisms may contribute to the activation of pol III 
transcription in response to adenovirus infection (Fig. 1.4).
1.8.7 Regulation in response to transformation by the DNA tumour virus SV40
Rodent fibroblasts that have been transformed by the DNA tumour virus 
SV40 display abnormally elevated levels of pol III transcription (75, 315, 469, 487, 
578). Like adenovirus, SV40 appears to activate pol III transcription by multiple 
mechanisms, since the activity of both TFIIIB and TFIIIC2 is significantly higher in 
extracts from SV40-transformed cell lines than in extracts from the untransformed 
parental cell line (315). The TFIIICa and TFIIICp subunits of TFIIIC2 are much 
more abundant in extracts from SV40-transformed cells, suggesting that the rise in 
TFIIIC2 activity may result from the overexpression of TFIIIC2 (315). However, 
there is also evidence for an increase in the proportion of cellular TFIIIC2 that is in a 
transcriptionally active form, as was observed in response to adenovirus infection 
(578). In contrast to the a  and P subunits of TFIIIC2, there is little or no change in 
the protein levels of TBP or BRF in response to SV40 transformation (315). Instead, 
the increase in TFIIIB activity appears to be due to the release of TFIIIB from 
repression by RB (315). This is dependent on the large T antigen of SV40 which, 
like El A, can bind and inactivate RB (315). The large T antigen also interacts with
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Figure 1.4
Subversion of normal regulatory controls of pol III transcriptional activity by 
adenovirus
Schematic diagram illustrating some of the mechanisms that may contribute to the 
activation of pol III transcription following adenovirus infection. Adenovirus 
stimulates the conversion of TFIIIC2 from the inactive TFIIIC2b form to the active 
TFIIIC2a form. This is thought to result from a selective increase in the levels of 
TFIIIC(3 mRNA and protein induced by the El A oncoprotein of adenovirus. El A 












and inhibits p53 (284). However, the effect of this interaction on the ability of p53 to 
repress pol III transcription has not yet been tested.
Adenovirus and SV40 appear to upregulate pol III transcription by very 
similar mechanisms (569). However, other viruses may stimulate pol III 
transcription differently. HBV and HTLV-1 both appear to be more restrictive in 
their effects, specifically targeting only one component of the basal pol III 
transcriptional machinery (168, 549). HBV induces a specific increase in TFIIIB 
activity; this is achieved via activation of Ras signalling (548, 549).
1.8.8 Regulation in response to other transforming agents and tumorigenesis
A broad range of transforming agents have been found to induce the 
overexpression of pol III products (168, 469, 487, 548, 568, 578). In addition to 
DNA tumour viruses such as SV40 (469, 487, 578) and RNA tumour viruses such as 
HTLV-1 (168), a variety of chemical carcinogens have also been shown to stimulate 
pol III transcription (161, 162, 469). An increase in the abundance of pol III 
transcripts is a very common feature of transformed cell lines (568). However, in 
most cases the mechanistic basis of this effect has not been studied. It has also 
recently been shown that pol III products are abnormally elevated in actual tumours 
(87, 88, 586). A possible explanation for the frequent overexpression of pol III 
transcripts in transformed and tumour cells is suggested by the very high incidence 
that RB and p53 become inactivated during neoplastic transformation. In 
untransformed cells these two key tumour suppressors play a major role in repressing 
pol III transcription (70, 579).
Although only a limited study, four different point mutations in RB that have 
been detected in human tumours have each been tested and found to prevent the 
tumour suppressor from repressing pol III transcription (59, 579). This provides 
direct evidence that the inactivation of RB in tumours can contribute to the elevation 
of pol III activity consistently observed in transformed and tumour cells. In normal 
cells the activity of RB is regulated by phosphorylation by the cyclin D- and cyclin 
E- dependent protein kinases (173). In many human cancers in which RB is wild- 
type, the cyclin D-dependent kinases are hyperactive providing an alternative 
mechanism by which RB function is lost. Indeed, cyclin D1 is overexpressed in 30-
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40% of primary breast tumours. In many oesophageal, bladder, lung and pancreatic 
carcinomas the gene for p i6, a specific inhibitor of the cyclin D-dependent kinases, 
is deleted. The overexpression of cyclin D- and E- dependent kinases in an 
untransformed mouse fibroblast cell line has been shown to stimulate pol III 
transcription (471). Moreover, the transcriptional response is significantly impaired 
in an SV40-transformed derivative of this cell line, consistent with the possibility 
that the stimulatory effect of the CDKs is achieved through the release of TFIIIB 
from repression by RB (471). Similar results were also obtained using a p i6 
ribozyme to lower the concentration of p i 6 in the cell and release endogenous cyclin 
D-CDK4/6 from repression. Moreover, hyperphosphorylated RB and TFIIIB are 
unable to interact (471). Thus, the inactivation of RB by hyperphosphorylation by 
the CDKs also appears to relieve pol III from its suppressive effects, providing 
another mechanism as to how pol III activity may become elevated in response to 
transformation. A third mechanism by which RB function can be lost is by its 
association with viral oncoproteins such as adenovirus El A or SV40 large T antigen 
(541). The E7 oncoprotein of human papillomavirus (HPV) has also been shown to 
bind and inactivate RB (132). HPVs have an etiological role in most cervical 
neoplasias (541). Significantly, the E7 proteins from the more malignant HPV 
strains, such as HPV-16 and -18, bind RB with higher affinity (206). Like El A and 
large T antigen, HPV E7 has also been shown to activate pol III transcription (504). 
Furthermore, analysis of several E7 mutants showed that this is dependent on the 
integrity of the LXCXE motif, which is the RB-binding site within E7 (504).
Since all three mechanisms by which RB is inactivated in cancers can also 
release pol III transcription from repression by the tumour suppressor, it is highly 
probable that the loss of RB function contributes to the elevated pol III activity found 
in a large variety of tumours and transformed cell types. However, it remains to be 
determined how the frequent missense mutations in p53 found in approximately half 
of all the major forms of human cancer affect its ability to inhibit pol III. In addition, 
constitutively active Ras has recently been shown to stimulate pol III transcription in 
vivo (471, 548). Activating mutations in Ras are also very frequently found in 
human malignancies, raising the possibility that Ras may also contribute to the 
overexpression of pol III transcripts in transformed cells and tumours (344).
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1.9 Objectives
The overall purpose of this project was to gain a better molecular 
understanding of how the mammalian pol III transcriptional apparatus is normally 
regulated and how it might become deregulated in cancer. For each of the instances 
of regulation where it has been investigated which component(s) of the basal pol III 
transcriptional apparatus are targeted, a change in the activity of TFIIIB or TFIIIC is 
implicated; in no case has the polymerase itself been found to be directly controlled. 
However, rather crude sources of TFIIIB and TFIIIC have often been used. A major 
objective was therefore to obtain more purified sources of active TFIIIB and TFIIIC 
to allow regulatory studies to be conducted with more confidence. Another aim of 
this approach was to help identify the transcriptional target of novel regulators 
through their consistent copurification with one of these two basal factors. The most 
highly purified fractions were used to investigate the deregulation of pol III 
transcription in ovarian cancer. This was of particular importance because although 
pol III transcript levels are frequently found to be abnormally elevated in 
transformed and tumour cells, in most cases the mechanistic basis for this has not 
been elucidated.
In a healthy cell the level of pol III transcription is restrained by two key 
tumour suppressors, RB and p53. The loss of these constraints on pol III activity 
may also contribute to the overexpression of pol III products consistently observed in 
transformed cells. Another aim of this research was to further investigate the 
regulation of pol III activity by the pocket proteins, especially why the binding of RB 
to TFIIIB inhibits pol III transcription.
A common mechanism of cellular regulation whose study has been largely 
neglected in the case of pol III transcription is that of phosphorylation. Moreover, 
several subunits of pol III components have previously been shown to be 
phosphorylated in vivo. The final aspect of this research investigated the candidacy 
of the protein kinases CKII and GSK-3 as novel kinase regulators of mammalian pol 
III transcription. CKII had previously been shown to stimulate pol III transcription 
in yeast and was also of particular interest because it is a putative cellular oncogene 
and has uncharacterised roles in stimulating growth and proliferation. GSK-3 
phosphorylates and inhibits the translation elongation factor eIF2B. The possibility 
existed therefore that it might also inhibit tRNA and 5S rRNA transcription, which
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All cell culture was performed in a class II hood using aseptic technique and 
sterile equipment and reagents.
Balb/c 3T3 (A31), NIH 3T3 and HeLa cells, and the rat ovarian epithelial cell 
lines ROSE 199-/3gal and ROSE 199-neu (115), were all grown in DMEM 
supplemented with 10% fetal calf serum, 2mM glutamine, lOOU/ml penicillin and 
lOOpg/ml streptomycin at 37°C in a 5% CO2 atmosphere. ROSE 199-/3gal and 
ROSE 199-neu, kindly provided by Bruce A. J. Ponder, were generated from the 
untransformed parental cell line ROSE 199 by transduction with retrovirus vector 
expressing the p~galactosidase gene or vector expressing the neu oncogene with an 
activating point mutation (V664E), respectively (115). The culture media of these 
two stably transfected cell lines additionally contained 0.6mg/ml of the antibiotic 
G418 to maintain selection.
All cells were appropriately passaged every 3 days (3T3s 1:5, HeLa and B- 
gal 1:10, neu 1:15) to maintain in log phase growth. To harvest a monolayer, cells 
were washed briefly with buffered trypsin-EDTA solution to remove serum that 
inactivates the trypsin and fresh solution was applied. Flasks were then incubated for
1-2 minutes at 37°C to allow trypsinisation to occur. To facilitate detachment of 
cells, flasks can be firmly tapped on the side. Once adherent cells have dissociated to 
a single cell suspension, DMEM that contains serum was immediately added to 
neutralise the trypsin.
2.2 Preparation of whole cell extracts
Cultured cells were harvested for extract preparation when subconfluent. 
This procedure was performed on ice and as quickly as possible so as to minimise
n
loss of activity during extract preparation. Approximately 0.5-3 x 10 cells were
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required for preparing extracts by the freeze-thaw method described below. First 
each 10cm petri dish of adherent cells was washed twice with 5ml of ice cold 
phosphate buffered saline (PBS) and then the cells were harvested into 10ml of ice 
cold PBS by scraping with a plastic spatula. The suspended cells were then decanted 
to a pre-cooled 50ml Falcon tube and gently pelleted by centrifugation at 1200 rpm 
for 8 min at 4°C. The cells were gently resuspended in 1ml of fresh ice cold PBS, 
transferred to an eppendorf tube and pelleted again by pulse centrifugation. The 
volume of the cell pellet was determined by comparison with measured volumes of 
water and should be between 50-150pl. The volume of the cell pellet is critical to 
this technique and larger pellets were subdivided. The pellet was resuspended in an 
equal volume of freshly made pre-cooled extraction buffer (20mM Hepes pH 7.8, 
450mM NaCl, 50mM NaF, 25% glycerol, 0.2mM EDTA, ImM DTT, 0.5mM PMSF, 
0.5pg/ml leupeptin, 0.7pg/ml pepstatin, lpg/ml trypsin inhibitor, 0.5pg/ml aprotinin, 
40pg/ml ubenimex [Bestatin]). This was snap-frozen on dry ice and then placed at 
30°C until thawed and then immediately snap-frozen again. This sequential freeze- 
thaw cycle was repeated twice more to ensure efficient lysis of cells. After the third 
thaw, the suspension was microcentrifuged for 7 min at 4°C to pellet the cell debris. 
The supernatant was carefully removed to a fresh tube, aliquoted into pre-cooled 
eppendorf tubes and snap frozen. The frozen extracts were stored at -70°C.
2.3 Isolation of RNA from cultured cells
Appropriate precautions were taken to avoid problems of contamination by 
RNase. Solutions were treated with diethylpyrocarbonate (DEPC) to inactivate 
ribonuclease (0.1% DEPC, shaken vigorously to get the DEPC in solution, left 
overnight at room temperature, then autoclaved to inactivate remaining DEPC).
Total cellular RNA was extracted using TRI reagent (Sigma), according to 
the manufacturer’s instructions. First, medium was aspirated from sub-confluent 
cultures in 10cm petri dishes and cells were gently washed twice with 5ml PBS to 
remove residual serum in case the same samples were also to be used for isolation of 
cellular protein. 1ml of TRI reagent was added to each 10cm petri dish of cells and 
dishes were rigorously scraped to detach and help lyse cells. This mixture was
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pipetted up-and-down several times to ensure formation of a homogenous lysate and 
transferred to a sterile eppendorf tube. The TRI reagent, a mono-phase solution of 
guanidine thiocyanate and phenol, effectively dissolves DNA, RNA and protein 
released on cell lysis. Samples were left to stand for 5 min at room temperature to 
allow complete dissociation of nucleoprotein complexes. 0.2ml of chloroform was 
then added to each tube and the samples were vortexed vigorously for 15 seconds. 
After allowing to stand at room temperature for 15 min, the samples were then 
centrifuged at 13,000g for 15 min at 4°C. This separates the mixture into three 
layers: an upper aqueous phase containing the RNA, which should be colourless and 
clear, a middle interphase that contains precipitated DNA and is whitish in colour, 
and a lower organic phase containing protein, which is the colour of the TRI reagent. 
The upper aqueous phases were removed to fresh eppendorf tubes taking particular 
care to avoid taking up any of the next layer. 0.5ml of isopropanol was added to 
each tube of aqueous RNA and mixed by inverting several times. The samples were 
left at room temperature for 5-10 min to ensure maximal precipitation of RNA before 
centrifugation at 13,000g for 10 min at 4°C to pellet the RNA. The supernatant was 
removed and the RNA pellet was washed with 1ml of 75% ethanol (made up with 
DEPC-H2O). Following a brief re-centrifugation (7500g, 5 min at 4°C), the 
supernatant was aspirated, pulse spun and a P20 pipette was used to remove residual 
amounts of ethanol. The pellet was redissolved in an appropriate volume of DEPC- 
H2O (10-30pl). To facilitate this, samples were heated at 60-65°C for 10-15 min and 
occasionally pipetted up-and-down. RNA samples were stored at -70°C. The 
concentration of RNA was quantified by UV spectrophotometry (absorbance at 
260nm x 40 x dilution factor = RNA concentration (pg/ml). The ratio of absorbance 
at 260nm to that at 280nm should be >1.8 and <2 for a sample relatively free of DNA 
or protein).
2.4 Northern blot analysis of total cellular RNA
For each sample analysed lOpg of RNA was used, made up to a volume of 
lOpl with DEPC-H20 and mixed with an equal volume of 2 x RNA sample buffer (1 
x MOPS (20mM MOPS pH 7.0, 8mM sodium acetate, ImM EDTA pH 8.0}, 4.4M
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formaldehyde, 54% formamide). The samples were heated at 65°C for 15 min to 
denature the secondary structure of RNA and then rapidly cooled on ice to prevent 
any renaturation. 2pl of 10 x RNA loading buffer (50% glycerol, ImM EDTA, 
0.25% bromophenol blue, 0.25% xylene cyanol FF) and 2pl of 1 mg/ml ethidium 
bromide was added to the chilled samples. The different species of RNA in each 
sample were separated according to size by electrophoresis through a denaturing 
formaldehyde 1% agarose gel (1% agarose, 2.2M formaldehyde, 1 x MOPS). After 
pre-running the gel in 1 x MOPS for 20 min at 40V, the samples were loaded and the 
gel was run for a further ~5 hours at 40V. The fractionated RNA was visualised 
under a UV transilluminator and photographed before soaking the gel in several 
changes of DEPC-H2O to leach out the formaldehyde. The gel was then immersed in 
20 x SCC (3M NaCl, 0.3M sodium citrate pH 7.0) for 20 min. This was the buffer 
used for capillary transfer of RNA to Hybond N nylon filters (Amersham).
The gel was set up for capillary transfer as described by Maniatis et al. (352) 
and this was allowed to proceed overnight. Thus, the 20 x SCC-soaked gel was 
placed inverted on a wick of Whatmann 3MM chromatography paper fed from a 
reservoir of 20 x SCC onto which pre-wetted nylon membrane cut to the size of the 
gel was placed ensuring that there were no air bubbles between the layers. Two 
pieces of pre-soaked Whatmann paper cut to size were placed on top of the 
membrane followed by a stack of paper towels to provide the capillary action. This 
was weighed down with a 500g ballast ensuring a tight connection between layers. 
Pieces of autoradiography film were placed at the edges of the gel to block the towels 
from directly contacting the wick which would provide a short-circuit and would 
inevitably result in poor RNA transfer.
Following overnight transfer, the RNA was fixed to the nylon membrane by 
UV-crosslinking (1200pjoules), washed with DEPC-H2O and stored in Saran wrap. 
To locate the RNA of interest, hybridisation was performed with a high specific 
activity radiolabelled DNA probe complementary in sequence to that particular 
RNA. The B2 gene probe was a 240 bp EcoRl-Pstl fragment from pTB14 (577). 
The ARPP P0 probe was a lkb EcoRI-HincRlI fragment from the mouse cDNA 
(240). The probes were labelled using the random oligonucleotide priming method 
of Feinberg and Vogelstein (142) and the Megaprime Random Priming Kit 
(Amersham). Thus, purified DNA template (25ng) was denatured by heating at 95°C
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for 5 min in the presence of random hexamer oligonucleotide sequences that can 
anneal to the DNA on the slow cooling of the mixture to room temperature. The 
annealed hexamer primes DNA synthesis. To initiate labelling, Klenow fragment of 
E. coli DNA polymerase I (1U), dATP, dGTP, dTTP (50pM each) and 40pCi of 
a 32P-dCTP (lOmCi/ml, 3000 Ci/mmol) were added and the reaction was allowed to 
proceed for lh at 37°C. The labelled DNA was denatured by heating at 95°C and 
was then chilled on ice until ready for use. First, the nylon filter with bound RNA 
was prehybridised by rotation in a hybridisation oven for 30 min at 45°C in 
hybridisation buffer (0.2M sodium phosphate buffer pH 7.2, ImM EDTA, 1% (w/v) 
BSA, 7% (w/v) SDS, 45% (w/v) formamide in DEPC-H2O). The radiolabelled probe 
was then added to fresh hybridisation buffer and incubated with rotation at 45°C 
overnight. To remove nonspecific radioactivity, the filter was rotated for 2 min at 
room temperature and then twice for 10-15 min at 68°C in wash solution (40mM 
sodium phosphate buffer pH 7.2, ImM EDTA and 1% w/v SDS). The filter was then 
exposed to autoradiography film overnight at -70°C. To strip the filter for reprobing, 
it was soaked in boiling water for 5-10 min.
2.5 Transient transfection
Cells were transiently transfected using the calcium phosphate precipitation 
method. Expression vectors coding for wild-type GSK-3 p (pJ3M-GSK-3p) and 
kinase-inactive GSK-3 p (pJ3M-GSK-3pkd) were kindly provided by Charles J. 
Sherr. To construct “empty” pJ3M expression vector, the insert in pJ3M-GSK-3p 
was excised by carrying out a double restriction enzyme digest with BamHl and 
Bglll. The linearised vector was then separated from the insert by electophoresis 
through a 1% low melting point agarose gel and gel-purified using the QIAquick gel 
extraction kit (Qiagen). Re-ligation of vector was carried out overnight at 15°C 
using T4 DNA ligase. Ligation product was used to transform E. coli competent 
cells. Mini-preparations of plasmid DNA were performed from 2ml overnight 
cultures (in LB broth containing 50pg/ml ampicillin) of a number of isolated 
colonies and used to verify that the cells contain the correct vector and that it lacks 
the insert before carrying out a large scale plasmid preparation. All the plasmid
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DNA used for transfection or transcription assays was purified using the QIAGEN 
Plasmid Maxi Protocol and was verified to be of very high quality and purity by UV 
spectrophotometry and electrophoretic analysis. Supercoiled plasmid DNA to be 
used for transfection was additionally ethanol-precipitated twice and then 
resuspended in a small volume of sterile water.
24 h prior to transfection, cells were split and seeded at -  4-6 x 105 cells per 
10cm dish (depending on cell type) resulting in a confluency of -55-70% at the time 
of transfection. To improve transfection efficiency, 4 h before transfection the cells 
were refed with fresh growth medium. 45 min before transfection, for each dish the 
total plasmid DNA to be transfected was diluted to a volume of 450jll1 in filter- 
sterilised 0.1 x TE buffer, pH 8.0 (ImM Tris pH 8.0, O.lmM EDTA pH 8.0) and 
50pl of 2.5M CaCb was added. To form calcium phosphate-DNA precipitates, the 
DNA-CaCh mixture was added dropwise to 500pl of 2 x HEPES-buffered saline 
solution, pH 7.1 (280mM NaCl, 1.5mM Na2H P04.2H20 , 50mM HEPES, pH 7.1 
with NaOH), with continuous swirling to mix. This was then vortexed for 15 
seconds and left to stand for 30 min at room temperature before adding to cells and 
swirling to mix evenly. DNA precipitates were left on the plates overnight before 
removing and washing the cells twice with warm PBS. Fresh medium was then 
added and the cells were incubated at 37°C for a further 48 h to allow expression of 
transfected DNA. Cells were harvested and total RNA extracted for analysis by 
primer extension.
2.6 Primer extension
Primer extension was used to analyse the expression levels of transfected pol 
III template VAi and also a cotransfected CAT gene used as an internal control for 
transfection efficiency. For each primer extension reaction, lpg of total RNA in 
1 OjLxl of DEPC-H2O was mixed with lOpl of 5 x First Strand Buffer (Life 
Technologies) and lpl (2.5ng) of y-32P end-labelled VAi (5'-CACGCGGGCGGTAA 
CCGCATG-3') or CAT (5'-CGATGCCATTGGGATATATCA-3') oligonucleotide 
as primer. This mixture was incubated at 80°C for 10 min followed by 2h at 50°C. 
30pl of RT mix (23pl DEPC-H20 , 0.5pl 1M DTT, 5pl 5mM dNTP mix, 0.5pl
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4mg/ml actinomycin D, 0.5pl RNasin, 0.5pl (100U) Superscript II Reverse 
Transcriptase (Life Technologies)) was then added to the samples to initiate reverse 
transcription which was allowed to proceed for 1 h at 42°C. Reaction products were 
ethanol precipitated overnight and washed with 70% ethanol before electrophoresis 
through a 7M urea 7% polyacrylamide gel.
2.7 RNA pol III in vitro transcription assay
The in vitro transcription of class III genes was reconstituted using either 
crude extracts or fractionated factors as a source of the basal pol III transcription 
components and 250ng of plasmid DNA containing a particular pol III template. 
Transcription reactions were performed in a volume of 25 pi in a final concentration 
of 12mM HEPES pH 7.9, 60mM KC1, 7.2mM MgCl2, 0.14mM EDTA, 1.2mM DTT, 
10% (v/v) glycerol, ImM creatine phosphate, 0.5mM each of rATP, rGTP and rCTP 
and lOpCi [a-32P] UTP (400 mCi/mmol) (Amersham). Components for 
transcription were assembled on ice. For transcription reactions reconstituted with 
fractionated factors, these were preincubated for 15 min at 30°C with the pol III 
template before the addition of nucleotides required to initiate transcription. After 1 
h incubation at 30°C, transcription was stopped by the addition of 250pl of 1M 
ammonium acetate/0.1% SDS containing 20pg of yeast tRNA that stabilises the 
synthesised RNA. The samples were then phenol-chloroform extracted to remove 
protein and DNA. The aqueous layer (250pl) was carefully transferred to a fresh 
eppendorf tube and 750pl of 96% ethanol was added to precipitate the RNA. The 
samples were mixed by inversion and left overnight at -20°C. The precipitated RNA 
was pelleted by centrifugation at 13,000g for 20 min. After washing with 70% 
ethanol (750pl), as much supernatant as possible was removed, taking care not to 
dislodge the pellet. The samples were then placed at 47°C for 5-10 min to dry. The 
RNA was redissolved in 4pl of formamide loading buffer (80% formamide, 0.1% 
xylene cyanol, 0.1% bromophenol blue) by vortexing for 20 min. Transcription 
products were resolved by electrophoresis through a 7% polyacrylamide sequencing 
gel containing 7M urea and 1 x TBE (44.5mM Tris base, 44.5mM boric acid, ImM 
EDTA pH 8.0). The gel was pre-run in 1 x TBE for 30 min at 40W and the samples
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were boiled for 2 min at 95°C and quenched on ice. 2pl of each sample was loaded 
and the gel was run for a further 1 hour at 40W. The gel was then vacuum-dried for 
1 h at 80°C and radiolabelled transcripts were detected by autoradiography.
Plasmid templates used for in vitro transcription assays were as follows. 
pVAi is a 221 bp SaR-BaW fragment of adenovirus 2 DNA containing the VAi gene 
subcloned into pUC18 (117). pLeu is a 240 bp EcoRl-Hindlll fragment of genomic 
DNA containing a human tRNALeu gene subcloned into pAT153 (577). pArg 
contains a human tRNAArg gene. pHu5S3.1 is a 638-bp BamUl-Sacl fragment of 
human genomic DNA containing a 5S gene subcloned into pBluescript SK+. 
pU6/Hae/RA2 contains the promoter of the human U6 gene followed by a 137 bp 
fragment of the rabbit p-globin gene (338).
2.8 Electrophoretic mobility shift assay (EMSA)
To assay for TFIIIC2 DNA-binding activity, EMSAs were performed using y- 
32P labelled oligonucleotide containing a B-block consensus (5'- 
AGAGGTCCTGAGTTCAAATCCCAG-3' (RJW1) annealed to the complementary 
3' to 5' strand (RJW2)). Spl binding was assayed using an oligonucleotide that 
contains a consensus Spl binding site (5'-ACTTGATTAACTGGGCGGAGTTAT 
GATTGA-3' (Ml) annealed to the complementary 3' to 5' strand (M2)). 
Oligonucleotides were 5' end-labelled using T4 polynucleotide kinase (PNK). Thus, 
40ng of RJW1 or Ml was incubated for 1 h at 37°C with 10 units of PNK and 20pCi 
of [y-32P]-rATP (lOmCi/ml, 3000Ci/mmol) in 1 x PNK buffer (Promega). The 
labelling reaction was stopped by heating at 65°C for 10 min. PNK enzyme was 
phenol-chloroform extracted and oligonucleotide was ethanol precipitated. 
Unincorporated label was removed by multiple washes of precipitated 
oligonucleotide with 70% ethanol, before resuspending in TE buffer, pH 8.0 (lOmM 
Tris pH 8.0, ImM EDTA). Unlabelled complementary oligonucleotide was then 
added in 2.5 fold excess and the mixture was heated in a hot block at 90°C for 2 min. 
The hot block was then turned off and the samples were left to cool slowly overnight. 
The annealed oligonucleotide was stored at 4°C until ready to use.
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The binding reactions were performed in a final volume of lOpl and an 
optimal salt concentration of 60mM KC1, as for in vitro transcription assays. Each 
reaction contained lpg of polydldC (2pi), lOOng of non-specific or specific 
competitor oligonucleotide (2pl), 0.25-0.5ng of labelled probe (2pl) and typically 1- 
4pi of protein extract or fractionated factors. Extract or protein factors were 
preincubated with unlabelled competitor DNA for 15 min at 30°C before the addition 
of labelled probe and a further 15 min incubation at 30°C. The formation of protein- 
DNA complexes was analysed by electrophoresis of samples on a prerun 4% 
nondenaturing polyacrylamide gel in 1 x TAE buffer (40mM Tris acetate, ImM 
EDTA pH 8.0) for Wi-2 h at 4°C. The gel was quickly dried to avoid dissociation of 
complexes formed and exposed to X-ray film overnight at -70°C.
2.9 In vitro transcription and translation of BRF
To transcribe BRF, lpg of pCITE vector (Novagen) containing the BRF 
sequence subcloned downstream of the T7 promoter was incubated at 37°C for 90 
min with 80 units of T7 phage RNA polymerase. RNA synthesis was carried out in 
T7 transcription buffer (40mM Tris pH 8.0, 25mM NaCl, 8mM MgCh, 2mM 
spermidine) supplemented with 5mM DTT, ImM of each rNTP and 20 units of 
RNase inhibitor (RNasin). Following phenol-chloroform extraction and ethanol 
precipitation, the synthesised BRF RNA was then washed with 70% ethanol and 
resuspended in 50pl DEPC-H2O.
Translation of the RNA was carried out using rabbit reticulocyte lysate 
(Promega), according to the manufacturer’s specifications. Translation reactions 
were performed at 30°C for 90 min in a final volume of 50pl. Reaction mixtures 
typically contained 25 pi of reticulocyte lysate, lpl of amino acid mixture that lacks 
methionine and cysteine (Promega), 2pl of synthesised RNA, lp l of RNasin (20 
units), 7pi of DEPC-H2O and 4pl of a mixture of [35S]-methionine and [35S]-leucine 
(14.3mCi/ml, lOOOCi/mM) (Amersham). To check translation products, a small 




Antibodies were coupled to protein A-Sepharose by incubating LDB-washed 
beads with crude antiserum or purified antibody on an orbital shaker for 1 h at 4°C in 
the presence of a cocktail of protease inhibitors (0.9pg/ml leupeptin, 1.2pg/ml 
pepstatin, 1.75pg/ml trypsin inhibitor, 0.9pg/ml aprotinin, 70pg/ml ubenimex 
[Bestatin]). The beads were then washed twice with LDB buffer (lOOmM KC1, 
20mM Hepes.Cl pH 7.9, 12mM MgCl2, O.lmM EDTA, 17% glycerol, 2mM DTT) to 
remove unbound antibody and other factors such as proteases present in the sera.
Immunoprecipitation reactions were typically carried out using 150pg of 
HeLa nuclear extract (20pl) incubated for 3 h at 4°C on an orbital shaker with 20 j l x 1 
of protein A-Sepharose beads carrying equivalent amounts of prebound 
immunoglobulin (IgG) for the different reactions. The beads were then gently 
pelleted by pulse centrifugation, supernatants were carefully removed and the beads 
were washed five times with 500pl of LDB. The bound material was released by 
adding an equal volume of 2 x protein sample buffer (12.5mM Tris pH 6.8, 1% SDS, 
10% p-mercaptoethanol, 20% glycerol, 0.25% bromophenol blue) and was analysed 
by Western blotting. For other immunoprecipitations, PC-B, PC-C or 35S-labelled in 
vitro translated proteins was used instead of nuclear extract. In the latter case, 
precipitated material and supernatant was analysed by autoradiography.
2.11 Separation of proteins by gel electrophoresis
Proteins were resolved by electrophoresis on denaturing (SDS) 
polyacrylamide gels. The gel recipes were based on the SDS discontinuous buffer 
system of Laemmli (306). Typically, proteins were electrophoresed on 7.8% 
polyacrylamide resolving minigels (containing 375mM Tris pH 8.8, 0.1% SDS). A 
4% polyacrylamide gel containing 125mM Tris pH 6.8 and 0.1% SDS was routinely 
cast as the stack. Before loading samples on the gel, they were boiled for 5 min in 1 
x protein sample buffer (6.25mM Tris pH 6.8, 0.5% SDS, 5% p-mercaptoethanol, 
10% glycerol, 0.125% bromophenol blue). Electrophoresis was carried out in 1 x 
protein running buffer (0.1% SDS, 76.8mM glycine, lOmM Tris, pH 8.3) at 70V
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initially until the bromophenol dye front had entered the resolving gel and then at 
140 V for ~ 1V2 h until the dye had reached the bottom of the gel.
2.12 Western blotting
Following resolution by SDS-PAGE, proteins were transferred to a 
nitrocellulose filter by electroblotting in 20mM sodium phosphate (pH 6.7) at 37V 
for 30 min using the BioRad Mini Trans-Blot Electrophoretic Transfer Cell. The 
filter was then washed for 10 min in 1 x TBS (25mM Tris pH 7.6, 150mM NaCl) and 
blocked for 1 h at room temperature in milk buffer (1 x TBS, 0.5% Tween-20, 4% 
skimmed milk powder (Marvel)). The blot was incubated with diluted primary 
antibody (typically a 1:1000 or 1:2000 dilution) overnight at 4°C. To remove excess 
primary antibody, the blot was washed for 2 min with milk buffer three times before 
incubating for 1 h at room temperature with the appropriate horseradish peroxidase- 
conjugated secondary antibody. The blot was then washed extensively to remove 
excess secondary antibody (3 x 2  min and 2 x 1 5  min with milk buffer followed by a 
5 min wash with TBS). The blot was developed by the enhanced chemiluminescence 
method (ECL, Amersham), according to the manufacturer’s instructions.
2.13 Transformation
For plasmid storage and propagation, E. coli XL-1 Blue supercompetent cells 
(Stratagene) were transformed. For the expression of recombinant proteins in 
bacteria, E.coli BL21 (DE3) pLys competent cells were used as host. For both E.coli 
strains, competent cells were thawed on ice. 50pl of XL 1-Blue cells or 20pl of BL21 
(DE3) pLys cells were used per transformation reaction. For each transformation, 
10-20ng (lp l) of plasmid DNA was added to the chilled aliquot of thawed cells and 
the contents of the tube were gently mixed by stirring with a pipette tip. After 
incubating on ice for 30 min, cells were heat shocked at 42°C for 45 seconds and 
then placed on ice for a further 2 min. 450pl of SOC medium (2% bacto-tryptone, 
0.5% yeast extract, 20mM glucose, lOmM NaCl, lOmM MgSCL, lOmM MgCL) was
83
then added and the cells were incubated at 37°C for 1 h on an orbital shaker 
(~200rpm). A variety of small volumes (200pl or less) of the transformation mixture 
were then plated on LB agar plates containing 50pg/ml ampicillin (Amp). Plates 
were incubated overnight at 37°C to allow transformed cells to grow and form 
colonies.
2.14 Plasmid DNA preparation
For large scale plasmid DNA preparation, a single isolated bacterial colony 
was first picked from a freshly streaked plate and used to inoculate 10ml of LB 
medium (10g/l bactotryptone, 5g/l yeast extract, 10g/l NaCl) containing appropriate 
selective antibiotic (50pg/ml ampicillin). After 6 h shaking at 37°C, 3ml of this 
mini-culture was used to inoculate 250ml of LB medium containing ampicillin. This 
larger bacterial culture was grown overnight at 37°C on an orbital shaker. Cells were 
then harvested by centrifugation at 6000g for 15 min at 4°C and plasmid DNA was 
prepared using the QIAGEN Plasmid Maxi Kit.
Following resuspension in 10ml of Buffer PI (50mM Tris pH 8.0, lOmM 
EDTA, lOOpg/ml RNase A), cells were subjected to alkaline lysis by incubating with 
10ml of Buffer P2 (200mM NaOH, 1% SDS) for 5 min at room temperature. The 
lysate was then quickly neutralised by adding 10ml of chilled Buffer P3 (3M 
potassium acetate, pH 5.5) and mixing immediately causing a precipitate of 
potassium dodecyl sulphate to form. The SDS-denatured proteins and chromosomal 
DNA were co-precipitated with detergent whereas plasmid DNA, which lacks any 
close protein associations, remained in solution. After 20 min incubation on ice, the 
precipitate was pelleted by centrifuging at 20,000g for 30 min at 4°C and the 
supernatant was removed and applied to a QIAGEN tip 500 pre-equilibrated with 
QBT buffer (750mM NaCl, 50mM MOPS pH 7.0, 15% isopropanol, 0.15% Triton 
X-100). This is an anion-exchange resin to which plasmid DNA was able to tightly 
bind. The resin was then washed twice with 20ml of Buffer QC (1M NaCl, 50mM 
MOPS pH 7.0, 15% isopropanol) before elution of purified plasmid DNA in QF 
buffer (1.25M NaCl, 50mM Tris pH 8.5, 15% isopropanol) and its precipitation 
using 0.7 volumes of isopropanol. After centrifugation at 15000g for 30 min and a
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70% ethanol wash, plasmid DNA was resuspended in a small quantity of sterile 
water or TE buffer pH 8.0.
2.15 Expression and purification of glutathione S transferase (GST)-fusion
proteins
A glycerol stock of BL21 (DE3) pLys bacteria transformed with the 
appropriate GST-fusion protein expression vector was thawed on ice. A loopful of 
cells was used to inoculate 20ml of LB medium containing appropriate selective 
antibiotics (GST-RB(379-928) expression vector: 50pg/ml ampicillin, lOpg/ml 
chloramphenicol; GST expression vector: 50pg/ml ampicillin) and grown overnight 
at 37°C. This culture was then used to inoculate 200ml of LB medium which was 
grown for -  1 h at 37°C to mid-logarithmic phase (optical density ~0.6). The culture 
was then transferred to an orbital shaker at room temperature and incubated with 
shaking (200rpm) for 30 min. lOOpM isopropyl-p-D-thiogalactopyranoside (IPTG) 
was then added to induce the expression of recombinant protein and cultures were 
incubated for a further 16 h at room temperature. Bacteria were harvested by 
centrifugation and resuspended in 9ml of ice-cold PBS containing 1% Triton X-100 
and 1% PMSF. Cells were lysed by sonicating briefly on ice (2 x 20 secs on 60- 
SOW). The cell debris was pelleted by centrifugation (12,000 rpm for 10 min at 4°C 
in a Sorvall High Speed Centrifuge). The supernatant, which should be clear but 
coloured, was carefully decanted to a fresh tube containing 200pl of glutathione- 
agarose beads and mixed by constant rotation for 30 min at 4°C. The beads were 
then washed extensively to remove unbound proteins (2 x 50ml ice cold PBS/1 % 
Triton X-100, 2 x 50ml ice cold PBS with no Triton X-100). To elute bound GST- 
fusion protein from the glutathione agarose beads, the beads were mixed by rotation 
with an equal volume of elution buffer (50mM Tris, 25mM glutathione, pH 8.0) for 
10 min at room temperature. This was repeated three times to ensure efficient 
elution. Samples were then dialysed in LDB for 5-6 h at 4°C, aliquoted and stored at 
-70°C.
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2.16 Expression and purification of 6 x Histidine (His)-tagged RB
A single colony of BL21 (DE3) pLys cells freshly transformed with His6Rb 
(379-928) construct was used to inoculate 50ml of LB medium. This culture was 
grown overnight at 37°C and used to inoculate 500ml LB. After 1-1% h further 
growth at 37°C (optical density of 0.6-0.8), the 500ml culture was placed in an 
orbital shaker at room temperature and immediately induced (150pM IPTG). Cells 
were incubated for a further 16-24 h to allow expression of His-tagged protein. 
Bacterial pellets were resuspended in TBS/1% Triton/1% PMSF. Sonication and the 
clearing of the lysate were performed as for GST-fusion protein preparations. 
Supernatant was incubated with 300pl of nickel-agarose beads (QIAGEN) in a final 
concentration of lOmM imidazole for 30 min at 4°C. The agarose beads were 
washed 5 x with 15ml of TBS containing lOmM imidazole followed by a further five 
washes with 15ml of TBS containing 40mM imidazole. His-tagged protein was 
batch eluted from the Ni-NTA (nitrilo-triacetic acid) resin by three sequential 10 min 
incubations at room temperature with 1 bead volume of TBS containing 150mM 
imidazole. Eluates were dialysed extensively in LDB as for purified GST-fusion 
proteins and stored in small aliquots at -70°C.
2.17 Coomassie Blue staining of protein gels
The purity and yield of bacterially expressed recombinant proteins was 
analysed by running small volumes (<5jnl) of purified protein on a SDS 
polyacylamide gel that was then stained with Coomassie Blue R250. First, the gel 
was fixed for 15 min in a 5:1:5 mixture of methanol, glacial acetic acid and water. 
To stain the gel, it was incubated in fixative containing 0.1% (w/v) Coomassie Blue 
R250 for ~30 min. Excess dye was removed by destaining in an aqueous solution of 
5% methanol and 7.5% acetic acid. The concentrations of purified recombinant 
proteins were estimated by comparison of the intensity of staining with that of known 
amounts of bovine serum albumin that were run on the same gel.
86
2.18 Column chromatography
All chromatographic procedures were performed in a cold room at 4°C using 
the Biorad Econo System except for DNA- and immuno- affinity purification that 
was carried out by hand in Biorad Polyprep® disposable columns. Buffers were all 
prepared using ultrapure deionised water obtained from a Millipore M illiQ piUs system 
and were autoclaved or filter-sterilised before use and pre-chilled at 4°C. The 
starting material for fractionation, nuclear extract from exponentially growing HeLa 
cells, was purchased from the Computer Cell Culture Centre (Mons, Belgium).
2.18.1 Fractionation of HeLa nuclear extract on phosphocellulose
Phosphocellulose chromatography was carried out by the method of Segall et 
al. (473). The day before fractionation, the phosphocellulose resin was prepared. 
The phosphocellulose (PI 1, Whatman), which is purchased as an anhydrous powder, 
was activated for use as a cation exchanger by washing first with base and then acid. 
A suitable amount of phosphocellulose was weighed out and stirred into 25 volumes 
of 0.5M NaOH. The phosphocellulose was left to settle for 5 min before decanting 
off the supernatant. It was then washed extensively with deionised water in a 
Buchner funnel until the filtrate pH was 11.0 or below. The phosphocellulose was 
then mixed with 25 volumes of 0.5M HC1 and left for 5 min. To avoid excessive 
hydrolysis and swelling, it was important that the phosphocellulose was not exposed 
to 0.5M NaOH or 0.5M HC1 for any longer than 5 min. After the acid wash, the 
phosphocellulose was washed with deionised water as previously until the filtrate pH 
was within several pH units of that of the starting buffer, i.e. pH 7.9. The 
phosphocellulose was then mixed with several changes of 1M Hepes.Cl pH 7.9 until 
the pH was within 0.5 units of the desired pH. The phosphocellulose was then left to 
equilibrate overnight in starting buffer, PC-A (0.1) (20mM Hepes.Cl pH 7.9, 20% 
glycerol, 0.2mM EDTA, lOOmM KC1, 0.5mM DTT).
The following morning the pH was checked and an empty column of suitable 
volume was packed with equilibrated phosphocellulose resin. The column was then 
attached to the Biorad Econo System and the gradient monitor was calibrated by 
washing with several volumes of low salt buffer (PC-A (0.1)) followed by several
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volumes of high salt buffer (PC-A (1.2)). The column was then reequilibrated in low 
salt buffer (PC-A(O.l)) ready for the application of extract.
The maximum protein binding capacity of phosphocellulose is ~10mg per ml. 
To avoid overloading the column, 5mg of nuclear extract (7.5mg/ml) was loaded per 
ml of resin. To allow the equilibration of applied protein with the column and 
adsorption to occur, extract was loaded slowly at a flow rate of 1 column volume per 
hour. PC-A (0.1) was applied at the same flow rate until protein was detected in the 
flow-through at which point the flow rate was increased to 2.5 column volumes per 
hour. A UV monitor measured absorbance at 280nm enabling the elution of protein 
from the column to be closely monitored. The Econo system was programmed to 
collect 1ml fractions. Individual fractions were directly tested for protein content 
using a colourimetric method based on the differential colour change of Bradford’s 
reagent, an acidic solution of Coomassie Brilliant Blue G-250, in response to various 
concentrations of protein. lOpl of fractions were mixed with lOOpl of a 1:10 dilution 
of Bradford’s reagent (Biorad) in a 96-well plate. The binding of protein to dye 
resulted in an immediate colour change. The column was washed with PC-A (0.1) 
until the flow-through peak had returned to near zero and little or no protein was 
detectable in eluted fractions. These flow-through fractions (PC-A) contain TFIIIA. 
Bound protein was then step-eluted by sequential washing with PC-A buffer (20mM 
Hepes.Cl pH 7.9, 20% glycerol, 0.2mM EDTA, 0.5mM DTT) containing 350mM 
KC1 (PC-A (0.35)), 600mM KC1 (PC-A (0.6)) and 1.2M KC1 (PC-A (1.2)). 
Fractions eluted by the 0.1 to 0.35M KC1 step constitute PC-B and contain both 
TFIIIB and pol III. PC-C constitutes fractions eluted by the 0.35 to 0.6M KC1 step 
and contains TFIIIC, pol III and SNAPc. PC-D is the 0.6 to 1.2M KC1 step fraction 
and contains the pol II factor TFIID and the pol I factor SL1.
Before aliquoting and snap freezing, PC-B and PC-C fractions were 
extensively dialysed to lower the salt concentration. Dialysis was carried out at 4°C 
using the Gibco BRL Microdialysis System in accordance with the manufacturer’s 
specifications. The dialysis membrane, stored in 20% ethanol, was prepared for 
dialysis by washing carefully with 4-5 changes of deionised water. The sheets of 
dialysis membrane have an exclusion limit of 12 to 14 kDa ensuring retention of the 
pol III factors but allowing exchange of ions. Fractions were dialysed against LDBO 
(20mM Hepes.Cl pH 7.9, 12mM MgCl2, O.lmM EDTA, 17% glycerol, 2mM DTT)
to a final salt concentration of ~100mM. The progress of dialysis was monitored by 
measuring the salt conductivity of fractions. Typically, PC-B fractions were dialysed 
for ~4-6 h and PC-C fractions were dialysed for —8-10 h.
To reduce the likelihood of protein degradation, freshly prepared PMSF 
(O.lmM final concentration) was added to chromatographic and dialysis buffers. 
O.lmM PMSF was also added to the starting material along with a cocktail of other 
protease inhibitors (0.9pg/ml leupeptin, 1.2pg/ml pepstatin, 1.75|ng/ml trypsin 
inhibitor, 0.9pg/ml aprotinin, 70pg/ml ubenimex [Bestatin]) which together can 
inhibit the major classes of cellular proteases. Fractions obtained by chromatography 
were stored at -70°C.
2.18.2 Heparin- and SP- Sepharose chromatography
Gradient chromatography on heparin-Sepharose was carried out using pre­
packed 1ml Hi-Trap Heparin columns obtained from Pharmacia Biotech. The 
column was equilibrated by washing with 5 column volumes of Hep buffer (20mM 
Hepes.Cl pH 7.9, 20% glycerol, 0.2mM EDTA, 5mM MgCl2, O.lmM DTT, 0.1 mM 
PMSF, O.lmM sodium metabisulphate) containing lOOmM KC1 (Hep 100). 
Typically, 15mg of HeLa nuclear extract (2ml) or ~4mg PC-B (~4mls) were 
fractionated. Samples were loaded onto the column at a flow rate of 0.05ml/min (3 
cvs/h). After extensive washing with Hep 100, bound protein was gradient eluted. 
The Econo System pump has two separate buffer inlets with buffer uptake from 
either inlet controlled by a proportioning valve enabling the formation of a gradient 
by the appropriate mixing of two different buffers. The system was programmed to 
form a linear lOOmM to 1M KC1 gradient in 1 h. The gradient was typically run in 3 
or 6 column volumes at a flow rate of O.lml/min. Eluted fractions (200pl) were 
dialysed against LDBO to a final KC1 concentration of lOOmM, as previously.
Gradient chromatography on SP-Sepharose was also carried out using a 
prepacked 1ml HiTrap column (Pharmacia Biotech). Chromatographic conditions 
and buffers were identical to those used for fractionation on heparin.
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2.18.3 Fractionation of PC-B on Cibacron Blue
A 1ml prepacked HiTrap Sepharose column (HiTrap Blue, Pharmacia 
Biotech) was also used for chromatography of fractions on Cibacron blue 3GA. The 
column was equilibrated by washing with 5 cvs of CB buffer (20mM Tris.HCl pH
7.9, 5mM MgCh, 10% glycerol, 3mM DTT, O.lmM PMSF) containing lOOmM 
NaCl (CB100). lmg of PC-B was then loaded at a flow rate of 0.05ml/min (3cvs/h). 
To remove unbound protein, the column was washed at O.lml/min (6cvs/h) with ~10 
column volumes of CB100. Several column volumes of CB buffer containing 1M 
NaCl were then applied until little or no more protein was being eluted (CB1000). 
CB buffer containing 2M NaCl and 5M urea (CB2000U) was then applied to elute 
even more tightly bound protein. 0.2ml fractions were collected, as programmed by 
the Econo System. Protein-containing fractions were dialysed against LDBO for ~ 
6-7 h until of approximately the same salt conductivity as LDB. The fractions were 
then dialysed for a further 3 h against LDB to ensure removal of any residual urea 
still present in the samples.
2.18.4 Fractionation of PC-B on hydroxyapatite
PC-B (lmg) was fractionated on hydroxyapatite using a prepacked 1ml 
Econo-Pac CHT-II column obtained from Biorad. The column was equilibrated by 
washing with 5 cvs of HAP buffer (10% glycerol, 60mM KC1, 5mM MgCL, 1.5mM 
DTT, O.lmM PMSF) containing lOmM potassium phosphate pH 7.0 (HAP10). PC- 
B, diluted 2-fold in HAP 10 buffer, was applied to the resin at a flow rate of 
0.02ml/min. The flow rate was then increased to 0.04ml/min. After washing 
extensively with HAP 10 buffer, bound protein was eluted with a 6ml linear gradient 
from lOmM to 500mM potassium phosphate pH 7.0 in HAP buffer. Fractions were 
dialysed into LDB as previously.
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2.18.5 Carboxymethyl chromatography
Fractionation on carboxymethyl was carried out using a prepacked 1ml 
carboxymethyl column obtained from Biorad. Typically, less than lmg of protein 
was applied to this column because of its low protein binding capacity. The column 
was equilibrated by washing with PC-A (0.1). Protein was applied at a flow rate of 
O.lml/min (6cvs/h). The column was washed at the same flow rate with PC-A (0.1). 
It had previously been shown that TFIIIB does not bind to this weak cation 
exchanger under these conditions, thereby avoiding the need for dialysis. 0.2ml 
flowthrough fractions were collected, aliquoted and snap-frozen immediately. These 
fractions were subsequently assayed for TFIIIB activity. TFIIIC and pol III were 
step-eluted with PC-A (1.2) and dialysed into LDB before aliquoting and snap 
freezing.
2.18.6 Purification of antisera for use in immunoaffinity chromatography
Antisera were purified on protein A-Sepharose beads (Pharmacia Biotech) by 
the low salt method of Harlow and Lane (195). 2mls of protein-A Sepharose beads 
were transferred to a disposable polypropylene column (Polyprep®, Biorad) and 
washed with several volumes of lOOmM Tris pH 8.0. To ensure the tight binding of 
immunoglobulins to the protein A, one-tenth volume of 1M Tris pH 8.0 was added to 
the thawed sample of antiserum. The antiserum (4ml) was slowly recirculated 
through the column of protein A-Sepharose for ~ lh  (four passes). The protein A- 
Sepharose column was then washed with 10 column volumes of lOOmM Tris pH 8.0 
(20mls, 1 h) followed by a further 10 column volumes of lOmM Tris pH 8.0. 
Purified immunoglobulin was eluted by lowering the pH by applying lOOmM glycine 
pH 3.0. To preserve the structure and activity of immunoglobulins, samples were 
immediately neutralised on elution by collecting in 0.5ml fractions in eppendorf 
tubes that already contained 50pl of 1M Tris pH 8.0 and mixing gently. Protein- 
containing fractions were pooled (4mls) and dialysed into LDB.
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2.18.7 Immunoafflnity purification of TFIIIB or TFIIIC
TFIIIC was immunopurified using the polyclonal antiserum 4286, which was 
raised by immunising rabbits with synthetic peptide RPGFSPTSHRLLPTP (human 
TFIIICp residues 897-911) coupled to keyhole limpet haemocyanin. The 
corresponding preimmune serum was used in control immunopurifications that were 
carried out in parallel. Prior to use, the sera were purified on protein A-Sepharose 
beads. Eluted antibodies were dialysed into LDB. 2 mis of PC-C fraction 
(~0.7mg/ml) was incubated with 300pl of purified antibody (~10mg/ml) on ice for 1 
h. This mixture was recirculated slowly through 350jul of protein A-Sepharose at 
4°C for ~2 h. The column was washed with 25 column volumes of CB buffer 
containing lOOmM NaCl (CB100). Immunoaffinity-purified TFIIIC was then eluted 
using CB buffer containing 2M NaCl and 2M urea. Fractions were dialysed into 
LDB buffer.
TFIIIB was immunopurified using either the 128 or 330 antiserum, which 
were raised against residues 533-547 and 664-677 of human BRF, respectively. The 
immunopurification procedure was identical to that for TFIIIC except that PC-B 
(2ml) or TFIIIB-containing heparin fractions (2ml) were used as starting material.
2.18.8 DNA-affinity purification of TFIIIC
TFIIIC was DNA-affinity purified using a B-block oligonucleotide resin 
carrying the B-block promoter sequence from the adenovirus VAi gene. The starting 
material for DNA-affinity chromatography, PC-C or immunoaffinity-purified TFIIIC 
in LDB, was diluted into BL70 buffer (70mM KC1, 0.1% IGEPAL CA-630 (Sigma), 
20mM Hepes.KOH pH 7.9, 12mM MgCl2, O.lmM EDTA, 17% glycerol, 9mM DTT, 
O.lmM PMSF, 0.5pg/ml leupeptin, 0.7pg/ml pepstatin, lpg/ml trypsin inhibitor, 
0.5pg/ml aprotinin, 40pg/ml ubenimex [Bestatin]). Prior to loading onto the column, 
the diluted starting material was incubated on ice for 10 min with 30pg poly(dl.dC) 
per mg of protein. This protein-DNA mixture (lm g of protein) was slowly 
recirculated through 350pl of affinity resin for ~75 min at 4°C. The column was 
washed with 20 column volumes of LDB. 5 column volumes of PC-A(0.35) were
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then sequentially applied, collecting 1 column volume fractions. 1 column volume 
of PC-A buffer (minus the EDTA) containing 2M KC1, 0.1% IGEPAL CA-630, and 
0.2mg/ml insulin was then applied and left for 10 min. The fraction was then 
collected and this was repeated with a further 5 column volumes of this high salt PC- 
A buffer. Fractions were dialysed into LDB, as previously. Dialysed fractions were 
then extensively aliquoted to avoid the need for multiple freeze-thaw cycles and 
immediately snap frozen on dry ice.
2.19 Measuring protein concentration
The protein concentration of samples were accurately estimated by 
quantitating the colour change in Bradford’s reagent (Biorad) on mixing 1ml of 
diluted reagent (1:10 in distilled water) with a small volume of the sample being 
assayed. The absorbance of this mixture at 595nm was measured in a UV 
spectrophotometer. For a narrow range of protein amounts (~l-12pg), the change in 
absorbance at 595nm in response to increasing amounts of protein is approximately 
linear. A standard curve was constructed by measuring absorbance at 595nm for 
known amounts of bovine serum albumin (BSA). For absorbances in the linear 
range of the standard curve, the protein concentration of samples was estimated by 
reading from the plotted graph the amount of protein that this absorbance equates to 
when using BSA as a standard. This was repeated using several different volumes or 
dilutions of the sample to obtain an average and a more accurate measurement of 
protein concentration. For absorbances outside the linear range of the standard 
curve, samples were appropriately diluted to try and obtain a reading within the 
linear range, which should give a more accurate estimation of protein concentration.
2.20 Silver staining
For very dilute protein samples, the use of Bradford’s reagent for estimating 
protein concentration was unsuitable. Instead, the protein concentration of samples 
was estimated by running small volumes of sample on a SDS-polyacrylamide gel,
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silver staining to visualise protein, and comparing the intensity of staining with that 
of known amounts of BSA run alongside the samples on the gel. This method of 
estimating protein concentration was identical to that used for bacterially-expressed 
recombinant proteins except that the polyacrylamide gel was stained with silver 
rather than Coomassie Blue. Silver staining is about 10-20 times more sensitive than 
using Coomassie Blue and enabled the detection of nanogram amounts of protein 
(detection limit ~2-5 ng per protein band).
To silver stain, first the gel was fixed by soaking in 250ml 50% methanol 
twice for 15 min. This was followed by a 15 min incubation in 5% methanol. The 
gel was then incubated in 250ml of deionised water containing 8pl of 1M DTT for 
15 min. After washing briefly with deionised water twice, the gel was then gently 
agitated for 15 min in a freshly prepared 0.1% solution of silver nitrate. To remove 
excess silver nitrate solution, the gel was washed twice briefly with deionised water 
followed by two quick washes with a small amount of freshly made developing 
solution (3% (w/v) sodium carbonate, 0.5ml 37% formaldehyde per litre, in distilled, 
deionised water). The remainder of the developing solution (~200ml) was then 
added and incubated with the gel until the silver stained protein bands were of the 
desired intensity. Staining was stopped by pouring off most of the developing 
solution and sprinkling solid citric acid into the remaining solution containing the gel 
with swirling. Citric acid was slowly added until the fizzing ceased, a little water 
was added and the gel was gently agitated in this solution for 15 min. The silver 
stained gel was then washed three times for 15 min in water. The gel was soaked in 
5% glycerol before drying.
2.21 Kinase assays
Protein fractions were assayed for the presence of particular kinases by 
incubating with micromolar amounts of specific peptide substrates and radiolabelled
99phosphate donor (2pCi y- P ATP, 3000mCi/mmol) thereby enabling the detection of 
phosphorylated peptide. Phosphorylation reactions were allowed to proceed for 20
n 9min at 30 C and were stopped by pipetting samples onto 2cm phosphocellulose 
paper discs (P81, Whatman). The discs were then immersed in ~200ml 75mM
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phosphoric acid and incubated on a shaking platform for 5 min. This washing step in 
75mM phosphoric acid, to remove unincorporated label, was repeated a further four 
times, followed by a 5 min wash with 70% ethanol. The discs were then left to air- 
dry and liquid scintillation counting was used to quantitate bound radioactivity.
2.22 Polymerase assays
Assays of RNA polymerisation activity were adapted from the method of 
Roeder (440). Reactions were carried out in a volume of 50pl in a final 
concentration of 6mM HEPES pH 7.9, 30mM KC1, 3.6mM MgC^, 6mM Tris pH
7.9, 200pM EDTA, 7.5mM ammonium sulphate, 800pM manganese chloride, 
600pM of rATP, rCTP and rGTP, 50pM UTP, 0.6mM DTT and 5% glycerol. Each 
reaction also contained 5pg of poly(dA.dT) (2pl) as non-specific template, 20pg 
BSA, lOpCi [a-32P] UTP (400Ci/mmol), and up to 15pl of protein fraction. After 20 
min incubation at 30°C, reactions were stopped by pipetting samples onto 2cm2 discs 
of Whatman DE51 paper. Discs were washed 6 x 5  min in 0.5M Na2HPC>4, twice in 
distilled water, twice in 96% ethanol and finally once in ether. As for kinase assays, 
levels of incorporated radioactivity were measured in a scintillation counter.
2.23 HAT assays
HAT reactions were carried out in 1 x HAT buffer (50mM Tris pH 8.0, 5% 
glycerol, O.lmM EDTA, 50mM KC1, ImM DTT, ImM PMSF) in a final reaction 
volume of 30pl containing lpg of purified chicken core histones (lmg/ml) and 
0.25 pCi of 14C acetyl CoA. Reactions were initiated by the addition of protein 
sample and were incubated at 30°C for 30 min. lOpl of 4 x protein sample buffer 
(25mM Tris pH 6.8, 2% SDS, 20% p-mercaptoethanol, 40% glycerol, 0.5% 
bromophenol blue) was added to stop the reactions. To resolve the core histones, 
samples were run on a 12% polyacylamide-SDS gel. The gel was fixed for 30 min 
and then impregnated with fluor by soaking in Amplify™ (Amersham) for 15-30
95




Partial purification of the mammalian 
RNA polymerase III general 
transcription factors TFIIIB and 
TFIIIC
3.1 Introduction
RNA polymerase III, with an aggregate molecular weight of 600-700 kDa 
and 16-17 different subunits, is the largest and most complex of the three nuclear 
RNA polymerases (83, 523, 554). Despite its complexity, in the absence of other 
proteins, the polymerase initiates transcription randomly (106, 188, 247, 555). 
Accurate and specific initiation of transcription requires the assistance of 
transcription factors that recruit the polymerase to the appropriate start sites of the 
appropriate sets of genes (405).
The transcription factors participate in highly specific protein-protein and 
protein-DNA interactions that are essential for the accurate recruitment of 
polymerase to the appropriate genes. For most genes, interaction is required between 
a transcription factor that specifically recognises the promoter elements and another 
transcription factor that specifically interacts with the appropriate polymerase. 
Although it is not inconceivable that the specificity of the three nuclear RNA 
polymerases for particular sets of genes could be achieved by utilising mutually 
exclusive, pol-specific domains of the same set of transcription factors, the utilisation 
of different transcription factors seems a much more attractive and simpler situation.
In 1980, Segall and co-workers demonstrated that the transcription factor 
requirements for specific pol II and pol III transcription are different (361, 473). 
Human cell-free extracts were fractionated on a phosphocellulose column and the 
ability of the various fractions, step-eluted with increasing concentrations of KC1, to 
reconstitute specific transcription of pol II and pol III templates was tested. No 
single fraction alone was able to reconstitute transcription of any pol II or pol III 
template tested. The PC-B fraction (0.1-0.35M KC1) in combination with the PC-C
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fraction (0.35-0.6M KC1) effectively reconstituted transcription of tRNA and VAi 
genes (473). Reconstitution of pol II transcription required three of the four step- 
eluted fractions, the PC-A fraction (0.1M KC1), the PC-C fraction (0.35-0.6M KC1) 
and the PC-D fraction (0.6-1.0M KC1) (361).
The activities in the PC-B and PC-C fractions required to reconstitute specific 
transcription of tRNA and VA genes were designated TFIIIB and TFIIIC, 
respectively (473). The expression of many other class III templates is also 
supported by these two fractions, suggesting that the basal factor requirements are 
similar for many class III genes (75, 272, 487). TFIIIB and TFIIIC are thus regarded 
as general pol III transcription factors, unlike TFIIIA which elutes in the PC-A 
fraction and is specifically required for 5S gene transcription (134,473).
The phosphocellulose fractions, resulting from the first step fractionation of 
cell-free extracts, are inevitably crude and it is clearly possible that the PC-B and PC- 
C fractions contain multiple factors that are required for pol III transcription. It is 
also worth noting that the activities in the PC-B and PC-C fractions that are required 
for one class III gene may be different for another class III gene. Reconstitution of 
pol II and pol III transcription both required the PC-C fraction, raising the possibility 
of a common factor (473). Further chromatography of this fraction on DEAE- 
cellulose separated the activities required for pol II and pol III transcription, lending 
support to the idea that there may be multiple transcription components in each of the 
PC fractions (473).
In the last twenty years there has been a considerable effort by a number of 
laboratories to purify TFIIIB and TFIIIC and determine their molecular composition. 
In the simple eukaryote Saccharomyces cerevisiae, a combined biochemical and 
genetic approach has enabled the identification of the polypeptide composition of 
both TFIIIB and TFIIIC. TFIIIB consists of three essential components, the TATA- 
binding protein (TBP) (264), the TFIIB-related factor (BRF) and a 90kD 
polypeptide, B" (24, 261). The genes for TBP (77, 146, 185, 221, 225, 462), BRF 
(64, 101, 342) and B" have all been cloned and TFIIIB activity has now been 
reconstituted using entirely recombinant subunits (266, 439, 452). Yeast TFIIIC 
consists of six subunits (23, 47, 156, 408, 505), which have also been cloned (325, 
355, 407, 505).
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The composition of TFIIIB and TFIIIC in higher eukaryotes is much less well 
defined. Two components of human TFIIIB have been unequivocally established; 
human homologues of yeast TBP and BRF (340, 371, 374, 484, 507, 552, 573). 
Very recently, a human homologue of yeast B" has also been cloned (463). 
Furthermore, it has been shown to be required for pol III transcription in vitro and 
chromatin immunoprecipitations indicate that it associates with the U6 promoter in 
vivo (463). These results, and the fact that it is a homologue to an essential 
component of yeast TFIIIB, suggest that human B" is a bona fide component of 
human TFIIIB. However, it is likely that human TFIIIB has additional subunits that 
have yet to be identified, these may be essential or may perform non-essential 
stimulatory functions. This may also be true for yeast TFIIIB, as that reconstituted 
from recombinant TBP, BRF and B" is significantly less active than native yTFIIIB, 
suggesting there may be other unidentified subunits that are missing, or perhaps 
important post-translational modifications are lacking (266, 452).
hBRF was first identified as a potential component of hTFIIIB following its 
specific immunoprecipitation from partially purified TFIIIB fractions using anti-TBP 
antibodies (374, 552). Using this approach, a variety of other candidate TBP- 
associated factors (TAFs) were identified that may be part of TFIIIB (91, 340, 374, 
507, 514). However, the functional significance of these TAFs is unclear. 
Moreover, a PC-B fraction contains at least two distinct TBP-containing complexes, 
TFIIIB and B-TFIID (524). The partially purified TFIIIB fractions used in these 
immunoprecipitations may have contained some B-TFIID. It has been established 
that the 172kD TAF described by Taggart et al. (507) as an essential component of 
TFIIIB is in fact the 170kD TAF that forms part of B-TFIID (371, 552). In addition, 
some of the TAFs appeared substoichiometric to TBP and hBRF. This may indicate 
that they are loosely associated or that they interact with TBP indirectly. The 
uncertainty as to the composition of hTFIIIB (434) is compounded by other evidence 
suggesting that it is a labile protein and also that the requirements may differ for 
different class III templates (91, 340, 365, 371, 463, 513-515).
In contrast to TFIIIB, which shows substantial conservation between yeast 
and humans (213, 316, 374, 552), hTFIIIC seems to have diverged significantly from 
its yeast counterpart (230, 231, 307, 331, 488). Fractionation of hTFIIIC on a variety 
of different columns splits it into two components, TFIIIC 1 and TFIIIC2 (118, 607).
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TFIIIC2 consists of five subunits, all of which have been cloned and partially 
characterised (230, 231, 291, 331, 488, 608). The composition of TFIIIC 1 is 
unknown.
In yeast, where the pol III transcriptional apparatus is best characterised, there 
has been very little work carried out on the regulation of pol III transcription. The 
bulk of the regulatory studies have been in the mammalian system. Unfortunately, a 
lot of this work has, necessarily, utilised rather impure and ill-defined fractions as 
sources of the major pol III components.
In this chapter, I describe the partial purification of hTFIIIB and hTFIIIC for 
use in dissecting the role of these two essential transcription factors in the regulation 
of RNA pol III transcription. hTFIIIB and hTFIIIC were partially purified using a 
combination of conventional and affinity chromatography. I also describe the use of 
my partially purified TFIIIC fractions to investigate further recent reports suggesting 




3.2.1 Screening of cation exchangers for effective separation of hTFIIIB and 
hTFIIIC
Since the early fractionations of Segall and co-workers (361, 473), 
chromatography on phosphocellulose has traditionally been used as the first 
fractionation step in any purification scheme of mammalian pol II or pol III 
transcription factors. To my knowledge, at least as far as the pol III transcription 
factors are concerned, the suitability of other columns as possible alternatives to 
phosphocellulose has not been investigated.
Although phosphocellulose is very effective at separating hTFIIIB and 
hTFIIIC, there are several disadvantages of using this particular resin compared to 
others. In addition to being time consuming, the need to activate the 
phosphocellulose the day prior to use, and to hand-pack the column, are two potential 
sources of considerable variation in the reproducibility of this chromatographic step. 
Indeed, inconsistency has been reported in the composition of the PC-B and PC-C 
fractions. TFIIIC1 elutes from phosphocellulose between 280 and 390 mM KC1 
(553). It can therefore be found both in the PC-B and PC-C fractions. The extent to 
which TFIIIC 1 is localised in each of these fractions seems prone to variability.
Phosphocellulose is a strong cation exchanger. The stronger binding of 
TFIIIC than TFIIIB to phosphocellulose may reflect the high affinity of TFIIIC for 
A- and B-block DNA, whereas TFIIIB has little or no affinity for DNA. I decided to 
test the ability of some other cation exchangers for their effectiveness at separating 
TFIIIB and TFIIIC.
Figure 3.1 shows the results of fractionation of HeLa nuclear extract on a 
heparin-Sepharose gradient. Gradient chromatography was performed as the elution 
properties of TFIIIB and TFIIIC were unknown. Heparin belongs to a family of 
negatively charged polysaccharides called glycoaminoglycans. The disaccharide 
repeating unit of heparin has four negatively charged functional groups, one 
carboxylate and three sulphate groups. Like phosphocellulose, heparin functions as a 
strong cation exchanger. In addition, heparin has pseudo-affinity properties, as it 
mimics nucleic acids (468). Given that TFIIIC has DNA-binding properties whereas 
TFIIIB does not, this latter property of heparin potentially offered improved
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resolution of TFIIIB and TFIIIC, compared with a cation exchanger separating solely 
by the criterion of charge.
Assaying of eluted fractions for TFIIIB activity and TFIIIC activity revealed 
that the recovery of active TFIIIB and TFIIIC is relatively good. However, there is a 
considerable overlap of the two activities (Fig 3.1, compare A & B). Indeed, all of 
the fractions containing TFIIIC activity, (fractions 48-58), also contained substantial 
TFIIIB activity (compare lanes 7-17 of Fig.3.1B with lanes 8-18 of Fig.3.1A). In 
addition, the peak of TFIIIB activity and the peak of TFIIIC activity closely 
cofractionated (fractions 50 & 51, compare lanes 10 & 11 of Fig.3.1A and lanes 9 & 
10 of Fig.3.1B). I concluded that heparin-Sepharose, at least using the elution 
conditions that I adopted here, is not suitable as a replacement for phosphocellulose 
in the initial fractionation of HeLa nuclear extract.
A similar fractionation was obtained using a sulphopropyl-Sepharose (SP-) 
cation exhanger. This is another strong cation exchanger, the functional group is a 
negatively charged sulphate group that is attached to the matrix through a propyl 
chain (468). As with the heparin column, all the fractions with TFIIIC activity also 
contained TFIIIB activity (Fig. 3.2 A & B). Although recovery of TFIIIB activity is 
reasonable, very poor recovery of TFIIIC activity was obtained. The poor recovery 
of TFIIIC activity may simply reflect inactivation during the chromatographic 
procedure. Another possibility is that the two components of TFIIIC, TFIIIC 1 and 
TFIIIC2, are separated by the gradient, as has previously been reported for a variety 
of different columns (118, 607). The few fractions that contained TFIIIC activity 
may represent the overlap between TFIIIC 1-containing and TFIIIC2-containing 
fractions. To test the possibility that TFIIIC 1 and TFIIIC2 fractionate differently, I 
tried combining fractions from different parts of the gradient to see if they would 
complement each other for TFIIIC activity. As shown in Figure 3.2 C, combining 
fractions from lower in the gradient than the fractions possessing TFIIIC activity, 
with fractions higher in the gradient, resulted in a synergistic increase in TFIIIC 
activity. This synergy suggests that TFIIIC is split into at least two essential 
components during gradient chromatography on SP-Sepharose.
I also considered using the weak cation exchanger carboxylmethyl (CM) for 
the initial fractionation of HeLa nuclear extract. However, the low binding capacity 




Fractionation of TFIIIB activity and TFIIIC activity on a heparin gradient
15mg of HeLa nuclear extract was applied to a 1ml heparin-Sepharose column. 
After washing with 10 column volumes of Hep buffer containing lOOmM KC1 
(Hep 100), fractions were eluted with a lOOmM- 1M linear KC1 gradient, generated by 
appropriate mixing of Hep 100 and Hep buffer containing 1M KC1 (Hep 1000). 
Eluted fractions were tested for the presence of TFIIIB or TFIIIC by in vitro 
transcription assays.
A) TFIIIB activity of eluted fractions.
Fraction numbers are indicated. SM, starting material; FT, flowthrough. TFIIIB 
activity was assayed using 4jul of the indicated fraction, 2pi of PC-C and 250 ng of 
pVAi; after 15 min incubation at 30°C, nucleotides were added to initiate 
transcription.
B) TFIIIC activity of eluted fractions.
Transcription reactions were performed as described in (A),except 2pl of PC-B was 
substituted for PC-C as the complementing fraction.
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Figure 3.2
Fractionation of TFIIIB activity and TFIIIC activity on SP-Sepharose
15mg of HeLa nuclear extract was applied to a 1ml SP-Sepharose column. After 
washing with 10 column volumes of lOOmM KC1 buffer (Hep 100, as in Fig.3.1), 
fractions were eluted with 6 column volumes of a lOOmM- 1M linear KC1 gradient. 
Eluted fractions were tested for the presence of TFIIIB or TFIIIC by in vitro 
transcription assays.
A) TFIIIB activity of eluted fractions.
Fraction numbers are indicated. SM, starting material; FT, flowthrough. Lane 1 of 
A, B and C; and lane 9 of C contain LDB buffer instead of a fraction. TFIIIB 
activity was assayed using 4pl of the indicated fraction, 2pl of PC-C and 250 ng of 
pVAi; after 15 min incubation at 30°C, nucleotides were added to initiate 
transcription.
B) TFIIIC activity of eluted fractions.
Transcription reactions were performed as described in (A),except 2pl of PC-B was 
substituted for PC-C as the complementing fraction.
C) Synergism of fractions for TFIIIC activity.
Transcription reactions were performed essentially as described in (A). As in (B), a 
PC-B fraction was substituted for PC-C as the complementing fraction. In lanes 4 
and 7, 2pl each of the two indicated fractions was added; in all the other lanes 4pl of 
the indicated fraction was added.
Fraction: - SM FT42 4344 45 46 47 48 49 50 51 52 53 54 55 56
VA
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Fraction: -  SM FT42 43 44 45 46 47 48 49 50 51 52 53 54 5556
VA
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Figure 3.3 shows the results of step elution chromatography on 
phosphocellulose. Step elution could be performed as the elution properties of 
TFIIIB and TFIIIC had previously been determined. Compared to gradient elution, 
this potentially offers increased rapidity of purification and concentration of samples, 
but reduced resolution. The in vitro transcription assays revealed that there is very 
good recovery of TFIIIB activity and TFIIIC activity. In contrast to the heparin and 
SP columns, there is complete resolution of TFIIIB activity and TFIIIC activity 
(Fig.3.3, compare A & B). The recovery of activity and resolution of TFIIIB and 
TFIIIC was consistent between different chromatographic runs (data not shown). I 
therefore concluded that of the cation exchangers tested, for the initial fractionation 
of HeLa nuclear extract, phosphocellulose is the column of choice, both in terms of 
resolution and recovery of activity.
3.2.2 Further purification of TFIIIB from PC-B
At each step of a purification scheme there are inevitable cumulative losses, 
both in terms of the amount of the protein of interest that is recovered and its activity. 
This limits the number of chromatographic steps that can be employed and requires a 
compromise between resolution and the yield and activity of the protein. The 
optimisation of each chromatographic step is paramount to obtaining reasonable 
quantities of active, relatively pure protein.
Although knowledge of the pi and molecular size of the protein of interest 
can provide certain information as to the behaviour of the protein on a particular 
column, the effectiveness of particular columns for purification can be determined 
largely only by trial and error (468).
I tested a variety of different column types for their effectiveness for the 
purification of TFIIIB from PC-B for potential use in a final purification scheme, and 
for cofractionation studies. The choice of columns to test was based on the need to 
combine columns that fractionate by different criteria in order to obtain optimal 
purification in the minimal number of steps, and information from previously 
reported attempts at purification of human TFIIIB.
Figure 3.4 A shows the results of step elution chromatography of PC-B on 
Cibacron blue 3G-A-Sepharose. Cibacron blue 3G-A is a blue dye adsorbent with
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Figure 3.3
Fractionation of TFIIIB activity and TFIIIC activity on phosphocellulose
HeLa nuclear extract was applied to a column of activated phosphocellulose at a final 
concentration of 5mg/ml of resin. The column was extensively washed with PC-A 
buffer containing lOOmM KC1 (PC-A(O.l)), until absorbance at 280nm of eluting 
fractions returned to zero. TFIIIB-containing fractions were eluted with PC-A buffer 
containing 350mM KC1 (PC-A(0.35)). TFIIIC-containing fractions were step eluted 
using PC-A buffer containing 600mM KC1 (PC-A(0.6)). After dialysis of eluted 
fractions against LDBO buffer, until the salt concentration returned to 100 mM KC1, 
fractions were tested for the presence of TFIIIB or TFIIIC by in vitro transcription 
assays.
A) TFIIIB activity of eluted fractions.
Fraction numbers are indicated. SM, starting material; FT, flowthrough. TFIIIB 
activity was assayed using 4pl of the indicated fraction, 2pl of PC-C and 250 ng of 
pVAi; after 15 min incubation at 30°C, nucleotides were added to initiate 
transcription.
B )  TFIIIC activity of eluted fractions.
Transcription reactions were performed as described in (A),except 2pl of PC-B was 
substituted for PC-C as the complementing fraction.
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pseudo-affinity properties. The dye behaves as an analogue of ADP-ribose and has 
affinity for most proteins that bind a purine nucleotide. The specificity of Cibacron 
blue is not limited to nucleotide-binding proteins, however. The dye will bind a 
large number of non nucleotide-binding proteins; interferon and human serum 
albumin were both purified with the aid of Cibacron blue chromatography. The 
binding of proteins to Cibacron blue is poorly understood; however, from the 
structure of the dye, hydrophobic and electrostatic interactions, and hydrogen 
bonding, are all likely (468).
Eluted fractions from the Cibacron blue column were tested for TFIIIB 
activity by in vitro transcription assay. Two different templates were separately 
tested; VAi and the U6 promoter fused to the p-globin gene (Fig.3.4 A). The U6 
promoter is a much weaker class III promoter than VAi, hence the lower transcript 
levels obtained with starting material using the U6 promoter compared to VAi 
(compare lane 2 of upper and lower panel, Fig.3.4 A). TFIIIB activity capable of 
supporting U6 transcription eluted in the 2M salt/5M urea fractions, with peak 
activity approximately half that of the starting material (Fig.3.4 A, upper panel, 
compare lane 2 and lanes 16 &17). A very low level of activity is detectable in the 
flowthrough and the fractions eluted with 1M salt (upper panel, lanes 3-11).
In contrast to the results obtained with the U6 promoter, no TFIIIB activity 
capable of supporting VAi transcription was detectable in any of the eluted fractions 
(lower panel, lanes 3-18). This suggests that the TFIIIB requirements for VAi 
transcription differ from those for U6 transcription. This finding is in general 
agreement with a number of studies suggesting that the TFIIIB requirement of type 
III promoters is different from that of types I and II (340, 365, 374, 463, 513, 514, 
552, 604).
Teichmann et a l also found that the human TFIIIB requirements for U6 and 
VAi transcription can be physically separated on Cibacron blue (514). In contrast to 
my results, Teichmann et a l found that TFIIIB activity capable of supporting VAi 
transcription was detectable in the 2M salt/5M urea fractions. TFIIIB activity 
capable of supporting U6 transcription was detected in largest amounts in the 
600mM NaCl elution, but significant activity was also detected in the 60mM NaCl 
flowthrough and 2M NaCl/5M urea elution (514). The presence of TFIIIB activity 
supporting U6 transcription in all these fractions implies that the column was
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overloaded in Teichmann’s study. The lack of TFIIIB activity for VAi transcription 
in my 2M NaCl/5M urea fractions could be explained by partial disruption of this 
form of TFIIIB by the 1M NaCl elution I adopted compared with Teichmann’s 0.6M 
NaCl elution. Waldshmidt et a l were able to obtain TFIIIB activity capable of 
reconstituting tRNA transcription in their 2M salt/5M urea fractions after an elution 
with 1M NaCl, however (545).
Another significant difference between the results I obtained and those of 
Teichmann et a l and Waldshmidt et a l is in the fractionation of the bulk of the 
protein. Teichmann et a l and Waldshmidt et a l found that the bulk of the protein 
eluted in the flowthrough and 0.6M elutions, and the 1M elution, respectively (514, 
545). The stronger binding of TFIIIB to Cibacron blue than the bulk of the protein 
and the increase in purity that this offers was the main reason for my considering 
Cibacron blue chromatography. I found that the bulk of the protein was retained on 
the column after elution with 1M NaCl and eluted with 2M salt/5M urea (data not 
shown). This discrepancy may be explained by the source of the Cibacron blue 
column used. Teichmann et a l (Teichmann, M., personal communication) and 
Waldshmidt et a l both used Cibacron blue-agarose columns purchased from Sigma, 
whereas the Cibacron blue column I used was purchased from Pharmacia Biotech. 
The Cibacron blue dye used by manufacturers is sometimes not very pure and may 
contain a variety of minor components or isomers of the main component (191). 
Variations in purity can have quantitative and qualitative effects on protein binding 
(468). The degree of substitution of dye can also have a significant effect on protein 
binding.
Teichmann et a l suggest that the TFIIIB required for U6 transcription is a 
subcomplex of the TFIIIB required for VAi transcription. By Cibacron blue 
chromatography, they were able to generate TFIIIB capable of supporting U6 
transcription from a TFIIIB fraction previously shown to be capable of supporting 
VAi transcription but not that of U6 (514). Another possible explanation for the lack 
of TFIIIB activity for VAi transcription that I observed, is the disruption of the 
complex with the dissociation of the TFIIIB subcomplex sufficient for U6 
transcription and the retention on the column of one or more components required for 
VAi transcription.
Although I have not attempted harsher elution conditions to investigate 
further this possibility, I have tested the effect of eluting with 0.6M NaCl rather than
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1M NaCl. When I eluted with 0.6M NaCl, I was able to recover low levels of 
TFIIIB activity for VAi transcription in the 2M NaCl/5M urea fractions (data not 
shown). This suggests that washing with 1M NaCl rather than 0.6M NaCl causes 
some disruption of the TFIIIB complex required for VAi transcription.
The fractionation of HeLa nuclear extract on heparin-Sepharose yielded 
reasonable quantities of active TFIIIB. I therefore decided to test whether this was 
also true using PC-B as the starting material. The subsequent use of the partially 
purified TFIIIB in regulatory studies makes recovery of reasonably active protein at 
this stage of purification an important requirement. Following application of the 
sample and washing to remove unbound protein, bound protein was eluted with a 3 
column volume lOOmM- 1M salt gradient. The TFIIIB activity of eluted fractions is 
shown in Figure 3.4 B. As with the nuclear extract, reasonable TFIIIB activity was 
recovered. A steeper gradient was applied than previously to keep the samples 
concentrated and thus less prone to inactivation.
The weak cation exchanger carboxymethyl, which is based on charged 
carboxylate groups, was also tested. Previous work has shown that, under certain 
conditions, TFIIIB does not bind the column and can be collected in the flowthrough 
whereas pol III and any contaminating TFIIIC bind to the column (White, R.J., 
personal communication). I was consistently able only to recover fractions with 
extremely low TFIIIB activity, however (data not shown). This may reflect 
inactivation of the TFIIIB caused by its inevitable dilution resulting from its elution 
in the flowthrough.
One of the columns Waldshmidt et al. used in their purification of human 
TFIIIB was hydroxyapatite (545). Hydroxyapatite ((Ca5(P0 4 )3 0 H)2) is an inorganic 
adsorbent made of a crystalline form of calcium hydroxide phosphate. The 
mechanism of adsorption of proteins to hydroxyapatite is not properly understood. It 
has been postulated that dipole-dipole bonding may be involved; however, the 
adsorption of buffer ions to the hydroxyapatite complicates matters and interactions 
may more resemble those of ion exchangers (468).
Figure 3.4 C shows the results of gradient chromatography of PC-B on 
hydroxyapatite. A lOmM-lM potassium phosphate (pH 7.0) gradient was applied 
over six column volumes to elute bound protein. TFIIIB activity eluted relatively 
early in the gradient, between 50mM and 250mM potassium phosphate (pH 7.0), 
reducing time required for purification and dialysis, which meant samples were left
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Figure 3.4 - Screening of resins for the further purification of TFIIIB
A) Cibacron blue chromatography of a PC-B fraction
lmg of PC-B was applied to a 1ml Cibacron blue column. After extensively washing 
with CB buffer containing lOOmM NaCl (CB100), bound protein was step eluted 
with CB buffer containing 1M NaCl (CB1000), followed by a second step elution 
with CB buffer containing 2M NaCl and 5M urea (CB2000U). Eluted fractions were 
assayed for TFIIIB activity by in vitro transcription.
Upper panel - Fraction numbers are indicated. SM, starting material; FT, 
flowthrough. TFIIIB activity was assayed using 4pl of the indicated fraction, 2pi of 
PC-C and 500 ng of pU6/Hae/RA.2; after 15 min incubation at 30°C, nucleotides 
were added to initiate transcription.
Lower panel - Transcription reactions were performed as described for the upper 
panel except 250ng of pVAi replaced pU6/Hae/RA.2 as the pol III template added.
B) Heparin gradient chromatography of a PC-B fraction
4 mg of PC-B was applied to a 1ml heparin-Sepharose column. After extensive 
washing, fractions were eluted with a lOOmM- 1M linear KC1 gradient. Eluted 
fractions were tested for TFIIIB activity by in vitro transcription assay. 
Transcription was carried out as described in (A) using 250 ng of pVAi as template.
C) Hydroxyapatite chromatography of a PC-B fraction
lmg of PC-B was applied to a 1ml hydroxyapatite column. After extensive washing 
with HAP buffer containing lOmM potassium phosphate pH7.0 (HAP 10), a lOmM- 
500mM potassium phosphate pH 7.0 gradient was applied. Eluted fractions were 
tested for TFIIIB activity by in vitro transcription assay as described in (B).
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at 4°C susceptible to inactivation and degradation for less time. As the in vitro 
transcription of Figure 3.4 C shows, good recovery of TFIIIB activity was obtained, 
although Bradford’s assay of eluted protein revealed that a lot of protein was eluted 
in similar fractions to TFIIIB, reducing the extent of purification obtained.
3.2.3 Verification of antibodies for use in immunoaffinity chromatography
Immunoaffinity chromatography separates the protein of interest from 
contaminating proteins on the basis of a biospecific interaction between the protein 
of interest and an antibody that has been immunologically raised against a specific 
part of that protein. The biospecificity of this technique provides the opportunity to 
achieve fold purification in a single step that cannot be achieved with four or five 
steps of conventional chromatography. It is possible to achieve > 90% purity from 
crude extract in a single immunoaffinity step. The success (or failure) of 
immunoaffinity chromatography is critically dependent on the quality of the 
antibodies used. The antibody is the ultimate adsorbent provided that it is highly 
selective for the protein of interest and that it binds the protein tightly but reversibly. 
Before embarking on immunoaffinity chromatography, it is crucial to verify that the 
antibodies to be used do indeed recognise the proteins that they were raised against 
and that they do not react with a host of other proteins.
The recent identification and cloning of several components of human TFIIIB 
and human TFIIIC has provided the opportunity to carry out immunoaffinity 
chromatography as a means of purification, which was previously not possible due to 
a lack of knowledge as to the composition of these two proteins. It enables the 
raising of antibodies against specific components of hTFIIIB and hTFIIIC that can be 
used for the immunoaffinity purification of these two activities.
We have three different BRF antibodies, 128, 482 and 330, each raised 
against a different C-terminal region of the human protein. 128 was raised against 
residues 533-547 of human BRF. This sequence has been strongly conserved in 
evolution and corresponds to part of the yeast homology region III, one of three 
regions of strong conservation within a diverged C-terminus. Yeast homology 
region III was identified as a sequence of strong conservation following the sequence 
comparison of BRF from three distant yeast species (271). The subsequent cloning
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of BRF from C.elegans and humans revealed that this region is strongly conserved in 
these organisms also (316). 482 was raised against residues 452-466 of human BRF, 
which corresponds to part of yeast homology region II. 330 was raised against 
residues 664-677 of human BRF, which corresponds to the extreme C-terminus of 
the protein. This part of the protein is not conserved between humans and C.elegans 
and is absent in the yeast BRFs (316). We also have an antibody against the TFIIICp 
subunit (TFIIIC 110) of TFIIIC2. This antibody, 4286, was raised against residues 
897-911 of human TFIIICp.
All of the aforementioned antibodies are rabbit polyclonals. Antibodies are 
raised by injecting the antigen into the animal at regular intervals and waiting for an 
immune reponse before bleeding the animal. It is essential that the antigen injected 
is as pure as possible as trace amounts of other proteins may be much more 
antigenic. Furthermore, approximately 90% of the antibodies in a rabbit antiserum 
are not specific to the antigen injected but represent immunoglobins that happened to 
be present in the animal at the time. The verification of the antibodies is thus 
absolutely essential.
The 4286 antiserum specifically recognises a 110 kDa polypeptide, which 
corresponds to the size of TFIIICp, both in a crude nuclear extract and in a PC-C 
fraction, as revealed by Western blotting (Figure 3.5). The presence of a few weaker 
bands of slightly smaller size in the lane of nuclear extract (lane 1) may represent 
TFIIICp that has been partially degraded or modified in some way. Five times as 
much protein was loaded in lane 1 compared to lane 2, yet the difference in intensity 
of the 110 kDa band obtained is less than two-fold. The PC-C fraction is clearly 
enriched for the 110 kDa polypeptide specifically recognised by this antiserum, as 
would be expected for TFIIICp. This suggests that the 110 kDa band seen in the lane 
of nuclear extract is indeed TFIIICp and not another polypeptide of the same size 
that the antibody has cross-reacted with.
The TFIIICp antiserum is also able to specifically immunoprecipitate 
TFIIIC2 from HeLa nuclear extract, of which TFIIICp is one of five subunits. 
Immunoblotting of precipitated material with an antiserum against the TFIIIC220 
(TFIIICa) subunit of TFIIIC2, Ab4 (481), revealed that the 4286 antiserum 
specifically coimmunoprecipitated TFIIIC220, whereas the corresponding
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Figure 3.5
The 4286 antiserum specifically recognises TFIIICp
75 jag of HeLa nuclear extract (lanel) and 15pg of PC-C (lane 2) were resolved on a 












The 4286 antiserum specifically immunoprecipitates TFIIIC2 from crude 
extract
HeLa nuclear extract (150pg) was immunoprecipitated using the 4286 antiserum 
(lane 2) or the corresponding preimmune serum (lane 1). After washing five times 
with 500pl of LDB buffer, immunoprecipitated material was resolved on a SDS- 
7.8% polyacrylamide gel and then analysed by immunoblotting using the Ab4 





preimmune serum did not (Figure 3.6). This suggests that 4286 can 
immunoprecipitate the native TFIIIC2 complex.
The three BRF antisera specifically recognise a 90 kDa polypeptide 
corresponding in size to human BRF, both in crude nuclear extract and in PC-B 
fractions, as revealed by immunoblotting (data not shown). They also specifically 
immunoprecipitate 35S-labelled in vitro translated human BRF from rabbit 
reticulocyte lysate, whereas the corresponding pre-immune sera do not (Figure 3.7 
and data not shown).
Figure 3.7 also shows the results of peptide elution experiments for 128 and 
482, in which I tested whether synthetic peptide corresponding to the sequence of 
BRF that these two antibodies were raised against could be used for elution of BRF 
from the antibody. Antibodies generally bind very tightly to their antigen and elution 
of the protein of interest from the antibody without requiring harsh conditions that 
inactivate the protein or destroy the antibody can prove difficult. Peptide elution, 
which acts by displacement competition between the peptide and the protein of 
interest for the antigen-binding site on the antibody, offers the best solution to this 
problem, if it is possible. With peptide elution the protein of interest can be gently 
eluted in a buffer of one’s choice.
As Figure 3.7 shows, the peptide specific for 482 can achieve efficient elution 
of immunoprecipitated BRF after only 30 min of incubation with the 482- 
immunoprecipitated material. In contrast, BRF immunoprecipitated with 128 could 
not be eluted with the synthetic peptide the antibody was raised against, even after 5 
hours of incubation together.
The BRF antisera were also tested for their ability to immunoprecipitate 
endogenous BRF by immunodepletion experiments using HeLa nuclear extract. 
Immunodepleted extracts were tested for their ability to support in vitro transcription 
of the VAi template in the absence of any other added proteins. Given that BRF is 
essential for VAi transcription, effective immunodepletion by the antisera should 
cause a sharp reduction in transcript levels. Extracts immunodepleted using 128 and 
330 were able to support only very low levels of VAi transcription compared to their 
corresponding pre-immune sera (Figure 3.8, lanes 11-14). In contrast, extract 
immunodepleted with 482 supported levels of transcription comparable to that of 
extract immunodepleted with the preimmune sera (Figure 3.8, lanes 9 & 10). This 
suggested that the 482 antiserum is unable to immunoprecipitate endogenous BRF,
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although it clearly is able to immunoprecipitate exogenous in vitro translated BRF 
(Figure 3.7). It may be that the epitope on BRF that 482 specifically recognises is 
involved in an endogenous interaction of BRF with other proteins and thus in a cell 
extract it is buried. In rabbit reticulocyte lysate, however, the in vitro translated 
human BRF should be relatively free of interactions with other proteins. The 
compatibility of human BRF and rabbit TFIIIB components is not known; however, 
regardless of this, the human BRF is likely to be in vast excess of proteins that 
potentially could interact. The BRF epitope in this environment should be exposed 
and thus can be specifically recognised by the 482 antiserum.
The possibility that 482 specifically recognises an epitope on BRF that is 
involved in protein-protein interaction is supported by the strong conservation of the 
sequence that the antibody was raised against between five disparate species (316). 
Conservation of sequence is suggestive of its involvement in protein-protein 
interactions. The sequence that 482 was raised against corresponds to part of the 
yeast homology domain II. This domain is implicated by a number of studies to be 
involved in the binding of TBP (11, 102, 265, 271).
As a positive control for the immunodepletion experiments, MTBP6 was used 
(Fig 3.8, lanes 1-3). This is a mouse monoclonal antibody that specifically 
recognises a sequence in the non-conserved N-terminal region of TBP. The presence 
of TBP in pol I- and pol II- specific complexes as well as TFIIIB restricts its 
usefulness in the immunopurification of TFIIIB compared with a TFIIIB-specific 
component such as BRF. As Figure 3.8 shows, MTBP6 is very effective at 
immunodepleting extracts of TFIIIB activity. Transcription can be restored by the 
addition of PC-B but not PC-C. MTBP6 also specifically coimmunodepletes BRF 
with the TBP, as revealed by Western blotting of immunodepleted extracts (data not 
shown).
3.2.4 Immunoaffinity purification of human TFIIIB
Having discarded 482 on the basis of its inability to immunoprecipitate 
endogenous BRF, the next stage was the application of the determined 
immunospecificity of 128 and 330 to column chromatography. Initially I kept
116
Figure 3.7
128 and 482 antisera specifically immunoprecipitate BRF
A) Time course of peptide elution of in vitro translated BRF specifically 
immunoprecipitated with 482 antiserum
Reticulocyte lysate (20pl) containing in vitro translated BRF was 
immunoprecipitated using equal amounts of the anti-BRF antibody 482 (lanes 2-5) or 
the corresponding preimmune serum (lane 1) prebound to protein A-Sepharose. 
After washing with LDB buffer to remove unbound protein and unincorporated label, 
20pl of 2.5mg/ml BRF-2 peptide (corresponding to the peptide sequence 482 
antiserum was raised against) was added. Immunoprecipitated material and BRF-2 
peptide were incubated on an orbital shaker for 0 h (lanel), 0.5 h (lanes 2 & 3) or lh 
(lanes 4 & 5) at 4°C. Supernatants were removed and the protein A-Sepharose beads 
were further washed five times with LDB buffer. Protein eluted into the supernatant 
and immunoprecipitated material retained on the protein A-Sepharose was resolved 
on a 7.8% SDS-polyacrylamide gel and then visualised by autoradiography.
B) Time course of peptide elution of in vitro translated BRF specifically 
immunoprecipitated with 128 antiserum
Immunoprecipitation was carried out essentially as described in (A) except 128 
antiserum (lanes 3-8 & lanes 10-15) and its corresponding preimmune serum (lanes 2 
& 9) were used. Precipitated material was agitated on an orbital shaker with 20pl of 
2.5mg/ml BRF-1 peptide (which correponds to the peptide sequence 128 antiserum 
was raised against) for 0 h (lanes 2 & 9), 1 h (lanes 3 & 4), 2 h (lanes 5 & 6), 3 h 
(lanes 7,8,10 &11), 4 h (lanes 12 & 13) or 5 h (lanes 14 &15). Supernatant was 
immediately removed at the specified time point and the protein A-Sepharose beads 
were further washed five times with LDB buffer. Protein eluted into the supernatant 
and immunoprecipitated material retained on the protein A-Sepharose was resolved 
on a 7.8% SDS-polyacrylamide gel and then visualised by autoradiography. Lane 1 
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Figure 3.8
Immunodepletion of RNA polymerase III transcriptional activity from 
HeLa nuclear extract using the anti-BRF antisera 128 and 330 but not with the 
482 antiserum
Identical amounts of the indicated antisera or preimmune sera prebound to 20pl of 
protein A-Sepharose beads were incubated with 150pg of HeLa nuclear extract on 
ice for 3 h. To keep the beads in suspension, the samples were gently mixed by 
tapping every 10 minutes. After 3 h the beads were pelleted and the supernatants 
were removed for analysis by in vitro transcription.
RNA polymerase III transcription was assayed using 2pi of the immunodepleted 
extracts and 250 ng of pVAi; after 15 min incubation at 30°C, nucleotides were 
added to initiate transcription. In lanes 2 and 3, 2pl of PC-B or PC-C, respectively, 
was added. Lanes 5 and 6 represent the activities from a duplicate immunodepletion 
using the same antiserum. MTBP6 (lanes 1-3) is a mouse monoclonal antiserum 
raised against the N-terminal region of TBP and is used as a positive control. The 
activity of extract immunodepleted with the anti-BRF antisera 482,128 or 330 is 
shown in lanes 9, 11 and 13, respectively. The activity of extract immunodepleted 
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conditions as similar as possible to those used for the immunodepletions, as these 
had worked exceptionally well.
As for the immunodepletions, antibody was prebound to protein A- 
Sepharose by agitation at 4°C for 3 h of a 1:1 mixture of antiserum and protein A- 
Sepharose. The protein A-Sepharose beads were then extensively washed with LDB 
buffer to remove unwanted material and transferred to a disposable Polyprep® 
column (Biorad). HeLa nuclear extract was then slowly recirculated through the 
column for ~ 2 h at 4°C. Recirculation was carried out by hand, as opposed to 
utilising a chromatographic machine, to minimise dilution and possible inactivation 
of the sample. Gravity flow through the column was slowed by means of an 
attachable valve. After ~2 h the recirculated material was collected for assaying how 
effectively the column had depleted the extract of TFIIIB activity and the column 
was washed with 12 column volumes of CB buffer containing lOOmM NaCl, to 
remove unbound protein. Bound protein was then eluted with CB buffer containing 
2M NaCl and 2M urea. Fractions containing protein were then dialysed for 6-10 
hours against LDBO buffer to remove the urea and renature the proteins, and to 
lower the salt.
A major difference between the immunopurification of TFIIIB and the 
immunodepletions is the need to recover TFIIIB activity. The tightness of antibody 
-antigen interactions poses the risk of disrupting intramolecular interactions within 
the TFIIIB complex when attempting to elute. Although peptide elution overcomes 
this problem, this was not a viable option for 128, as shown in Figure 3.7. The 
interaction between antigen and antibody is likely to be composed of electrostatic 
and hydrophobic interactions and H-bonding. This is why elution buffers for 
conventional chromatography generally work badly; they are targeting only a single 
type of interaction; for example, a high ionic strength buffer will weaken electrostatic 
forces, but it also strengthens hydrophobic interactions.
It has been reported that TFIIIB is quite a labile protein (235). This limits 
how harsh elution conditions can be used to disrupt the antibody-antigen interaction 
without irreversibly disrupting the protein. Chromatography on Cibacron blue 
revealed surprisingly that hTFIIIB activity is recoverable from fractions exposed to 
2M salt/5 M urea, however (see Figure 3.4 A). Elution was therefore attempted with 
2M salt/2M urea; the concentration of urea was reduced to cut the time needed for 
sufficient dialysis.
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It was possible that without the covalent coupling of antibody to protein A- 
Sepharose by chemical crosslinking, such a harsh elution buffer may also remove 
antibody. Such eluted antibody may be inhibitory in an in vitro transcription assay 
and would prevent reuse of the column. I therefore tested whether covalent coupling 
was necessary by screening a range of salt and/or urea concentrations for their ability 
to remove antibody prebound to protein A-Sepharose. The levels of antibody 
removed by the buffer and the levels remaining bound to protein A was analysed by 
Western blotting, probing directly with an anti-rabbit secondary antibody. The 
majority of antibody appeared to remain bound to the protein A-Sepharose under 
harsh elution conditions. Although some antibody could be detected in the 2M 
salt/2M urea supernatants, this amount was not more than two fold greater than that 
detected with other buffers, including LDB.
Some TFIIIB activity was recovered in the 2M salt/2M urea fractions. The 
immunodepletion of TFIIIB activity from the starting material was very poor, 
however. This was surprising, considering that such good immunodepletion was 
obtained by immunoprecipitation. Although I only recirculated the nuclear extract 
for ~ 2 h compared with 3 h agitation in an immunoprecipitation, a previous time 
course of binding of BRF by 128 revealed little difference between 2 and 3 h, with 
low levels bound after only 30 min. However, the length of time needed for 
interaction is not necessarily transferable between the batch-like adsorption of an 
immunoprecipitation and column adsorption. It is also noteworthy that in an 
immunoprecipitation all of the starting material is in contact with protein A- 
Sepharose for the entire incubation length, which is clearly not possible with a 
recirculated starting material.
The tight binding of an antibody to its antigen is thought to involve more than 
one step and is slow compared with most interactions of enzymes with their 
substrates (468). For immunoaffinity chromatography, there are two interactions that 
concern us; the interaction of antibody with protein A and the interaction of antibody 
with its specific antigen. Of these two interactions, the interaction of antibody and 
antigen is thought to be significantly slower kinetically. To try and improve 
immunodepletion, I decided to preincubate the antibody and antigen before applying 
to the column. In addition to allowing more time for this interaction to occur, this 
method enables all of the antigen to be exposed to the antibody for the entire time. 
Preincubation is also advantageous because where antibody is bound to protein A-
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Sepharose first, a proportion (estimated to be nine-tenths) of the antibody is 
effectively lost as the antibody has bound to the Sepharose beads in such an 
orientation that it is unable to bind antigen.
Preincubation of HeLa nuclear extract with the antiserum for 1 h on ice prior 
to recirculating the mixture slowly for ~ 2 h did improve immunodepletion and 
recovery of activity, but only to a small extent (data not shown). This is despite 
reducing the ratio of antibody to extract 6.7 fold in order to try and conserve 
antiserum and reduce the effect of any proteases that may be present in the 
antiserum. However, the amount of antibody did not seem to be the limiting factor 
for immunodepletion, as increasing the amount of antibody relative to the amount of 
extract three-fold had no significant effect.
It seems plausible that the poor immunodepletion may be due in part to the 
vast quantity of other proteins in the nuclear extract that may lead to steric hindrance, 
perhaps weakly interacting non-specifically with the antigen-binding site of the 
antibody or with the antigen itself. Furthermore, in a nuclear extract the endogenous 
interactions of the protein of interest are likely to be intact; one or more of these 
specific interactions may be mediated by the antigenic site or be very close to it, 
rendering it poorly accessible. The TFIIIB activity that is immunodepleted may 
reflect TFIIIB in which the endogenous interactions have temporarily been disrupted. 
In an immunoprecipitation the frequent agitation of the sample is more likely to 
mechanically disturb any weak non-specific or specific interactions that prevent the 
antigen and antibody interacting. The epitope that 128 was raised against is highly 
conserved, so it is quite probable that it is involved in a specific interaction with 
another component of the transcriptional machinery.
I therefore decided to repeat the chromatographic procedure but using a more 
purifed source of TFIIIB as starting material, a PC-B fraction rather than crude 
nuclear extract. PC-B lacks TFIIIC activity, so at least one TFIIIB-interacting 
protein that could obscure the epitope has probably been displaced. Pol III activity is 
found in PC-B fractions, so one or more specific interactions involving pol III 
subunits and BRF or other TFIIIB components could still be intact. I decided to keep 
the amount of antiserum constant, which meant an increase in the proportion of 
antibody relative to total protein, although PC-B is clearly enriched for TFIIIB.
Analysis of fractions revealed a complete lack of transcriptional activity in 
the recirculated starting material, suggesting very effective immunodepletion;
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however, recovery of activity was not improved from previous attempts. Another 
possible explanation for this remarkable transformation in transcriptional activity of 
the recirculated starting material was that it was getting inactivated in some way, 
such as by protein degradation by proteases in the serum.
To investigate this possibility further, I carried out an in vitro transcription 
assay for TFIIIB activity using PC-B preincubated in the presence or absence of 128 
or 330 antiserum or the corresponding preimmune sera. The reactions in which PC- 
B was preincubated with 128 or 330 produced no transcript. This could be a specific 
inhibitory effect caused by the antibodies; however, the reactions preincubated with 
preimmune sera also lacked transcriptional activity, implying protein degradation or 
something potently inhibitory common to all the sera. Although a cocktail of 
protease inhibitors was added to the PC-B fraction prior to adding the antiserum, it is 
possible that insufficient was added. To test this, I titrated increasing amounts of the 
cocktail of inhibitors into in vitro transcription reactions containing PC-B and 
antiserum. This had no discemable effect on the level of transcript. Although the 
cocktail contained inhibitors of the major types of proteases, it is likely that some 
proteases present would have remained active. I therefore decided to purify the 
antisera on protein A-Sepharose by the low salt method of Harlow and Lane (195), 
prior to preincubation with PC-B, in order to remove any contaminating proteases or 
inhibitory activities present.
Purifying the antisera appeared to solve this problem. Preincubation of 
purified antiserum with PC-B in an in vitro transcription assay did not adversely 
affect transcript levels. It also revealed that using PC-B as starting material did 
improve immunodepletion, but the bulk of activity remained in the starting material. 
Recovery of activity concurrently improved and this was improved further by a 
reduction of the size of the column relative to the amount of purified antibody and 
PC-B. This was to try to concentrate samples on elution, in order to preserve their 
activity.
To increase the purity of eluted fractions I attempted washing the column 
more stringently before elution. This proved unsuccessful; increasing the 
concentration of salt in the wash buffer from lOOmM to 200mM resulted in a 
complete loss of recoverable activity. There are two obvious possible interpretations 
of this result; one is that one or more essential components of TFIIIB are very 
loosely associated with the complex and are dissociated when the salt concentration
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is increased. This association may also have been weakened by the interaction of the 
antibody with TFIIIB. It has been reported previously that TFIIIB is not a stable 
molecular entity (235), lending support to this interpretation. The other 
interpretation is that the specific interaction formed between the antibody and TFIIIB 
is very weak and disrupted by the increase in salt concentration. The elution of 
activity in the flowthrough could easily escape detection due to excessive dilution. 
The first interpretation seems more likely; as discussed earlier, antibodies generally 
interact very tightly with their specific antigen. The formation of a tight antigen- 
antibody complex is a slow process, however, and it is possible that insufficient time 
was allowed for this to form; perhaps only weak interactions easily disrupted by salt 
existed between the antigen and the antibody.
In light of the improved immunodepletion and recovery of activity obtained 
using PC-B rather than nuclear extract as my starting material, I carried out an 
immunopurification using a PC-B fraction that had been purified further on another 
column. A fraction enriched for TFIIIB from a heparin gradient of a PC-B fraction 
was used (BHep). The in vitro transcription assay for TFIIIB activity of eluted 
fractions is shown in Figure 3.9 (lanes 10-18). Another column using PC-B as the 
starting material was run in parallel; the activity of eluted fractions from this column 
were assayed at the same time and are also shown in Figure 3.9 (lanes 1-9). For both 
columns, the first fraction eluted with 2M salt/2M urea contained the bulk of the 
eluted TFIIIB activity. A low level of TFIIIB activity was also detectable in the peak 
FT fraction from each column; this may represent weakly bound TFIIIB that 
interacted non-specifically with the columns.
Immunodepletion of TFIIIB activity was improved drastically using BHep as 
starting material rather than PC-B. Using PC-B, immunodepletion is -30% 
(compare lanes 1 & 2), whereas with BHep it is over 90% efficient (compare lanes 
10 & 11). This is probably a reflection of the epitope recognised by the BRF 
antibody being more exposed in the more purified fraction. It is also noteworthy that 
the purified antiserum preincubated with the BHep fraction inhibits transcription 
(lane 18), although it does not when incubated with PC-B (data not shown). This 
suggests that the antiserum may specifically inhibit TFIIIB, but this requires further 
investigation. The effect of purified preimmune serum on BHep has not been tested, 
so it is plausible that the effect is non-specific. Assuming that it is a specific effect,
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Figure 3.9
Immunoaffinity purification of human TFIIIB
Human TFIIIB was immunopurified in parallel from two different sources of TFIIIB, 
PC-B (lanes 1-9) and the more purified BHep (lanes 10-18). Following 
preincubation of the starting material with purified 330 antiserum on ice for 1 h, this 
mixture was slowly recirculated through a column of protein A-Sepharose for ~ 2 h. 
The column was then washed with 20 column volumes of CB buffer containing 
lOOmM NaCl (CB100). Protein was eluted with CB buffer containing 2M salt/5M 
urea (CB2000U). After dialysis to remove the urea and lower the salt concentration 
to lOOmM KC1, fractions were assayed for TFIIIB activity by in vitro transcription.
Fraction numbers are indicated. SM, starting material; R, recirculated starting 
material; FT, flowthrough; SM+Ab, preincubated starting material and antiserum 
mixture. Lane 3 contains LDB buffer. TFIIIB activity was assayed using 12pl of the 
indicated fraction, 2pl of PC-C and 250 ng of pVAi; after 15 min incubation at 30°C, 
nucleotides were added to initiate transcription.
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the lack of inhibition observed with PC-B may reflect the masking of the inhibitory 
effect due to an excess of TFIIIB that is not interacting with the antibody.
The immunoaffinity purified BHep fraction, whose TFIIIB activity is shown 
in Figure 3.9 (lane 13), represents my most purified TFIIIB fraction. Considering 
that it has been subjected to three different chromatographic steps, three extensive 
dialyses, exposure to the denaturant urea and at least three freeze-thaw cycles the 
activity of this fraction is remarkably good. Silver staining of the fraction revealed 
that it represents a complex set of polypeptides (data not shown). The TFIIIB is 
estimated to have been purified in the range of 100-400 fold from HeLa nuclear 
extract. This partially purified TFIIIB fraction represents a significant improvement 
in the purity of TFIIIB compared to most sources of TFIIIB that are commonly used 
in regulatory studies of the pol III transcriptional apparatus.
3.2.5 Immunoaffinity purification of human TFIIIC
In parallel to developing an immunoaffinity step for the purification of human 
TFIIIB, the same was done for human TFIIIC. The procedure that gave the best 
immunopuriflcation of hTFIIIC was essentially the same as that for hTFIIIB.
In contrast to the relatively poor immunodepletion observed using 330 or 128 
and PC-B, preincubation of PC-C with purified 4286 antiserum resulted in >90% 
depletion of TFIIIC activity. It may be that the epitope on TFIIICp specifically 
recognised by 4286 is much more accessible than the epitopes on BRF recognised by 
128 and 330, respectively. There are other possible explanations, however, such as 
the kinetics of the interaction. The TFIIIC contained in PC-C also represents a purer 
source of TFIIIC than PC-B is of TFIIIB.
Although excellent immunodepletion was consistently obtained using the 
4286 antiserum, recovery of TFIIIC activity was much more variable between 
different chromatographic runs. This seems to be a feature of this protein; it has also 
been found to be the case for TFIIIC eluted from phosphocellulose (312), suggesting 
it is relatively easily inactivated.
For an immunoaffinity step to achieve any degree of purification the antibody 
used must interact specifically with the protein of interest. The antibody specifically
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selects the protein of interest for adsorption and not other proteins, although 
inevitably there is some non-specific binding both to the antibody and the protein A- 
Sepharose. It is theoretically possible that the immunodepletion of hTFIIIC from 
PC-C observed using 4286 antiserum and the immunodepletion of hTFIIIB from PC- 
B observed using 128 or 330 is simply due to non-specific binding to protein A- 
Sepharose or the antibody. I have tested this possibility for all three antisera by 
carrying out mock immunopurifications using the appropriate preimmune serum, 
which is preincubated either with PC-B or, for the 4286 preimmune serum, PC-C. 
As a positive control, an immunopurification using the appropriate antiserum was 
carried out in parallel.
Figure 3.10 A shows the results obtained using the 4286 antiserum and the 
corresponding preimmune serum. No TFIIIC activity was eluted in any of the 
fractions from the mock immunopurification (Fig.3.10 A, lanes 12 to 17). For the 
4286 column run in parallel, some TFIIIC activity was eluted (see lane 5), although 
recovery of TFIIIC activity from this particular chromatographic run was very poor 
compared to that often obtained (see, for example, Figure 3.10 B). More indicative 
of the specificity of the immunoaffinity step is the extent of immunodepletion of 
TFIIIC activity using 4286 compared to the preimmune serum. With 4286, there was 
almost complete immunodepletion of TFIIIC activity from PC-C ( Fig.3.10 A, 
compare lanes 1 and 3), whereas using preimmune serum resulted in no or very little 
immunodepletion (compare lane 11 with lanes 1 & 3). Although the activity of the 
recirculated PC-C from the preimmune serum is slightly lower than that of the 
starting material, this is not entirely unexpected given that it was recirculated at 4°C 
for ~2h and exposed to purified preimmune serum which is slightly inhibitory 
(compare lanes 1, 10 and 11). The recirculated material is also likely to have been 
diluted slightly compared to the starting material. Immunopurification using the 
4286 antiserum thus appears to specifically immunodeplete PC-C of TFIIIC activity. 
A similar result was obtained for 330 and 128; they specifically immunodepleted PC- 
B of TFIIIB activity, whereas mock immunopurifications with the preimmune sera 
did not deplete PC-B of TFIIIB activity (data not shown).
Although there is a very slight inhibitory effect of the preimmune serum on 
the PC-C, this pales into insignificance when compared with the inhibitory effect of 
the purified 4286 antiserum (compare lanes 10 &2). Such a strong inhibitory effect 
of the antiserum compared to the preimmune serum suggests that this inhibition is a
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Figure 3.10
Immunoaffinity purification of human TFIIIC
TFIIIC was immunopurified from a PC-C fraction using anti-TFIIICp antibody 4286. 
2mls of PC-C was preincubated with 300pl of purified 4286 antiserum on ice for ~ 
lh. This solution was then recirculated through a 350pl column of protein A- 
Sepharose at 4°C for ~ 2h. Recirculated material was collected and the column was 
washed with 25 column volumes of CB buffer containing lOOmM NaCl (CB100). 
Immunopurified TFIIIC was eluted with CB buffer containing 2M salt, 2M urea 
(CB2000U). Eluted fractions were dialysed against LDBO buffer for 8-12 h until the 
salt concentration was ~ lOOmM, and then were further dialysed against LDB buffer 
for 2-4 h to ensure removal of any residual urea. Eluted fractions were then tested 
for TFIIIC activity by in vitro transcription assay.
Transcription was reconstituted using 12pl of the indicated fraction, 2pl of PC-B and 
250ng of pVAi. Fraction numbers are indicated. SM, starting material; R, 
recirculated starting material; FT, flowthrough; SM+Ab/PI, preincubated starting 
material and antiserum or preimmune serum mixture.
A) 4286 specifically immunopurifies hTFIIIC
Lanes 1-9 show the TFIIIC activity of fractions eluted from the 4286 immunoaffinity 
column. Lanes 10-18 show the TFIIIC activity of fractions from a mock 
immunopurification conducted at the same time using the corresponding preimmune 
serum.
B) Immunopurification of hTFIIIC with good recovery of activity
Transcription reactions were carried out as described above. Lanes 5-13 show the 
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specific effect. The reason for the inhibition requires further investigation; it may be 
that the region of TFIIICp that 4286 was raised against is involved in the interaction 
with another component of the transcriptional apparatus. A less interesting but 
equally plausible explanation is that antibody bound to TFIIICp may simply 
sterically restrict TFIIICP’s interactions, mediated through other sites of the protein, 
with other pol III components, thus preventing the formation of a functional pre­
initiation complex.
Figure 3.10 B shows the results of another immunopurification using 4286, 
for which there was very good recovery of TFIIIC activity. Two of the eluted 
fractions had activity almost comparable to that of the starting material. No TFIIIC 
activity was detected in the flowthrough. Estimation of the concentration of the 
eluted fractions by comparison with known amounts of protein on a silver stained gel 
suggests that the fractions are purified 10-20 fold compared to PC-C. This represents 
a 100-200 fold purification from HeLa nuclear extract. This is a significant 
improvement in the purity of TFIIIC compared to that often used in regulatory 
studies involving human TFIIIC.
Attempts to try and improve upon this level of purification by washing the 
immunoaffinity column more stringently before elution resulted in a complete loss of 
activity, as was found to be the case for the TFIIIB immunoaffinity columns.
3.2.6 DNA-affinity purification of TFIIIC
TFIIIC binds specifically and with high affinity to the B-block region of the 
split internal promoter of tRNA and VAi genes (44, 73, 107, 154, 553, 607). This 
unique property has previously been exploited for the partial purification of TFIIIC, 
both in yeast and in humans (71, 156, 408, 505). In contrast to TFIIIC, human 
TFIIIB and pol III alone are completely devoid of sequence-specific DNA-binding 
activity and are only able to interact with DNA non-specifically and with low 
affinity.
TFIIIC was purified using a B-block oligonucleotide, containing the B-block 
region of the adenoviral VAi gene, coupled to Sepharose beads (246). I purified
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TFIIIC essentially as described by Dean and Berk (118), but with a few 
modifications from their method (see 2.18.8 and below).
Figure 3.11 show the results of purification on this resin of a PC-C fraction. 
After washing the resin with 20 column volumes of LDB buffer, bound protein was 
eluted in two steps. As the in vitro transcription assay shows, TFIIIC activity was 
recovered both in the 0.35 M KC1 elution (Fig.3.11, lanes 5-10) and in the 2M 
KC1/0.1% IGEPAL elution (Fig.3.11, lanes 11-15).
This contrasted with the results of Dean and Berk, who were unable to detect 
any TFIIIC transcriptional activity either in their 0.25M KC1 elution or in their 2M 
KC1/0.1% NP40 elution (118). However, combining 0.25M KC1 eluate with that 
from the 2M KC1/0.1% NP40 elution was able to restore transcriptional activity, 
suggesting that TFIIIC was split into two components by fractionation on the B- 
block resin, as previously observed on Mono Q (118).
The presence of TFIIIC transcriptional activity in both the 0.35M KC1 elution 
and in the 2M KC1/0.1% IGEPAL elution that I found suggested that TFIIIC 
fractionates heterogeneously on this column but is not resolved into separate 
components. However, when I combined the peak TFIIIC fraction from the 0.35M 
KC1 elution with that of the 2M KC1/0.1% IGEPAL elution there was a synergistic 
increase in transcription levels (compare lanes 6 and 11 with lane 16). This suggests 
that the two fractions do represent different complementing TFIIIC species; that 
transcriptional activity could be obtained by the fractions alone may reflect cross­
contamination of the two activities. It is also possible that the complementing PC-B 
fraction is contaminated with one of the two activities; TFIIIC 1 elutes from 
phosphocellulose between 280 and 390 KC1 and thus may be found to some extent in 
the PC-B fraction.
In contrast to the PC-B fraction that I used, the PC-B fraction used by Dean 
and Berk had been rechromatographed on phosphocellulose and gradient eluted and 
subsequently tested by in vitro transcription assays reconstituted with Mono Q- 
purified TFIIIC 1 and TFIIIC2, for the presence of these two activities (118).
In order to try and obtain better synergy, I reconstituted the in vitro 
transcription reaction using a more purified source of TFIIIB from a heparin gradient 
that should lack TFIIIC 1 or TFIIIIC2. Unfortunately, however, little synergy was 
obtained; a reconstitution using PC-B done in parallel suggested that the aliquots of 
the high salt fractions used were not active. Dean and Berk reported that the activity
129
Figure 3.11
DNA-affinity purification of human TFIIIC
Human TFIIIC was DNA-affinity purified from PC-C on a B-block oligonucleotide 
resin. After extensive washing with LDB buffer, bound protein was eluted in two 
steps of PC-A buffer containing 0.35M KC1 (PC-A(0.35)) and PC-A buffer 
containing 2M KC1 but lacking EDTA ((PC-A(-EDTA)(2.0)). Eluted fractions were 
assayed for TFIIIC activity by in vitro transcription.
Transcription was reconstituted using 12pl of the indicated fraction, except in lanes 
16-18 in which 6pl of both fractions was used. As the source of TFIIIB and pol III, 
2pl of PC-B was added to each reaction. pVAi (250ng) was used as the specific pol 
III template. Fractions were preincubated for 15 min at 30°C with PC-B and 
template before transcription was initiated by nucleotide addition.
SM, starting material; R, recirculated starting material; FT, flowthrough. Lanes 5-10 
show the TFIIIC activity of PC-A(0.35)-eluted fractions. Lanes 11-15 show the 
TFIIIC activity of PC-A(-EDTA)(2.0)-eluted fractions.
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of the high salt eluate was not stable to multiple rounds of freeze/thaw and that the 
inclusion of BSA (O.lmg/ml) in the elution buffer was critical for the recovery and 
stability of activity (118). Although I did not use BSA I did add insulin, which is 
sometimes used as an alternative to BSA, to a final concentration of 0.2mg/ml. To 
my knowledge BSA is not any better at stabilising dilute proteins than insulin. 
However, my fractions seemed extremely susceptible to inactivation.
It was important to distinguish whether the low salt eluate and the high salt 
eluate of mine contain overlapping TFIIIC activities and to what extent their ability 
to reconstitute transcription alone is the consequence of a contaminated PC-B 
fraction. To address this, I carried out band shift analyses of the fractions using a B- 
block oligonucleotide as my specific probe. Since TFIIIC 1 cannot bind to the B- 
block, the amount of probe bound should be a direct reflection of the level of 
TFIIIC2 activity of the fractions, although in the context of the whole promoter 
TFIIIC 1 levels affect stability of binding. The band shift assays suggested that there 
is considerable overlap of activities, at least in terms of TFIIIC2 DNA-binding 
activity. This result may reflect the higher concentration of salt that I used for the 
low salt elution compared to that used by Dean and Berk (0.35M KC1 versus 0.25M 
KC1) (118). The lOOmM increase in salt concentration may significantly destabilise 
the interaction of TFIIIC2 with the B-block, although this requires further 
investigation.
Silver staining of the fractions revealed that a large number of bands seem to 
be common to both the low salt and the high salt fractions. Although some of these 
bands may be contaminants, the silver stain is supportive of some overlap of two 
distinct TFIIIC activities in the low and high salt fractions, as suggested by band shift 
and in vitro transcription analyses. The silver stain also clearly showed strong 
enrichment of particular polypeptides in the high salt fraction compared to the low 
salt fraction and vice-versa, which is supportive of the existence and partial 
separation of two distinct TFIIIC activities.
TFIIIC (combination of the peak 0.35M KC1 fraction and the peak 2M KC1 
fraction) has been purified ~ 8-12 fold from PC-C. This represents an -80-120 fold 
purification of TFIIIC from HeLa nuclear extract.
Potentially, TFIIIC could be purified up to 10-20 fold more by 
immunoaffinity chromatography (as described in 3.2.5) of this sequence-specific 
DNA-affinity purified TFIIIC to give a final purification in the range of 800-2400
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fold. However, the extreme susceptibility of the DNA-affinity purified TFIIIC to 
inactivation makes it unlikely that activity would be recoverable following its 
application on another column. This was not necessarily the case for the 
immunoaffinity purified TFIIIC, however, which seemed more resistant to 
inactivation. The opportunity thus existed to combine two different affinity steps for 
the purification of human TFIIIC.
In order to have sufficient immunoaffinity-purified TFIIIC for further 
chromatography on the B-block oligonucleotide resin, I carried out several large 
scale immunopurifications of TFIIIC. In vitro transcription assays and silver staining 
revealed a similar level of purification and recovery of activity to that obtained on a 
small scale. The immunopurified TFIIIC was applied to the B-block column and 
DNA-affinity chromatography was carried out in an identical manner to that for PC- 
C. Unfortunately, however, neither TFIIIC transcriptional activity nor B-block 
binding activity could be recovered.
3.2.7 Investigation of the reported HAT activity of human TFIIIC
The packaging of DNA into chromatin has a general repressive effect on 
nuclear transcription. The structure of chromatin is dynamic, however, and the 
modification of local chromatin structure is an additional level by which the 
transcription of specific genes is controlled (588). There are two groups of factors 
that can affect the chromatin state; nucleosome remodelling factors and proteins that 
affect the acetylation state of histones. Histone acetyltransferases (HATs) acetylate 
histones at N-terminal lysine residues reducing the basicity of the histone (500). 
This has been correlated with a less compact chromatin state and the stimulation of 
transcription (534).
A number of in vitro and in vivo studies have demonstrated that pol III 
transcription is subject to chromatin-mediated repression, although different class III 
templates seem to vary widely in their susceptibility to repression (411). Kundu et 
al. have shown that human TFIIIC2 can partially relieve chromatin-mediated 
repression of a tRNA gene in vitro at a higher concentration than is required for 
transcription of the DNA template (298). Work from the same laboratory suggests 
that human TFIIIC possesses weak intrinsic histone acetyltransferase activity (230,
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298). Pretreatment of TFIIIC with /?-hydroxymercuribenzoic acid (PMA) resulted in 
a partial loss of both TFIIIC HAT activity and TFIIIC-dependent chromatin 
transcription, but with no effect on DNA transcription (298). This suggests that the 
relief of chromatin repression by TFIIIC may be mediated, at least in part, by its 
intrinsic HAT activity. For the yeast U6 gene, TFIIIC has a dominant role in 
relieving chromatin repression; disruption of chromatin structure only enhances 
transcription when TFIIIC interactions with the B-box are impaired (357, 384). It is 
interesting to note, however, that yeast TFIIIC lacks any detectable HAT activity.
Kundu et al. immunopurified hTFIIIC on M2 agarose from a cell line 
expressing a FLAG-tagged TFIIICp subunit (298). Suprisingly, an in-gel HAT assay 
using this purified TFIIIC revealed weak HAT activity associated with three 
polypeptides of ~220kDa, ~110kDa and ~90kDa, corresponding in size to the 
TFIIICa, TFIIICp and TFIIIC5 subunits of TFIIIC2 (298). This result has been 
confirmed using recombinant proteins for TFIIICp (298) and TFIIIC5 (230).
In light of the weakness of the HAT activity observed, I attempted to verify 
that hTFIIIC does indeed possess HAT activity using my partially purified TFIIIC 
fractions. Figure 3.12 A shows the results of a comparison of the HAT activity of 
my immunopurified TFIIIC with a partially purified TFIIIB fraction, using core 
histones as the specific substrate for acetylation. This clearly shows that the 
immunopurified TFIIIC fraction has significantly higher levels of HAT activity than 
the partially purified TFIIIB fraction assayed in parallel (compare lanes 2 & 3). 
Consistent with the results from Roeder’s laboratory, the HAT activity of the 
partially purified TFIIIC fraction was very low compared with that of p300 (compare 
lanes 1 & 2). As found by Roeder and coworkers, histones H3 and H4 were 
specifically acetylated, with the preferential acetylation of histone H4. There was no 
detectable autoacetylation of hTFIIIC.
In contrast to Kundu et al., no sodium butyrate was included in the HAT 
reaction mixture (298). Sodium butyrate is a deacetylase inhibitor but was omitted 
on the basis that it can have non-specific inhibitory effects and this could reflect the 
low HAT activity of the hTFIIIC observed by Kundu et al. (298). The HAT 
activities observed with the various fractions shown in Figure 3.12 A thus represent 
the level of acetylation relative to deacetylation. It is thus plausible that the 
difference in histone acetylation observed between the immunopurified TFIIIC and
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the partially purified TFIIIB fraction simply reflects higher levels of deacetylase 
activity in the TFIIIB fraction. TFIIIB specifically cofractionates and associates with 
the retinoblastoma protein, pRb (314). As discussed in Chapter 4, pRb has recently 
been shown to associate with the histone deacetylase HDAC1 (53, 349), lending 
support to this possibility.
It is important to realise that the TFIIIB and TFIIIC fractions assayed are 
partially purified fractions. Given the very weak HAT activity of the 
immunopurified TFIIIC fraction, this activity observed could easily be caused by a 
small level of contamination of the fraction with a potent HAT such as p300.
To investigate the reported HAT activity of hTFIIIC further, I decided to 
carry out HAT assays on immunoprecipitated TFIIIC, TFIIIB and mock 
immunoprecipitated material obtained using the appropriate preimmune sera. This 
revealed no significant differences in the HAT activities of immunoprecipitated 
TFIIIC and TFIIIB compared to the mock immunoprecipitations (data not shown). It 
may be that the amount of TFIIIC immunoprecipitated is too low for its weak HAT 
activity to be detectable above background levels, or its HAT activity may be 
partially inactivated by the vigorous agitation required during immunoprecipitation.
Figure 3.12 B (lanes 1-6) shows the HAT activity of TFIIIC-containing 
fractions from the DNA-affinity column of Fig. 3.11. This reveals a slight depletion 
of HAT activity from the PC-C used as starting material (compare lanes 1 & 2). A 
very low level of HAT activity is detectable in the FT fraction (lane 3). In contrast, 
there is a very significant enrichment of HAT activity in the peak fraction from the 
2M KC1 elution and the peak fraction from the 0.35M KC1 elution (lanes 5 & 6 
respectively), both of which are enriched in TFIIIC activity. This result is supportive 
of hTFIIIC possessing intrinsic HAT activity.
The TFIIIC DNA-affinity fractions are purified on the basis of their specific 
B-block binding activity. Previously it has been shown that TFIIICp and an N- 
terminal 83 kDa fragment of TFIIICa are sufficient to reconstitute the B-block 
binding activity of hTFIIIC (481). The strong enrichment in HAT activity in the B- 
block affinity-purified TFIIIC fractions thus correlates well with the finding by 
Kundu et al. (298), that TFIIICa and TFIIICp contain their own intrinsic HAT 
activity, since the fractions should be particularly enriched in these two subunits of 
TFIIIC2.
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Lanes 7 & 8 of Fig. 3.12 B show the HAT activity of an immunopurified 
TFIIIC fraction and a mock-immunopurified TFIIIC fraction, respectively. There is 
very little difference in HAT activity of the two fractions, which is not supportive of 
hTFIIIC possessing intrinsic HAT activity. Analysis of the HAT activity of other 
TFIIIC immunopurified fractions revealed a similar result.
Together my results are unable to verify the finding by the Roeder laboratory 
that human TFIIIC possesses weak intrinsic HAT activity (230, 298) although some 
results in support of this were obtained.
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Figure 3.12
HAT activity of partially purified TFIIIC fractions
A) Comparison of HAT activity of an immunopurified TFIIIC fraction with a 
partially purified TFIIIB fraction and p300
Equal amounts of immunopurified TFIIIC (lane 2) and a partially purified TFIIIB 
fraction (BHep) (lane 3) were assayed for HAT activity. A small quantity of 
recombinant p300 (lane 1) was also assayed as a positive control. Lane 4 lacks any 
additional source of protein apart from the core histones added as the specific 
substrate for assaying acetylation. The fractions were incubated for 30 min at 30°C 
with 1 pg of chicken core histones and 0.25pCi of 14C acetyl CoA in a final reaction 
mixture of 50mM Tris pH 8.0, 5% glycerol, O.lmM EDTA, 50mM KC1, ImM DTT 
and ImM PMSF. Samples were resolved on a 12% polyacrylamide-SDS gel. After 
fixing the gel, it was incubated in Amplify™ (Amersham) for 15-30 min to reduce 
the exposure time of the gel required. Acetylated products were visualised by 
autoradiography, after exposure to BIOMAX X-ray film (Kodak) for 3 days at -  
80°C.
B) B-block affinity-purified TFIIIC fractions are enriched in HAT activity
Fractions were assayed for HAT activity as described in (A), lp l of p300 was 
assayed (lane 9) and 15pi of all other fractions (lanes 1-8). Lanes 1-6 represent peak 
fractions from the DNA-affinity column of Fig.3.11. SM, starting material; R, 
recirculated starting material, FT; flowthrough; 2M, peak fraction from 2M KC1 
elution; 0.35, peak fraction from the 0.35M elution. Although equal volumes of 
fractions were assayed, silver staining revealed that the 2M KC1 and the 0.35M KC1 
fractions assayed were approximately four times less concentrated than SM and R. 
Lanes 7 & 8 represent the first eluted fraction of the 4286 immunoaffinity column 
and the mock immunoaffinity column respectively of Fig.3.10A (lanes 5 & 13). 
Silver staining revealed that these two fractions are of comparable concentration.
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3.3 Discussion
3.3.1 Partial purification of mammalian TFIIIB
Despite considerable effort in the past fifteen years by a number of different 
laboratories, substantial purification of intact and active mammalian TFIIIB has 
remained rather elusive. A great many studies have implicated TFIIIB as a target for 
regulation, but these have tended to rely on rather impure sources of hTFIIIB 
obtained through conventional chromatography. The cloning and identification of 
TBP and hBRF as essential components of hTFIIIB provided the opportunity to use a 
novel approach, namely that of immunoaffinity chromatography, as a means of 
purification. It is now well documented that this technique can potentially achieve 
levels of purification in a single step that conventional chromatographers may 
struggle to even approach over a whole purification scheme. A significant 
proportion of my time and effort was therefore devoted to developing an effective 
immunoaffinity step for purifying TFIIIB, as well as screening a number of different 
conventional column types for potential use in a final fractionation scheme. 
Attempts have previously been made to immunopurify hTFIIIB in our laboratory 
using anti-TBP antibodies; however, this approach resulted only in the isolation of 
disrupted hTFIIIB complexes inactive for transcription (570). An immunoaffinity 
step was therefore developed using antibodies against BRF. There was the additional 
advantage of BRF being specific to TFIIIB, whereas TBP is part of pol II- and pol I- 
specific complexes as well as TFIIIB.
Three different BRF antibodies, each raised against a different region of the 
BRF protein, were tested for their potential use in the immunopurification of TFIIIB. 
However, only two of these, 128 and 330, were capable of immunodepleting 
endogenous BRF. There was very little to choose between the 128 and 330 antisera 
in terms of the yield of active TFIIIB typically obtained or the extent of purification. 
In the final purification scheme, nuclear extract was first purified on 
phosphocellulose and a heparin gradient prior to the immunoaffinity step, resulting in 
a 100-400 fold purification of active hTFIIIB from HeLa nuclear extract. This 
represents a significant improvement in the purity of TFIIIB compared to that 
normally used for regulatory studies in our laboratory.
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During gradient chromatography on Mono Q, hTFIIIB fractionates into two 
components, suggesting that one or more subunits may be loosely associated. In 
support of this, washing the immunoaffinity column with buffer containing 200mM 
NaCl rather than lOOmM NaCl prior to the high salt elution of bound hTFIIIB 
complex was consistently found to result in a complete loss of TFIIIB activity. 
Whatever the reason, the inability to wash the immunopurified complex very 
stringently without the loss of transcriptional activity meant that only a modest level 
of purification (-10 fold) was obtained by the immunoaffinity step.
The cause of this loss of activity is an important issue to be resolved as it may 
provide valuable information as to how the immunoaffinity step could be improved. 
It may be that the hTFIIIB complex is intrinsically unstable, as suggested by Huet et 
al. for the yeast TFIIIB complex. Alternatively, it may be that the particular BRF 
antibodies used weaken the association of one or more subunits of TFIIIB. If the 
latter possibility were to be true, other BRF antibodies raised against different 
regions of the BRF protein may offer the opportunity to wash more stringently 
without incurring a loss of activity. Another possible explanation is that washing 
with buffer containing 200mM NaCl disrupts the interaction between the antibody 
and TFIIIB. The establishment of a tight antigen-antibody complex is thought to 
occur in more than one step and is rather slow kinetically. Perhaps insufficient time 
was allowed for progression from the initial weak interaction of antigen with 
antibody to the formation of a stronger interaction that is relatively resistant to salt. 
This could easily be tested simply by preincubating the antigen and antibody for 
longer periods of time, for example overnight at 4°C, and seeing whether the column 
can be washed any more stringently without the loss of activity.
During the preparation of this manuscript, Schramm et al. reported the 
cloning of human B" (463). They also show that antibodies raised against hB" 
specifically deplete extracts of pol III transcriptional activity. Significantly, the 
addition of recombinant hB" alone to depleted extracts was able to rescue 
transcription, suggesting that hB" is not tightly associated with other TFIIIB 
components. Conversely, for extracts depleted of pol III transcriptional activity 
using anti-BRF or anti-TBP antibodies, a combination of recombinant TBP and BRF 
were found to be sufficient to restore transcription. Together, these results suggest 
that the TFIIIB I immunopurified using anti-BRF antibodies may be partially
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deficient in B". The sensitivity of the TFIIIB complex to washing with 200mM 
NaCl may reflect the complete loss of weakly associated hB". Thus, the addition of 
recombinant hB" to eluted fractions from the immunoaffinity column washed with 
200mM NaCl may be able to restore pol III transcriptional activity. It would also be 
of interest to see if recombinant B" can stimulate transcription synergistically when 
mixed with active immunopurified TFIIIB that was obtained.
The recent work of Schramm et al. suggests that hB", like its yeast 
counterpart, is only loosely associated with the TFIIIB complex. A better approach 
to achieving highly purified active TFIIIB may therefore be to separately 
immunopurify hB" and TBP-BRF and to reconstitute the active complex by mixing 
the separately purified components. The tendency of a protein complex to dissociate 
easily makes the substantial purification of intact complex extremely difficult to 
achieve.
3.3.2 Partial purification of mammalian TFIIIC
As with hTFIIIB, washing the immunopurified TFIIIC complex more 
stringently before eluting from the antibody column resulted in a significant 
reduction in the level of eluted TFIIIC activity. The cause of this loss of activity has 
not been investigated; however, hTFIIIC is relatively easily dissociated into two 
components, TFIIIC 1 and TFIIIC2 (118, 607). The TFIIIC 1 component remains 
almost completely undefined, possibly because it is not a very stable entity itself. 
The sensitivity to washing at increased salt concentrations might therefore be caused 
by the disruption of the interaction between TFIIIC 1 and TFIIIC2, or perhaps, weak 
interactions within the TFIIIC 1 subcomplex.
Immunopurified TFIIIC is estimated to have been purified -100-200 fold 
from HeLa nuclear extract while DNA-affinity purified TFIIIC is estimated to have 
been purified -80-120 fold. Unfortunately, the single attempt to combine the DNA- 
affinity and immunoaffinity purification steps failed to yield active TFIIIC. It might 
be an insufficient amount of immunoaffinity-purified TFIIIC was applied to the B- 
block oligonucleotide column. The attempt to combine the two purification steps 
certainly deserves repeating. Having obtained two different sources of partially
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purified TFIIIC that have been purified by different criteria, this enabled the 
significance of results obtained with one source of TFIIIC to be verified using the 
other source of purified protein.
For future work there is a lot of scope for improving upon the level of 
purification obtained, if required. All five subunits of TFIIIC2 have been cloned and 
each of these is a potential target in an immunoaffinity step depending on the extent 
of their surface exposure. The TFIIIC could also be purified further by conventional 
chromatography prior to an immunoaffinity step. The behaviour of TFIIIC on a 
variety of conventional column types was not investigated as part of this work. It 
would also be interesting to test the behaviour of TFIIIC on an oligonucleotide resin 
encompassing both the A- and B-block, to see if this stabilises TFIIIC 1 and the 
interaction between TFIIIC 1 and TFIIIC2, thereby enabling their co-elution as a 
single complex.
3.3.3 Human TFIIIC as a histone acetyltransferase
The DNA-affinity purified TFIIIC is significantly enriched in HAT activity 
compared with PC-C, supporting the findings of the Roeder laboratory that hTFIIIC 
has weak intrinsic HAT activity (230, 298). However, the immunoaffinity purified 
TFIIIC was not enriched in HAT activity compared with a mock immunopurified 
TFIIIC fraction of comparable concentration. Other proteins present in these 
partially purified fractions can account for both of these results. The enrichment in 
HAT activity in the DNA-affinity purified TFIIIC could easily result from the 
specific or non-specific co-fractionation of small amounts of a potent HAT, such as 
p300. Similarly, the lack of enrichment observed in the immunopurified TFIIIC 
could easily result from background levels of acetylation and deacetylation that have 
a masking effect on the HAT activity of the TFIIIC. These results suggest that if 
hTFIIIC does have intrinsic HAT activity, it is very weak. The enrichment in HAT 
activity in partially purified TFIIIC fractions can only be regarded as weak 
supporting evidence for the role of hTFIIIC as a HAT.
In the last five years a number of transcriptional coactivators for pol II 
transcription have been found to possess HAT activity; these include GCN5 (60), 
PCAF (601), p300 (398), CBP (398), TAFU250 (378) and the nuclear hormone
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receptor coactivators ACTR (85) and SRC1 (496). The intrinsic HAT activities of 
GCN5 and CBP have recently been demonstrated to be essential for their coactivator 
function (303, 359). It is now widely accepted that histone acetylation of 
chromatinised templates facilitates their transcription. Histone acetylation of a 
chromatinised 5S rRNA gene has been shown to facilitate binding of the 5S gene- 
specific factor TFIIIA and increase transcription of this gene (229, 321, 529, 534). 
Both in yeast and in humans, TFIIIC has been shown to be able to relieve chromatin- 
mediated repression of pol III transcription (66, 298). Thus, recent reports that 
hTFIIIC has intrinsic HAT activity are not too surprising. The treatment of hTFIIIC 
with the HAT inhibitor PMA results in a partial loss of HAT activity and inhibits 
TFIIIC-dependent chromatin transcription without affecting transcription of naked 
DNA (298). Although this is suggestive of a link between hTFIIIC relief of 
chromatin repression and its HAT activity, the inhibitory effect of PMA on TFIIIC- 
dependent chromatin transcription may be coincidental.
Human TFIIIC has diverged significantly from its yeast counterpart and none 
of the reported HAT-containing subunits of human TFIIIC have significant sequence 
homology to any of the yeast subunits. In accordance with the lack of homology, no 
HAT activity has been found to be associated with yeast TFIIIC (83). Thus, relief of 
chromatin-mediated repression by yeast TFIIIC seems to be by a HAT-independent 
mechanism and the same may be true for hTFIIIC.
In recent years it has become clear that some of the HATs efficiently 
acetylate non-histone proteins both in vitro and in vivo. Among the targets for 
acetylation of non-histone proteins are transcription factors. The acetylation of 
transcription factors can have both a stimulatory and an inhibitory effect on 
transcription, depending on the particular transcription factor and the site of 
acetylation. For example, acetylation of p53 at a site directly adjacent to its 
sequence-specific DNA-binding domain increases the sequence-specific DNA- 
binding activity of p53 and transcription of p53-activated genes (178). In contrast, 
the acetylation of HMGI(Y) within its DNA-binding domain disrupts its binding to 
DNA and reduces transcription of HMGI(Y)-responsive genes (386). The HAT 
activity of hTFIIIC is extremely weak compared to that of many other HATs, which 
raises the issue as to whether such a weak activity is physiologically significant. It is 
possible, however, that the activity is so weak because histones are a poor substrate 
for hTFIIIC and the in vivo target of hTFIIIC HAT activity is non-histone proteins
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that remain to be identified. To date this possibility has not been investigated, 
although it would appear that hTFIIIC does not possess autoacetylation activity.
Several lines of evidence suggest that the enzymatic activity of histone 
acetyltransferases may be regulated. The HAT activity of CBP increases sharply at 
the Gl-S transition of the cell cycle (4). This coincides with the 
hyperphosphorylation of CBP and a peak of cdk2/cyclin E activity, implicating the 
involvement of a phosphorylation event (4). The HAT activity of hGCN5 is also 
regulated by phosphorylation; phosphorylation by DNA-PK inhibits its HAT activity 
(20). There is also some evidence that suggests that the HAT activities of p300 and 
PCAF can be regulated by the viral oncoprotein El a (289). The weak HAT activity 
of hTFIIIC tested may be due to the lack of an activating post-translational 
modification, such as phosphorylation. All five subunits of TFIIIC2 are
' i ' j
metabolically labelled with Pi in vivo (481). It may be that one of these 
phosphorylation events stimulates the HAT activity of hTFIIIC. At present, 




Repression of TFIIIB by the pocket 
proteins
4.1 Introduction
The retinoblastoma protein, RB, is an important tumour suppressor that is 
frequently inactivated in a variety of different human malignancies (173, 214, 557, 
580). Indeed, it has been suggested that the regulatory pathway involving RB may 
be disrupted in all human cancers (557). RB is involved in constraining the growth 
and proliferation of the cell (173, 214, 557, 580). In the absence of RB function the 
cell is desensitised to environmental conditions and normal regulatory signals and is 
prone to uncontrolled growth and proliferation. Introduction of the wild-type Rb 
gene into a number of different human cancer cell lines that lack functional RB was 
found to suppress growth and proliferation, soft agar formation and tumorigenicity in 
nude mice (42, 233, 427). Definite proof for the essential role of RB as a tumour 
suppressor is provided by gene knockout experiments in mice. Homozygous 
inactivation of the Rb gene is lethal, mouse embryos die in midgestion with neuronal 
and haematopoietic defects implicating a role for RB in differentiation. However, 
heterozygotes survive and are strongly predisposed to cancer (232, 245, 322, 347, 
396,581).
A diverse array of cellular proteins have been found to associate with RB and 
novel targets are still being discovered (214, 512, 566). The relative contributions of 
the various targets to the physiological effects of RB is still the subject of intense 
study. Probably the best characterised target of RB is the E2F family of transcription 
factors (3, 132, 310, 556). E2F is a heterodimeric transcription factor composed of 
an E2F polypeptide, of which there are six types, and a DP polypeptide, of which 
there are three types (3). RB inhibits E2F by binding to and masking its 
transactivation domain, thus preventing E2F activating gene expression from 
promoters that contain E2F-binding sites (131, 560). E2F-RB complexes can bind to 
E2F-binding sites in promoters and repress basal transcription from these promoters
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(131, 560). Thus, RB converts E2F from a transcriptional activator to a 
transcriptional repressor (560). This dominant repressive effect on transcription is 
dependent, at least at some E2F-regulated promoters, on histone deacetylase activity 
(53, 346, 349). The histone deacetylase HDAC1 can associate with RB and is 
specifically recruited to E2F-regulated promoters via this association (53, 346, 349).
The E2F transcription factors regulate the expression of a battery of genes 
many of which encode proteins essential for DNA replication or which promote cell 
cycle progression (131, 566). Overexpression of E2F-1 can drive quiescent cells 
through G1 and into S phase of the cell cycle (428). On the basis of the identity of 
the genes that are regulated by E2F, one would predict that inhibition of E2F by RB 
would be a potent block upon cell proliferation (131, 566). Overexpression of RB in 
many cell types causes a G1 arrest; however, without inactivating all the genes 
encoding E2F and DP proteins one cannot be certain the arrest is solely due to 
inactivation of E2F (131).
The activity of RB is tightly regulated and depends on its phosphorylation 
status (239, 418, 482, 557). In a hypophosphorylated state RB is active, whereas in a 
hyperphosphorylated state RB is inactive. The phosphorylation of RB is controlled 
by cyclin-dependent kinases (CDKs) (239, 418, 482, 557). The CDKs integrate 
negative and positive growth signals from the environment. For example, the 
synthesis of the D-type cyclins is rapidly induced on mitogenic stimulation; on 
growth factor withdrawal, cyclin D synthesis ceases immediately (418). Cyclin D 
may act as a growth factor sensor (418). The activity of CDKs depends on the levels 
of the regulatory cyclin subunits (239, 418, 482). The CDKs enable RB to indirectly 
sense the environment and to coordinate gene expression required for cellular growth 
and proliferation with growth factor availability (214, 239, 418, 482).
One of the major checkpoints of the cell cycle is the restriction point, R, in 
late G1 (404). Passage through R constitutes a transition from a serum-dependent to 
a serum-independent state and cells are committed to a single round of DNA 
replication and cell division (404). RB is a major determinant of whether cells can 
pass through R (482, 557).
The restraining influence of RB on cell proliferation, that is, an increase in 
cell number, can be largely explained by its inhibitory effect on E2F (566). 
However, it is difficult to reconcile the ability of RB to suppress cell growth, that is, 
an increase in cell mass, with its ability to inhibit E2F (566). With the exception of
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c-myc, none of the known E2F targets provide any obvious links to the control of 
cell growth (566). One might imagine that controlling cell proliferation is sufficient 
to achieve indirect control of cell growth. However, inhibition of DNA replication 
has little immediate effect on the growth of a variety of different mammalian cell 
types (566). Although cell proliferation and growth are undoubtedly intimately 
linked, available evidence suggests that any dependency is the other way round. In 
bacteria and yeast it is necessary for the cell to reach a critical size threshold before 
DNA replication and cell division can proceed (394). This has also been found to be 
true for murine fibroblasts (273).
A significant imbalance between growth and proliferation will cause a cell to 
undergo apoptosis (428, 566). Although the overexpression of E2F drives quiescent 
cells into S phase, they then apoptose (428). This strongly suggests that the control 
of E2F is insufficient to account for the growth inhibitory effects of RB. RB is also 
in vast molar excess of E2F in the cell (214, 557).
Recently it has been shown that RB represses pol III transcription in vitro and 
in vivo (579). There is also some evidence suggesting that pol I transcription may be 
a physiological target of RB (78, 539). Repression of pols I and III provide a 
potential mechanism by which RB can achieve growth control (567, 568). The rate 
of growth of cells is directly proportional to the rate of protein accumulation, which 
is largely dependent on the rate of protein synthesis (27). rRNA and tRNA are 
important determinants of the biosynthetic capacity of the ce ll. The levels of rRNA 
and tRNA in the cell are unlikely to be in large excess for reasons of cell economy 
and it is possible that suppression of their synthesis by RB results in their becoming 
limiting for translation, thus restricting cellular growth.
Knockout mice provided definite proof that pol III transcription is a 
physiological target of RB. Primary embryonic fibroblasts from Rb'1' mice 
synthesised tRNA and 5S rRNA at a rate approximately 5-fold higher than 
equivalent cells from Rb+/+ mice (579). In contrast, the overall level of pol II 
transcription remained unchanged.
RB specifically represses TFIIIB (93, 314). In a reconstituted system 
repression of VAi transcription by recombinant RB can be overcome by addition of 
partially purified TFIIIB whereas addition of pol III or TFIIIC fractions had little or 
no effect (314). In this reconstituted system in the absence of added RB, TFIIIC was 
found to be the limiting factor whereas TFIIIB was in relative excess (314). This
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demonstrates the potency of the repressive effect of RB on TFIIIB; RB severely 
reduces the level of pol III transcription yet its target, TFIIIB, is not even initially 
limiting for transcription in this system. Furthermore, pull-down assays and 
immunoprecipitations revealed that RB and TFIIIB stably interact (314). This is 
supported by the cofractionation of a population of endogenous RB molecules with 
endogenous TFIIIB over a variety of different chromatographic columns (314). 
TFIIIB activity was also found to be specifically elevated in primary embryonic 
fibroblasts from Rb'1' mice (314). This large body of evidence clearly demonstrates 
that TFIIIB is a specific target for repression by RB. This is also consistent with 
previous data which showed that TFIIIB is the limiting factor for pol III transcription 
during the G1 phase of the cell cycle, a time when RB is active; and that it is no 
longer limiting in S phase, a time when RB is inactivated by hyperphosphorylation 
(571).
The retinoblastoma protein RB is structurally and functionally related to two 
other cellular proteins called p i07 and pl30 (173, 385, 580). Collectively, the three 
proteins are often referred to as the pocket proteins because they share most 
extensive sequence homology in a bipartite region called the pocket domain. The 
pocket domain of RB is both necessary and sufficient for its proliferation- and 
growth-suppressive functions (427). Like RB, the ectotopic expression of p i07 and 
pl30 in tumour cells can inhibit cellular growth and proliferation (97, 427, 593, 615). 
The pocket domains of the three pocket proteins bind a number of common target 
proteins such as E2F and the oncoproteins of several DNA tumour viruses, 
suggesting that there may be some redundancy between the pocket proteins (131, 
173, 214, 385). pl07 and pl30 are much more closely related to each other (~50% 
amino acid identity) than to RB (30-35% identity). Gene knockout experiments 
revealed that there is significant redundancy between p i07 and p i30. p i07- or pi 30- 
deficient mice develop normally, however, plO T1' p i30 '1' double knockout mice die 
shortly after birth (99). In contrast, mice lacking RB die in midgestion, suggesting 
that some distinct functions of RB cannot be performed by pl07 or pl30 (95, 245, 
322).
Recently, Sutcliffe et al. showed that p i07 and p i30 are also able to repress 
pol III transcription; thus, this is a property shared by all three pocket proteins (504). 
In this chapter evidence is presented which suggests that endogenous p i07 and p i30 
stably interact with a specific component of the pol III transcriptional apparatus.
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Although it has been established that RB specifically represses TFIIIB, the 
mechanism by which RB achieves this has, until recently, not been investigated. In 




4.2.1 Repression of pol III transcription by recombinant RB
To investigate the mechanism(s) by which RB specifically represses TFIIIB, 
it was necessary to have a purified source of RB for use in assays and for this RB to 
be active in its ability to inhibit pol III transcription. Since the Rb gene has been 
cloned, the production of recombinant protein was an attractive alternative to 
purifying the protein from natural sources. Although RB is quite an abundant 
nuclear protein and it is ubiquitously expressed, it was judged that purification of 
sufficient quantities from natural sources would probably require vast amounts of 
nuclear extract. It was also predicted that sufficient purification of RB from its many 
targets and other cellular proteins could be very difficult and time consuming.
For quantitative reasons and ease of purification, it was thus decided to 
express RB heterologously using Escherichia coli as host. Suitable RB expression 
vectors were already available for the expression of RB as a glutathione-S- 
transferase (GST) fusion protein or as a His6 fusion protein. Both of these RB fusion 
proteins were expressed for use in assays enabling the verification of results obtained 
with one RB fusion protein by testing the effect of the other. Where results differ, 
this suggests the effects seen may not be due to RB but may be a consequence of the 
specific tag or contaminants that have co-purified. The “tagging” of RB enabled its 
rapid and efficient purification in a single step on an affinity column specific for the 
tag. Rather than express full-length protein, RB containing residues 379-928 
(RB(379-928)) was expressed, as this has been found to give higher levels of 
expression. White et al. previously demonstrated that this region of RB is sufficient 
to inhibit pol III transcription (579).
Having expressed and purified RB, it was essential to test that the protein is 
active in its ability to repress pol III transcription. When expressing eukaryotic 
proteins in a prokaryotic system obtaining biologically active protein can sometimes 
be a big problem (468). This may be caused by the lack of an essential post- 
translational modification or incorrect folding resulting from the environment in 
which it was expressed and the lack of appropriate molecular chaperones (468). The 
protein may also be inadvertently inactivated by the procedure used to extract and 
purify it. The procedures used for disrupting cells to obtain the protein of interest are
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often quite harsh and the balance between disrupting too gently and obtaining very 
poor yields and disrupting too harshly and inactivating the protein seems quite fine.
I have been able to purify both GST-RB(379-928) and His6-RB(379-928) that 
are of very high activity in their ability to repress in vitro pol III transcription, as 
shown in Figure 4.1 for GST-RB(379-928), for example. However, consistent with 
the findings of others, there seemed to be considerable variation in the activity of the 
purified RB between different preparations (314). Attempts to pinpoint the cause of 
the variation in activity of RB between different batches have been unsuccessful to 
date. It was thus essential that each preparation of GST-RB(379-928) or His6- 
RB(379-928) was individually tested for its ability to repress pol III transcription 
before use in an assay.
As shown in Figure 4.1, addition of nanogram amounts of GST-RB(379-928) 
to an in vitro pol III transcription assay can potently inhibit transcription of the 
specific pol III template. This is not a non-specific effect of the buffer composition 
of the recombinant RB, as an equivalent amount of the same buffer was added to the 
reaction shown in lane 1 which contains no recombinant protein (compare lanes 1 
and 3& 4). As an additional control, GST that was made and purified in parallel to 
the RB was added to one of the reactions. Addition of the same amount of GST as 
the largest amount of RB added clearly demonstrated that the inhibition of pol III 
transcription by the GST-RB(379-928) is specific (compare lane 2 with lanes 3 & 4). 
Addition of GST did not inhibit transcription at all; rather perhaps it very slightly 
stimulated transcription compared with no addition of recombinant protein (compare 
lanes 1 & 2). This may be a non-specific stabilising effect on the pol III transcription 
components caused by the addition of protein.
4.2.2 Recombinant RB potently represses pol III transcription in the presence 
of histone deacetylase inhibitor
Transcriptional repression by RB of E2F-regulated promoters involves at 
least two distinct mechanisms. RB binds to E2F within its transactivation domain, 
preventing it from interacting with the basal pol II transcription factor TFIID (448). 
However, the ability of RB to inhibit transactivation by E2F does not account for its 
ability to reduce transcription to below the basal levels observed when the E2F
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Figure 4.1
Repression of pol III transcription by recombinant RB
250 ng of pVAi was preincubated for 15 min at 30°C with HeLa-PC-B (2pl) and 
HeLa-PC-C (2pl) (all lanes) in a reaction volume of 15pl containing GST-RB elution 
buffer (lane 1), 250 ng of GST (lane 2) or with 250 ng or 125ng of GST-RB(379- 
928) (lanes 3 and 4, respectively). Transcription was initiated by the addition of a 
mixture of rATP, rCTP, rGTP and [a32P]-UTP and was allowed to proceed for 1 h. 
Ethanol-precipitated transcription products were separated on a 7M urea 7% 
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binding sites are unoccupied. Additionally, several RB mutants have been isolated 
that bind E2F but fail to significantly repress transcription of E2F-regulated 
promoters (52).
As discussed in the previous chapter, the acetylation of chromatin is an 
important mechanism by which transcription may be regulated. A number of 
transcriptional activators have been found to possess intrinsic histone 
acetyltransferase activity which for several coactivators has been shown to be 
essential for their activating function (303, 359, 500). Hence, the discovery that 
several transcriptional repressors, such as Mad and NCoR, associate with histone 
deacetylases and that this activity is essential for their repressive function (5, 308) 
came as little or no surprise. The possibility of an involvement of histone 
deacetylases in transcriptional repression by RB was loosely suggested by the finding 
that two RB binding proteins, RbAp46 and RbAp48, are part of the mammalian Sin3 
deacetylase complex (52).
Recently, three different groups have independently shown that RB 
specifically interacts with the histone deacetylase HDAC1 both in vitro and in vivo 
(53, 346, 349). Furthermore, E2F1, RB and HDAC1 can form a trimeric complex in 
vitro (53, 349). However, an E2F mutant that is unable to bind RB also failed to 
bind HDAC1 (53). This suggested that RB might act as a bridging factor between 
HDAC1 and E2F to enable the recruitment of deacetylase activity to E2F-regulated 
promoters. The significance of the association between RB and histone deacetylase 
was tested by Luo et al. using the chromatin immunoprecipitation method (346). 
They found that the acetylation status of histones at a chromatinised promoter 
changed upon binding of RB (346). The deacetylation of histones is predicted to 
result in a more compact chromatin structure that is less accessible to transcription 
factors and thus inhibitory to transcription (177). Treatment of cells with the potent 
histone deacetylase inhibitor trichostatin A (TSA) relieved RB-mediated repression 
of some of the E2F-regulated promoters tested. Although this demonstrated that 
deacetylase activity is required for the full repressive effect of RB at some E2F- 
regulated promoters, other promoters seemed insensitive to treatment with TSA, 
indicating that the involvement of associated deacetylase activity in RB-mediated 
repression is selective.
RNA polymerase III transcription is also likely to be affected by acetylation, 
as exemplified by recent reports suggesting that TFIIIC2 possesses histone
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acetyltransferase activity. It is plausible that the histone deacetylase activity 
associated with RB antagonises the HAT activity of TFIIIC2. To test whether the 
repression of pol III transcription by RB requires histone deacetylase activity, the 
effect of increasing amounts of TSA on transcription carried out in the presence or 
absence of exogenous RB was tested (503). Figure 4.2 shows the effects of TSA on 
in vitro transcription from the VAi template (503). The GST-RB (379-928) potently 
repressed transcription of the VAi gene (compare lanes 1 & 2). Repression was 
maintained in the presence of increasing amounts of TSA (even-numbered lanes). 
Transcription carried out in the presence of added GST was not affected by the 
presence of TSA (odd-numbered lanes), indicating that the lack of derepression in 
the presence of RB is not due to the TSA having a non-specific toxic effect on 
transcription.
It is plausible that RB utilises different mechanisms to repress transcription at 
different pol III templates. For example, some pol III templates may be more 
susceptible to acetylation than others. I therefore decided to test the effect of TSA on 
a tRNA gene, which has a weaker promoter than VAi, and thus perhaps is more 
susceptible to acetylation. As Figure 4.3 shows, similar results were obtained to 
those with the VAi gene (503). Transcription carried out with nuclear extract in the 
absence of recombinant protein was largely unaffected by the inclusion of TSA at a 
concentration of -500 nM in the transcription reaction mixture (lanes 1 & 2). 
Similarly, transcription carried out in the presence of 250 ng of GST and increasing 
amounts of TSA remained at a fairly constant level (lanes 3-6). Together, these 
results suggest that the TSA is not inhibitory to transcription and that in vitro 
tianscription with endogenous factors is not affected by acetylation/deacetylation. 
As with the VAi template, inclusion of increasing amounts of TSA did not relieve 
repression by RB (lanes 7-10). TSA is a specific and irreversible inhibitor of histone 
deacetylases and a concentration of 100 nM is sufficient to block HD AC function. 
Repression by RB of tRNA transcription was maintained in the presence of ~500nM 
TSA. Clearly, recombinant RB is able to repress pol III transcription in vitro by a 
mechanism that does not require histone deacetylase activity.
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Figure 4.2
Repression of VAi transcription by RB is maintained in the presence of the 
histone deacetylase inhibitor Trichostatin A
pVAi (250 ng) was transcribed using 10pg of HeLa nuclear extract that had been 
preincubated for 15 min at 30°C with 250 ng of GST (odd-numbered lanes) or GST- 
RB(379-928) (even-numbered lanes). Reactions 3 and 4 also contained 165 nM TSA 
and reactions 5 and 6 contained 330 nM TSA. Transcription was initiated by the 
addition of nucleotides and allowed to proceed for 1 h.
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Figure 4.3
Repression of tRNA synthesis by recombinant RB is unaffected by the presence 
of increasing concentrations of TSA
250 ng of pLeu was transcribed using lOpg of HeLa nuclear extract that had been 
preincubated for 15 min at 30°C without addition (lanes 1,2 and 11), with 250 ng of 
GST (lanes 3-6) or with 250 ng of GST-RB(379-928) (lanes 7-10). TSA was 
included at a concentration of 165nM (lanes 4 and 8), 331nM (lanes 5 and 9) or 
496nM (lanes 2, 6 and 10). Transcription was initiated by the addition of a mixture 
of rATP, rCTP, rGTP and [a32P]-UTP and was allowed to proceed for 1 h at 30°C. 
Ethanol-precipitated transcription products were separated on a 7M urea 7% 
polyacrylamide sequencing gel and were visualised by autoradiography.
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4.2.3 Fractionation of HDAC1 and TFIIIB
It is surprising that TSA had no effect on pol III transcription in light of 
recent reports suggesting that TFIIIC, which is essential for transcription from both 
of the promoters investigated, has intrinsic HAT activity. However, the transcription 
assays were conducted using pol III templates carried in plasmid DNAs. It is very 
unlikely that the pol III templates would be assembled into their native chromatin 
conformation in this in vitro system, although the assembly of some histones onto the 
plasmid DNAs is plausible. The possibility therefore remained that acetylation or 
deacetylation does have an important role in the regulation of pol III templates in 
their natural chromatin environment. Furthermore, the possibility also existed that 
repression by RB of pol III transcription in its natural chromatin context involves 
histone deacetylase activity.
Although it has been demonstrated that endogenous RB and endogenous 
HDAC1 specifically interact with each other, it is not known what proportion of RB 
in vivo is associated with HDAC1 (53, 346, 349). This raises the question as to 
whether the endogenous RB that associates with TFIIIB is also associated with 
HDAC1.
HDAC1 preferentially binds to the active, hypophosphorylated form of RB, 
suggesting that its association is important for RB function (346). HDAC1 interacts 
with RB via an LXCXE-like motif (IACEE) (349); deletion of this motif severely 
compromises their coimmunoprecipitation (349). HDAC1 binds to the A/B pocket 
domain of RB (residues 379-792). This same domain of RB is required for its 
proliferation- and growth-suppressive functions and for its ability to inhibit pol III 
transcription (568). The viral oncoproteins of several DNA tumour viruses bind the 
same region of RB through an LXCXE motif. This disrupts the interaction between 
RB and HDAC1 and also the interaction between RB and E2F (53, 84). This 
suggests that the binding sites of HD AC 1 and E2F on RB may overlap. However, 
E2F, RB and HDAC1 can form a trimeric complex in vitro (53, 349). In vivo, RB 
and HDAC1 cooperate to repress certain E2F-regulated promoters; in a RB'7' 
background the same promoters are insensitive to TSA, presumably because HDAC1 
cannot be recruited (346).
It is well established that TFIIIB and RB specifically interact with each other 
in vitro and in vivo and at physiological ratios (314). Substitutions in the A/B pocket
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domain of RB that disrupt this interaction prevent RB from repressing pol III 
transcription (93). Repression of pol III transcription by RB can also be overcome 
by adenoviral El A and SV40 large T antigen (579). It is predicted that the binding 
of these viral oncoproteins to the pocket domain of RB disrupts the interaction 
between TFIIIB and RB (314). This suggests that TFIIIB and HDAC1 probably bind 
to the same region of RB, since the interaction of HD AC 1 with RB is disrupted by 
viral oncoproteins. However, it is not known whether the binding sites of TFIIIB 
and HDAC1 on RB overlap or are distinct, or whether the binding of one precludes 
the binding of the other. E2F, RB and HDAC1 can form a trimeric complex in vitro 
despite viral oncoproteins being able to disrupt the binding both of HD AC 1 and E2F 
to RB.
If the binding of HDAC1 and TFIIIB to RB is mutually exclusive it is 
unlikely, unless another deacetylase is involved, that the repression of pol III 
transcription by RB in vivo involves deacetylase activity. Immunoprecipitations 
were performed to see whether endogenous TFIIIB and HDAC1 specifically interact 
and, if they do, whether this occurs in a RB-dependent or a RB-independent manner. 
The HDAC1 polyclonal antiserum used was unable to coimmunoprecipitate BRF, an 
essential subunit of TFIIIB, from HeLa nuclear extracts (data not shown). The 
antiserum was also unable to coimmunoprecipitate RB from the same extracts (data 
not shown). However, this antiserum does immunoprecipitate and has previously 
been reported to coimmunoprecipitate RB from MCF7 extracts (388). This apparent 
discrepancy in the ability of the antiserum to coimmunoprecipitate RB is probably a 
reflection of the different extracts used. HeLa cells are HPV-transformed and 
contain high levels of the viral oncoprotein E7. HPV E7 protein has previously been 
shown to prevent RB from associating with deacetylase activity (53). Thus, the 
absence of RB in the immunoprecipitated material from HeLa nuclear extracts may 
be because none of the HDAC1 in these extracts is associated with RB. HeLa cells 
may also contain less HDAC1 than MCF7 cells which could result in less HDAC1 
being immunoprecipitated and the levels of coimmunoprecipitated proteins could be 
reduced to below the levels of detection. The lack of a positive control for the 
immunoprecipitation precludes any interpretation regarding the absence of BRF in 
the immunoprecipitated material. Unfortunately, the similarity in size of HDAC1 
and the heavy chain of immunoglobulins prevented a clear result from the converse
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experiment of immunoprecipitating with a BRF antiserum or a RB antiserum and 
seeing if HD AC 1 specifically coimmunoprecipitates (data not shown).
It was also tested whether endogenous HDAC1 and TFIIIB cofractionate 
during column chromatography. The consistent cofractionation of two proteins over 
a variety of different chromatographic columns is suggestive of a stable association. 
Western blotting of fractions from heparin gradient chromatography of a PC-B 
fraction revealed that HDAC1 cofractionates closely with TFIIIB activity through 
this column (data not shown). However, the bulk of the protein appears to have 
fractionated in similar fractions, suggesting that the cofractionation of TFIIIB and 
HDAC1 on this column may be fortuitous (data not shown).
Fractions from Mono Q gradient chromatography of a PC-B fraction were 
also tested. As Figure 4.4 shows, HDAC1 fractionates extremely heterogenously 
with some HDAC1 detectable in many of the fractions assayed and some adjacent 
fractions containing quite variable amounts of HD AC 1. The column is clearly not 
overloaded, which could contribute to the heterogeneity, as HDAC1 is notably absent 
from the flowthrough (lane 2) indicating its specific retention on the column.
Fractionation of TFIIIB on a Mono Q gradient splits TFIIIB into two 
essential components called 0.38M-TFIIIB and 0.48M-TFIIIB, respectively (91, 340, 
371). 0.38M-TFIIIB consists minimally of TBP and BRF. 0.48M-TFIIIB has not 
been characterised, but is thought to consist minimally of a human homologue of 
yeast B" (340). 0.38M-TFIIIB activity was found to peak in fractions 54, 55 and 56 
whereas 0.48M-TFIIIB activity peaked in fractions 57, 58 and 59 (White, R.J., 
unpublished observations). The 0.48M-TFIIIB peak fractions contain only very low 
levels of HD AC 1 and clearly show a depletion in the levels of HD AC 1 compared to 
the starting material, PC-B (compares lanes 10-12 with lane 1). It is likely that these 
fractions are significantly less concentrated than the starting material, however.
In contrast, two of the 0.38M-TFIIIB peak fractions contain very high levels 
of HD AC 1 compared to the other eluted fractions. Fraction 55 is clearly enriched in 
HDAC1 compared to the starting material, PC-B, and while fraction 56 contains a 
similar amount of HDAC1 to the starting material the fraction is probably 
significantly more dilute than the PC-B. Fractions 55 and 56 contain much more 
HDAC1 than any other eluted fraction assayed with the sole exception of fraction 51
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Figure 4.4
Fractionation of HDAC1 during gradient chromatography of PC-B on Mono Q
PC-B was applied to an FPLC Mono Q column. After washing extensively with 
buffer Q containing lOOmM KC1, fractions were eluted with a linear 100-500mM 
KC1 gradient. Fractions were then extensively dialysed into LDB, aliquoted, snap 
frozen and stored at -80°C. Equal volumes (15pl) of the various fractions* were 
resolved on a SDS-7.8% polyacrylamide gel and then analysed by Western blotting 
with an antiserum specific for HDAC1 (C l9, Santa Cruz).
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which contains approximately two-thirds as much HDAC1 as fraction 56 (compare 
lanes 8 & 9 with lanes 3-7 and 10-14). Although fractions 55 and 56 are peak 
0.38M-TFIIIB fractions, suggesting that HDAC1 and TFIIIB may associate, fraction 
54 also contains high levels of 0.38M-TFIIIB yet contains low levels of HDAC1 
comparable to other fractions with very little TFIIIB activity. The most 
straightforward interpretation of this is that the high levels of HD AC 1 in fractions 55 
and 56 are not due to a stable association with TFIIIB. However, without knowing 
how TFIIIB itself has fractionated interpretation is near impossible.
Although the TFIIIB activity of individual fractions is probably a good 
indication of the amounts of TFIIIB protein in the fractions, it is not a substitute and 
may not accurately reflect the distribution of the protein. For example, fractions 52 
and 53 have much lower 0.38M-TFIIIB activity than fractions 54-56 but it is 
plausible that they actually contain higher amounts of TFIIIB. These two fractions 
perhaps contain high levels of a specific repressor of TFIIIB that has cofractionated 
but which is not associated with the TFIIIB in fractions 54-56. Indeed RB, which 
has previously been demonstrated to specifically and stably interact with and repress 
TFIIIB, peaks in fractions 52 and 53 with much lower levels in fractions 54-56 (data 
not shown). Unfortunately, the BRF antisera cross-reacted badly with other proteins 
of a similar size to BRF in the fractions, which meant the BRF content of individual 
fractions was uncertain (data not shown). The amounts of 0.48M-TFIIIB protein 
present in individual fractions was prevented from being determined by a lack of 
knowledge as to its molecular composition and a lack of antibodies against any of its 
components.
The functional significance of any interaction between TFIIIB and HDAC1 is 
also important; for example, if HD AC 1 inactivates TFIIIB higher levels of HD AC 1 
may be expected in fractions of lower TFIIIB activity depending on the protein 
levels. Collectively, the available evidence on the fractionation of HDAC1 and 
TFIIIB on a Mono Q gradient is not supportive of a close cofractionation of the two 
proteins. However, the results are open to differential interpretation due to 
uncertainty as to how reliable an indicator TFIIIB activity is of the levels of TFIIIB 
protein in the fractions.
Recently, it has been shown that RB does not require histone deacetylase 
activity for repression of pol III transcription in vivo (503). This is consistent with 
the lack of requirement observed in vitro (see Figs 4.2 & 4.3). As well as using
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transiently transfected pol III templates, which as in the in vitro system may not be 
properly assembled into chromatin, the effects of inhibiting deacetylase on 
transcription of an endogenous gene in its natural chromatin environment was also 
tested (503). Untransfected Rb'f~ and Rb+/+ mouse embryonic fibroblasts were 
cultured in the presence or absence of TSA and total RNA was then extracted for 
analysis of the expression of the B2 gene by northern blotting (503). The B2 gene 
family was chosen for the northern analysis as previously it has been shown that 
these genes are highly susceptible to chromatin-mediated repression. Interestingly, 
TSA elicited an increase in B2 expression levels in both types of fibroblasts (503). 
This effect is specific, since the levels of a pol II transcript encoding acidic ribosomal 
phosphoprotein P0 (ARPP P0) remained relatively constant. This represents the first 
in vivo evidence that acetylation can influence pol III transcription. It may be that 
deacetylases function in antagonising the reported HAT activity of TFIIIC2. The 
relative increase in B2 RNA levels in response to TSA was no greater for the Rb+/+ 
cells than for the Rb'A cells and the higher levels of expression in the Rb'A cells was 
maintained (503). Thus, the effect of inhibiting histone deacetylases on pol III 
transcription in vivo is RB-independent. It may be that an endogenous histone 
deacetylase can interact directly with a component of the pol III transcriptional 
apparatus or is recruited via a protein other than RB. The western blots of the Mono 
Q fractions clearly showed that there is a lot of endogenous HDAC1 that is not 
associated with RB (data not shown). Alternatively, the effect of HD AC function on 
pol III transcription may be indirect.
TSA treatment strongly stimulated transcription of a chromosomally 
integrated class III gene but had no effect in vitro and only a very slight stimulatory 
effect on transcription of a transiently transfected template (503). This suggests that 
histone deacetylases and the reported HAT activity of TFIIIC2 probably influence 
pol III transcription through the acetylation or deacetylation of nucleosomal histone 
proteins and the modulation of local chromatin structure. Although it remains 
possible that the physiological target of histone deacetylases and TFIIIC2 HAT 
activity are non-histone proteins, it is less likely that the effect of acetylation or 
deacetylation of these proteins would be restricted to pol III transcription carried out 
in a chromatin environment. In contrast to the TSA effect on pol III transcription 
that appears to be restricted to pol III templates that are fully assembled into 
chromatin, TSA sensitivity of E2F-regulated promoters was also observed using
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transiently transfected templates (53, 349) which are only partially assembled into 
chromatin. This suggests that transcription of E2F-regulated promoters may be 
regulated by the acetylation or deacetylation of non-histone proteins or it may be that 
these genes are more susceptible to chromatin-mediated repression.
4.2.4 Immunopurification of a pol III holoenzyme
A variety of different mechanisms have been proposed for how RB 
specifically inactivates TFIIIB. One possibility is that RB disrupts the TFIIIB 
complex in some way, perhaps displacing one or more components. Another nuclear 
phosphoprotein called Drl utilises this mechanism to repress pol III transcription. 
Drl can specifically displace BRF from its interaction with TBP (576). Mutational 
analysis suggests that BRF and Drl compete directly for overlapping binding sites on 
TBP (576). The binding of BRF to TBP is maintained in the presence of RB, 
consistent with the ability of anti-RB antibodies to coimmunoprecipitate both of 
these proteins (314, 503). However, RB may displace an unidentified component of 
TFIIIB from the complex. Alternatively, intramolecular interactions within TFIIIB 
may be disrupted that inactivate the complex without any component actually being 
displaced from it.
RB contains regions of homology to both BRF and TBP, suggesting there 
may be some structural similarity (314). Larminie et al. proposed a model in which 
RB mimics TBP and BRF enabling it to disrupt interactions of these two proteins 
with other components of the complex (314). Subsequently, it has been found that 
the regions of homology of RB and TBP bear no structural resemblance. It remains 
to be determined whether the regions of homology of RB and BRF are structurally 
alike (275).
RB can inhibit pol I transcription by preventing UBF from binding to the 
rDNA promoter (539). Similarly, RB may inhibit TFIIIB by preventing contacts 
with promoter DNA. For most pol III templates, TFIIIB is recruited to the promoter 
through protein-protein interactions with TFIIIC. In yeast, once TFIIIB has been 
recruited TFIIIC can be stripped away and TFIIIB alone will remain bound to 
promoter DNA capable of supporting multiple rounds of transcription initiation 
(263). In contrast, in vertebrates any interactions between TFIIIB and DNA are very
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weak and studies to date have been unable to detect a TFIIIB footprint (568). There 
is circumstantial evidence, however, that DNA contacts are made and that their 
disruption will impair transcription (568).
RB may inhibit TFIIIB by disrupting any of its intermolecular interactions 
that are required for transcription. The interactions of TFIIIB with TFIIIC, pol III or 
promoter DNA are all potential targets for disruption. Below I describe the 
immunoisolation of a pol III complex containing TFIIIB, TFIIIC and RNA 
polymerase III. This provided the opportunity to test whether RB represses pol III 
transcription by specifically disrupting the interactions between TFIIIB and TFIIIC 
or TFIIIB and pol III.
Using isolated components, the formation of a functional preinitiation 
complex on pol III templates has been demonstrated to occur in a precisely ordered 
and stepwise fashion (318). However, alternative assembly pathways may exist in 
vivo. For RNA polymerase II transcription, a similar stepwise assembly pathway has 
been defined in vitro. However, in vivo several large complexes that contain pol II, 
some or all of the general initiation factors and various cofactors have been 
discovered (187, 286). These so-called holoenzymes can exist in the absence of 
DNA and suggest an alternative assembly pathway of the pol II preinitiation complex 
in vivo whereby many or all the essential initiation components are simultaneously 
recruited to the promoter as part of this preassembled complex (187, 286). In yeast, 
evidence from a combined biochemical and genetic approach by Young and co­
workers strongly suggests that the physiologically relevant form of pol II that is 
recruited to most pol II promoters in vivo is a pol II holoenzyme (38, 521).
Such holoenzymes are seemingly not restricted to the pol II system. 
Functional pol III complexes containing TFIIIB, TFIIIC and pol III, but which are 
not associated with DNA, have been isolated by gel filtration or density gradient 
centrifugation both from Drosophila and human cell extracts (65, 585). The stability 
of these complexes to 1M KC1 suggests that they are unlikely to result from the 
fortuitous aggregation of constituent components (585). Further support for the 
possible existence of a pol III holoenzyme is provided by the recent 
immunopurification from HeLa cell extracts of a complex that contains all the 
essential components for tRNA, 5S RNA and VAi transcription (551). Using 
immobilised anti-FLAG monoclonal antibody, this complex was purified from a 
HeLa cell line that constitutively expresses a FLAG epitope-tagged subunit of pol III.
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After washing with low salt so as not disturb any weak interactions, the complex was 
eluted with FLAG peptide. In addition to the various pol III subunits, western blot 
analysis revealed that low levels of BRF, TBP, TFIIICa and TFIIICP had co­
purified. Footprinting analyses revealed that TFIIIC1 was also present in the eluate. 
In contrast, none of these proteins were detectable in the eluate from a control 
immunopurification using nuclear extract from untransfected HeLa cells.
An RNA polymerase holoenzyme as originally defined in prokaryotes is an 
entity composed of RNA polymerase and other subunits that can initiate specific 
transcription autonomously. Many of the reported pol II “holoenzymes” required 
additional factors in order to carry out transcription and thus strictly do not really 
represent holoenzymes. In contrast, the immunopurified pol III complex described 
above was capable of pol III transcription of tRNA, 5S RNA and VAi genes alone 
and thus may be regarded as a true holoenzyme (551).
Unlike the pol III complexes isolated by gel filtration and density gradient 
centrifugation, this immunopurified complex was disrupted by a moderate increase in 
salt concentration; however, it was stable to dilution, suggesting that it was unlikely 
to have resulted from a concentration-dependent non-specific aggregation of 
components (551). Preincubation of the nuclear extract prior to immunopurification, 
with ethidium bromide or Chromomycin A3 which are reagents commonly used to 
distinguish between DNA-dependent and DNA-independent protein associations, 
had no effect on the levels of holoenzyme immunopurified (551). Therefore, DNA 
was unlikely to be responsible for the association of TFIIIB, TFIIIC and pol III in 
this complex.
The immunopurification of a complex containing TFIIIB, TFIIIC and pol III 
by Wang et al.(551) raised the possibility that the same may be achievable using one 
of the various antisera that we have against specific components of the basal pol III 
transcriptional apparatus. This was tested by carrying out immunopurifications, 
essentially by the same method as described in the previous chapter, with the 
different antisera and assaying for the coimmunopurification of TFIIB, TFIIIC and 
pol III. Unfractionated HeLa nuclear extract was used as the starting material as 
phosphocellulose chromatography disrupts the holoenzyme complex (551), which 
may partly explain why the existence of such complexes has largely eluded
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detection. The other advantage of using an unffactionated extract is that TFIIIB, 
TFIIIC and pol III will be present at physiological ratios.
After recirculating a mixture of preincubated antiserum and nuclear extract 
through a column of protein A-Sepharose for ~ lh  at 4°C, any unbound material was 
removed by washing with 20 cvs of a low salt buffer (CB100). Bound material was 
then eluted with a buffer containing 2M salt and 2M urea, as previously. Eluted 
material was tested for the presence of TFIIIB and TFIIIC by in vitro transcription 
assays. The presence of RNA polymerases in the eluted material was assayed by 
virtue of their ability to transcribe poly(dA.dT) in a transcription factor-independent 
manner.
The mouse monoclonal antibody MTBP6 (424), which specifically 
recognises an epitope in the N-terminal region of TBP, was found to consistently 
coimmunopurify low levels of TFIIIC and polymerase with TFIIIB immunopurified 
from HeLa nuclear extract (Figure 4.5 and data not shown). The level of 
immunodepletion of TFIIIB from the nuclear extract was rather poor (Fig. 4.5 A, 
compare lane 1 with lanes 2 & 11), as previously observed with the BRF antisera 128 
and 330, when using such crude extract. Despite this, reasonable amounts of TFIIIB 
activity were detected in the eluted fractions from the two MTBP6 columns (Fig 4.5 
A, lanes 4-10 & 13-18), whereas no activity was detected in the FT fractions (lanes 3 
& 12), which is consistent with the specific immunopurification of TFIIIB by 
MTBP6. A control immunopurification was carried out in parallel using a rabbbit 
polyclonal antibody called SI-1 raised against another N-terminal region of TBP. In 
contrast to MTBP6, the SI-1 antibody consistently failed to deplete TFIIIB activity 
from extracts when used in immunoprecipitations (data not shown). In support of the 
specificity of the immunopurification of TFIIIB by MTBP6, there was no TFIIIB 
activity either in the FT or any of the other eluates from the SI-1 column, nor did any 
appear to have been depleted from the starting material (data not shown).
As Figure 4.5 B shows, very low levels of TFIIIC were also immunodepleted 
from the starting material (compare lanes 1 and 2). As for TFIIIB, no TFIIIC was 
found in the flowthrough (Fig. 4.5 B, lane 3). The depleted TFIIIC activity eluted 
entirely in fractions containing TFIIIB activity. For both of the columns, the peak 
fraction of TFIIIC activity was also the peak fraction of TFIIIB activity (compare 
Fig.4.5 A & B, lanes 6 and lanes 14). Clearly, a very small amount of TFIIIC in the 
nuclear extract copurified with the TFIIIB specifically immunopurified by the
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MTBP6 antibody. Some polymerase was also retained on the column and was found 
to elute in the same peak TFIIIB fractions as TFIIIC (Fig. 4.5 C).
The retention of small amounts of TFIIIC and polymerase on the column with 
TFIIIB and their elution in the same fractions suggested that some TFIIIB, TFIIIC 
and pol might be specifically associated together in a complex. However, it was also 
possible that the copurification of small amounts of TFIIIC and polymerase with 
TFIIIB was entirely fortuitous due to non-specific interactions with the column or 
with each other and TFIIIB. The former possibility was tested by assaying the 
fractions from the control SI-1 column to see if any TFIIIC or polymerase binds 
independently of TFIIIB. No TFIIIC or polymerase was found to bind to the SI-1 
column, which suggests that their retention on the MTBP6 column was not due to 
adventitious association with protein A-Sepharose.
The BRF antisera 128 and 330 which were shown in the previous chapter to 
specifically immunopurify TFIIIB from nuclear extract, were also tested to see if any 
TFIIIC or polymerase is copurified. Significantly, the two antisera, which 
immunopurify similar amounts of TFIIIB, behaved very differently in their ability to 
copurify TFIIIC and polymerase. The 330 antiserum, like MTBP6, consistently 
copurified TFIIIC and polymerase with TFIIIB (data not shown). In contrast, the 
128 antiserum consistently failed to copurify TFIIIC or polymerase with TFIIIB 
(data not shown). The inability of 128 to copurify TFIIIC or pol and the consistency 
of these results renders it extremely unlikely that non-specific interactions are 
responsible for the coimmunopurification of TFIIIB, TFIIIC and pol observed using 
MTBP6 or 330. The epitope on BRF that 128 recognises may be involved in the 
specific interactions of BRF with TFIIIC and pol III or may be spatially close to 
these regions, thus preventing the antibody from precipitating any TFIIIB in the 
extracts that is specifically associated with TFIIIC and polymerase.
Although the results indicate that the coimmunopurification of TFIIIB, 
TFIIIC and pol III is caused by specific interactions between the components, the 
data provide no information as to how this is achieved. The most obvious 
mechanism is that the three components form a trimeric complex. However, TFIIIB 
can interact directly both with TFIIIC and pol III, raising the alternative possibility 
that partial complexes such as TFIIIB-TFIIIC and TFIIIB-pol III are responsible for 
the coimmunopurification of the three components.
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Figure 4.5 - Copurification of low levels of TFIIIC and polymerase activity with 
TFIIIB immunopurified from HeLa nuclear extract using a monoclonal 
antiserum specific for TBP
The results are shown from two separate immunoafflnity columns performed in 
parallel in which different volumes of the MTBP6 antibody contained in tissue 
culture supernatant was used. Lanes 2-10 represent fractions from the column in 
which 500pl of MTBP6 was preincubated with 1ml of nuclear extract prior to 
recirculation through protein A-Sepharose. Lanes 12-18 represent fractions from the 
column in which 1ml of MTBP6 was used. For both columns, numbered fractions 
(eg, 1,2,3...) correspond to fractions sequentially eluted with CB buffer containing 
2M KC1 and 2M urea, obtained after washing bound material with 20cvs of low salt 
buffer (CB100). R: recirculated starting material. FT: flowthrough. The starting 
material used (SM) was the same HeLa nuclear extract for both columns.
A) TFIIIB activity of eluted fractions
To assay for TFIIIB activity, in vitro pol III transcription was reconstituted using 2 pi 
of PC-C as a source of TFIIIC and pol III, 250 ng of pVAi as the specific pol III 
template and 12pl of the individual fraction as the sole source of any TFIIIB. Note 
only 2pl of SM and R were assayed rather than 12pl.
B) TFIIIC activity of eluted fractions
Fractions were assayed for TFIIIC by reconstituted pol III transcription also, 
essentially as described in (A), except a PC-B fraction was used rather than PC-C, 
the fractions themselves providing the sole source of any TFIIIC.
C) Polymerase activity of eluted fractions
Equal volumes of fractions were assayed for polymerase content by their ability to 
transcribe poly(dA.dT). Levels of polymerisation were determined by the amounts 
of [a  P]-UTP incorporated into transcripts. At the end of the reaction, samples were 
spotted onto phosphocellulose discs, to which transcripts can bind. These discs were 
washed extensively to remove any unincorporated label. The levels of 
polymerisation were then quantitated by scintillation counting of the discs. 
Reactions were performed in the presence of lpg/ml a-amanitin.
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The TFIIICP antiserum, 4286, was also found to consistently 
coimmunopurify TFIIIB, TFIIIC and pol III, providing further support for the 
specific association of these three components (data not shown). Although TFIIIC 
can interact directly with TFIIIB and there is recent evidence for a comparable 
interaction of TFIIIC with pol III (129), this latter interaction may be very weak 
since TFIIIB is essential for the recruitment of pol III to TFIIIC-bound promoters. 
One of the principal functions of TFIIIB within the transcription complex is thought 
to be for it to act as a bridging factor between TFIIIC and pol III (568). Thus, the 
coimmunopurification of TFIIIB, TFIIIC and pol by 4286 is more consistent with the 
purification of a trimeric complex than partial complexes.
Regardless of which antiserum was used, much lower levels of the two 
copurifying components were depleted than the component to which the antiserum 
was raised. This is consistent with the results of Wang et al. (551) and may reflect a 
low abundance of pol III “holoenzymes” in the cell relative to the abundance of the 
“free” forms of the different components. It is also quite probable that the epitopes 
recognised by the antisera are more accessible on the “free” forms, which will bias 
the immunoprecipitation in their favour.
The consistent copurification of TFIIIB, TFIIIC and polymerase using three 
different antisera against three different components of the pol III machinery is 
supportive of the existence of pol III complexes akin to the pol III holoenzyme of 
Wang et al.(551). However, stringent controls to eliminate the possible involvement 
of DNA have to date not been carried out. Furthermore, none of the fractions 
assayed were able to support in vitro pol III transcription in the absence of any other 
factors; thus these complexes do not represent true pol III holoenzymes that can 
autonomously initiate transcription (data not shown). It may be an unidentified 
essential component is missing. Alternatively, the copurification may have resulted 
from partial complexes, which are unable to assemble into a functional preinitiation 
complex. Another possibility is quenching of the holoenzyme activity; for example, 
excess “free” TFIIIC in the same fraction as the TFIIICP-immunopurified complex 
is likely to compete directly with the holoenzyme for binding pol III promoters, thus 
preventing transcription. Regardless, these complexes enabled the effect of RB on 
the intermolecular interactions of TFIIIB with pol III and TFIIIC to be tested.
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4.2.5 RB disrupts the interaction between TFIIIB and TFIIIC
To assay for any effects of RB, immunopurifications were carried out as 
described above, except that after washing the immobilised pol III “holoenzyme” 
with low salt buffer, the immunopurified complex was exposed to a solution of 
recombinant RB. This solution was then collected to assay for the presence of any 
component displaced by RB. The column was washed again briefly before elution of 
any protein that remained bound. This eluate was assayed for the specific 
disappearance of any component that is normally eluted here.
Since RB potently represses pol III transcription, any TFIIIB or TFIIIC eluted 
in the solution containing recombinant RB may not be detected by in vitro 
transcription assays. Instead, the presence of TFIIIC in any of the fractions was 
assayed on the basis of its specific DNA-binding activity, rather than its 
transcriptional activity. TFIIIC binds specifically to the B-block region of type II 
promoters. Figure 4.6 A shows the results of an electrophoretic mobility shift assay 
(EMSA) using a radiolabelled B-block oligonucleotide to assay specifically for 
TFIIIC DNA-binding activity in the various fractions from two MTBP6 
immunoaffinity columns. For one of the MTBP6 columns, the 
immunoimmmobilised pol III “holoenzyme” was exposed to a solution of GST- 
RB(379-928) (Fig. 4.6 A, lanes 8-16). For the sister MTBP6 column on which 
purification was performed in parallel, the immunoimmobilised pol III 
“holoenzyme” was exposed to a solution of recombinant GST (Fig. 4.6 A, lanes 1-7).
As expected, for the column exposed to GST, strong TFIIIC DNA-binding 
activity was detected in the high salt eluates (Fig. 4.6 A, lanes 4-7), whereas TFIIIC 
DNA-binding activity was absent from the solution containing GST, which was 
slowly recirculated through the column for ~ 0.5 h (Fig. 4.6 A, lanes 1-3). A 
strikingly different result was obtained for the column exposed to GST-RB(379-928). 
Although, some TFIIIC DNA-binding activity was detected in the high salt eluates, 
this was much reduced compared with that of the corresponding eluates from the 
GST-exposed column (Fig 4.6 A, compare lanes 13-16 with lanes 4-7), suggesting 
that RB might have displaced some of the TFIIIC specifically bound to TFIIIB. This 
was confirmed by the appearance of significant amounts of TFIIIC DNA-binding 




RB displaces TFIIIC from immunopurified complexes containing TFIIIB, 
TFIIIC and polymerase
A) EMSA using the B-block oligonucleotide as probe to assay for TFIIIC DNA- 
binding activity in the various fractions from two MTBP6 immunoaffinity columns 
to which an immunopurified complex of TFIIIB, TFIIIC and polymerase was bound. 
One of the columns was exposed to a solution of GST prior to elution with buffer 
containing 2M salt and 2M urea, whereas the other column was exposed to RB. The 
TFIIIC DNA-binding activity of fractions from the GST-exposed column are shown 
in lanes 1-7 and that of fractions from the RB-exposed column are shown in lanes 8- 
16. Reactions 1-3 contained fractions of the recirculated solution of GST and 
reactions 4-7 contained fractions eluted with high salt and urea from the same 
column. Reactions 8-12 contained sequentially collected fractions of the recirculated 
solution of GST-RB(379-928). Reactions 13-16 contained the 2M salt/2M urea 
fractions from the RB-exposed column.
4pl of each fraction was tested. To prevent non-specific binding to the probe the 
fractions were preincubated for 15 min at 30°C with lpg of polydldC and lOOng of
^9non-specific oligonucleotide prior to addition of 0.5ng of [y Pj-ATP labelled B- 
block oligonucleotide. Formation of DNA-protein complexes was analysed by 
electrophoresis on a native 4% polyacrylamide gel.
B) EMSA of fractions from two 330 immunoaffinity columns to which an 
immunopurified complex of TFIIIB, TFIIIC and polymerase was bound. Reactions 2 
and 3 contained a high salt fraction from a GST-exposed column. Reactions 4-9 
contained fractions from a RB-exposed column. Reactions 4-7 contained fractions 
from the recirculated solution of RB, whereas reactions 8 & 9 contained a high salt 
fraction. Lane 1 contained probe only. Reactions of odd-numbered lanes contained 
lOOng of unlabelled B-block oligonucleotide as a specific competitor. Even- 
numbered lanes contained non-specific competitor.
ns: non-specific competitor; s: specific competitor
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The various RB or GST eluates and high salt eluates were also assayed for 
the presence of TFIIIB and polymerase. In vitro transcription assays revealed that 
TFIIIB was retained on the column after exposure to RB and eluted in the high salt 
eluates, the same was true for polymerase (data not shown). Thus, the appearance of 
TFIIIC in the RB eluate does not result from the displacement of the whole 
“holoenzyme” or a TFIIIB-TFIIIC subcomplex in which the integrity of the 
interaction between TFIIIB and TFIIIC may be maintained. It is only TFIIIC that is 
displaced strongly, suggesting that RB disrupts the intermolecular interaction 
between TFIIIB and TFIIIC.
The lack of TFIIIC DNA-binding activity in the GST fractions of the control 
column clearly demonstrates that the displacement of TFIIIC is a specific effect of 
RB rather than a non-specific effect due to the addition of excess amounts of 
recombinant protein. However, the reduced mobility of the TFIIIC-B-block DNA 
complex in the RB eluates compared to the mobility of the complex in the high salt 
eluates is curious. This is not unusual for TFIIIC; TFIIIC-B-block DNA complexes 
of varying mobilities are often found when TFIIIC-containing fractions are assayed. 
Generally, more dilute fractions tend to result in complexes of higher mobility. The 
molecular composition of the different shifts commonly produced is unknown. 
TFIIIC 1, which is not required for the B-block binding activity of TFIIIC, may not 
be part of some of the complexes. The interaction of other proteins with TFIIIC is 
also likely to affect mobility. It is possible that the reduced mobility of the TFIIIC- 
B-block DNA complex in the RB eluates is caused by the binding of recombinant 
RB to TFIIIC. Indeed, an interaction between TFIIIC2 and overexpressed RB has 
been previously reported (93). However, the anti-RB antibodies tested were unable 
to supershift the complex and the addition of recombinant RB to the high salt eluates 
had no effect on mobility of the shift obtained with these fractions (data not shown).
The effect of GST and GST-RB(379-928) on a pol III “holoenzyme” purified 
using the BRF antiserum 330 was also tested. As for the “holoenzyme” purified 
using the anti-TBP antibody MTBP6, RB specifically displaced TFIIIC from the 
complex. As Figure 4.6 B shows, the RB eluates from this column also produced a 
different TFIIIC shift to the high salt eluates. It was essential to be sure that the 
different shifts obtained were all caused by the specific binding of TFIIIC to the B- 
block oligonucleotide, as opposed to the non-specific binding of some other protein 
in the fractions. To test this the fractions were incubated with excess unlabelled
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competitor DNA prior to addition of labelled B-block oligonucleotide. Two types of 
competitor DNA were used; non-specific competitor which differs in sequence to the 
B-block oligonucleotide and specific competitor which is identical to the B-block 
oligonucleotide probe but unlabelled. Thus, the intensity of a shift caused by the 
non-specific binding of protein will be significantly reduced by addition of either 
competitor DNA, as both will be able to compete for binding of the protein. In 
contrast, the intensity of a shift caused by specific binding to the labelled probe will 
be unaffected by non-specific competitor DNA, but greatly reduced by specific 
competitor DNA. As shown in Figure 4.6 B, the preincubation of the fractions with 
specific competitor DNA dramatically reduced the intensity of the shifts compared to 
the observed effects when the same fractions were preincubated with non-specific 
competitor DNA. Despite the difference in the mobility of the shift produced by the 
RB eluates and the high salt eluates, it is clear that both shifts are caused by 
sequence-specific binding to the B-block oligonucleotide.
His6-RB was also found to displace TFIIIC from the immunoimmobilised pol 
III “holoenzymes”, thus verifying the results obtained with GST-RB(379-928) (data 
not shown). These results strongly indicate that RB specifically disrupts the 
interaction between TFIIIB and TFIIIC. Subsequently, extensive 
immunoprecipitations have confirmed these preliminary findings that RB may 
disrupt the specific interaction between TFIIIB and TFIIIC (503).
Together, these experiments and the immunoprecipitations by Sutcliffe et al.
(503) clearly demonstrate that RB disrupts the interaction between TFIIIB and 
TFIIIC2. However, it is unclear if TFIIIC 1 is also displaced as the B-block 
oligonucleotide binding activity of TFIIIC is a property of TFIIIC2 and TFIIIC 1 is 
not required for this function (481). Pol III templates with type III promoters such as 
7SK and vertebrate U6 snRNA genes are TFIIIC2-independent but they do require 
TFIIIIC1 for accurate transcription (397, 604). RB has been found to repress the 
transcription of every pol III template tested including vertebrate U6 genes (579). 
Therefore, if RB does not displace TFIIIC 1 there must be additional mechanisms by 
which RB represses transcription. It may be RB represses transcription by different 
mechanisms at different pol III promoters and by more than one mechanism at some 
promoters. 7SK and U6 transcription requires a specialised complex called PTF or 
SNAPc, which is thought to interact with TFIIIB assisting its recruitment to the 
promoter (568, 604). Recent evidence suggests that RB disrupts this interaction
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(215). Although there may be multiple other mechanisms by which RB specifically 
inhibits TFIIIB, disruption of the interaction between TFIIIB and TFIIIC2 will 
inhibit the transcription of most class III genes.
4.2.6 pl07 and pl30 stably interact with TFIIIB
Although the three pocket proteins share extensive sequence homology and 
there is some redundancy between the proteins, gene knockout experiments revealed 
that some functions of RB cannot be performed by pl07 or p i30 (95, 245, 322). 
Some of these unique functions of RB may be essential for its function as a potent 
tumour suppressor. Overexpression of p i07 or p i30 can induce a G1 arrest in some 
cell lines; however, the genes encoding p i07 and p i30 do not seem to be targeted for 
inactivation in cancers. It is thus unclear whether p i07 and p i30 are bona fide 
tumour suppressors. It was therefore interesting to determine whether p i07 and p i30 
can also repress pol III transcription or whether this is a unique property of RB 
among the pocket proteins. Primary embryonic fibroblasts from RB'7' mice, which 
are wild type for p i07 and p i30, display substantially elevated levels of pol III 
transcription suggesting that the repression of pol III transcription by RB cannot be 
compensated for by pl07 or p i30 (579). This does not exclude the possibility that 
p i07 and p i 30 also repress pol III transcription, but suggests that p i07 and p i30 
may target a different component of the pol III transcriptional apparatus to RB or 
they may function at different times of the cell cycle.
Recently, it has been shown that p i07 and p i30 can also repress pol III 
transcription, both in vitro and in vivo (504). Thus, this is a function shared by all 
three pocket proteins. Pull-down assays and immunoprecipitation assays using 
recombinant components have demonstrated that the BRF subunit of TFIIIB can 
interact with p i07 and p i30 (504). This suggested that p i07 and p i30, like RB, 
might specifically target TFIIIB. However, it was important to determine whether 
p i07 and p i30 interact with BRF in a physiological context. Immunoprecipitations 
were therefore carried out using endogenous extracts to which no exogenous factors 
had been added (504). Using antisera raised against the different pocket proteins, 
endogenous RB, p i07 and p i30 have been immunoprecipitated from HeLa nuclear 
extract. The precipitated material was then washed extensively, resolved on SDS-
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PAGE and probed for the presence of BRF by Western blotting (504). Figure 4.7 
shows the results of such an immunoprecipitation. As expected, the antiserum 
against RB, which was used as a positive control, coprecipitated BRF (lane 1). The 
p i07 antiserum also coprecipitated BRF, at similar levels to the RB antiserum 
(compare lanes 1 & 2). In contrast, an antiserum against the TAFi48 subunit of SL1 
was unable to immunoprecipitate BRF (lane 3), demonstrating the specificity of the 
coimmunoprecipitation of BRF observed with the RB and p i07 antisera. The 
presence of BRF in the material that coprecipitated with RB and pi 07 was confirmed 
by using a second antiserum raised against a different region of BRF (data not 
shown). BRF is also coprecipitated by an antiserum against pl30 (504). These 
results have been confirmed by the converse immunoprecipitation, using a BRF 
antiserum or the corresponding preimmune serum, in which the coprecipitation of 
p i07 and 130 was specifically probed for (504).
Since endogenous p i07 and p i30 were found to specifically interact with 
endogenous BRF, it was postulated that a population of endogenous pl07 and p i30 
might copurify with TFIIIB depending on the stability of the interaction. The 
immunopurified TFIIIB and TFIIIC, and DNA-affinity purified TFIIIC generated as 
described in the previous chapter, were probed by Western blotting for p i07 and 
p i30 to see if these two proteins have specifically copurified with TFIIIB. 
Unfortunately, however, no p i07 or p i30 was detected in any of these purified 
fractions (data not shown). It may be the fractions are too dilute to detect the 
presence of p i07 or p i30 with the available antisera (data not shown). Some other 
partially purifed fractions have been tested, however, p i07 and p i30 were found to 
copurify with TFIIIB, but not with pol III or TFIIIC2 (504).
As a further test for a stable interaction between TFIIIB and p i07 or p i30, it 
was examined whether endogenous p i07 and p i30 would cofractionate with TFIIIB 
during gradient chromatography of a PC-B fraction on heparin-Sepharose. Bound 
protein was eluted with a linear salt gradient and the individual fractions were then 
probed for the presence of TFIIIB and pl07 or pl30 (504). As Figure 4.8 shows, 
TFIIIB (upper panel) and p i30 (lower panel) cofractionated very closely on the 
heparin-Sepharose salt gradient. The same was found to be true of p i07 (data not 
shown). Both pocket proteins and TFIIIB were found to peak in fractions 20 to 22 
and then tail off sharply (Figure 4.8 & data not shown). This close cofractionation of 
p i07 and p i30 with TFIIIB was confirmed using alternative antisera against both
173
pocket proteins (data not shown). The fractionation of cyclin A on the gradient was 
also assayed and was found to fractionate differently (data not shown). Thus, like 
RB, it appears that p i07 and p i30 also specifically target TFIIIB and that the 
association of p!07 and p i30 with TFIIIB is relatively stable.
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Figure 4.7
Endogenous BRF coimmunoprecipitates with endogenous pocket proteins
HeLa nuclear extract (150jLxg) was immunoprecipitated using anti-RB antibody C-15 
(lane 1), anti-pl07 antibody C-18 (lane 2), and anti-TAFi48 antibody M-19 (lane 3). 
Precipitated material was resolved on a SDS-7.8% polyacrylamide gel and then 




pl30 cofractionates with TFIIIB during gradient chromatography of PC-B on 
heparin-Sepharose
The upper panel shows the TFIIIB activity of individual fractions, and the lower 
panel shows the p i30 content of the same fractions. Fraction numbers are indicated. 
SM, starting material. FT, flowthrough. TFIIIB activity was assayed by 
reconstituted pol III transcription reactions using 4 pi of the individual fractions, 2pi 
of PC-C and 250 ng of pVAi. The p i30 content of fractions was determined by 
resolution of equal volumes (15pl) of the individual fractions by SDS- 7.8% PAGE 
followed by immunoblotting with the anti-pl30 antiserum Rb2.
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Discussion
4.3.1 Mechanisms of repression of TFIIIB by RB
Paradoxically, E2F has been described both as an oncoprotein and as a 
tumour suppressor (556). Ectopic expression of E2F-1 can drive quiescent cells all 
the way through G1 into S phase. Furthermore, when E2F-1 is overexpressed with 
other known oncogenes it leads to cellular transformation, thereby conforming to a 
widely accepted operational definition of an oncogene. It therefore came as 
something of a surprise when E2F-l‘/_ mice started to exhibit hyperplasia of certain 
tissues and even neoplasia as they aged (556). There has been considerable 
speculation as to how E2F can act both as an oncoprotein and as a tumour 
suppressor. One of a variety of speculations is that it is related to the ability of RB to 
convert E2F from a transcriptional activator to a transcriptional repressor (556). E2F 
activates the expression of a variety of genes required for cellular proliferation. 
However, when associated with RB, E2F may actively repress these very same 
genes. Loss of E2F in a RB-positive background may therefore actually cause 
increased expression of these proliferation-promoting genes.
The active repression of some E2F-regulated genes by RB is dependent on 
histone deacetylase activity (346). HDAC1 has been found to associate with RB and 
it is thought to be recruited by RB to E2F-regulated promoters where it may then 
deacetylate nucleosomal histones resulting in a more compact chromatin structure 
that is repressive to transcription (52, 53, 346, 349). Since RB stably interacts with 
TFIIIB, which forms part of the pol III preinitiation complex, it seemed plausible that 
RB may also recruit deacetylase activity to class III genes, and that this may be 
required for the ability of RB to repress pol III transcription.
Support for a role of histone deacetylation in the regulation of pol III 
transcription was provided by recent reports that human TFIIIC2 has intrinsic HAT 
activity (230, 298). Furthermore, human TFIIIC was shown to relieve chromatin- 
mediated repression of a tRNA gene in vitro (298). Additionally, histone acetylation 
has previously been shown to facilitate the transcription of a 5S gene assembled into 
chromatin in vitro (321, 529, 534). Nonetheless, the presence of the potent and 
irreversible histone deacetylase inhibitor TSA had no effect on the repression of pol 
III transcription by RB either in vitro, as described here, or in vivo (503). It is
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unclear though whether or not the RB molecules that interact with TFIIIB are also 
associated with histone deacetylase. TSA has been found to stimulate transcription 
of chromosomal B2 genes in vivo in an RB-independent manner, suggesting that 
histone acetylation and deacetylation does have an important physiological role in 
regulating pol III transcription (503). However, since RB disrupts the interaction 
between TFIIIB and TFIIIC2, for the majority of class III genes it is unlikely that any 
TFIIIB recruited to the promoter will remain associated. Thus, any deacetylase 
activity recruited to TFIIIB indirectly through association with RB is also unlikely to 
stay associated with a class III promoter and may therefore not affect the chromatin 
structure of these genes.
All three of the pocket proteins can repress pol III transcription and they each 
specifically target the same factor, TFIIIB, for repression (314, 504, 579). This 
implies redundancy between the proteins; however, p i07 and p i30 are unable to 
compensate for the loss of RB on pol III transcription (579). pl07 and p i30 may 
utilise a different, and possibly less potent, mechanism to repress TFIIIB. Indeed, 
p i07 and p i30 have also been found associated with histone deacetylase activity 
(144). Unlike RB, it may be that pl07 and pl30 interact with TFIIIB but do not 
displace it from the promoter, which may enable the stable recruitment of 
deacetylase activity to class III promoters. The tumour suppressor p53, which also 
interacts with TFIIIB and represses pol III transcription, has also been found to 
associate with deacetylase activity, which is essential for its ability to repress certain 
pol II-transcribed genes (388).
In the pol II system, RB blocks E2F recruiting TFIID to promoters (448). 
This is analogous to the disruption of the interaction between TFIIIB and TFIIIC2 by 
RB, which is likely to prevent the recruitment of TFIIIB to class III promoters. 
Although the “holoenzyme” studies and the subsequent immunoprecipitations that 
were performed provide compelling evidence that RB disrupts the interaction 
between TFIIIB and TFIIIC2, a few class III genes that have previously been shown 
to be repressed by RB are TFIIIC2-independent. Thus, the disruption of this 
interaction cannot be the sole mechanism by which RB is able to repress 
transcription. Indeed, some other immunoprecipitations performed suggested that 
RB also disrupts the interaction between TFIIIB and pol III (503). This provides a 
potential mechanism by which RB represses TFIIIC2-independent genes. However, 
there was little discernible effect of RB on the interaction of TFIIIB and pol III in the
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“holoenzyme” studies. The reason for this discrepancy is unknown. It may be that 
RB can more easily disrupt the interaction between TFIIIB and TFIIIC2 than that 
between TFIIIB and pol III. Perhaps insufficient RB was recirculated through the 
column and the interaction with TFIIIC2 was preferentially disrupted. In contrast to 
the immunoprecipitation, a small amount of TFIIIC2 remained associated with the 
immunoaffinity column after exposure to RB, suggesting that disruption was 
generally less effective in this system.
There may be other mechanisms by which RB can repress pol III 
transcription in addition to these. Recent work by Hirsch et al. suggests that RB 
might disrupt the interaction between TFIIIB and SNAPc (215). The intramolecular 
interaction between BRF and TBP within TFIIIB seems to be unaffected by RB (314, 
503). Unfortunately, a lack of knowledge as to the composition of TFIIIB largely 
prevents any effect of RB on any other intramolecular interactions within TFIIIB 
from being studied. Human TFIIIB is thought to contain a human homologue of 
yeast B", which has recently been cloned; however, as yet we have no molecular 
reagents against this component, so any effects RB may have on it cannot be 
properly tested (463).
An interesting question is the relative contribution of the different 
mechanisms by which RB can repress pol III transcription, in a physiological 
context. This may differ for different genes. TFIIIC2-dependent genes are predicted 
to be completely repressed either by the disruption of the interaction between TFIIIB 
and TFIIIC2 or that between TFIIIB and pol III. In vivo, RB may utilise both of 
these mechanisms or one may predominate. If both mechanisms are used the 
question arises as to whether this is necessary or whether there is redundancy, such 
that if only one of the mechanisms is lost this would not have any effect on the 
ability of RB to repress the gene. The utilisation of more than one mechanism by RB 
in vivo may act as a kind of a fail-safe; it may also allow some local control to be 
exerted on the global repression of pol III transcription by RB if different class III 
genes utilise distinct mechanisms to different extents. However, it is presently 
unclear to what extent this is the case or whether the different mechanisms can be 
individually regulated. Clearly, a lot of unanswered questions remain regarding the 
mechanisms by which RB represses pol III transcription.
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4.3.2 Implications of a pol III holoenzyme
The immunoaffinity purification of a complex containing TFIIIB, TFIIIC and 
pol III, as described in this chapter, enabled the effect of RB on the intermolecular 
interactions of TFIIIB to be tested. It also provides support for a growing body of 
evidence suggesting that a pol III holoenzyme may exist in vivo, or at the very least, 
associations between components of the pol III preinitiation complex off the DNA, 
which may represent PIC assembly intermediates. This has important implications 
for the regulation of pol III transcription. Much of the regulation of pol III 
transcription is thought to occur at the initiation stage. Once a preinitiation complex 
has been formed it is extremely stable and can support multiple rounds of 
transcription (73). In yeast there is a facilitated recycling pathway in which 
polymerase is recycled without being released from the template, allowing very rapid 
multiple round transcription (123). Thus, clearly the regulation of the formation of 
the preinitiation complex is extremely important.
The ordered and stepwise assembly pathway defined in vitro provides 
multiple opportunities at which preinitiation complex formation at a specific class III 
gene may be regulated, namely each stage that a component is recruited. In contrast, 
if the components of the preinitiation complex are preassembled into a functional 
holoenzyme prior to recruitment, the regulation of the assembly of a preinitiation 
complex at a specific gene is limited to a single step. However, controlling the 
formation of the pol III holoenzyme off the DNA will allow the global regulation of 
pol III transcription. Although the concomitant recruitment of all the essential 
components that constitute the preinitiation complex will result in control of 
assembly at a specific gene being restricted to a single step, this does not necessarily 
constitute less control being exerted.
Regulation of preinitiation complex formation at a specific class III gene 
achieved through the recruitment of a holoenzyme is likely to occur less through 
modulation of protein-protein interactions, as for a stepwise assembly pathway, and 
more through modulation of protein-DNA interactions. The holoenzyme is likely to 
be hampered in mobility and its ability to find a gene to which it can bind. Control 
of local chromatin structure is likely to play a very significant role in the regulation 
of recruitment of a holoenzyme. The recruitment of a holoenzyme will probably
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require multiple interactions between components in the complex and a large 
segment of DNA. This may be necessary for the high degree of sequence specificity 
to enable the appropriate target genes to be found in the vast excess of non-specific 
sites in the eukaryotic genome. The multiple protein-DNA interactions are all 
potential targets for regulating the recruitment of the holoenzyme.
It may be that preinitiation complex formation can occur both by a stepwise 
pathway and through recruitment of a preassembled “holoenzyme” in vivo. Since 
the transcription factor requirements are not the same at all class III genes, it may be 
that there are several types of pol III holoenzymes or some genes may utilise a 
holoenzyme, whereas others do not. When pol III transcription is reconstituted in 
vitro using fractionated factors, a time lag occurs prior to the attainment of a linear 
transcription rate (174, 568). This is because of the time it takes for assembly of the 
preinitiation complex. However, when the pol III “holoenzymes” isolated by density 
gradient centrifugation or an unfractionated extract is tested, no lag is obtained; this 
is consistent with the presence of preassembled complexes fully active for 
transcription (174, 248, 585). This is strongly supportive of the existence of a 
physiologically relevant pol III holoenzyme in vivo that can start transcription as 
soon as it has been recruited to an appropriate gene. Nonetheless, any pol III 
holoenzymes that do exist in vivo seem to be of quite low abundance; Wang et al. 
estimated that approximately 10% of the total pol III in their extract was in a 
holoenzyme form (551). Consistent with this, my immunopurifications resulted in a 
very poor yield of the “holoenzyme” relative to the yield of the component to which 
the antibody was raised, although this may also reflect disruption of some 
“holoenzyme” by the antibody and poor epitope accessibility.
4.3.3 pl07 and pl30 also target TFIIIB
Since the three pocket proteins share their most extensive homology in the 
pocket domain and it is this same domain which is essential for the ability of RB to 
repress pol III transcription, the finding that p i07 and p i30 also repress pol III 
transcription was not unexpected (504). Furthermore, they seem to target the same 
transcription factor, TFIIIB, with which they can stably associate at physiological 
concentrations, as described in this chapter (504). Since TFIIIB is required for the
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expression of all pol III templates, by specifically targeting this factor, like RB, p i07 
and p i30 may be able to repress the transcription of every class III gene.
The discovery that endogenous RB, p i07 and p i30 all bind to endogenous 
TFIIIB raises questions as to whether there is competition between the pocket 
proteins for binding to TFIIIB. The proportion of TFIIIB that is bound by each of 
the pocket proteins in vivo is likely to affect the relative contributions of RB, p i07 
and pi 30 to the repression of pol III transcription, as well as their relative affinities.
The contributions of the pocket proteins to transcriptional repression have 
been analysed by transfecting cycling NIH 3T3 cells either with wild type HPV16 E7 
oncoprotein, which potently binds to all three pocket proteins, or with an E7 GLY26 
mutant, which can only bind p i07 and p i30 (504). Binding of E7 prevents the 
pocket proteins from interacting with some of their cellular targets. Transfection 
with the wild type E7 protein resulted in a substantial increase in pol III transcription, 
suggesting that the interactions between the pocket proteins and TFIIIB were 
disrupted. The GLY26 mutant also stimulated transcription, but the activation 
obtained was only 27% of that observed with wild type E7 protein (504). Thus, 
although p i07 and p i30 contributed to repression, RB seemed to have the much 
more dominant role in these cycling NIH 3T3 cells.
The binding of the three pocket proteins to the same transcription factor 
suggests that they repress pol III transcription in a very similar, if not an identical 
manner, which in turn implies that there may be some redundancy between the 
proteins. The phenotypes of knockout mice suggest otherwise; synthesis of tRNA 
and 5S rRNA is five fold more active in primary fibroblasts from Rb'A mice, with 
functional pl07 and pl30, than the corresponding cells from Rb+/+ mice (579). The 
inability of p i07 and p i30 to compensate for loss of RB suggests that the pocket 
proteins are functionally distinct. The mechanism(s) by which p i07 and p i30 
repress pol III transcription have yet to be investigated. Indeed, although p i07 and 
p i30 have been shown to stably bind TFIIIB, it has not yet been demonstrated that 
TFIIIB is actually inhibited by these two pocket proteins. It may be that p i07 and 
p i30 repress transcription by a different mechanism to RB and perhaps less potently. 
Although loss of RB may enable more p i07 and p i30 to bind more of their 
molecular target, TFIIIB, because of a lack of competition from RB, this clearly is 
not sufficient to enable p i07 and p i30 to fully compensate. However, this may
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simply be a reflection of the relative amounts of the pocket proteins, since there is 
considerably more RB than p i07 or p i30 in a normal cell.
Although the protein levels of RB stay relatively constant through the cell 
cycle, levels of pl07 and pl30 change dramatically (173). pl30 is highly abundant 
in quiescent cells, but is rapidly downregulated when cells re-enter the cell cycle. In 
contrast, p i07 is present at very low levels in GO, and is present in highest amounts 
in S, G2 and M phase. In addition to varying protein levels, the activity of p i07 and 
pl30, like RB, is regulated by phosphorylation (173). After the Gl/S transition, all 
three pocket proteins are hyperphosphorylated and remain inactive until the next G1 
phase. The cell cycle-dependent changes in the relative abundance of the different 
pocket proteins means that the relative contributions of the individual pocket proteins 
to repression are likely to differ temporally. Support for this is provided by the 
regulation of E2F by the pocket proteins (131, 173). pl07 and pl30 can also bind 
E2F. However, the temporal association of each pocket protein with E2F during the 
cell cycle is quite different. The pl30-E2F complex predominates in quiescent 
fibroblasts, whereas a RB-E2F complex occurs mainly in G1 phase. The pl07-E2F 
complex occurs predominantly in S phase. A similar situation probably exists for the 
regulation of pol III transcription by the pocket proteins. Each pocket protein may 
have its own characteristic temporal profile of interaction with TFIIIB. In support of 
this, targeted disruption of the genes encoding p i07 and p i30 made little difference 
to pol III transcript levels in cycling mouse embryonic fibroblasts (504). However, 
when these cells were made quiescent by serum withdrawal a significant increase in 
pol III transcript levels was observed in the p l0 T A p l30 'A cells compared to pol III 
transcript levels of the corresponding cells expressing wild-type p i07 and p i30
(504). Thus, during the GO phase p i07 or p i30 exert a repressive effect on pol III 
transcription that cannot be compensated for by RB. Recently, Scott et al. reported 
that in GO phase cells, -70% of TFIIIB is bound by RB and -30% is bound by pl30 
(471). Although the three pocket proteins all repress pol III transcription and they 
target the same factor, TFIIIB, their relative contributions to the repression of TFIIIB 
appear to differ at different times of the cell cycle. Thus, whereas RB can exert an 
inhibitory influence on TFIIIB both in GO and G l, the repressive effects of p i30 
upon pol III activity are largely limited to GO. The levels of p i30 are substantially 
reduced following exit from GO phase and thus the protein likely makes little or no
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contribution to the repression of pol III transcription by the pocket proteins when 
cells are cycling.
Recently, fibroblasts from Rb~A p i0 T Ap  130~A triple knockout mice have been 
analysed for pol III activity. The activation of pol III transcription in these triple 
knockout cells was found to be greater than that in fibroblasts from mice lacking 
either one, or any two, of the pocket proteins (470). Thus, regardless of the 
mechanism, it is clear that all three pocket proteins have a physiological role in the 
repression of pol III transcription.
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Chapter 5.
Deregulation of pol III transcription in 
ovarian cancer
5.1 Introduction
Transfer RNA (tRNA) and 5S ribosomal RNA (5S rRNA) have essential 
enzymatic and/or structural roles in translation. These pol III transcripts perform a 
housekeeping function and it was thus expected that any genes encoding such 
products be constitutively active. However, it is now clear that the transcription of 
tRNAs and 5S rRNA, and most other pol III templates, is strongly regulated (568, 
569). This enables the production of such transcripts to be adjusted to meet the 
metabolic demands of the cell.
The retinoblastoma protein and the unrelated tumour suppressor p53 both 
repress pol III transcription (70, 579). Missense mutations in p53 occur in 
approximately half of all human tumours (222, 223). The effects of such mutations 
on pol III transcription have yet to be reported, but it seems plausible that many will 
impair the ability of p53 to repress pol III transcription. It has been suggested that 
RB function may be compromised in all human malignancies (557). Although 
clearly a limited survey, several subtle mutations that have arisen in RB in small cell 
lung carcinomas have been shown to prevent it from repressing pol III transcription 
(59, 579). This demonstrates that mutations that arise in RB in tumours can 
compromise its ability to regulate pol III transcription.
The constraint imposed upon pol III transcription by these two key tumour 
suppressors and their frequent loss of function in human cancers suggests that 
elevated pol III transcription may be a common feature of human malignancies. 
Indeed, it has been suggested that elevated pol III transcription may constitute an 
important step in tumour development (313, 569). tRNAs and 5S rRNA are 
important determinants of the biosynthetic capacity of the cell (394, 567). Following 
mitogenic stimulation of resting cells, rRNA and tRNA synthesis increases, 
ribosomes assemble into polysomes, translation factors are activated and a net
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increase in protein synthesis is observed (445). The elevated synthesis of tRNAs and 
rRNA in response to mitogens suggests that these RNA species are not normally in 
excess and that their synthesis is tightly controlled according to the biosynthetic 
needs of the cell. The unrestrained proliferation of tumour cells requires sustained 
growth, which in turn is dependent upon active protein synthesis (566). It may be 
that the levels of tRNA and 5S rRNA in a normal proliferating cell are insufficient to 
support the increased or sustained protein synthesis required by tumour cells in order 
to maintain cell size during rapid proliferation. It has yet to be proven that tRNA and 
5S rRNA levels are limiting, but this provides a plausible explanation for the 
targeting of pol III transcription for repression by RB and p53. It would also explain 
the targeting of pol III transcription for activation by a number of viral oncoproteins 
(569).
The growth-suppressive function of RB may be mediated, at least in part, by 
its repressive effect on the synthesis of tRNA and 5S rRNA. Cells are unable to 
enter S phase and replicate their DNA until they have accumulated an adequate level 
of protein (273, 517). Therefore, by restraining growth the cell is prevented from 
proliferating uncontrollably. Loss of growth control is thus essential for tumour 
development. The contention that the control of protein synthesis is an important 
aspect of growth regulation is supported by a multitude of evidence demonstrating 
the deregulation of protein synthesis in transformed cells (445, 494). Indeed, 
abnormal activation of translation factors is sufficient to cause neoplastic 
transformation. Overexpression of the translation initiation factor eIF4E in primary 
fibroblasts induces morphological transformation; moreover, these cells can induce 
tumours in nude mice (319, 320). Mutational activation of another translation factor, 
eIF2a can also cause malignant transformation (128). Activation of the oncoprotein 
c-myc causes an increase in the abundance of both of these factors; this is also 
accompanied by an increase in the rate of protein synthesis and cellular growth (446, 
447). The protein synthesis apparatus is also deregulated in real tumours. The 
expression profile of some 45,000 genes in gastrointestinal tumours has been studied 
using the recently developed methodology of serial analysis of gene expression 
(SAGE) (614). Only 108 pol II transcripts were found to be expressed at increased 
levels in the tumours relative to normal colonic epithelium. 48 of these transcripts 
encode ribosomal proteins and 5 encode translation factors (614). Together, the
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available evidence strongly suggests that the deregulation of protein synthesis is 
intimately linked to carcinogenesis. The deregulation of pol III transcription may 
represent another manifestation of a selection for changes in the protein synthetic 
machinery during tumour development.
If pol III transcription truly does have an important role in tumour 
development, it is predicted that it will be abnormally elevated in a range of 
transformed and tumour cells. Indeed, pol III products are found to be overexpressed 
in many types of transformed cell line (16, 168, 292, 350, 469, 487, 548, 549, 578). 
Fibroblasts transformed with a temperature-sensitive mutant of the SV40 large T 
antigen downregulate pol III transcription at the non-permissive temperature whilst 
reverting to a normal phenotype and morphology, suggesting a tight link between 
transformation and pol III activation (469). Moreover, when different SV40- 
transformed cell lines are compared, those which most efficiently induce tumours in 
nude mice display the highest levels of pol III products, whereas in the less 
tumorigenic cell lines there are lower levels of pol III transcripts (469, 578). Pol III 
transcription is activated by a broad range of transforming agents, including DNA 
tumour viruses, RNA tumour viruses and chemical carcinogens (569). Hepatitis B 
virus (HBV), a DNA virus, and a RNA virus called human T-cell leukaemia virus 
type 1 (HTLV-1) are both important causative agents in human cancers and both 
stimulate an increase in pol III transcript levels following transformation (569). The 
activation of pol III transcription in transformed cells is very general but it is not 
universal. There are a few reported cases in which pol III transcriptional activity is 
not abnormally elevated in transformed cells, such as in the Rb+/+p53+/+ 
osteosarcoma cell line U20S (579).
A recent SAGE study has shown that only 21% of genes overexpressed in 
colorectal cancer cell lines are also overexpressed in primary colorectal carcinomas 
(614). Clearly, substantial differences in behaviour can exist between transformed 
cells in culture and tumours in vivo. Transformed cells in culture provide a useful 
model for real tumours; however, it is of paramount importance to determine how 
closely the behaviour of the transformed cells studied mimics that of the tumours in 
vivo. Recently, it has been shown that pol III transcripts are elevated in rodent and 
human tumours in vivo, verifying the physiological significance to real tumours of 
the abnormally elevated levels of pol III transcription consistently observed in many 
transformed cell lines (87, 88). In one study, samples from eighty human tumours,
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representing nineteen different types of cancer, were tested (87). BC200, a pol III 
product of unknown function, was found to be overexpressed in many, but not all, of 
the primary human tumours. The levels of 7SL RNA, an essential pol III product 
that forms part of the signal recognition particle, were elevated in every tumour 
examined relative to the corresponding normal tissue (87).
Recently, we have been investigating pol III transcription in ovarian cancer, 
the leading cause of death from gynaecological malignancies in the United States 
(159). Ovarian tumour samples and corresponding normal healthy tissue from the 
same patients were examined by RT-PCR for the levels of 5S rRNA, 7SL RNA and 
two different types of tRNA (586). For each of the four patients whose tissue 
samples were tested, a substantial increase in the levels of each of these pol III 
transcripts was observed in the tumour samples (586). In contrast, no change was 
detected in the levels of the mRNA encoding acidic ribosomal phosphoprotein 
(ARPP PO) or glyceraldehyde phosphate dehydrogenase (GAPDH), demonstrating 
the specificity of the overexpression of pol III products. The genes encoding tRNA, 
5S rRNA and 7SL RNA have distinct promoter structures and transcription factor 
requirements. Despite these differences, each of these transcripts was found to be 
abnormally elevated in these tumour samples, suggesting that there may be a general 
elevation of pol III transcript levels in ovarian cancer. The use of intron-specific 
primers for determining the levels of tRNA ensured that they provided an accurate 
indication of the rate of ongoing transcription, as the introns are rapidly processed 
from primary transcripts and degraded (586). Thus, the substantial elevation of pol 
III transcript levels seems to be caused by an activation of pol III transcription rather 
than an increase in the stability of transcripts (586). Consistent with our findings of 
increased levels of pol III transcripts in ovarian cancer, Chen et al. reported an 
increase in BC200 RNA levels in the one ovarian carcinoma sample that they tested 
(87).
Although abnormally elevated levels of pol III transcripts have been observed 
in a broad range of transformed cell lines, in most cases the mechanistic basis of this 
effect has not been elucidated. Similarly, in the studies of tumours in vivo by Chen 
et al. the mechanism(s) responsible for the substantial increase in the levels of pol III 
transcripts was not investigated. Loss of function of RB and p53 and the release of 
TFIIIB from repression by these two pocket proteins may account for pol III 
activation in many tumours. However, TFIIIB activity has been shown to be in
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relative excess in several types of mammalian cell, so the deregulation of TFIIIB in 
these cells may have little or no effect on pol III transcriptional output (74, 151,218, 
571, 577, 578). In such cells, pol III or TFIIIC may be targeted for activation. In 
support of this, higher levels of pol III have been found in mouse myeloma cells 
relative to healthy tissue; in contrast, the levels of pol II were unchanged (467). The 
DNA-tumour viruses SV40 and adenovirus seem to utilise multiple mechanisms to 
ensure high levels of pol III transcription (569). The adenoviral El a oncoprotein and 
the SV40 large T antigen both bind to RB relieving repression of TFIIIB. 
Additionally, both viruses increase the TFIIIC activity of infected cells. SV40- 
transformed fibroblasts overexpress TFIIIC2, which is the rate-limiting factor for pol 
III transcription in these cells (315, 578). The adenoviral infection of HeLa cells has 
been reported to result in an increase in the concentration of TFIIIC2 (606). 
Independently, it has been reported to result in a specific increase in the proportion of 
TFIIIC2 that exists in the transcriptionally active TFIIIC2a form (488).
The targeting of TFIIIC for activation is seemingly not restricted to 
transformed cells. We have recently been investigating the mechanistic basis for the 
observed activation of pol III transcription in human ovarian carcinomas. In nine out 
of nine ovarian tumours examined, substantially elevated TFIIIC2 activity was 
observed relative to that of normal healthy tissue from the same women (586). Thus, 
the activation of pol III transcription in ovarian cancer may be caused by abnormally 
high levels of TFIIIC2 activity (586). This will depend, however, on whether or not 
TFIIIC2 activity is limiting in normal ovarian cells; if it is in vast excess, increasing 
it further is unlikely to have much effect on transcriptional output. The investigation 
of the physiological significance of elevated TFIIIC2 activity on pol III transcription 
in ovarian cancer is described in this chapter.
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5.2 Results
5.2.1 TFIIIB is limiting for pol III transcription in nuclear extract from a
human ovarian tumour cell line
TFIIIC2 must be a limiting factor in normal ovarian epithelial cells for the 
abnormally high levels of TFIIIC2 in the ovarian tumours analysed to be at least 
partly responsible for the activation of pol III transcriptional output consistently 
observed in these tumour samples. Figure 5.1 is a schematic diagram explaining the 
concept of a limiting factor. A limiting factor may be defined as a factor that 
stimulates the process when its concentration or activity is increased whilst that of 
any other factors remains constant. In the upper diagram of Figure 5.1 there is a 
relative deficiency of TFIIIC compared to TFIIIB and pol III. Addition of more 
TFIIIC stimulates transcription; therefore, TFIIIC can be regarded as a limiting 
factor. In contrast, in the lower diagram TFIIIC is in relative excess and although 
addition of more TFIIIC increases promoter occupancy, because of a deficiency in 
TFIIIB it does not increase transcriptional output. Therefore, in this situation TFIIIC 
is not a limiting factor.
Unfortunately, there were insufficient amounts of extract from the human 
ovarian tumour samples and healthy ovarian epithelial tissue from the same patients 
to investigate which factors are limiting in these extracts. Nuclear extract from a 
human ovarian tumour cell line, A27-80, was tested to see if TFIIIB or TFIIIC is 
limiting. To determine which factor or factors of the basal pol III transcriptional 
machinery are limiting in a particular cell type, add-back experiments are performed. 
This involves carrying out in vitro transcription reactions using a constant amount of 
cell extract in each reaction and separately titrating in increasing amounts of purified 
sources of each factor to see if they stimulate transcription. Figure 5.2 shows the 
results of such add-back experiments using nuclear extract from the human ovarian 
tumour cell line A27-80. As highly purified sources of TFIIIB and TFIIIC, 
immunoaffinity-purified TFIIIB and TFIIIC were used. A conventionally purified 
source of pol III was used. As Figure 5.2 A shows, the addition of partially purified 
TFIIIB strongly stimulated transcription. Although the immunopurified TFIIIC also 
stimulated transcription, this effect was much less than with the TFIIIB. The purified 
source of pol III had no stimulatory effect; in fact at the higher doses there seemed to
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Raising the level of TFIIIB stimulates pol III transcription reconstituted with 
extract from a human ovarian tumour cell line
A) Transcription reactions were reconstituted using lOpg of A27-80 nuclear extract 
and 250 ng of pVAi. Reactions 2, 3 and 4 were supplemented with 2, 4 and 8pi, 
respectively, of TFIIIB that had been immunopurified from PC-BHep using the 
antiserum 330 against BRF. Reactions 6, 7 and 8 were supplemented with 2, 4 and 
8pi, respectively, of TFIIIC that had been immunopurified from PC-C using the 
antiserum 4286 against TFIIICp. Reactions 9, 10 and 11 were supplemented with 2, 
4 and 8 pi, respectively, of an A25(1.0) fraction which is highly enriched in RNA 
polymerase III, generated by DEAE Sephadex chromatography of a PC-B fraction.




be a slight inhibitory effect. This may be due to quenching, the pol III may sequester 
active TFIIIB or TFIIIC which may otherwise have been able to participate in 
transcription. These results obtained using the VAi gene were confirmed using a 
tRNA gene as template (Figure 5.2 B). Thus, for both promoters tested TFIIIB was 
the major limiting factor for pol III transcription. This is consistent with the elevated 
levels of TFIIIC2 observed in ovarian tumour samples. It may be that TFIIIC is the 
limiting factor in normal ovarian cells, but the increase in the levels of TFIIIC2 in 
human ovarian tumour cells result in TFIIIB becoming more limiting in place of 
TFIIIC. However, it is equally plausible that TFIIIC is not limiting in normal non- 
tumorigenic ovarian epithelial cells.
5.2.2 Extracts from new-transformed rat ovarian epithelial cells have higher 
pol III transcriptional activity than extracts from untransformed control 
cells
Since normal healthy ovarian epithelial tissue was unavailable for analysis, an 
ovarian epithelial cell line, ROSE 199-flgal, was used. Two different cell lines were 
examined, ROSE 199-pgal and ROSE 199-neu. The parental cell line, ROSE 199, is 
an established cell line of rat ovarian surface epithelium derived from normal, non- 
tumorigenic rat ovarian epithelium (2). ROSE 199-neu was generated by retroviral 
transfection of the parental cell line with mutationally activated neu oncogene (115). 
The cellular neu gene encodes a 185 kD protein related to, but distinct from, the 
epidermal growth factor receptor (EGFR) (459). Neu is a member of the erbB family 
of receptor tyrosine kinases (241). It is amplified and/or overexpressed in 
approximately one-third of human ovarian epithelial cancers and is associated with a 
poor prognosis (30, 491). ROSE 199-neu cells exhibit transformed phenotypes in 
vitro and the tumorigenic phenotype in vivo and are regarded as a useful model of 
human ovarian cancer (115). ROSE 199-pgal was generated by transduction of 
ROSE 199 with the j3-galactosidase gene (115). In contrast to the potent 
oncogenicity of neu, the Jd-galactosidase gene does not induce transformed 
phenotypes nor tumorigenicity and ROSE 199-figal cells have been used as a model 
of normal ovarian epithelial cells (115).
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If ROSE 199-Pgal and ROSE 199-neu truly are good models of normal 
ovarian epithelial cells and cancerous ovarian epithelial cells, respectively, and pol 
III activation does have an essential role in ovarian cancer, one may expect ROSE 
199-neu cells to support higher levels of pol III transcription than ROSE 199-Pgal 
cells. This was investigated by carrying out in vitro transcription assays using equal 
amounts of extract of actively cycling ROSE 199-J3gal cells and ROSE 199-neu cells 
that were prepared in parallel. As Figure 5.3 shows, the neu extract supported a 
significantly higher level of pol III transcription than the Pgal extract at all the 
amounts of extract tested, both using the VAi gene and a tRNAleu gene. This 
behaviour mimics the elevated levels of pol III transcription observed in the human 
ovarian tumour samples relative to healthy tissue. The same result has consistently 
been obtained using four different preparations of Pgal and neu extracts (data not 
shown).
5.2.3 TVew-transformed ROSE 199 cells mimic human ovarian epithelial
tumours by displaying elevated TFIIIC2 activity
Although the ROSE 199-neu cells have higher levels of pol III transcriptional 
activity than the ROSE 199-Pgal cells, the mechanistic basis for this may be very 
different to that for the elevated levels of pol III transcripts observed in the human 
ovarian tumour samples. It was therefore tested whether the ROSE 199-neu cells 
also display elevated TFIIIC2 activity. As Figure 5.4 A shows, extracts from ROSE 
199-neu cells have higher TFIIIC2 activity than an equal amount of pgal extract, as 
assayed by its specific B-block oligonucleotide DNA-binding activity. This result 
has been confirmed using four different preparations of pgal and neu extracts (data 
not shown). As a control, extracts were also analysed by electrophoretic mobility 
shift assay using an oligonucleotide carrying a Spl binding site as probe. Spl, Sp2 
and Sp3 all specifically bind to this oligonucleotide and produce protein-DNA shifts 
of different mobilities, as shown in Figure 5.4 B. The Spl oligonucleotide DNA- 
binding activities of the same two pairs of Pgal and neu extracts shown in Figure 5.4 
A, were tested and are shown in Figure 5.4 B. For both pairs of extracts, Spl 
oligonucleotide binding is slightly higher for the pgal extracts, despite these extracts
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Figure 5.3
Neu-transformed ROSE 199 cell extracts have higher RNA polymerase III 
transcriptional activity than untransformed Pgal-transfected ROSE 199 cell 
extracts
A) In vitro transcription assay using ROSE 199-neu cell extract (odd-numbered 
lanes) and ROSE 199-/3gal cell extract (even-numbered lanes). Lanes 1 and 2 
contained 5pg of protein extract, lanes 3 and 4 contained 10pg of protein extract, 
lanes 5 and 6 contained 15pg of protein extract and lanes 7 and 8 contained 20pg of 
protein extract. All reactions contained 250 ng of pVAi template. Transcription was 
initiated by the addition of nucleotides and allowed to proceed for 1 h at 30°C.
B) As for (A), except that 250 ng of pLeu was used as the specific pol III template 
rather than pVAi.
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Figure 5.4
Extracts from /lew-transformed ROSE 199 cells display elevated TFIIIC2 
activity
A) EMSA using 0.5 ng of B-block oligonucleotide probe, lpg of poly(dl.dC) 
competitor and no protein (lane 1), or 10pg of protein extracts from ROSE 199-Pgal 
cells (lanes 2, 3 and 6), or ROSE 199-neu cells (lanes 4, 5 and 7). Reactions 2-5 
were carried out using one set of pgal and neu extracts that were prepared in parallel 
(#1) and reactions 6 and 7 were performed using a different set of Pgal and neu 
extracts (#2). Reactions 2, 4, 6 and 7 also contained lOOng of unlabelled non­
specific oligonucleotide. Reactions 3 and 5 also contained lOOng of unlabelled B- 
block oligonucleotide as specific competitor.
B) EMSA using 0.35ng of Spl oligonucleotide probe, lpg of poly(dl.dC) 
competitor and no protein (lane 1), or lOpg of protein extracts from HeLa cells 
(lanes 2 & 3), ROSE 199-Pgal cells (lanes 4, 6 and 7), or ROSE 199-neu cells (lanes 
5, 8 and 9). Reactions 4 and 5 were carried out using the set of Pgal and neu extracts 
used in reactions 2-5 of (A) (#1) and reactions 6-9 were performed using the set of 
Pgal and neu extracts used in reactions 6 and 7 of (A) (#2). Reactions 2, 4, 5, 6 and 
8 also contained lOOng of unlabelled non-specific oligonucleotide. Reactions 3, 7 
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displaying lower TFIIIC2 DNA-binding activity than the corresponding neu extracts. 
The other extracts were also tested and in every case protein binding to the Spl 
oligonucleotide was about the same for the Pgal and neu extracts or slightly lower 
for the neu extracts (data not shown). This clearly demonstrates that the increase in 
TFIIIC2 DNA-binding activity consistently observed in the neu extracts is a specific 
phenomenon and is not caused by a general loss of DNA-binding proteins during 
preparation of J3gal extracts or a general increase in DNA-binding proteins following 
transformation of ROSE 199 cells by neu.
5.2.4 TFIIIC is a limiting factor for pol III transcription in extracts of the
untransformed ovarian epithelial cell line ROSE 199-pgal
ROSE 199-Pgal and ROSE 199-neu seem to mimic the behaviour of normal 
human ovarian epithelium and human ovarian tumours respectively, at least in terms 
of some aspects of pol III transcription. It was therefore of interest to see if TFIIIC is 
limiting in extracts of the ROSE 199-Pgal cells, as this would provide an indication 
as to whether the increase in TFIIIC2 activity in ovarian tumours may be responsible 
for the increase in pol III transcriptional output.
In the initial add-back experiments, the phosphocellulose fractions PC-B and 
PC-C, which are enriched in TFIIIB and TFIIIC respectively, were used (Figure 5.5). 
The PC-C fraction strongly stimulated transcription in a dose-dependent manner. 
The highest dose of PC-C added stimulated transcription ~ 10-fold compared to that 
obtained with the same amount of Pgal extract without addition of any PC fraction 
(Figure 5.5, compare lanes 1 & 5 with lanes 6-8). Addition of PC-B also stimulated 
transcription (Figure 5.5, compare lanes 1 & 5 with lanes 2-4), but to a much lesser 
extent than with comparable amounts of PC-C; the highest dose of PC-B titrated in 
increased transcription only 2.6 fold. Although this result suggests that TFIIIC is 
limiting, PC-B and PC-C are relatively crude fractions and contain a lot of other 
proteins; one or more of these proteins that have cofractionated with TFIIIC may be 
responsible for the stimulatory effect of PC-C, instead of TFIIIC itself. To test this 
possibility, add-back experiments were carried out using PC-C and heat-treated PC-C 
(HT PC-C). TFIIIC 1 and TFIIIC2 are both unusually sensitive to mild heat
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treatment and are inactivated by warming at 47°C for 15 min (291, 485, 575). Prior 
to use in the add-back, the inactivation of the TFIIIC in the HT PC-C fraction was 
verified by its inability to reconstitute in vitro transcription in the presence of an 
active PC-B fraction (data not shown). As Figure 5.6 shows, the inactivation of 
TFIIIC in the HT PC-C fraction completely abolished its ability to stimulate 
transcription when added to the pgal extract. Thus, the stimulatory effect of PC-C 
on transcription reconstituted with Pgal extracts does seem to be due to TFIIIC rather 
than some other protein(s) which also fractionated on phosphocellulose in the PC-C 
fraction.
Immunoaffinity-purified TFIIIC, generated as described in Chapter 3, was 
also tested, as shown in Figure 5.7. This highly purified source of TFIIIC stimulated 
transcription in a dose-dependent manner when titrated into pgal extracts (compare 
lane 1 with lanes 2-4). In contrast, mock immunopurified TFIIIC made in parallel as 
described in Chapter 3 using the 4286 preimmune serum, had little or no effect on 
transcription (Figure 5.7, lanes 5-7). This provides further support that TFIIIC is 
limiting in Pgal extracts.
The same 4286 antiserum used to immunopurify TFIIIC from PC-C was also 
capable of purifying a pol III “holoenzyme” from nuclear extract, as described in 
Chapter 4. It was therefore important to verify that the immunopurified TFIIIC was 
not contaminated with any TFIIIB or pol III. As Figure 5.8 shows, the 
immunoaffinity-purified TFIIIC can reconstitute transcription when combined with a 
PC-B fraction that provides a source of TFIIIB and pol III (lanes 2 & 3). However, it 
is unable to reconstitute transcription when combined with a PC-C fraction, which 
provides a source of TFIIIC and pol III (lanes 6 & 7). Thus, the immunopurified 
TFIIIC does not seem to be contaminated with TFIIIB. RNA polymerisation assays 
revealed that the immunopurified TFIIIC is also free of pol III (data not shown). 
This result is unsurprising, as any interaction between TFIIIC and pol III is thought 
to be mediated by TFIIIB and phosphocellulose chromatography effectively 
separates TFIIIB and TFIIIC (473, 568).
The ability of DNA-affinity purified TFIIIC (see Chapter 3) to stimulate 
transcription when added to Pgal extracts was also tested (Figure 5.9). This source 
of TFIIIC, purified on the basis of the specific B-block DNA-binding activity of 
TFIIIC2, strongly stimulated transcription up to ~5-fold of that obtained in the
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Figure 5.5
TFIIIC is a limiting factor in ovarian epithelial cell extracts
In vitro transcription assay using lOpg of ROSE 199-figal cell extract and 250ng of 
pVAi template. Reactions 2, 3 and 4 were supplemented with 2, 4 and 8pl of PC-B, 
respectively. Reactions 6, 7 and 8 were supplemented with 2, 4 and 8pl of PC-C, 
respectively. Reactions 1 and 5 contained no additional protein. Transcription was 
initiated by addition of nucleotides following a 15 min preincubation at 30°C.
199
1 2 3 4 5 6 7 8
Figure 5.6
Heat inactivation of TFIIIC prevents PC-C from stimulating pol III 
transcription in ROSE 199-/feal cell extracts
Transcription reactions were reconstituted using lOpg of ROSE 199-flgal cell extract 
and 250ng of pVAi template. Reactions 2, 3 and 4 were supplemented with 2pl, 4pl 
and 6pl of PC-C, respectively. Reactions 5, 6 and 7 were supplemented with 2pl, 
4pl and 6pl, respectively, of the same PC-C fraction as in reactions 2-4, except that it 




Raising the level of TFIIIC stimulates pol III transcription in ovarian epithelial 
cell extracts
In vitro transcription assay using lOpg of ROSE \99-/3gal cell extract and 250ng of 
pVAi template. Reactions 2, 3 and 4 were supplemented with 3, 6 and 9pl, 
respectively, of TFIIIC that had been immunopurified from PC-C using antiserum 
4286 against TFIIICp. Reactions 5, 6 and 7 were supplemented with 3, 6 and 9pl of 






Immunopurified TFIIIC contains no trace of TFIIIB
In vitro transcription assay using 250 ng of pVAi template, lp l of PC-B (all lanes 
except 5-7) and lp l of PC-C (lanes 4-8). TFIIIC that had been immunopurifed using 
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Figure 5.9
tRNA synthesis is stimulated by raising the level of TFIIIC in ovarian epithelial 
cell extracts
Transcription reactions were reconstituted using lOpg of ROSE 199-flgal cell extract 
and 250ng of pLeu template. Reactions 2 and 3 were supplemented with 3 pi and 





absence of added TFIIIC (Figure 5.9, compare lane 1 with lanes 2 & 3). This 
transcription assay was carried out using a tRNAIeu gene as the specific template. 
The different sources of TFIIIC (PC-C, immmunopurifled TFIIIC and DNA-afflnity 
purified TFIIIC) have all been tested and found to stimulate transcription 
reconstituted with pgal extracts both using the VAi gene and the tRNAleu gene as the 
specific pol III template. Together, these results strongly suggest that TFIIIC is a 
limiting factor for pol III transcription in the untransformed rat ovarian epithelial cell 
line, ROSE 199-Pgal. Thus, the elevated TFIIIC2 activity of ROSE 199-neu cells is 
likely to contribute to the elevated pol III transcriptional output of these cells. That 
TFIIIC is limiting in ROSE 199-Pgal cells clearly does not mean that the same is true 
in human ovarian epithelium. However, it does raise this possibility and suggests 
that the elevation of TFIIIC2 activity in human ovarian cancers may be of functional 
significance to the increase in pol III transcript levels.
The promoters of class III genes are quite diverse in structure and can be 
loosely categorised into one of three types, each of which has distinct transcription 
factor requirements (568). Only types I and II promoters are TFIIIC2-dependent. 
Within each of these three types there is still considerable variation in promoter 
structure and also the strength of the promoter. The consequence of this variability is 
that the limiting factor(s) for pol III transcription in a given cell extract may be 
different for different class III genes, even if they are of the same promoter type. 
The results obtained suggest that TFIIIC is limiting in ROSE 199-Pgal cell extracts 
at least for the transcription of some class III genes. The VAi gene and a tRNAleu 
gene were primarily tested; these genes both have a type II promoter but the 
promoter of the tRNA gene is much weaker. Affinity-purified TFIIIC also 
stimulated transcription reconstituted using Pgal extract when using the 7SL gene as 
the specific pol III template (data not shown).
The evidence suggesting that TFIIIC can stimulate tRNA synthesis in 
untransformed ovarian epithelial cells is of particular physiological significance 
because of the fundamental role of tRNA in translation and the fact that elevated 
levels of TFIIIC2 were found in nine out of nine human ovarian tumours analysed. 
The deregulation of TFIIIC2 has never previously been reported in human 
malignancies. It has not as yet been demonstrated that tRNA and 5S rRNA synthesis 
has an essential role in tumorigenesis. If this is found to be the case, it may be that
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the deregulation of TFIIIC2 is a widespread phenomenon in ovarian cancer and 
perhaps other cancers in which TFIIIC2 is a major limiting factor in the normal 
nontumorigenic cell type.
5.2.5 TFIIIB and TFIIIC are both limiting for pol III transcription in cell
extracts of the transformed cell line ROSE 199-neu
In the extract from a human ovarian tumour cell line that was tested TFIIIB 
was found to be the major limiting factor for pol III transcription (Figure 5.2). It was 
of interest to determine if this was also the case in the transformed cell line ROSE 
199-neu, or whether TFIIIC was still limiting as in the /^/-transfected cells, despite 
the significant increase in TFIIIC2 activity in the new-transformed cells. As Figure
5.10 A shows, PC-B (lanes 2-4) and PC-C (lanes 9-11) both stimulated transcription 
when separately titrated into extracts of ROSE 199-neu cells (compare with lanes 1 
& 8). However, PC-C stimulated transcription to a greater extent than equal volumes 
of PC-B. The PC-B and PC-C fractions were of comparable TFIIIB and TFIIIC 
activity, respectively. As previously, the effect of HT PC-C was also tested and was 
found unable to stimulate transcription (lanes 12-14), suggesting that TFIIIC rather 
than some contaminant present in the PC-C was responsible for the ability of PC-C 
to stimulate transcription.
In support of this, immunopurified TFIIIC was able to stimulate transcription 
reconstituted with unfractionated neu extracts (Figure 5.10 B, compare lanes 2 & 3 
with lane 1) whereas mock-immunopurified TFIIIC was not (Fig. 5.10 B, lanes 4 & 
5). Immunopurified TFIIIB also stimulated transcription (lanes 6 & 7) but mock 
immunopurified TFIIIB was unable to (lanes 8 & 9). As for the immunopurified 
TFIIIC, the immunopurified TFIIIB used was tested for contamination with pol III 
and, in this case, TFIIIC. None of the different preparations of purified TFIIIB 
contained pol III, as assayed by the ability of the fractions to support transcription of 
poly(dA.dT) (data not shown). Immunopurified TFIIIB also lacked TFIIIC as Figure
5.11 shows for a variety of different preparations of TFIIIB of varying activity. The 
immunopurified TFIIIB preparations reconstituted transcription when combined with 
PC-C but were consistently unable to do so when combined with PC-B. The PC-B
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fraction was able to reconstitute some transcription when combined with a weakly 
active immunopurified TFIIIC fraction, however. Thus, TFIIIB and TFIIIC both 
seem to be limiting in extracts of ROSE 199-neu. This result has been confirmed 
with several independent preparations of neu extract (data not shown).
Heat treatment of PC-B, as done for PC-C, selectively inactivates TBP (575). 
The ability of HT PC-B to stimulate transcription reconstituted with neu cell extracts 
was tested to see if TBP, an essential component of TFIIIB, was required for the 
ability of PC-B to stimulate transcription. As Figure 5.10 A shows, HT PC-B 
actually stimulated transcription more strongly than equal amounts of the same PC-B 
fraction that was not heat treated. This suggests that TBP is not required for the 
stimulatory effect of PC-B. Indeed, the result suggests that TBP may have a slight 
inhibitory effect; this is probably caused by the TBP being in excess and sequestering 
components that are limiting into inactive complexes. That PC-B and 
immunopurified TFIIIB have a stimulatory effect on transcription reconstituted with 
neu extracts is therefore likely to be caused by a relative deficiency in one or more of 
the TAFs of TFIIIB, such as BRF, in the neu extracts.
The inactivation of TBP in the HT PC-B was verified by testing the ability of 
the fraction to reconstitute transcription when combined with a PC-C fraction, as 
shown in Figure 5.12 A. Only a trace amount of specific pol III transcript was 
produced compared to that obtained using untreated PC-B. In support of the 
stimulation observed with HT PC-B (Fig. 5.10 A & Fig. 5.12 B) suggesting that TBP 
may not be limiting, the titration of increasing amounts of recombinant TBP into neu 
extracts actually reduced the level of transcription to below that obtained with neu 
extract alone (Figure 5.12 B). This dose-dependent decrease in transcription in 
response to recombinant TBP suggests that TBP is in relative excess in the neu 
extracts and that titrating in more results in a quenching effect whereby essential 
components that are limiting are prevented from participating in transcription.
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Figure 5.10
TFIIIB and TFIIIC both stimulate pol III transcription when independently 
titrated into «e«-transformed ROSE 199 ovarian epithelial cell extracts
A) In vitro transcription assay using 250ng of pVAi template and lOpg of ROSE 
199-neu cell extract (all reactions). PC-B was added to reactions 2-7: reactions 2 and 
5, 2 pi; reactions 3 and 6, 4pl; reactions 4 and 7, 6pl. The PC-B that was added to 
reactions 5-7 is the same as that added to reactions 2-4 except that it was heated at 
47°C for 15 min prior to use (HT PC-B). PC-C was added to reactions 9-14: 
reactions 9 and 12, 2pl; reactions 10 and 13, 4pl; reactions 11 and 14, 6pl. The PC- 
C added to reactions 12-14 was heated at 47°C for 15 min prior to use.
B) In vitro transcription add-back experiment using immunopurified fractions. All 
the reactions contained 250ng of pVAi template and lOpg of ROSE 199-neu cell 
extract. TFIIIC that had been purified using the 4286 antiserum against TFIIIC p was 
added to reactions 2 (3pi) and 3 (6pl). Reactions 4 and 5 contained 3pi and 6pl 
respectively, of material that was mock immunopurified using the 4286 preimmune 
serum. TFIIIB that had been purified using the 330 antiserum against BRF was 
added to reactions 6 (3pi) and 7 (6pl). Reactions 8 and 9 contained 3pi and 6pl, 




TFIIIC Control TFIIIB Control
Figure 5.11
Immunopurified TFIIIB is free of TFIIIC
In vitro transcription assay using 250ng of pVAi template, lp l of PC-B fraction 
(lanes 2-4, 6 and 8) or PC-C fraction (lanes 1, 5, 7 and 9), and 12pl of TFIIIB that 
had been immunopurified using antiserum 330 against BRF (lanes 4-9). Lane 2 
contained 12pl of TFIIIC that had been immunopurified using antiserum 4286 
against TFIIICp. Three independent preparations of immunoaffinity TFIIIB of 
differing activity were assayed for contamination with TFIIIC: Preparation A, lanes 4 
and 5; Preparation B, lanes 6 and 7; Preparation C, lanes 8 and 9.
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Prep A Prep B Prep C
i 1 i 1 i------------ 1
PC-B: -  +  +  +  -  +  -  +
PC-C: +  -  -  -  +  _  +  _  +
Affinity TFIIIB: -  - -  +  +  +  +  +  +
Affinity TFIIIC: -  -  _ _ _ _  _
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Figure 5.12
TBP is not required for the stimulatory effect of TFIIIB on pol III transcription 
reconstituted with ROSE \99-neu cell extracts
A) In vitro transcription assay reconstituted with 250ng pVAi template, 2pl of PC-B 
(reactions 2-5) and 2pl of PC-C (all reactions). The PC-B added to reactions 3 and 5 
was heated at 47°C for 15 min prior to use.
B) Transcription of pVAi (250ng) using ROSE 199-neu cell extract (lOpg) 
preincubated (15 min at 30°C) with no addition (reactions 1 and 10) or with 1, 2, 3 or 
4pl of recombinant TBP (reactions 2, 3, 4 and 5, respectively) or with 1, 2, 3 or 4pl 
of HT PC-B (reactions 6, 7, 8 and 9, respectively).
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5.3.1 Deregulation of TFIIIC2
The activation of pol III transcription in the transformed ovarian epithelial 
cell line ROSE 199-neu provides another example to add to a long and growing list 
of transformed cell types that display elevated pol III transcription. Furthermore, 
extracts of ROSE 199-neu cells showed a specific increase in TFIIIC2 activity. The 
significance of this is that this same molecular abnormality was observed in nine out 
of nine human ovarian tumours analysed, each of which also displayed elevated pol 
III transcription (586). This analysis of human ovarian tumours represents a limited 
survey. However, the finding that the transformed rat ovarian epithelial cell line 
ROSE 199-neu, which is considered a useful model of certain aspects of human 
ovarian cancer (115), also has substantially elevated TFIIIC2 activity suggests that 
this phenomenon may be widespread and, perhaps, fundamental to ovarian cancer. 
Clearly there is a need to analyse a larger number of ovarian tumour samples for 
changes in pol III transcript levels and also the mechanistic basis for any changes. 
Increased TFIIIC2 activity has previously been observed in SV40-transformed 
murine cell lines and also in adenoviral-infected HeLa cells (315, 488, 578, 606). 
Although elevated pol III transcript levels have recently been reported in a number of 
human cancers the molecular basis for this has not been studied (87). It remains to 
be determined whether changes in TFIIIC2 activity are also found in other human 
malignancies.
The mechanism by which TFIIIC2 activity is increased in ROSE 199-neu 
cells has not yet been investigated. It may be that TFIIIC2 is overexpressed as seems 
to be the case in the human ovarian tumours that were analysed (586). Alternatively, 
perhaps there is an increase in the proportion of TFIIIC2 that is in the active 
TFIIIC2a form. This may be caused by a specific increase in TFIIIC(3 concentration 
or by phosphorylation induced changes (217, 488). The stable transfection of ROSE 
199 cells with activated neu oncogene activates pol III transcription and elevates 
TFIIIC2 activity when compared to the same cell line stably transfected with a J3- 
galactosidase gene. This suggests that the neu oncogene and its normal cellular
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counterpart impinge directly or indirectly on pol III transcription somehow, and that 
at least one of the targets is TFIIIC2.
The neu/c-erbB2 gene encodes an EGFR-like receptor tyrosine kinase (RTK) 
(241, 399). erbB2 is a member of the erbB family of RTKs, which also includes 
EGFR (erbB), erbB3 and erbB4 (241, 399). Activation of the tyrosine kinase activity 
of the erbB family members occurs through receptor dimerisation induced by ligand 
binding. No direct ligand for erbB2 has yet been discovered despite extensive efforts 
(241, 399). However, the agonists for the other erbB family members are bivalent 
and erbB2 is the preferred heterodimerisation partner for all the other erbB family 
members (399). erbB2 kinase activity can also be activated by overexpression of 
erbB2, which is a frequent occurrence in human ovarian cancers, and causes 
spontaneous dimerisation (399). Activation of tyrosine kinase activity of the 
receptors triggers autophosphorylation of specific tyrosine residues within the 
cytoplasmic domain. These phosphotyrosines act as docking sites for specific 
downstream proteins (399). The erbB2 receptor seems to influence a diverse range 
of intracellular signalling pathways; this will also depend on its dimerisation partner 
(241, 399). Recently it has been shown that cyclin D1 is a critical downstream target 
of activated neu (323). The induction of cyclin D1 expression by neu is dependent 
on E2F (323). Furthermore, Ras, Rac, Rho, extracellular signal-regulated kinase, c- 
Jun N-terminal kinase and p38 are all involved (323). Perhaps, neu raises TFIIIC2 
activity indirectly via the phosphorylation of TFIIIC2 by an intracellular kinase that 
is part of one of the kinase signalling cascades induced by neu. Alternatively, as for 
the cyclin D1 promoter, perhaps the TFIIIC2 promoter contains E2F-binding sites 
and increased expression of TFIIIC2 mRNA induced by E2F is responsible for the 
increased TFIIIC2 activity of «ew-transformed ROSE 199 cells.
The identification of cyclin D1 as a critical downstream effector of neu- 
induced transformation suggests that TFIIIC2 may not be the only pol III 
transcription component that is targeted in the ROSE 199-neu cells. Cyclin D l, in 
combination with its kinase partner cdk4 or cdk6, has a critical role in the 
phosphorylation and inactivation of RB (482). Since RB represses TFIIIB, TFIIIB 
activity may also be elevated in the «e«-transformed cells. This has not yet been 
investigated.
Neu is amplified and/or overexpressed in approximately one-third of human 
ovarian cancers (30, 159, 491). However, the neu status of the nine human ovarian
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tumour samples that displayed elevated TFIIIC2 activity has not been determined. It 
may be that the deregulation of TFIIIC2 occurs independently of neu in some or 
perhaps all of these tumours. The molecular basis of human ovarian cancer is poorly 
understood, largely owing to the inaccessible position of the ovary and the fact that 
the tumours are often very advanced at the time of detection (159). However, in 
addition to the changes in neu, mutations in K-ras and p53 have also frequently been 
detected (159). Ras has previously been shown to increase TBP abundance and is 
also involved in neu signalling (323, 548, 549). Like RB, p53 can inhibit TFIIIB. 
TFIIIB activity may therefore be elevated in some ovarian cancers. Perhaps multiple 
components of the pol III transcriptional apparatus are deregulated in ovarian cancer, 
as has previously been reported for several transformed cell types (569). The 
increased TFIIIC2 activity of the nine ovarian tumour samples analysed seems to 
have resulted from the overexpression of its subunits (586). The molecular basis for 
this overexpression has yet to be elucidated, but potentially neu, K-ras or p53 may be 
involved.
5.3.2 TFIIIC is limiting in ROSE 199-figal cell extracts
PC-C, immunoaffinity purified TFIIIC and DNA-affinity purified TFIIIC were each 
found to consistently stimulate pol III transcription reconstituted with ROSE 199- 
Pgal cell extracts. In contrast, heat-treated PC-C and mock-immunopurifled TFIIIC 
did not stimulate transcription. This suggests that TFIIIC is limiting for transcription 
in this untransformed ovarian epithelial cell line. Therefore, the increase in TFIIIC2 
activity in the transformed cell line ROSE 199-neu is likely to contribute, at least to 
some extent, to the increased pol III transcriptional activity of these cells. Although 
TFIIIC has been found to be limiting in ROSE 199-Pgal cells, clearly one cannot 
make the assumption that this is also true in normal human ovarian epithelial cells. 
As a spontaneously immortalised cell line, ROSE 199-Pgal cells will have undergone 
some changes relative to normal ovarian epithelial cells in vivo. Furthermore, 
although pol III transcription is well conserved between mammalian species, there 
are inevitably differences and the limiting factor(s) for pol III transcription in rodent 
and human ovarian epithelial cells may be very different. In the extract from the
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human ovarian tumour cell line A27-80, TFIIIB was found to be the major limiting 
factor for pol III transcription. In contrast, both TFIIIB and TFIIIC were found to 
significantly stimulate transcription when titrated into extracts of ROSE 199-neu 
cells. This difference in the limiting factor(s) suggests that the same may also be true 
for normal human ovarian epithelial cells when compared with ROSE 199-Pgal cells.
For most class III genes, TFIIIC transcriptional activity is dependent not only 
on TFIIIC2 but also TFIIIC 1. Although ROSE 199-neu cells display an increase in 
TFIIIC2 activity, a concomitant increase in TFIIIC 1 activity has not been tested for. 
Conversely, the finding that TFIIIC is limiting in ROSE 199-f3gal cell extracts has 
not been dissected any further. Thus, it is at present unclear whether TFIIIC2, 
TFIIIC 1 or both these components are limiting in ROSE 199-figal cell extracts. It is 
therefore plausible that the increase in TFIIIC2 activity in ROSE 199-neu cells does 
not contribute to the activation of pol III transcription in these cells because it is 
TFIIIC 1 and not TFIIIC2 that is limiting in the untransformed ROSE 199-Pgal cells. 
Although this possibility is considered unlikely, it deserves further investigation.
5.3.3 More than one limiting factor
The finding that both TFIIIB and TFIIIC can significantly stimulate 
transcription when independently titrated into extracts of ROSE 199-neu cells 
indicates that both of these factors are limiting in these extracts. Such a situation 
may arise where one of the two limiting factors is only slightly in excess of the other 
limiting factor. For example, suppose TFIIIB is in slight excess of TFIIIC. Despite 
this, it is unlikely that every single TFIIIC molecule that is promoter-bound at any 
given time will be associated with TFIIIB. By raising the concentration of TFIIIB 
the probability of a collision between “free” TFIIIB in solution and promoter-bound 
TFIIIC may be increased resulting in an increase in the number of active preinitiation 
complexes. If, however, TFIIIB is in vast excess raising its concentration further is 
unlikely to significantly alter the probability of these collisions. Indeed, it may 
actually inhibit transcription, for example by sequestering some pol III from 
participating in active complex formation.
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The limiting factor(s) for pol III transcription in a given cell type can also 
vary depending on cell cycle position. For example, using extracts of synchronised 
proliferating HeLa cells it has been shown that in G1 phase extracts TFIIIB is 
limiting and the addition of partially purified TFIIIC had no effect (571). In contrast, 
in G2 phase extracts TFIIIC is limiting and the addition of the same partially purified 
TFIIIC fraction strongly stimulated transcription (571). In this particular study all 
the extracts have been prepared from asynchronously proliferating cells. It is likely 
that TFIIIC is only limiting in ROSE 199-j3gal cells in a restricted window of the cell 
cycle. Similarly, elevated levels of TFIIIC2 activity observed in asynchronous 
extracts of ROSE 199-neu cells may be restricted to a particular part of the cell cycle. 
The fact that there can be more than one limiting factor in a given cell type and that 
the identity of the limiting factor(s) can change with time, for example depending on 
cell cycle position, may explain why several DNA-tumour viruses target multiple 
components of the pol III transcriptional apparatus. Thus, the deregulation of 
TFIIIC2 may only be one of several changes in the pol III transcriptional apparatus 
of ROSE 199-neu cells and human ovarian tumours.
214
Chapter 6.
Modulation of pol III transcription by 
phosphorylation
6.1 Introduction
Protein phosphorylation is arguably the most ubiquitous control mechanism 
of protein function and certainly the most studied. Primary stimulation or repression 
of transcription in eukaryotes is largely independent of de novo protein synthesis, 
suggesting the involvement of posttranslational modifications such as 
phosphorylation or acetylation (238). The cellular response to extracellular stimuli 
commonly involves changes in gene expression. This is dependent upon a complex 
network of intracellular signal transduction pathways of protein kinases that integrate 
these extracellular signals and transmit them to the nucleus. Thus, protein 
phosphorylation has a critical role in regulating transcription, whether directly by the 
phosphorylation of the transcription factors themselves or indirectly, for example by 
the phosphorylation of upstream activators or repressors.
Little is known as to which kinase signalling pathways impinge on pol III 
transcription; however, several kinases have been reported to have an effect. The 
pocket proteins RB, pl07 and pl30 all repress pol III transcription (93, 314, 503, 
504, 579). The activity of the pocket proteins depends on their phosphorylation 
status; in a hyperphosphorylated state the pocket proteins are inactive (173, 239, 418, 
482, 557). The cyclin-dependent kinases that regulate the phosphorylation of the 
pocket proteins may therefore indirectly exert a regulatory effect on pol III 
transcription. Another cyclin-dependent kinase, p34cdc2/cyclin B l, is implicated in 
the mitotic repression of pol III transcription. Mitotic repression of pol III 
transcription can be reproduced in vitro and is achieved through the phosphorylation 
and inactivation of TFIIIB (169, 327, 572). p34cdc2/cyclin Bl is the major mitotic 
kinase and can specifically phosphorylate and inactivate affinity-purified Xenopus 
TFIIIB (169, 587). Therefore, the downregulation of pol III transcription during
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mitosis may be achieved, at least in part, by the phosphorylation of TFIIIB by 
p34cdc2/cyclin Bl.
The hepatitis B virus X protein, which can induce liver cancer in transgenic 
mice (274), has been shown to substantially elevate pol III transcription in a variety 
of cell lines (16, 256, 304, 548, 549). This is dependent on Ras signalling (548, 549). 
Dominant negative Ras or a Ras famesylation inhibitor both block X-induced 
activation of pol III transcription (548). Constitutively active Raf, a Ras effector, can 
overcome this block (548). Moreover, constitutively activated Ras can increase 
tRNA transcription in cells not infected with X protein (548). Since activating 
mutations in Ras are a very frequent occurrence in human cancers (344), this may be 
another mechanism by which pol III transcription is deregulated in transformed and 
human tumour cells. X protein induces an increase in the abundance of TBP, which 
may be sufficient to account for the increase in pol III transcription in some cell lines 
(527, 548, 549). The X protein enhances the transcription of the TBP gene (256). 
This involves three distinct Ras-activated pathways (256), suggesting that the Ras- 
Raf-MEK-MAP kinase pathway may not be the only Ras pathway that can affect pol 
III transcription.
The highly conserved TOR (target of rapamycin) pathway is also implicated 
in the regulation of pol III transcription. Treatment of budding yeast cells with the 
antibiotic rapamycin induces the Go program of molecular events, including the 
repression of pol III transcription (611). This is TOR-dependent, as extracts from 
rapamycin-treated yeast strains that lack the rapamycin ligand FKBP12 have 
comparable pol III transcriptional activity to extracts from untreated cells (611). 
Direct evidence that TOR signalling can influence pol III transcription is provided by 
the phenotype of a yeast strain, tor2ts, harbouring a temperature sensitive mutation in 
the highly conserved TOR kinase, Tor2. Extracts from the tor2ts strain harvested at 
the permissive temperature have similar pol III transcriptional activity to extracts 
from cells that are wild-type for Tor2 (611). In contrast, extracts from tor2ts cells 
harvested at the restrictive temperature have much lower pol III transcriptional 
activity than wild-type cells (611).
In yeast, protein kinase CKII (formerly known as casein kinase II) is required 
for high levels of basal pol III transcription (216). A yeast strain, cka2ts, bearing a 
temperature-sensitive lesion in the catalytic a ' subunit of CKII, has significantly
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reduced CKII activity compared to wild-type cells, both at the permissive and non- 
permissive temperature (163, 216). Accordingly, cka2ts cells and extracts prepared 
from this mutant strain display substantially diminished levels of tRNA and 5S 
rRNA synthesis (163, 216). When cka2ts cells are shifted to the restrictive 
temperature, concomitant with a further decrease in CKII activity, pol III 
transcription is reduced (216). In contrast, basal pol I- and pol II- transcription were 
found to be unaffected by the severely reduced CKII activity of the cka2ts strain 
(216). Titration of increasing amounts of purified wild-type CKII into extracts of 
cka2ts cells stimulated pol III transcription in a dose-dependent manner, consistent 
with a positive role for CKII in yeast pol III transcription (216). Further evidence 
was provided by the inhibition of tRNA synthesis in wild-type extracts by the 
commonly used CKII inhibitor, 2,3-diphosphoglycerate (216). The deficiency in pol 
III transcriptional activity of cka2ts cell extracts could also be specifically rescued by 
TFIIIB purified from wild-type cells, implicating TFIIIB as the CKII-responsive pol 
III factor (163, 164). Addition of TFIIIC or pol III had no effect (163, 164). TFIIIB 
is strongly phosphorylated by CKII in vitro; moreover, the dephosphorylation of 
TFIIIB eliminated its ability to rescue pol III transcription in CKII-deficient extracts 
(163, 164). Specifically, it is the TBP subunit of TFIIIB that is efficiently 
phosphorylated by CKII. Furthermore, CKII enhances the ability of recombinant 
TBP to stimulate pol III transcription in cka2ts cell extracts (163, 164). Although this 
suggests that TBP is at least one of the physiological targets of CKII among the pol 
III transcription components, it remains to be determined how the phosphorylation of 
TBP by CKII might stimulate pol III transcription. Nevertheless, the evidence is 
very convincing for an essential role for CKII in pol III transcription in yeast. In this 
chapter the role of CKII in mammalian pol III transcription is investigated.
CKII is a highly conserved Ser/Thr kinase (7). It is ubiquitously expressed in 
eukaryotes and is found both in the cytoplasm and the nucleus (7). Although the 
exact physiological role of CKII is not known, many lines of evidence suggest that 
CKII has essential roles in cell proliferation and growth (7). There is elevated CKII 
activity in rapidly dividing cells, both normal and transformed (243, 387). Indeed, a 
comparison with the proliferation marker Ki67 suggested that CKII would be a 
reliable marker protein for proliferation (387). Hence, CKII is elevated in tumour 
cells but also in normal cells with high mitotic activity, for example colorectal 
mucosa or embryonic cells during highly proliferative stages (387). Certain
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mitogens can stimulate CKII activity, for example insulin, insulin-like growth factor- 
I or EGF (76, 279, 414, 493). Indeed, CKII is required for cell cycle progression 
(192, 413). Microinjection of antibodies against the positive-acting regulatory p 
subunit of CKII into human primary fibroblasts at various times of the cell cycle 
revealed that CKII is required for transition of Go/Gj, early Gi, and Gi/S phases of 
the cell cycle (413). Disruption of the CKA1 and CKA2 genes that encode the a  and 
a ' catalytic subunits respectively of CKII in yeast is lethal, demonstrating that the 
functions of CKII in the cell are essential (402). Further evidence in support of a role 
for CKII in growth and proliferation is provided by the identity of many of the 
proteins that can be phosphorylated by CKII. Many of the protein substrates are 
involved in gene expression and protein synthesis, for example RNA polymerases I 
and II, DNA topoisomerases, nucleolin, HMG and ribosomal proteins and a number 
of translation initiation and elongation factors (7, 419). Additionally, CKII 
phosphorylates many signal transduction proteins and also transcription factors 
including nuclear oncoproteins such as myc, myb, fos and jun (7, 419). All of these 
substrates are consistent with a proliferative or growth promoting function for CKII.
Like many proteins with a positive role in cell proliferation and cell growth, 
CKII has oncogenic properties. The first hint of this came from the discovery that 
CKII activity is markedly and specifically elevated in the leukaemia-like cattle 
disease theileriosis, caused by the parasitic protozoan Theileria parva (400, 401). 
Furthermore, there is no evidence that tyrosine kinases or other signaling pathways 
are deregulated, suggesting that the upregulation of CKII in theileriosis is highly 
significant to the development of this disease (400, 401). CKII has since been found 
to be abnormally active in a variety of human cancers, including leukaemias and 
solid tumours (141, 160, 387). Direct evidence of the oncogenicity of CKII was 
provided by transgenic mice overexpressing the catalytic a  subunit, that develop 
lymphomas from six months of age with an incidence of 15-20% per year (474). The 
latency of onset and monoclonality of the lymphomas indicates that other mutations 
are required for transformation. However, coexpression of a c-myc transgene with a 
CKIIa transgene resulted in polyclonal neonatal leukaemia (474, 600). Thus, c-myc 
and CKIIa can cooperate to transform lymphocytes in a two-step pathway. 
Deregulation of the lymphoid oncogene tal-1 or loss of the tumour suppressor p53, in
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combination with CKIIa overexpression is also sufficient to transform lymphocytes 
(600).
Since tRNA and 5S rRNA are important determinants of the biosynthetic 
capacity of the cell, the positive role of CKII in pol III transcription in yeast 
correlates well with its apparent proliferative and growth-promoting roles. Indeed, 
the stimulation of basal pol III transcription by CKII may be a critical aspect of its 
growth-promoting function. In support of this, it has been reported that CKII can 
phosphorylate the pol I transcription factor UBF in mice, resulting in the stimulation 
of pol I transcription (540). Thus, CKII may coordinately upregulate pol I- and pol 
III- transcription ensuring the levels of tRNA and ribosomal RNAs are sufficient to 
meet the growth demands of the cell.
RNA pol III transcription has been found elevated in a number of human 
tumours and many transformed cells and is activated by several oncoproteins and 
repressed by two key tumour suppressors. Since CKII is a putative oncogene it was 
therefore of particular interest to determine whether CKII has a stimulatory role in 
mammalian pol III transcription. CKII is remarkably well conserved between yeast 
and mammals. Furthermore, the pol III factor target of CKII in yeast, TFIIIB, is also 
required for mammalian pol III transcription and two of its subunits, TBP and BRF, 
are quite well conserved. However, it has previously been reported that CKII can 
phosphorylate the human La antigen, which inhibits the reported in vitro ability of La 
to stimulate recycling of the human pol III transcription complex (140). It remains to 
be determined though whether inhibition of this activity by CKII is ever responsible 
for limiting the rate of pol III transcription under physiological conditions. A La 
homologue has also been found in yeast, but is not required for viability (603).
Preliminary experiments carried out to investigate whether glycogen synthase 
kinase-3 p (GSK-3p) can affect pol III transcription are also described in this chapter. 
GSK-3p is one of two isoenzymes, a  and p, of mammalian GSK-3, each of which is 
encoded by a separate gene (594). These two isoenzymes are highly related and are 
thought to perform similar functions; however, the majority of studies on mammalian 
GSK-3 have been with the p isoform or have not discriminated between the two 
forms.
GSK-3 p is a highly conserved Ser/Thr kinase and is thought to have an 
important role in translation control (423, 561). GSK-3p phosphorylates the
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translation initiation factor eIF2B, which inhibits its guanine nucleotide exchange 
activity, thus preventing the regeneration of active eIF2 that is required for each new 
round of translation initiation (423, 562). Following mitogenic stimulation, the 
phosphatidylinositol 3-kinase (PI3K) pathway switches off GSK-3p, thereby 
allowing activation of translation (561, 562). The inhibition of translation by GSK- 
3p may be accounted for solely by its effect on eIF2B; however, it is possible that 
GSK-3 p also targets other essential components of the translational apparatus. Thus, 
it may be that GSK-3 p inhibits pol III transcription. Even if the levels of tRNA and 
5S rRNA are not rate-limiting under these circumstances, their reduction may 
provide a kind of fail-safe mechanism, for example if eIF2 were to become 
independent of eIF2B regulation. Furthermore, the coordinate downregulation of 
tRNA and 5S rRNA synthesis with the inhibition of translation is better for the 
economy of the cell, as the production of these transcripts is energetically costly. In 
support of a role for GSK-3 p in regulating pol III transcription, treatment of serum- 
stimulated fibroblasts with the PI3K inhibitor wortmannin has been found to inhibit 
pol III transcription (470). However, PI3K has several other downstream effectors in 
addition to GSK-3 p, and any of these may be responsible for the inhibitory effect of 
wortmannin on pol III transcription. For example, the p70 S6 kinase lies 
downstream of PI3K (422); it is required for the serum induction of ribosomal 
protein synthesis and thus is another strong candidate for a role in regulating pol III 
transcription.
Another substrate of GSK-3p is cyclin D1 (124). GSK-3P phosphorylates 
cyclin D l, targeting it for proteolytic degradation by the 26S proteasome (124). The 
primary function of the D-type cyclins, in combination with their catalytic cdk 
partner, is the phosphorylation and inactivation of the retinoblastoma protein (214). 
Therefore, GSK-3P, by negatively regulating cyclin Dl stability, may have a 
physiological role in ensuring that RB is not inappropriately inactivated. Thus, 
GSK-3 p may negatively regulate pol III transcription indirectly via its effect on the 
activity of RB.
In addition to its inhibitory effects on cyclin Dl levels and eIF2B, GSK-3p, 
which is remarkably well conserved between distantly related eukaryotic species, is 
also involved in essential developmental processes including axis formation in 
Xenopus, cell fate determination in Dictyostelium and segment polarity in
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Drosophila (563). The role of GSK-3 p in development is mediated through its 
involvement in Wnt signalling (69, 412). GSK-3p, facilitated by a multiprotein 
complex that includes the adenomatous polyposis coli (APC) tumour suppressor, 
phosphorylates p-catenin targeting it for degradation by the proteasome, as is the 
case for cyclin Dl (69, 412). Wnt signalling inactivates GSK-3p, enabling the 
accumulation of p-catenin and its translocation to the nucleus where it can interact 
with members of the LEF/TCF family of HMG-box containing transcription factors 
and activate transcription of genes containing LEF/TCF binding sites (69, 412).
Although the primary role of Wnt signalling is in development, in adult 
tissues it also has a role in regulating cell proliferation (412). Inappropriate 
activation of Wnt signalling is implicated in a variety of different human cancers 
(382, 412). The APC tumour suppressor is frequently mutated in colon cancer and 
the GSK-3 P phosphorylation sites of P-catenin are also found to be mutated in 
human tumours, both of these effects resulting in increased levels of p-catenin and 
increased transcription of LEF/TCF-responsive genes (382). Many of these genes 
are involved in development and provide no obvious links to tumorigenesis. 
Recently, however, a few pro-proliferative targets of Wnt signalling have been 
identified, such as the c-myc and cyclin Dl genes, both of which are transcriptional 
targets of the p-catenin/TCF transcription complex (204, 382, 518). In addition to 
positively regulating cyclin Dl gene expression (518), Wnt signalling also reduces 
cyclin Dl proteolysis, both of which effects correlate with the inhibition of GSK-3p 
(435).
Thus, GSK-3 p is negatively regulated by at least two distinct signalling 
pathways, namely the PI-3K pathway and Wnt signalling. These two pathways 
inhibit GSK-3 p through different mechanisms and lead to distinct downstream 
events (126). However, signalling through both pathways affects cyclin Dl 
proteolysis (124, 435). The negative regulation of GSK-3 p by mitogens and many of 
its functions are consistent with an anti-proliferative, growth restraining role for 
GSK-3 p. Consistent with this, GSK-3 p has also been shown to phosphorylate and 
inhibit c-jun and can phosphorylate other transcription factors involved in cell 
proliferation, such as myc, myb and CREB (563). Thus, the inhibition of pol III 
transcription may be one aspect of a general physiological role of GSK-3P in 
inhibiting growth and proliferation under certain circumstances.
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GSK-3P is also implicated in Alzheimer’s disease (254). A key event in the 
pathogenesis of this disease is the hyperphosphorylation of the microtubule- 
associated protein tau (254). Normal, underphosphorylated tau has essential 
functions in microtubule nucleation, organisation and stability (254). 
Hyperphosphorylation of tau impairs these functions and promotes the formation of 
paired helical filaments, the building blocks of the neurofibrillary lesions of 
Alzheimer’s disease (254). GSK-3P phosphorylates tau; moreover, GSK-3p has 
been shown to reduce microtubule abundance and disrupt microtubule organisation 
when overexpressed with tau, suggesting that the phosphorylation of tau by GSK-3P 
may be physiologically relevant to the tau phenotype in Alzheimer’s disease (254, 
328, 343, 542).
As its name suggests, GSK-3p also functions in glycogen metabolism. The 
phosphorylation of glycogen synthase by GSK-3p inactivates it, thus inhibiting 
glycogen synthesis (502). Recently, a positive role in cell survival has also been 
reported for GSK-3P (219). Mice deficient in GSK-3P have been generated and 
found to die in mid-gestation due to excessive hepatocyte apoptosis (219). This 
phenotype is consistent with hypersensitivity to TNFa toxicity, as displayed by mice 
that lack NFkB function (219). Indeed, GSK-3p_/' cells displayed significantly 
reduced N FkB function implying that GSK-3P has a role in N F kB activation (219). 
Clearly, GSK-3p performs a variety of functions within the cell. Unlike CKII, a role 




6.2.1 The CKII inhibitors 2,3-diphosphogIycerate and quercetin potently 
inhibit mammalian pol III transcription in vitro
In yeast, CKII is required for high levels of basal pol III transcription (163, 
164, 216). To investigate whether CKII has a similar role in pol III transcription in 
mammals, the effect on transcription of the two well-known CKII inhibitors 2,3- 
diphosphoglycerate (DPG) and quercetin was tested. As Figure 6.1 shows, specific 
pol III transcription reconstituted in vitro with HeLa PC-B and PC-C fractions and a 
human tRNAleu gene was severely repressed both by 2,3-diphosphoglycerate and 
quercetin. The decrease in transcription was dose-dependent, with little or no tRNA 
synthesis detectable at the higher dose. The low concentrations of DPG and 
quercetin used in this experiment have previously been shown to potently and 
specifically inhibit CKII phosphorylation of established natural substrates, including 
yeast TFIIIB (216, 364, 530). Similar repression of pol III transcription in the 
presence of DPG or quercetin was observed when transcription was reconstituted 
with unfractionated HeLa nuclear extract or the VAj gene as template (data not 
shown). Another commonly used CKII inhibitor, the ATP analogue 5,6-dichloro-l-P 
-D-ribofuranosylbenzimidazole (DRB), was also found to reduce the levels of pol III 
transcription in a HeLa nuclear extract (257). The fact that three unrelated 
compounds that function as specific inhibitors of CKII kinase activity have the same 
effect on pol III transcription suggests that the repression observed is a specific 
response to a decrease in CKII activity. The effect of quercetin and DRB on pol III 
transcription in vivo has also been tested. Both CKII inhibitors caused a reduction in 
the levels of pol III transcripts (470), suggesting that the reduction in mammalian pol 
III transcription observed in vitro with these CKII inhibitors is of physiological 
significance.
6.2.2 CKII activates mammalian pol III transcription in vitro
DPG, DRB and quercetin are all potent inhibitors of CKII, and at the 
concentrations that were used in these experiments have been shown to have no
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Figure 6.1
Pol III transcription decreases in the presence of the CKII inhibitors DPG and 
quercetin
Each transcription reaction contained 2pl of HeLa PC-B, 2 j l x 1 of HeLa PC-C and 
250ng of pLeu encoding a tRNAleu gene (all lanes). In addition, lanes 2 and 3 
contained 2,3-diphosphoglycerate, 6mM and 12mM respectively. Lane 6 contained 
50pM of quercetin and lane 7 contained lOOpM of quercetin. Lanes 1, 4, 5 and 8 
contained appropriate amounts of control buffer for the two inhibitors. Following a 
15 min preincubation at 30°C, nucleotides were added to initiate transcription, which 
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effect on a range of other kinases. However, although these chemical CKII inhibitors 
are highly specific, none of them can be regarded as totally specific for CKII, 
especially at higher concentrations. Therefore, it was necessary to verify that CKII 
does indeed have a positive influence on mammalian pol III transcription in vitro, as 
suggested by the inhibitory effect of the CKII inhibitors. To test this, in vitro 
transcription reactions were carried out in the presence of increasing amounts of a 
peptide substrate containing a consensus CKII phosphorylation site. This CKII 
peptide was specifically designed based on the sequence preferences of CKII (295, 
296). The minimal sequence requirements for a CKII phosphorylation site is 
Ser/Thr-x-x-Asp/Glu (419). CKII is unusual in that it has a strong preference for 
acidic residues whereas the specificity determinants of most Ser/Thr kinases are 
basic (419). A multitude of different peptides containing a CKII phosphoacceptor 
site have been analysed for their kinetic properties and their specificity as a CKII 
substrate (419). The CKII peptide substrate used in these experiments is highly 
specific for CKII and has favourable kinetic properties (295, 296). The presence of 
CKII peptide in a cell extract provides an alternative substrate for phosphorylation by 
CKII from the endogenous CKII substrates. Thus, the CKII peptide should compete 
with endogenous substrates for phosphorylation by CKII. Therefore, the peptide is 
effectively a competitive inhibitor of the kinase. By being a better substrate or 
present in much larger amounts, such peptides can divert the kinase for which they 
contain a phosphoacceptor site from the phosphorylation of its endogenous substrates 
(540).
Titrating in increasing amounts of CKII peptide into a crude HeLa nuclear 
extract caused a dose-dependent decrease in pol III transcription of the VAi gene 
(Figure 6.2). Transcription was inhibited approximately 90-fold in the presence of 
40pg of the CKII peptide (Fig. 6.2, compare lanes 1 and 4). In contrast, the addition 
of identical amounts of a peptide containing a consensus phosphoacceptor site for 
protein kinase A (PKA) had no effect on the level of transcription (compare lanes 5, 
6 and 7 with lanes 1 and 8). The highly specific inhibitory effect of the CKII peptide 
is probably caused by the ability of this peptide to reduce the phosphorylation of 
endogenous substrates by CKII, whereas the PKA peptide is unable to do this. To 
support this interpretation, the ability of recombinant CKII to phosphorylate the PKA 
and CKII peptides was tested in an in vitro kinase assay. CKII phosphorylated the 
CKII peptide approximately 40-fold more efficiently than the PKA peptide or
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Figure 6.2
Competitive inhibition of CKII with a peptide containing a consensus CKII 
phosphoacceptor site specifically represses pol III transcription
All reactions contained 2pl of HeLa nuclear extract and 250ng of pVAi (all lanes). 
In addition, lanes 2-4 contained increasing amounts of a peptide containing a CKII 
phosphoacceptor site (20pg, 30pg and 40pg, respectively). Lanes 5-7 contained 
increasing amounts of a peptide containing a PKA phosphoacceptor site (20pg, 30pg 
and 40pg, respectively). No peptide was added to lanes 1 and 8. Reaction mixtures 
were preincubated with added peptide for 15 min at 30°C prior to the addition of 
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Figure 6.3
The competitor peptide containing a CKII phosphoacceptor site is specifically 
and potently phosphorylated by CKII
In vitro kinase assays were performed using three different peptide substrates, 
peptide containing a CKII phosphoacceptor site, peptide containing a GSK-3 
phosphoacceptor site (CREB) and peptide containing a PKA phosphoacceptor site. 
Each of these peptide substrates was individually incubated with 0.5 pi of 
recombinant CKII or GSK-3. 10|rCi [y-32P] ATP was included in each reaction 
mixture as a source of radiolabelled phosphate donor. In vitro phosphorylation 
reactions were allowed to proceed for 20 min at 30°C. Reactions were then stopped 
by pipetting samples onto 2cm phosphocellulose discs (Whatman P81) that the 
peptides are designed to bind and unincorporated label was removed by extensive 
washing with 75mM phosphoric acid. The level of phosphorylation of the peptide 
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another peptide containing a phosphoacceptor site for GSK-3 (Figure 6.3), 
confirming that the CKII peptide is likely to be able to strongly compete with 
endogenous substrates for phosphorylation by CKII, whereas the PKA peptide 
cannot. Recombinant GSK-3 and p42 MAPK were also tested for their ability to 
phosphorylate the CKII peptide. Consistent with previous data demonstrating the 
specificity of the CKII peptide for CKII, the level of phosphorylation of the CKII 
peptide by these two kinases was negligible (Figure 6.3 and data not shown).
Production of detectable amounts of the appropriately sized transcript in an in 
vitro transcription assay requires correct initiation, elongation, termination and re­
initiation of transcription. The inhibitory effect of the CKII peptide could be caused 
by a defect in any of these steps. To try and determine at which of these steps the 
CKII peptide has its inhibitory effect, primer extension analysis of the transcripts 
produced in the presence or absence of CKII peptide in an in vitro pol III 
transcription assay, was performed. Whereas all the transcripts produced in a 
standard pol III run-off assay are detected and can be distinguished only on the basis 
of size, primer extension analysis will only detect a subset of the transcripts; cDNAs 
will only be produced from RNA species that contain a specific sequence that can 
hybridize to the radiolabelled primer added. Therefore, most of the non-specific 
transcripts produced will not be detected. In addition to primer extension analysis 
reducing background noise, the size of the cDNAs can be used to map the 5' 
terminus of the RNAs and thus determine if transcription initiated at the correct site.
Figure 6.4 shows the results of primer extension analysis of RNA from in 
vitro pol III transcription of the VAi gene in HeLa nuclear extract in the presence or 
absence of CKII peptide. No cDNA of any size could be detected following primer 
extension of RNA from a transcription reaction that contained CKII peptide (Fig. 6.4, 
compare lane 3 with lanes 1, 2, 4 and 5), suggesting that the inhibitory effect of the 
CKII peptide may occur at the level of transcription initiation. The presence of PKA 
peptide resulted in a cDNA of the same size as in the absence of any added peptide, 
demonstrating the specificity of the effect of the CKII peptide.
The effect of the CKII peptide was also tested in a more purified transcription 
system using fractionated factors rather than a crude extract and a tRNA gene as the 
pol III template, rather than VAi (Figure 6.5). As for VAi transcription, tRNA 
synthesis was inhibited in a dose-dependent manner and was almost completely
228
abolished by the higher doses of CKII peptide. In contrast, neither the PKA peptide 
nor a third peptide containing a consensus phosphoacceptor site for p34cdc2 had any 
effect on the level of tRNA synthesis demonstrating the sequence-specificity of the 
effect of the CKII peptide on transcription.
The consistent reduction in pol III transcription when CKII activity is 
specifically inhibited, whether by a chemical CKII inhibitor or by peptide containing 
a CKII phosphorylation site, suggests that CKII has a positive influence on pol III 
transcription. Indeed, transcription is almost completely abolished by doses of 
inhibitor commonly used to specifically inhibit CKII kinase activity, suggesting that 
CKII may be essential for high levels of mammalian pol III transcription, at least in 
vitro.
The influence of CKII on mammalian pol III transcription in vivo has also 
been tested further. An antisense approach was adopted, as has previously 
successfully been used to deplete cells of endogenous CKII activity (414, 474). 
Primary human fibroblasts (IMR-90) were exposed to oligodeoxynucleotides 
complementary to the start region of mRNAs coding for the positively-acting 
regulatory p subunit of CKII. This provoked a significant reduction in the 
abundance of endogenous CKIip protein, severely impairing the CKII activity of the 
cells (257). RNA was harvested from these cells and analysed by RT-PCR using 
intron-specific primers against two different tRNA species, thus providing an 
indication of the rate of ongoing pol III transcription (104, 105). Exposure of cells to 
antisense CKIIp oligonucleotides substantially reduced the levels of tRNA synthesis 
in vivo relative to that of untreated cells or cells treated with sense CKIip 
oligonucleotides (257). In contrast, there was no change in the abundance of mRNA 
encoding glyceraldehyde phosphate dehydrogenase (257), demonstrating the 
specificity of the effect of the antisense CKIip oligonucleotides on tRNA synthesis.
The inhibitory effect of depleting cells of CKIip protein on mammalian pol 
III transcription in vivo could be very indirect. Although the exact functions of CKII 
in cell growth and proliferation have yet to be elucidated, there is considerable 
evidence that it has essential roles in these two processes. Indeed, decreasing 
endogenous CKII activity using antibodies against CKIip can inhibit progression 
through particular stages of the cell cycle (413). Depletion of CKII activity with 
antisense CKIip oligonucleotides from IMR-90 fibroblasts has previously been
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Figure 6.4
Primer extension analysis of transcripts produced by in vitro transcription of 
the VAi gene in the presence of CKII peptide or PKA peptide
In vitro transcription reactions were reconstituted with 2pi of HeLa nuclear extract 
(all lanes), 250ng of pVAi (all lanes) and 40pg of peptide containing a consensus 
phosphoacceptor site for CKII (lane 3) or PKA (lane 5). After a 15 min 
preincubation at 30°C, transcription was initiated by the addition of equimolar 
concentrations of rATP, rCTP, rGTP and rUTP, none of which were radiolabelled. 
DNA was removed from transcription reaction products by treating samples with
99RNase-free DNase. 2.5ng of [y- P]-labelled oligonucleotide primer specific for a 
coding region of the VAi gene was added to each RNA sample for primer extension 
analysis. After heating the samples at 80°C for 10 min to denature the RNA, the 
samples were incubated for ~2h at 50°C to allow the slow annealing of the primer to 
the complementary sequence present in RNA species. Reverse transcription was 
then allowed to proceed for lh at 42°C. cDNA products were analysed on a 7M urea 
7% polyacrylamide sequencing gel.
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Figure 6.5
tRNA synthesis is inhibited specifically by a competitor peptide with a 
consensus CKII phosphoacceptor site
Pol III transcription was reconstituted in vitro with HeLa PC-B (2pl) and PC-C (2pi) 
and a tRNAleu gene as the specific pol III template (250ng of pLeu) (all lanes). 
Additionally, lanes 2-5 contained increasing amounts of a peptide containing a CKII 
phosphoacceptor site (lOpg, 20pg, 30pg and 40pg, respectively). Lanes 7-10 
contained increasing amounts of a peptide containing a PKA phosphoacceptor site 
(lOpg, 20 jug, 30pg and 40pg, respectively). A peptide containing a p34cdc2 
phosphoacceptor site was added to lanes 12-15 (lOpg, 20pg, 30pg and 40pg, 
respectively). No peptide was added to reactions 1, 6 and 11. Reaction mixtures 
were preincubated with added peptide for 15 min at 30°C prior to the addition of 






1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
shown to transiently inhibit cell growth stimulation by EGF (414). Since pol III 
transcription is also subject to cell cycle and growth control (96, 255, 363, 525, 569, 
571), it may be that the decrease in tRNA synthesis is an indirect response to a 
change in the growth or proliferative rate of the cell caused by the reduction in the 
abundance of CKII(3 protein. Alternatively, perhaps CKII regulates the activity of a 
transcription factor that can modulate the transcription of genes encoding 
components of the pol III transcription apparatus. Such indirect mechanisms might 
be responsible for the pol III transcriptional response to CKII in vivo. However, the 
potent inhibitory effect of reducing endogenous CKII activity on pol III transcription 
in vitro demonstrates that CKII can directly influence pol III transcription 
independently of changes in gene expression of pol III components or the 
proliferation status of the cell.
The sensitivity of mammalian pol III transcription in vivo to a decrease in 
CKII activity is very important as it demonstrates that CKII can influence 
mammalian pol III transcription in a physiological context as well as in vitro. The in 
vivo pol III response mimics that in vitro, suggesting an activating function for CKII 
in mammalian pol III transcription. The evidence for this is derived from the effect 
on transcription of reducing the endogenous CKII activity. The converse 
experiments were also performed in which the abundance of CKII is artificially 
raised above endogenous levels. The overexpression of CKII in human 
osteosarcoma cells had no effect on pol III transcription (257). Similarly, titrating in 
increasing amounts of recombinant CKII into in vitro transcription reactions 
reconstituted with HeLa nuclear extract or HeLa PC-B and PC-C fractions failed to 
stimulate transcription (data not shown). The lack of a stimulatory effect of 
exogenous CKII can be reconciled with the decrease in pol III transcription when 
endogenous CKII levels are reduced if endogenous CKII is normally in relative 
excess. In support of this possibility, endogenous CKII is saturating for pol III 
transcription in wild type yeast cell extracts (216).
In HeLa extracts containing the highly specific CKII peptide, endogenous 
CKII is competitively inhibited from phosphorylating its natural substrates and is 
thought to become limiting for its stimulatory effect on mammalian pol III 
transcription, hence the decrease in pol III transcription observed. If the inhibitory 
effect on pol III transcription of the CKII peptide truly is caused by a reduction in the 
CKII phosphorylation of endogenous substrates, then the impaired pol III
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transcription of extracts or fractionated factors containing CKII peptide should be 
rescued by the addition of recombinant CKII. As Figure 6 . 6  shows, the addition of 
recombinant CKII to a HeLa extract containing CKII peptide strongly stimulated 
transcription. This provides direct evidence that CKII has an activating function in 
mammalian pol III transcription in vitro. The recombinant CKII substantially 
rescued transcription that was almost completely abolished by the presence of CKII 
peptide in these extracts (Figure 6 .6 , compare lanes 4 and 5). In contrast, addition of 
the same amount of recombinant CKII had no stimulatory effect in HeLa extracts 
containing PKA peptide rather than CKII peptide (Fig. 6 .6 , compare lanes 7 and 8 ). 
Addition of CKII to extracts lacking peptide had little stimulatory effect on 
transcription, as previously observed (Fig 6 .6 , compare lane 2 with lanes 1 & 3). 
Similarly, transcription of a tRNAIeu gene using HeLa PC-B and PC-C, repressed by 
the addition of CKII peptide, could also be rescued by recombinant CKII (data not 
shown). These results demonstrate that CKII contributes significantly to the level of 
mammalian pol III transcription in vitro but also that it is in excess for pol III 
transcription in unfractionated HeLa extracts and HeLa PC-B or PC-C fractions.
6.2.3 CKII and TFIIIB interact stably
The responsiveness of pol III transcription reconstituted with PC-B and PC-C 
to CKII peptide or chemical CKII inhibitors and the inability of CKII to stimulate 
such transcription except in the presence of peptide or inhibitor, suggests that some 
endogenous CKII has copurified with the pol III transcription components in PC-B 
or PC-C. This copurification on phosphocellulose might be because CKII physically 
interacts with a component of the pol III transcription apparatus or it may be entirely 
fortuitous. These phosphocellulose fractions are relatively crude and contain many 
proteins. The possibility that CKII may stably associate with a component of the pol 
III transcription apparatus was further investigated by seeing if CKII is present in 
highly purified fractions of the different pol III transcription components.
As a sensitive means of assaying for the amount of CKII activity in these 
fractions, in vitro kinase assays were performed using peptide containing a CKII 
phosphoacceptor site as substrate. Immunoaffinity-purified TFIIIB fractions were 
found to contain between 2- and 4- fold as much CKII activity as mock-
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Figure 6.6
Recombinant CKII rescues pol III transcription reconstituted in the presence of 
peptide containing a consensus phosphoacceptor site for CKII
All reactions contained 2pl of HeLa nuclear extract and 250ng of pVAi (all lanes). 
In addition, reactions 4 and 5 contained 30pg of peptide containing a 
phosphoacceptor site for CKII. Reactions 7 and 8 contained 30pg of PKA peptide, 
lp l of recombinant CKII was also added to reactions 2, 5 and 8 . Following a 15 min 
preincubation at 30°C, nucleotides were added to initiate transcription, which was 
allowed to proceed for 1 h at 30°C.
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imrnunopurified TFIIIB fractions generated using columns carrying preimmune 
serum (data not shown). In contrast, immunoaffinity-purified TFIIIC fractions 
contained only low levels of CKII activity similar to the levels found in mock- 
immunopurified TFIIIC fractions (data not shown). An immunoaffinity-purified 
TFIIIB fraction and a mock-immunopurified TFIIIB fraction were also assayed for 
PKA activity. This was found to be similar in the two fractions, demonstrating the 
specificity of the higher levels of CKII activity found in the immunoaffinity-purified 
TFIIIB fraction (data not shown).
These results suggest that CKII and TFIIIB may stably interact. It was 
therefore investigated whether they cofractionate during gradient chromatography. 
As Figure 6.7 shows, the TFIIIB activity and CKII activity of eluted fractions were 
found to closely coincide following gradient chromatography of a PC-B fraction on 
hydroxy apatite. PKA activity was also assayed and found to fractionate differently 
(data not shown). Similar cofractionation of TFIIIB and CKII was observed 
following gradient chromatography of a PC-B fraction on heparin-Sepharose (data 
not shown). Eluted fractions from Mono Q gradient chromatography of a PC-B 
fraction were also analysed. A Mono Q gradient resolves TFIIIB into two essential 
components, B' and B", that elute at 0.38M KC1 and 0.48M KC1, respectively (374). 
B' consists minimally of TBP and BRF, whereas the composition of B" is uncertain 
but is thought to contain a human homologue of yeast B" (374). Two significant 
peaks of CKII activity were found to elute from Mono Q. Comparison with the 
elution profile of TFIIIB revealed that the CKII peak that eluted slightly later in the 
gradient coincides with the peak of B' activity (Figure 6 .8 ). In contrast, peak B" 
fractions contained hardly any CKII activity. The specificity of this cofractionation 
of a sizeable proportion of the CKII in a PC-B fraction with B' was further 
demonstrated by the fractionation of DNA-dependent protein kinase (DNA-PK) and 
GSK-3. DNA-PK eluted early in the gradient, well before B' or B", whereas the 
bulk of GSK-3 activity eluted in the flowthrough (data not shown).
The criteria by which heparin, hydroxyapatite and Mono Q separate proteins 
are distinct. The cofractionation of TFIIIB and CKII during gradient 
chromatography on each of these three distinct adsorbent types suggests that TFIIIB 
and CKII stably interact. The specific cofractionation of CKII with B' and not B" on
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Figure 6.7
TFIIIB and CKII cofractionate during gradient chromatography of PC-B on 
hydroxyapatite
Gradient-eluted fractions were assayed for TFIIIB by in vitro transcription 
reconstituted with 2pl of PC-C, 250 ng of pVAi and 4pl of eluted fraction. CKII 
activity of individual fractions was assayed by in vitro phosphorylation reaction 
using peptide containing a consensus CKII phosphoacceptor site as the substrate. 
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A subpopulation of CKII molecules closely cofractionates with TFIIIB B'
activity during gradient chromatography of PC-B on Mono Q
The TFIIIB B' activity of individual fractions was assayed by in vitro transcription 
reaction reconstituted with the VAi gene as the specific pol III template (250ng), 
TBP-immunodepleted nuclear extract (4pl) and the individual Mono Q fraction 
(2pl). The levels of VAi transcript produced were quantitated by phosphoimager 
analysis*.
To assay for B" activity, transcription reactions were reconstituted with 250ng of
pVAi, 2pl of PC-C, 2pl of the Mono Q fraction of peak B' activity (fraction number
55) and 2pl of the individual Mono Q fraction. As for B' activity, the levels of VAi
★
transcript produced were quantitated by phosphoimager analysis .
CKII activity of individual fractions was assayed by in vitro phosphorylation reaction 
using peptide containing a consensus CKII phosphoacceptor site as the substrate. 
Fraction numbers are indicated. FT, flowthrough.
’Determ ination o f  B' and B" activity o f  M ono Q fractions by in vitro transcription assay and 





















Mono Q suggests that CKII may directly interact with either the TBP or BRF 
component of TFIIIB.
As an independent test of a physical association of endogenous TFIIIB and 
CKII, immunoprecipitation experiments were performed. Antiserum against the 
BRF subunit of TFIIIB was consistently found to coimmunoprecipitate CKII activity 
from HeLa nuclear extract or HeLa PC-B (Figure 6.9 and data not shown). A low 
level of CKII activity was also detected in immunoprecipitates of the pre-immune 
serum, presumably due to non-specific interactions; however, this was always 
significantly less than the amount of CKII activity immunoprecipitated with the BRF 
antiserum. On average, approximately three times as much CKII activity is detected 
in immunoprecipitates obtained using the BRF antiserum as in those obtained with 
the appropriate pre-immune serum (Fig. 6.9 and data not shown). The converse 
experiment was also performed, in which CKII was specifically immunoprecipitated 
from HeLa nuclear extract using an antiserum raised against the catalytic a  subunit 
of CKII and the presence of TFIIIB in the precipitated material was assayed for by 
Western blotting using an antiserum raised against BRF. The typical results of such 
an immunoprecipitation are shown in Figure 6.10. As positive controls, antisera 
against BRF itself and RB, which has previously been shown to bind to TFIIIB (93, 
314, 315, 503, 504), were used and as expected precipitated significant amounts of 
BRF (Fig. 6.10, lanes 1 and 2). The CKIIa antiserum was also found to 
immunoprecipitate BRF; indeed, comparable levels of BRF coprecipitated with CKII 
as found in immunoprecipitates obtained using the RB antiserum (Fig. 6.10, compare 
lanes 2 and 3). In contrast, an antiserum against the TAFi48 subunit of the pol I- 
specific transcription factor SL1 was unable to immunoprecipitate BRF (lane 4), 
demonstrating the specificity of the presence of BRF in immunoprecipitates obtained 
with the CKIIa antiserum. This specific coimmunoprecipitation of BRF with an 
antiserum raised against the catalytic a  subunit of CKII was confirmed using a 
second antiserum raised against a different region of BRF (data not shown). This 
coimmunoprecipitation data, along with the consistent cofractionation of CKII and 
TFIIIB through a variety of different column types, suggests that a subpopulation of 




Coimmunoprecipitation of CKII activity with endogenous TFIIIB
Immunoprecipitation reactions were carried out using equivalent amounts of 330 
antiserum raised against BRF or the corresponding pre-immune serum, prebound to 
protein A-Sepharose, and 20pl of PC-B. Following 3h incubation at 4°C on an 
orbital shaker, samples were pelleted, supernatants were removed and the 
immunoprecipitated material was washed five times with 250pl of LDB. 
Immunoprecipitates were then assayed for CKII activity by in vitro phosphorylation 
using peptide containing a consensus phosphoacceptor site for CKII as substrate, [y- 
32P] -ATP (lOpCi) was included in each reaction mixture as a source of radiolabelled 
phosphate donor, enabling the levels of phosphorylation of CKII peptide substrate to 
be estimated by liquid scintillation counting. Results shown are the averages and 
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Endogenous CKII interacts with TFIIIB
HeLa nuclear extract (150ju-g) was immunoprecipitated using anti-BRF antiserum 
128 (lane 1), anti-RB antibody C-15 (lane 2), anti-CKIIa antibody H-286 (lane 3) or 
anti-TAFi48 antibody M-19 (lane 4). Precipitated material was resolved on a SDS- 




TFIIIB is sufficient to restore pol III transcription to wild-type levels in cell 
extracts of the yeast cka2ts strain (163, 164). Transcriptional rescue by TFIIIB is 
abolished if TFIIIB is pretreated with phosphatase (164). These observations suggest 
that TFIIIB is the CKII-responsive component of the pol III transcription apparatus 
in yeast. TBP, an essential component of TFIIIB both in yeast and mammals, is the 
preferred substrate of yeast TFIIIB for phosphorylation by CKII (163, 164). 
Phosphorylation by CKII enhances the ability of recombinant TBP to stimulate pol 
III transcription in cka2ts extracts (163, 164). These data suggest that 
phosphorylation of TBP by CKII may mediate the stimulation of pol III transcription 
in yeast by CKII. Since TBP is likely to be the physiological target of CKII in yeast 
it was therefore of considerable interest as to whether an interaction between human 
TFIIIB and CKII is dependent on TBP. This was investigated by heat inactivating 
TBP in a PC-B fraction and assaying whether TFIIIB and CKII still 
coimmunoprecipitate. As Figure 6.11 shows, the heat inactivation of TBP had little 
or no detectable effect on the ability of an antiserum raised against the catalytic a  
subunit of CKII to specifically immunoprecipitate BRF (compare lanes 2 and 5). An 
in vitro transcription assay confirmed that the TBP in the heat treated PC-B used in 
this immunoprecipitation experiment had been inactivated, at least in its ability to 
support transcription (data not shown). As a positive control an antiserum against 
RB was used. Surprisingly, the coimmunoprecipitation of BRF with RB was 
diminished when heat treated PC-B was used, suggesting that TBP might facilitate 
the interaction between RB and BRF. This possibility warrants further investigation, 
although the effect of heat inactivating TBP on the levels of BRF in RB 
immunoprecipitates was much less in other immunoprecipitation experiments 
conducted (data not shown). These experiments also suggested that heat inactivated 
TBP can still interact with BRF (data not shown), causing questions to be raised as to 
the exact nature by which TBP is heat inactivated and the molecular basis for the loss 
of its ability to support pol III transcription. Therefore, although the heat inactivation 
of TBP was consistently observed to have no effect on the level of BRF that 
coimmunoprecipitated with CKII, it can not be concluded from this that an 
interaction between CKII and TFIIIB is independent of TBP.
In Figure 6.11, several bands of slightly different mobility about the size of 
BRF are detected with the BRF antiserum used. Confirmation that these bands 
correspond to BRF and are not non-specific proteins recognised by the antiserum has
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Figure 6.11
Heat inactivation of TBP has no effect on the endogenous association of BRF 
and CKII
20pl of untreated PC-B (lanes 1-3) or HT PC-B (lanes 4-6) was immunoprecipitated 
using anti-Rb antibody C-15 (lanes 1 and 4), anti-CKIIa antibody H-286 (lanes 2 and 
5) or anti-TAFi48 antibody M-19 (lanes 3 and 6 ). After extensive washing with LDB 
buffer, precipitated material was resolved on a SDS-7.8% polyacrylamide gel and 































been obtained using a second antiserum that was raised against a different region of 
BRF (data not shown). This phenomenon of multiple BRF bands has previously 
been observed using these BRF antisera (315, 504). These different forms of BRF 
may represent splice variants of BRF, of which several have recently been identified 
and cloned (365). Alternatively, the different bands may correspond to differentially 
phosphorylated forms of a single BRF species.
Many protein kinases can stably interact with their substrates. Therefore, the 
identification of proteins that associate with a particular kinase can sometimes help 
identify putative substrates. The consistent cofractionation and 
coimmunoprecipitation of endogenous human TFIIIB and CKII, suggestive of their 
physical association, raises the possibility that TFIIIB may be a physiological 
substrate for phosphorylation by CKII. The amino acid sequence of human TBP, 
hBRF and hB" were searched for potential CKII phosphoacceptor sites based on the 
minimal sequence requirements for this kinase. The sequence of hTBP has two 
potential CKII phosphoacceptor sites, the sequence of hBRF has a total of twelve 
potential CKII phosphoacceptor sites and the recently cloned hB" contains a 
remarkable 46 potential CKII phosphorylation sites (data not shown). Thus, hTBP, 
hBRF and hB" could all be phosphorylated by CKII, depending on the surface 
accessibility of these potential CKII phosphoacceptor sites. Preliminary data suggest 
that human BRF and hB" are phosphorylated by CKII in vitro (257).
6.2.4 CKII kinase activity promotes the interaction between TFIIIB and
TFIIIC2
Assuming that CKII phosphorylates TFIIIB in vivo and that this 
phosphorylation is responsible for the stimulatory effect of CKII on mammalian pol 
III transcription, the question then arises as to how this phosphorylation stimulates 
transcription. The primary function of TFIIIB in pol III transcription at most class III 
genes is to act as a bridging factor between promoter-bound TFIIIC and RNA 
polymerase III, thus allowing the recruitment of pol III to the appropriate promoters. 
It was therefore investigated whether CKII kinase activity can influence the essential 
interactions of TFIIIB with either TFIIIC or pol III. At present there is no evidence
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to suggest that CKII has any influence on the interaction between TFIIIB and pol III, 
however, coimmunoprecipitation experiments suggest that CKII activity does affect 
the interaction of TFIIIB with TFIIIC.
The monoclonal antibody MTBP6 , which specifically recognises a sequence 
in the N-terminus of TBP, efficiently immunoprecipitates the TBP-containing pol III 
factor TFIIIB from HeLa extracts. Furthermore, TFIIIC2 is specifically
coimmunoprecipitated with TFIIIB (data not shown). This antibody therefore
enabled the effect of CKII kinase activity on the interaction between TFIIIB and 
TFIIIC2 to be investigated. The effect of the CKII inhibitor quercetin on the ability 
of the MTBP6  antibody to coprecipitate TFIIIC2 was tested. As Figure 6.12 A 
shows, the inclusion of quercetin in immunoprecipitation reactions, to specifically 
inhibit CKII kinase activity, reduced the levels of TFIIIC2 that coprecipitated. The 
amount of TFIIIB that was immunoprecipitated did not change (Fig 6.21 A, lower 
panel and data not shown), however, suggesting that the inhibition of CKII kinase 
activity impairs the interaction between TFIIIB and TFIIIC; hence the reduced levels 
of TFIIIC2 in the immunoprecipitates. The levels of TBP in the precipitated material 
were unaffected by the inclusion of quercetin in the reactions (Figure 6.12 A, lower 
panel). Similarly, the levels of BRF1 in the immunoprecipitates remained the same 
(data not shown); demonstrating the specificity of the decrease in the levels of 
coprecipitated TFIIIC2 in response to inhibiting CKII activity with quercetin. 
Additionally, similar doses of quercetin have been shown to have no effect on the 
coprecipitation of BRF with CKII (257).
A similar reduction in the levels of TFIIIC2 that are coprecipitated with 
TFIIIB was observed in the presence of the unrelated CKII inhibitor, DRB (Figure 
6.12 B, lanes 6  and 7). Immunoprecipitation experiments have also been carried out 
with HeLa nuclear extract supplemented with radiolabelled in vitro translated BRF 
and the 4286 antiserum that is specific for the TFIIICp subunit of TFIIIC2. The 
4286 antiserum is able to coprecipitate BRF with TFIIIC2 (503). However, the 
presence of quercetin or DRB was found to abolish the coprecipitation of BRF (257), 
providing supporting evidence for the observed inhibitory effect of reducing CKII 
activity on the interaction of endogenous TFIIIB and TFIIIC2. Together, these 
results suggest that CKII kinase activity can promote the interaction of TFIIIB and 
TFIIIC2. A model is proposed in which the phosphorylation of TFIIIB by CKII 
promotes the interaction between TFIIIB and TFIIIC (Figure 6.13). It remains
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Figure 6.12
The CKII inhibitors quercetin and DRB compromise the interaction of
endogenous TFIIIB and TFIIIC
A) HeLa nuclear extract (150pg) was immunoprecipitated using no antibody (lane 1) 
or anti-TBP monoclonal antibody MTBP6  (lanes 2-6). Lanes 3 and 4 contained 
lOOpM or 500pM quercetin, respectively. Lanes 1, 2, 5 and 6  contained appropriate 
amounts of control buffer. After extensive washing with LDB buffer, precipitated 
material was resolved on a SDS-7.8% polyacrylamide gel and analysed by western 
blotting with anti-TFIIICp antiserum 4286 (upper panel), or with anti-TBP antibody 
SL30 (lower panel).
B) HeLa nuclear extract (150pg) (lane 1 and lanes 3-7) was immunoprecipitated 
using no antibody (lane 1) or anti-TBP monoclonal antibody MTBP6  (lanes 2-7). 
Lanes 4 and 5 contained 150pM or 500pM quercetin, respectively. Lanes 1-3 
contained appropriate amounts of control buffer. Lane 7 contained 120pM DRB and 
lane 6  contained 1.2 % ethanol as a buffer control for the DRB. After extensive 
washing with LDB buffer, precipitated material was resolved on a SDS-7.8% 
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Figure 6.13
Model proposing that CKII may promote the interaction between TFIIIB and 
TFIIIC by the direct phosphorylation of TFIIIB
The specific inhibition of CKII kinase activity by quercetin or DRB causes a 
reduction in the levels of TFIIIB and TFIIIC that are associated. Since CKII stably 
interacts with TFIIIB and the TFIIIB component BRF can be phosphorylated by 
CKII in vitro this suggested that CKII might facilitate the interaction between TFIIIB 







uncertain as to whether the stimulatory effect of CKII on the interaction between 
TFIIIB and TFIIIC is sufficient to account for the activating function of CKII on 
mammalian pol III transcription or whether CKII may influence pol III transcription 
by additional mechanisms. The interaction of TFIIIB and TFIIIC is essential for 
transcription initiation of most class III genes, which makes it an excellent candidate 
for transcriptional control. Whereas CKII stimulates the interaction of TFIIIB and 
TFIIIC2 and in doing so may positively regulate pol III transcription, the tumour 
suppressor RB disrupts the interaction between TFIIIB and TFIIIC2 (see Chapter 4 
and (503)). The targeting of the interaction of TFIIIB and TFIIIC by both a tumour 
suppressor and a putative oncogene product suggests that this interaction can be rate- 
limiting for pol III transcription and is tightly regulated. It remains to be determined 
whether the antagonistic effects of CKII and RB on this interaction are related or 
whether they occur by distinct mechanisms.
6.2.5 Recombinant GSK-30 inhibits pol III transcription in vitro
To begin to investigate whether GSK-3P has a role in regulating pol III 
transcription, the effect was tested of adding bacterially expressed recombinant GSK- 
3p to pol III transcription reactions reconstituted in vitro. As Figure 6.14 shows, 
titrating in increasing amounts of recombinant GSK-3P caused a dose-dependent 
decrease in the levels of pol III transcription. The specificity of this decrease in the 
levels of correctly sized tRNA transcript with increasing doses of GSK-3P is 
demonstrated by the levels of two very large transcripts of unknown identity that are 
produced in the reactions. Whereas these large transcripts were undetectable in 
reactions that lacked GSK-3p, the reactions with the higher doses of GSK-3P and 
reduced levels of tRNA synthesis generally displayed higher levels of these two 
transcripts. This may be caused by increased availability of polymerase for non­
specific transcription or perhaps GSK-3p inhibits transcription termination and these 
transcripts are derived from read-through transcription of the tRNA gene.
This clear inhibition of pol III transcription in vitro in response to increasing 
amounts of recombinant GSK-3p suggests that GSK-3P may negatively regulate pol 
III transcription, consistent with its inhibitory effect on eIF2B and a role for GSK-3p
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Figure 6.14
Glycogen synthase kinase-3 p represses pol III transcription
pLeu template (250 ng) was transcribed using 2pl of PC-B and 2pl of PC-C in the 
presence of 0.5pl, lpl or 4pl of recombinant GSK-3P (New England Biolabs) (lanes 
2, 3, and 4, respectively). Lanes 1, 5 and 6  contained appropriate amounts of control 
buffer. Prior to the addition of nucleotides to initiate transcription, reaction mixtures 
were preincubated for 10 min at 30°C. Transcription was allowed to proceed for 1 h. 
Ethanol-precipitated transcription products were separated on a 7M urea 7% 
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in restraining cellular growth (423, 561, 562). The extent of the inhibition is 
relatively small, however, compared to that observed in the presence of recombinant 
RB or when CKII activity was inhibited, for example. It may be that the 
recombinant GSK-3p is of low activity compared to that of recombinant RB, maybe 
lacking an activating post-translational modification or perhaps GSK-3 p is only a 
weak repressor of pol III transcription. The relatively mild inhibitory effect of GSK- 
3p may also reflect the fact that, for many substrates, the minimal sequence 
requirements for phosphorylation by GSK-3p are a phosphorylated serine residue in 
the + 4 position (563). Therefore, for GSK-3P to phosphorylate its endogenous 
substrates this commonly requires a priming phosphorylation event by another kinase 
(563). A limiting amount of priming kinase will restrict any effect of increased 
levels of GSK-3p.
6.2.6 Lithium, a potent and specific inhibitor of GSK-3, stimulates pol III
transcription in vitro
Since the addition of recombinant GSK-3 p caused a decrease in the levels of 
pol III transcription, it was predicted that inhibiting endogenous GSK-3p activity 
should increase the levels of pol III transcription. To test this, CREB 
phosphopeptide, a synthetic peptide that contains a consensus phosphoacceptor site 
for GSK-3 (147, 550), was titrated into transcription reactions. This peptide was 
predicted to compete with endogenous substrates for phosphorylation by GSK-3, in 
an analogous manner to the earlier described use of a peptide containing a CKII 
phosphoacceptor site as a competitive inhibitor of CKII. Unexpectedly and in 
apparent contradiction to the transcriptional inhibition observed using recombinant 
GSK-3 (3, the CREB phosphopeptide also caused a dose-dependent decrease in the 
levels of pol III transcription, although the decreases were only small relative to 
those observed using CKII peptide when it was assayed in parallel (data not shown). 
Perhaps GSK-3a and GSK-3 p, both of which can phosphorylate the CREB 
phosphopeptide (147), have opposing effects on pol III transcription and the 
inhibitory effect predominates. Although possible, this is deemed unlikely as the 
available evidence suggests there is substantial functional redundancy between the
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two GSK-3 isoforms (219). An alternative plausible explanation is that the CREB 
phosphopeptide is not totally specific for GSK-3.
The CREB phosphopeptide is derived from the GSK-3 phosphoacceptor site
1 ? Qat Ser of the cAMP response element binding protein (CREB) and is commonly 
used as the substrate for assaying GSK-3 activity in crude and fractionated extracts 
(147). It is phosphorylated ~ 40 fold more efficiently by recombinant GSK-3 (3 than 
by recombinant CKII in an in vitro kinase assay (Figure 6.3). However, in the 
relatively crude fractions that are used to reconstitute pol III transcription in vitro 
there are likely to be a whole host of different kinases, one of which may be able to 
phosphorylate the CREB peptide reasonably efficiently. Indeed, problems of high 
levels of background phosphorylation of GSK-3 peptide substrates in crude cell 
extracts have previously been reported (454). Thus, the inhibitory effect of the 
CREB peptide on pol III transcription may result from the competitive inhibition of a 
kinase other than GSK-3 that has an activating role in pol III transcription. The 
likelihood of the non-specific phosphorylation of the CREB peptide is increased by 
the presence of two serine residues in this short peptide (147). Although this peptide 
has been synthetically phosphorylated on the + 4 Ser, it may become 
dephosphorylated by endogenous phosphatases in crude extracts. This would create 
an additional potential phosphorylation site and would prevent the phosphorylation 
of this peptide by GSK-3 without prior phosphorylation at the + 4 position by 
another kinase.
To distinguish between GSK-3-specific phosphorylation of the CREB peptide 
in crude cell extracts and non-specific background phosphorylation of this peptide, 
lithium ions (Li+) have been used (454). Lithium ions are a potent and specific 
inhibitor of GSK-3, both in vitro and in vivo (207, 280, 454, 498). Doses of lithium 
ions that were found to almost completely abolish GSK-3 activity in vitro had 
negligible effect on a range of other protein kinases tested that included CKII, PKA, 
JNK and MAPK, demonstrating the specificity of the kinase inhibitory effect of 
lithium ions for GSK-3 (280, 498). To date no other lithium-sensitive kinases have 
been identified, suggesting that the sensitivity of GSK-3 to lithium may be a unique 
feature of this kinase (454). The inhibitory effect of lithium is also highly conserved, 
forms of GSK-3 from invertebrates such as Dictyostelium and Drosophila as well as 
those from vertebrates such as Xenopus and mammals all displaying sensitivity to 
lithium (207, 280, 454, 498). GSK-3 is not the sole target of lithium action,
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however. Lithium is also a potent inhibitor of inositol monophosphatase (IMPase) 
and inositol polyphosphate 1-phosphatase (IPPase), key enzymes required for the 
synthesis and recycling of inositol (34, 186).
The physiological effects of lithium are diverse. Lithium has profound 
effects on development in numerous organisms (260, 280, 348, 497, 536) and is one 
of the most effective drugs used for the treatment of bipolar disorder (582). Several 
hypotheses have been proposed as to how lithium might exert these effects (34, 280, 
582). The inositol depletion hypothesis is based on the inhibitory effect of lithium on 
the inositol phosphatases, IMPase and IPPase (34). Repression of these enzymes by 
lithium is proposed to reduce the free pool of inositol which ultimately will lower the 
intracellular concentration of the second messenger inositol (l,4,5)-triphosphate (IP3) 
(34). This in turn will have severe consequences for phosphoinositide signalling, 
providing a potential molecular mechanism by which at least some of the 
physiological effects of lithium may be achieved (34). Lithium-induced blockage of 
cell cycle transitions in sea urchin embryos is prevented by the microinjection of 
myo-inositol, suggesting that the inhibition of IMPase or IPPase may be involved in 
mediating this effect of lithium (28). Similarly, in Xenopus, duplication of the dorsal 
axis induced by lithium treatment was prevented by exogenous myo-inositol, 
implicating the involvement of IMPase or IPPase (6 8 ). Recently, a class of 
compounds that are ~ 1000 fold more potent than lithium in inhibiting IMPase have 
become available, providing a powerful tool for dissecting which physiological 
effects of lithium are mediated through the inhibition of IMPase (15). These novel 
inhibitors of IMPase were found to have no discernible effect on the morphogenesis 
of Xenopus embryos in contrast to the dorsalisation induced by lithium, so clearly 
the inhibition of IMPase is not sufficient to account for this effect of lithium (280).
The discovery that GSK-3 is also potently repressed by lithium identified a 
highly appealing alternative target to IMPase or IPPase by which the physiological 
effects of lithium may be mediated, the role of GSK-3 in cell fate determination in 
many eukaryotic species (563) correlating well with the effects of lithium on 
development. In support of the candidacy of GSK-3 as the dominant endogenous 
target of lithium action and the use of lithium as an inhibitor of GSK-3 in vivo, 
lithium treatment actually phenocopies loss of GSK-3 function (207, 219, 280, 502). 
For example, insulin signalling inactivates GSK-3, stimulating glycogen synthesis; 
lithium also stimulates glycogen synthesis (89, 502). Expression of a dominant
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negative mutant of GSK3P dorsalises Xenopus embryos (205); lithium also causes 
dorsalisation (259, 260, 280). In Dictyostelium, the disruption of GSK-3 alters cell 
fate (197); lithium mimics this effect (348, 536). There is also considerable evidence 
of lithium antagonising GSK-3 function in vivo. Thus, lithium treatment induces p- 
catenin accumulation in Drosophila and mammalian cells, mimicking the effects of 
wnt signalling (498). GSK-3, which is inactivated by wnt signalling, phosphorylates 
p-catenin, targeting it for degradation (69, 382, 412, 450). In addition to the effects 
of lithium on body axis formation in Xenopus embryos, Li+ has also been shown to 
result in the activation of an AP-1 luciferase reporter (207), consistent with previous 
observations that GSK-3 P inhibits c-jun activity (46). The overexpression of GSK-3 
in cultured human neurons induces an Alzheimer’s disease-like phosphorylation of 
the microtubule-associated protein tau (190). Lithium reduces tau phosphorylation 
by GSK-3 (498) and can counteract the inhibitory effect of GSK-3 on tau-induced 
processes outgrowth (224, 328). Normal hypophosphorylated tau promotes 
microtubule assembly and nucleation (224, 254, 328). The inhibition of these 
functions of tau by GSK-3-dependent phosphorylation (328, 343, 542) suggests that 
the efficacy of lithium in treating depression and other disorders of the nervous 
system is likely to be mediated at least in part through the inhibition of GSK-3. 
Thus, GSK-3 seems to be a major physiological target of lithium action.
Lithium ions are widely and routinely used to investigate GSK-3 function 
(333, 449, 502). The effects of lithium seem to be considered a reliable indication of 
the possible involvement of GSK-3 in a particular process (333, 449). The striking 
correlation between the physiological effects of lithium in evolutionarily distant 
species and the consequences of disrupting GSK-3 function, suggests that there is 
some justification in regarding the effects of lithium on a particular process as a good 
indication of whether or not GSK-3 is involved.
The effect of lithium ions on pol III transcription reconstituted in vitro was 
therefore tested. As a source of lithium ions, lithium chloride was used. Chloride 
ions have previously been shown to have little effect on GSK-3 activity (280). To 
control for the addition of lithium chloride, the effect of adding an equal 
concentration of sodium chloride was assayed in parallel. As Figure 6.15 shows, 
millimolar concentrations of LiCl, commonly used to specifically inhibit GSK-3 
(333), stimulated tRNA synthesis relative to the levels obtained with an equal
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concentration of NaCL Little or no stimulation was observed in the presence of 
20mM LiCl (data not shown), possibly because at this concentration the inhibition of 
endogenous GSK-3 was too slight to have any effect on pol III transcription. At a 
concentration of lOOmM LiCl, or higher, transcription was less than with NaCl, 
probably because of non-specific inhibitory effects of lithium (data not shown). Pol 
III transcription reconstituted in vitro is very sensitive to changes in ionic strength, 
hence the variation in the levels of pol III transcription between the different doses of 
sodium chloride. Nonetheless, there is a clear stimulatory effect of lithium ions on 
the levels of tRNA synthesis. Stimulation of pol III transcription by lithium ions was 
also observed using the VAi gene as template, but to a much lesser extent (data not 
shown). This differential sensitivity to lithium may reflect the difference in promoter 
strength of the two genes. The VAi promoter is stronger than the promoters of tRNA 
genes and thus is likely to be less sensitive to changes in the levels or activity of 
repressors or activators.
6.2.7 Lithium ions increase the pol III transcriptional activity of cells
The stimulation of pol III transcription in vitro by doses of lithium ions that 
are sufficient to inhibit endogenous GSK-3 activity together with the inhibition of 
pol III transcription by recombinant GSK-3 p suggests that GSK-3 p may be a 
repressor of pol III transcription, at least in vitro. To investigate this possibility 
further, the effect on pol III transcription of inhibiting GSK-3 activity in vivo using 
lithium was tested. The concentrations of lithium chloride used to inhibit GSK-3 in 
vivo and the length of time cells are incubated in media to which LiCl has been 
added that are reported in the literature vary considerably. Therefore the effect on 
pol III transcription of a range of different concentrations of LiCl and incubation 
times were tested.
Asynchronous populations of actively proliferating Balb/c 3T3 (A31) murine 
fibroblasts were cultured for 12 h in media supplemented with a range of different 
concentrations of LiCl, or NaCl as a control. Cell extracts were then prepared, and 
transcriptional activity was assessed by in vitro transcription assay. Extracts from 
Li+-treated cells generally had elevated pol III transcriptional activity compared to
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Figure 6.15
Stimulation of pol III transcription by lithium ions
pLeu template (250 ng) was transcribed using 2pl of PC-B and 2pl of PC-C in the 
presence of 40mM, 60mM or 80mM NaCl (lanes 1, 3 and 5, respectively) or LiCl 
(lanes 2, 4 and 6, respectively). Following a 15 min preincubation at 30°C, 
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control extracts, as shown in Figure 6.16, using a tRNAArg gene as template. 
Extracts from cells that were incubated in media containing 12.5 mM LiCl were of 
similar transcriptional activity to their NaCl-treated counterparts. However, extracts 
prepared from cells cultured in media containing 25 mM LiCl, 50 mM LiCl or 75mM 
LiCl all supported higher levels of tRNA synthesis than equal amounts of extracts 
from cells treated with the same concentrations of NaCl. Extracts prepared from 
A31 cells that were treated with lOOmM LiCl had lower levels of transcriptional 
activity than the corresponding extracts prepared in parallel from cells treated with 
lOOmM NaCl, suggesting that at this concentration lithium may have non-specific 
inhibitory effects.
A time course in which A31 cells were incubated in media containing 25 mM 
LiCl or 25 mM NaCl for different lengths of time before harvesting was also 
conducted. As Figure 6.17 shows, all the extracts prepared from Li+-treated cells had 
elevated pol III transcriptional activity compared to the corresponding extracts from 
Na+-treated cells, apart from the pair of extracts from the cells that were treated for 
the shortest period of time. The reproducibility of this specific increase in the 
transcriptional activity of extracts from cells treated with low concentrations of 
lithium ions was tested by independently preparing several extracts from different 
batches of A31 cells treated with 25 mM LiCl or 25mM NaCl for 12 h. Extracts 
prepared from Li+-treated cells consistently displayed substantially higher levels of 
pol III transcriptional activity than the corresponding extracts from Na+-treated cells 
(data not shown). The concentration of LiCl in the culture media that was required 
to specifically raise the pol III transcriptional activity of cell extracts was quite low. 
Furthermore, the intracellular concentration of lithium ions after 12 h incubation is 
likely to be lower than that in the media in which the cells were cultured. It has 
previously been reported that after a 4 h incubation of Xenopus embryos in LiCl the 
intracellular concentration of lithium ions did not exceed 5% of the extracellular 
concentration (50). The low concentration of lithium chloride required to increase 
pol III transcriptional activity increases the likelihood that this is a specific response 
to the inhibition of GSK-3 rather than some non-specific effect of lithium ions.
The consistently higher pol III transcriptional activity of extracts prepared 
from Li+-treated cells was observed by in vitro transcription assay using a tRNA 
gene as the specific pol III template. Since the earlier in vitro studies suggested that 
the sensitivity to lithium, and thus potentially to repression by GSK-3, may differ for
255
Figure 6.16
Extracts from cells treated with lithium ion display increased pol III 
transcriptional activity
BALB/c3T3 A31 cells were grown in DMEM supplemented with 10% fetal calf 
serum, lOOU/ml penicillin, and lOOpg/ml streptomycin to a confluency of ~ 80 %. 
Cells were then incubated for 12 h in fresh media supplemented with varying 
concentrations of NaCl or LiCl. After 12 h, cells were harvested and whole cell 
extracts were prepared by the freeze-thaw method. The tRNAArg gene (250ng of 
pArg) was transcribed using lOpg of cell extract from cells treated with 12.5mM 
NaCl or LiCl (lanes 1 and 2, respectively), 25mM NaCl or LiCl (lanes 3 and 4, 
respectively), 50mM NaCl or LiCl (lanes 5 and 6, respectively), 75mM NaCl or LiCl 
(lanes 7 and 8, respectively), or lOOmM NaCl or LiCl (lanes 9 and 10, respectively).
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Figure 6.17
The pol III transcriptional activity of cells increases in response to Li+
Exponentially growing BALB/c3T3 A31 cells were incubated for varying lengths of 
time in DMEM supplemented with 10% fetal calf serum, lOOU/ml penicillin, 
lOOpg/ml streptomycin, and 25mM NaCl or LiCl. At the appropriate times, cells 
were harvested and whole cell extracts were prepared. pLeu (250ng) was transcribed 
using lOpg of cell extract from cells incubated in media supplemented with 25mM 
NaCl or LiCl for 2 h (lanes 1 and 2, respectively), 6 h (lane 3: NaCl, lane 4: LiCl), 
12 h (lane 5: NaCl, lane 6: LiCl), or 24 h (lane 7: NaCl, lane 8: LiCl). Transcription 
products were resolved on a 7M urea 7% polyacrylamide sequencing gel and were 
visualised by autoradiography.
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different class III genes this was tested using corresponding pairs of extracts from 
Na+- and Li+-treated cells. Figure 6.18 shows the results of pol III transcription 
reactions using the same pair of extracts with three different class III genes as 
template. As expected, the extract from the Li+-treated cells supported higher levels 
of transcription of a tRNAleu gene than the same amount of the corresponding extract 
from Na+-treated cells. 5S rRNA gene transcription reconstituted with the same pair 
of extracts was substantially elevated in the extract from the Li+-treated cells 
compared to that obtained with the extract from the Na+-treated cells, indeed to a 
significantly greater extent than observed using a tRNA gene as template. In 
contrast, when the same pair of extracts were assayed for their ability to support VAi 
transcription, the levels of VAi transcript produced were slightly higher in extract 
from the Na+-treated cells. This differential effect of treating cells with lithium ions 
on the pol III transcriptional activity of extracts when reconstituted with different 
class III genes is consistent with the effects of lithium on pol III transcription in vivo 
being specific.
6.2.8 Pol III transcripts are specifically elevated in Li+-treated cells
It is conceivable that the increased pol III transcriptional activity of extracts 
from Li+-treated cells relative to extracts from Na+-treated cells could result from the 
two treatments having differential effects on the recovery of pol III transcription 
components or their susceptibility to inactivation during extract preparation. 
Therefore, as an independent test of the stimulatory effect of lithium ions on pol III 
transcription in vivo, total RNA was isolated from Li+- and Na+-treated A31 cells and 
the levels of B2 RNA, a murine-specific pol III transcript, were compared by 
Northern blot analysis. B2 transcripts were found to be substantially more abundant 
in Li+-treated cells relative to Na+-treated cells (Figure 6.19, upper panel). This 
effect is specific, because Na+- and Li+-treated cells express similar levels of a pol II 
transcript encoding acidic ribosomal phosphoprotein PO (ARPP PO) (Figure 6.19, 
lower panel). This specific increase in the abundance of B2 transcripts in Li+-treated 
cells relative to Na+-treated cells is consistently observed in different RNA 
preparations from Na+- and Li+-treated cells (Fig 6.19 and data not shown). Thus, 
lithium ions can increase the levels of pol III transcription both in vitro and in vivo.
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Figure 6.18
Differential effect of lithium ions on pol III transcription of different class III 
genes
The same pair of extracts from Na+- and Li+- treated A31 cells were tested for their 
ability to support pol III transcription of three different class III genes, tRNALeu gene
(A), 5S rRNA gene (B), and VAi gene (C). Transcription was reconstituted with 
lOpg of extract (for (A), (B), and (C), lane 1: extract from Na+-treated cells, lane 2: 
extract from Li+-treated cells) and 250ng of pol III template. Nucleotides were 
added to initiate transcription, which was allowed to proceed for 1 h at 30°C. 













B2 RNA levels are specifically increased in A31 cells that have been cultured in 
the presence of millimolar concentrations of lithium ions
Northern blot analysis of total RNA (lOpg) prepared from three independent sets of 
Na+- or Li+- treated A31 cells (odd-numbered lanes: Na+-treated; even-numbered 
lanes: Li+-treated). Cells were incubated in media supplemented with 12.5 mM NaCl 
or LiCl (lanes 3 and 4, respectively) or 25mM NaCl or LiCl (lanes 1 & 5, and lanes 2 
& 6, respectively) for 9 h (lanes 1 and 2) or 12 h (lanes 3-6) and then harvested. The 
upper panel shows the blot probed with a B2 gene and the lower panel shows the 
same blot that has been stripped and reprobed with the acidic ribosomal 
phosphoprotein PO (ARPP PO).
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The lack of a change in the levels of the pol II transcript ARPP PO in Li+-treated cells 
in contrast to the elevated expression of B2 transcripts demonstrates that the 
stimulation of pol III transcription in vivo by lithium ions is highly specific and not 
due to a general increase in nuclear transcription.
Although these results are supportive of a postulated function for GSK-3 in 
the repression of pol III transcription it is clearly possible that this specific increase 
in pol III transcription in vivo in response to lithium treatment is mediated by a 
different mechanism to the specific repression of GSK-3 by lithium ions. Therefore, 
as a more direct investigation of the possible involvement of GSK-3 p in regulating 
pol III transcription in vivo, attempts were made to overexpress GSK-3P in cells by 
carrying out transient transfections using an expression vector encoding GSK-3 p. 
Primer extension analysis was used to determine the levels of transcription of a 
cotransfected VAi gene that was used as a Pol III reporter. To enable the levels of 
VAi transcription to be normalised for variation in transfection efficiency, cells were 
also transfected with a control plasmid that contained the CAT gene under the 
control of the constitutively active cytomegalovirus (CMV) promoter.
Similar levels of VAi transcript were produced in cells transfected with 
“empty” expression vector as in cells transfected with the same amount of expression 
vector encoding GSK-3p (Fig 6.20, compare lanes 2 and 5). The expected dose- 
dependent decrease in the levels of VAi transcription in cells transfected with 
expression vector encoding GSK-3 p was not observed. The slightly reduced level of 
VAi transcription observed in cells transfected with the lower dose of GSK-3 p may 
result from slightly reduced transfection efficiency, although there were no 
quantifiable differences in the levels of CAT RNA for the different transfections 
(data not shown). In repeated transfections, the expression vector encoding GSK-3p 
reproducibly had little or no effect on the levels of VAi transcription relative to cells 
transfected with a kinase-inactive GSK-3 p form or “empty” expression vector (data 
not shown). These results suggest that GSK-3 P has little or no influence on pol III 
transcription in vivo, in contrast to the repression of pol III transcription observed in 
vitro with the addition of recombinant GSK-3 p.
Recently, it has been shown that GSK-3p regulates cyclin D l, targeting it for 
degradation by the 26S proteasome (124). This GSK-3P-induced reduction in cyclin 
Dl levels is predicted to cause a decrease in the activity of the cyclin Dl-dependent
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Figure 6.20
Primer extension analysis of VAi transcript levels following transient 
transfection of NIH 3T3 fibroblasts with expression vector encoding GSK-3p
NIH 3T3 fibroblasts (~6 x 105 cells) were transiently transfected with 4pg of pVAj, 
4pg of pCAT and lOpg or 20pg of pJ3M-GSK-3p, encoding wild-type GSK-3p 
(lanes 1 and 2, respectively), lOjug or 20pg of pJ3M-GSK-3pkd, encoding kinase 
inactive GSK-3P (lanes 3 and 4, respectively), or 20pg of “empty” pJ3M vector that 
lacks an insert (lane 5). Cells transfected with lOpg of pJ3M-GSK-3p or pJ3M- 
GSK-3pkd (lanes 1 and 3) were also transfected with lOpg of “empty” pJ3M vector, 
thereby ensuring that the amount of plasmid DNA transfected was the same for each 
reaction. VAi primer extension products are shown.
262
O -*—* O <L> >
GSK-3J3 kd GSK-3p
1 2 3 4 5
kinases, cdk4 and cdk6, whose primary function is the phosphorylation and 
inactivation of RB. Therefore, GSK-3 p, through the regulation of cyclin D l, may be 
able to regulate the activity of RB; hence the lack of any effect of GSK-3p on VAj 
transcript levels in vivo was very surprising. Even if GSK-3 p does not influence pol 
III transcription directly, GSK-3 p was expected to have an indirect effect as a result 
of its ability to regulate cyclin Dl proteolysis, since RB is an established repressor of 
pol III transcription. Furthermore, it has previously been shown that cells transfected 
with an expression vector encoding cyclin Dl display elevated levels of pol III 
transcription, consistent with the inactivation of RB (C.A. Cairns, unpublished 
observations).
One possible explanation for the lack of any effect on pol III transcription of 
transfecting cells with an expression vector encoding GSK-3 P is that the GSK-3 p is 
poorly expressed. Therefore, duplicate transfections were performed in parallel to 
enable analysis of both RNA levels by primer extension and protein expression by 
western blotting. The transfected GSK-3P protein has an N-terminal myc-tag 
enabling its detection with the myc epitope-specific 9E10 monoclonal antibody and it 
to be distinguished from endogenous GSK-3p. Figure 6.21 A shows the level of 
expression of myc-tagged GSK-3 P protein for the duplicate transient transfection for 
which the primer extension analysis is shown in Figure 6.20. Expression of 
transfected GSK-3 p protein was very low. The kinase-inactive GSK-3 P form was 
expressed at much higher levels (Fig 6.21 A, compare lanes 2 and 3 with lanes 4 and 
5). Although transfecting cells with a larger amount of expression vector encoding 
GSK-3 p increased the levels of expression, this was still very poor relative to the 
levels of kinase-inactive GSK-3 p and had no detectable effect on the levels of VAi 
transcription of transfected cells. Since the levels of expression of transfected 
proteins can vary between cell types, transfections were also attempted in HeLa cells 
and NIH 3T3 fibroblasts, in case the poor level of expression of GSK-3 p was 
specific to Balb/c 3T3 A31 cells. Several different preparations of high quality DNA 
of the GSK-3 p expression vector were also tested, as the quality of the DNA is 
critical to the efficiency of transfection. However, none of these changes made any 
significant difference, the GSK-3 p protein was consistently expressed only at low 
levels (data not shown). Figure 6.21 B and C shows the results of Western blotting 
of protein extracts from transfected HeLa cells. Expression of GSK-3 p protein was
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Figure 6.21
GSK-3p is poorly expressed in transfected cells and has no effect on cyclin D 
protein levels
(A) Equal amounts of total protein (50pg) prepared from transiently transfected NIH 
3T3 fibroblasts (~6 x 105 cells) were resolved by SDS-7.8% PAGE and analysed by 
western blotting for the expression levels of myc-tagged GSK-3 p by probing with 
anti-myc antibody 9E10. Lanes 2 and 3: protein extract from cells transiently 
transfected with 10pg or 20pg of pJ3M-GSK-3p, respectively. Lanes 4 and 5: 
protein extract from cells transiently transfected with lOpg or 20pg of pJ3M-GSK- 
3pkd, respectively. Lane 1: protein extract from cells transiently transfected with 
20pg of “empty” pJ3M vector.
(B) Protein extracts (50pg) from transiently transfected HeLa cells were similarly 
resolved by SDS-7.8% PAGE and analysed by western blotting using the anti-myc 
antibody 9E10. Lane 1: 50pg extract from cells transfected with pJ3M (20pg). Lane 
2: 50pg extract from cells transfected with GSK-3p expression vector (20pg pJ3M- 
GSK-3P). Lane 3: 50pg extract from cells transfected with GSK-3pkd expression 
vector (20pg pJ3M-GSK-3pkd).
(C) 50pg of the same HeLa protein extracts analysed for myc-GSK-3p in (B) were 
independently analysed for endogenous cyclin Dl protein levels by western blotting 
with the anti-cyclin Dl antibody R-124.
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very poor (Figure 6.21 B). The low levels of GSK-3 p protein that were expressed 
had no detectable effect on endogenous cyclin Dl levels (Figure 6.21 C). Thus, the 
lack of an effect on the levels of VAi transcript can be accounted for by the very poor 
expression of GSK-3 p. The use of the VAi gene as the Pol III reporter for these 
transient transfections compounded the problems of poor GSK-3 p expression, 
subsequent comparative experiments in vivo using lithium suggesting that VAi gene 
transcription in vivo may be much less sensitive to any repressive effect of GSK-3 p 
than tRNA genes or the 5S rRNA gene. The available evidence in support of a role 
for GSK-3P in regulating pol III transcription in vivo is therefore only conjectural, as 
it is derived from the stimulatory effect of lithium ions on pol III transcription in vivo 
and is based on the assumption that it is the specific inhibition of GSK-3 by Li+ that 
is responsible for the observed stimulation.
Any effect GSK-3 p might have on pol III transcription in vivo could be very 
indirect, such as through modulating cyclin Dl levels. However, the ability of 
recombinant GSK-3P to repress pol III transcription in vitro that was reconstituted 
with fractionated HeLa factors suggests that GSK-3 P can influence pol III 
transcription in a much more direct manner. Indeed, this result suggests that GSK-3 p 
may actually target one of the components of the basal pol III transcriptional 
apparatus. The primary amino acid sequence of cloned components of the pol III 
transcriptional apparatus were searched for the GSK-3 consensus phosphoacceptor 
site Ser-x-x-x-Ser(P) (where x represents any amino acid), to see if any of the pol III 
transcription components are potential substrates for GSK-3. TFIIICp has eleven 
Ser-x-x-x-Ser motifs; TFIIICa has nine such motifs, while TFIIIC5 and TFIIICy 
both have three. Additionally, there are four Ser-x-x-x-Ser motifs in the primary 
sequence of BRF and one in TBP. The surface accessibility of these
phosphoacceptor sites is not known, nor whether the serine residue in the + 4 
position is phosphorylated in a physiological environment, which is required to 
generate a phosphoacceptor site for GSK-3. However, the number of potential GSK- 
3 phosphoacceptor sites suggests that at least one component of the pol III 
transcriptional apparatus may be phosphorylated by GSK-3.
Some kinases stably interact with their substrates. It was therefore 
investigated whether GSK-3 stably interacts with TFIIIB or TFIIIC, which would be 
strongly supportive of a role for GSK-3 in the regulation of pol III transcription.
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Since the consistent cofractionation of two proteins is highly suggestive of a stable 
association, it was tested whether GSK-3 p is enriched in any of the immunopurified 
TFIIIB or TFIIIC fractions, or DNA affinity-purified TFIIIC fractions. However, 
GSK-3 p was not detectable by Western blotting in any of these fractions (data not 
shown). As a more sensitive assay, these fractions were tested for GSK-3 activity in 
an in vitro kinase assay using CREB phosphopeptide as substrate. Only very low 
levels of phosphorylation were detected, which were similar for the different 
fractions (data not shown). Western blot analysis of equal amounts of HeLa PC-B 
and PC-C for GSK-3 p protein indicated a significant enrichment of GSK-3 p protein 
in PC-B relative to PC-C or unfractionated HeLa nuclear extract (data not shown). 
Since PC-B is enriched in TFIIIB and lacks TFIIIC, this suggested that GSK-3 P 
might associate with TFIIIB. However, PC-B and PC-C are extremely crude, 
increasing the likelihood of this cofractionation of GSK-3 p with TFIIIB being 
entirely fortuitous. In support of this possibility, GSK-3 did not cofractionate with 
TFIIIB during gradient chromatography of a PC-B fraction on Mono Q (data not 
shown). Immunoprecipitations were also carried out to see if endogenous GSK-3 
associates with endogenous TFIIIB or TFIIIC2. However, GSK-3 was not found to 
specifically coimmunoprecipitate with either of these factors (data not shown). 
Together, these immunoprecipitation experiments and analyses of fractionated 
factors provided little evidence in support of a stable association of GSK-3 with a 
component of the pol III transcriptional apparatus. However, this possibility cannot 
be excluded at present as an interaction with TFIIIC 1 or pol has yet to be tested.
It was also investigated whether recombinant GSK-3 p or CKII have any 
effect on TFIIIC B-block DNA-binding activity. Electrophoretic mobility shift 
assays were carried out using B-block oligonucleotide as the specific probe and 
unfractionated extract or PC-C in the presence of exogenous GSK-3 p or CKII and a 
suitable phosphate donor. However, neither kinase had any significant effect either 
on the intensity or the mobility of TFIIIC-specific shifts (data not shown). These 
results suggest that neither recombinant GSK-3 P nor CKII have any influence on 
TFIIIC B-block binding activity, nor can they bind or phosphorylate the B-block 
binding components of TFIIIC as this would be predicted to cause a change in the 
mobility of the shifts. The CKII inhibitor quercetin was also found to have no effect 
on TFIIIC B-block binding activity (data not shown), providing further evidence of
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6.3.1 Protein kinase CKII activates mammalian pol III transcription and
specifically interacts with TFIIIB
A combined biochemical and genetic approach by Schultz and colleagues had 
earlier shown that the ubiquitous Ser/Thr kinase CKII activates basal pol III 
transcription in the yeast Saccharomyces cerevisiae by phosphorylating TFIIIB (163, 
164, 216). Since CKII and TFIIIB are both highly conserved between yeast and 
mammals, this suggested that CKII might have a similar stimulatory effect on pol III 
transcription in mammals as it does in yeast. The data presented here showing that 
CKII is required for efficient mammalian pol III transcription was therefore not 
entirely unexpected. Thus, three unrelated CKII inhibitors, 2,3-DPG, quercetin and 
DRB, each potently repressed pol III transcription reconstituted in vitro with HeLa 
cell extract or partially purified fractions. Peptide containing a consensus 
phosphoacceptor site for CKII also significantly reduced the levels of pol III 
transcription. This inhibition was substantially relieved by the addition of 
recombinant CKII demonstrating the specificity of the inhibitory effect of CKII 
peptide and the activating influence of CKII upon mammalian pol III transcription. 
As in yeast, recombinant CKII was unable to completely restore pol III transcription 
to the levels observed in the absence of added peptide, however. Perhaps some of 
the endogenous CKII is peptide-inhibited but still remains stably associated with its 
pol III substrate, thus preventing recombinant CKII from functionally substituting for 
endogenous enzyme effectively.
The addition of recombinant CKII to HeLa cell extracts in the absence of 
peptide or other CKII inhibitor had no effect on the levels of pol III transcription in 
vitro. Similarly, the overexpression of CKII in vivo by transfection caused no 
change in the levels of pol III transcription in actively proliferating human 
osteosarcoma cells (257). However, in support of the repression of pol III 
transcription in vitro in response to inhibiting endogenous CKII activity, the 
depletion of endogenous CKII activity in vivo using antisense oligonucleotides 
inhibited pol III transcription (257). Together, these results suggested that CKII has 
an activating function in mammalian pol III transcription but is in relative excess in 
actively proliferating HeLa and osteosarcoma cells. Since CKII is activated in
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response to serum and certain mitogens (76, 279, 493), it may be that in resting cells 
CKII is limiting for pol III transcription and exposure to exogenous CKII will 
stimulate pol III transcription.
The consistent cofractionation and coimmunoprecipitation of endogenous 
human CKII and TFIIIB suggests that they associate stably. Since many kinases 
interact with their substrates and yeast TFIIIB is phosphorylated by CKII, this 
suggested that CKII might phosphorylate mammalian TFIIIB. Indeed, very recent 
preliminary data indicates that purified recombinant human BRF and the recently 
cloned human B" factor are both phosphorylated by CKII in vitro (257). Human 
BRF has also very recently been shown to be phosphorylated in vivo, moreover, the 
CKII inhibitors quercetin and DRB have been found to reduce the phosphorylation of 
BRF (470). In contrast to the observed phosphorylation of recombinant human BRF 
and B", recombinant CKII specifically and efficiently phosphorylates the TBP 
subunit of yeast TFIIIB, but at present there is no evidence that yBRF or yB" are 
phosphorylated by CKII (163, 164). Perhaps the CKII phosphorylation sites of 
hBRF and hB" that can be phosphorylated by recombinant CKII in vitro are poorly 
conserved in the homologous yeast proteins. In yeast TBP there are four consensus 
CKII phosphorylation sites (S/TxxD/E). However, only one of these two sites, SI 83, 
is absolutely conserved in human TBP and molecular modelling of yeast TBP 
indicates that this serine is buried in the crystal structure of TBP and therefore highly 
unlikely to be accessible for phosphorylation by CKII (81). However, it remains 
possible that human TBP might be phosphorylated by CKII. The human factor 
contains another consensus CKII phosphorylation site that is absent from yeast TBP.
In support of BRF being a physiological target of CKII in mammals, the heat 
inactivation of TBP in a HeLa PC-B fraction had no effect on the levels of 
endogenous BRF that CKII was able to coimmunoprecipitate. This suggested the 
interaction between BRF and CKII may be direct or at least not mediated by TBP. 
Surprisingly, however, the heat-inactivated TBP, verified by its inability to support 
pol III transcription, was found to be able to still interact with BRF, so the possibility 
that TBP may be involved in mediating the interaction between BRF and CKII could 
not be excluded. GST-BRF has recently been successfully expressed and purified in 
our laboratory for the first time, providing the opportunity to test whether CKII and
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BRF can interact directly or whether this association is dependent upon TBP or some 
other factor.
Having ascertained which components of the pol III transcriptional apparatus 
are phosphorylated by CKII, the sites of phosphorylation within these components 
can then be mapped by phosphopeptide analysis. Many protein substrates that are 
phosphorylated in vitro by a particular kinase are not physiological substrates for this 
kinase. Therefore, it will be essential to determine whether these mapped sites are 
phosphorylated by CKII in vivo. This can be achieved by in vivo metabolic labelling 
with [ P]-orthophosphate carried out in the presence or absence of CKII peptide 
inhibitor or antisense oligonucleotide, followed by phosphopeptide mapping of 
immunoprecipitated, gel-purified pol III components. Having identified particular 
serine or threonine residues that CKII phosphorylates in a particular pol III 
component in vivo as well as in vitro, the functional significance of phosphorylation 
of these residues can then be investigated by site-directed mutagenesis. Thus, the 
effect on pol III transcription of substituting a Ser or Thr phosphorylated in vivo by 
CKII with an alanine residue can be tested by transiently transfecting cells with 
expression vector encoding the wild-type subunit or the non-phosphorylatable mutant 
and carrying out primer extension analysis of the RNA levels of a cotransfected VAi 
gene. Alternatively, the phosphorylatable residue can be substituted with an 
aspartate residue to see if this mimics the phosphorylated state and results in 
constitutive activation of pol III transcription.
6.3.2 CKII stimulates the interaction between TFIIIB and TFIIIC2
The activation of pol III transcription by CKII in yeast is thought to be 
achieved by the phosphorylation of TBP (163, 164). However, the molecular 
mechanism by which this may stimulate pol III transcription has yet to be elucidated. 
In contrast, in mammals it was found that the inhibition of CKII activity in cell 
extrac:s specifically reduced the levels of TFIIIC2 that coimmunoprecipitated with 
TFIIIB. This suggests that CKII activity may stimulate the interaction between 
TFIIIB and TFIIIC2, providing a potential mechanism by which CKII activates pol 
III transcription in mammals. However, the effect of inhibiting CKII activity on the 
levels of coimmunoprecipitating TFIIIC2 was quite small compared to the potent
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inhibitory effect of similar doses of CKII inhibitor on pol III transcription in vitro, 
suggesting that there may be additional mechanisms by which CKII exerts its 
stimulatory effect on mammalian pol III transcription. Nonetheless, the interaction 
between TFIIIB and TFIIIC2 is essential for pol III transcription of most class III 
genes, so the effect of CKII activity on this interaction may be sufficient to account 
for its stimulatory effect, depending on whether this interaction is usually limiting for 
pol III transcription. This is very likely since RB, an established physiological 
repressor of pol III transcription, also targets this interaction (503). The targeting of 
this interaction by both RB and CKII indicates the importance of the binding of 
TFIIIB to TFIIIC2 for pol III transcription and suggests that the regulation of this 
interaction may be crucial for the physiological control of pol III transcription.
6.3.3 CKII -  upregulation versus constitutive enhancement of pol III
transcription
Although the data indicate a stimulatory role for CKII in pol III transcription 
in mammals, as previously shown for Saccharomyces cerevisiae, it is less clear to 
what extent CKII is able to regulate pol III transcription, either in yeast or in 
mammals. This is largely because of uncertainty as to the extent to which CKII itself 
is regulated (7, 419). In the past, there was controversy as to whether the expression 
and activity of CKII is regulated or whether CKII is a constitutively active kinase 
that is permanently expressed at constant levels from so-called housekeeping genes 
(7). Today, all researchers in the field agree that CKII is subject to some sort of 
regulation, although its control remains poorly understood (7). CKII does not seem 
to be regulated by any known second messenger and no major signal transduction 
pathway has convincingly been demonstrated to regulate CKII (7). Nonetheless, the 
protein levels and specific activity of CKII have been found to be elevated in rapidly 
proliferating cells and a range of tumours and in response to certain mitogens (76, 
243, 279, 387, 493).
Several proteins have recently been identified that are able to modulate CKII 
activity and thus may represent upstream regulators of CKII. Thus, both p53 and 
p21WAF1 can bind to the regulatory p subunit of CKII, inhibiting CKII activity (170,
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171). Very recently, several stress stimuli have been shown to stimulate CKII 
activity; this could be blocked by the p38 MAP kinase inhibitor SB203580, implying 
that p38 MAP kinase may regulate CKII (457). Indeed, phosphorylation-activated 
p38a MAP kinase can directly bind the regulatory p subunit of CKII causing an 
increase in CKII kinase activity (457). Perhaps MAP kinase signalling is involved in 
the physiological regulation of CKII. CKII is also likely to be regulated at the level 
of gene expression. The promoter for the CKIIa gene contains many features 
characteristic of housekeeping genes, but it also contains binding sites for Etsland 
NF-kB (294). These two transcription factors can both bind to the CKIIa promoter 
and are major determinants of promoter activity (294). The stimulation of pol III 
transcription by CKII may also be regulated by the modulation of its intracellular 
location. Thus, in dividing cells CKII is found mainly in the nucleus, whereas in 
quiescent cells it is located mainly in the cytosol (6, 511). CKII may also be 
regulated by the promiscuous interactions of the catalytic (a  and a ')  and regulatory 
subunits (p) with other proteins that prevents their binding to each other and the 
formation of the CKII holoenzyme (6). Thus, the protein kinases Mos, RafA and 
p90Rsk can each specifically bind to CKIIp (6, 41, 86). However, this binding 
prevents CKIip from interacting with and thus activating CKIIa (6). Similarly, 
CKIIa can interact with the catalytic subunit of protein phosphatase 2A (PP2A) but 
cannot simultaneously bind CKIip (212). The binding of several kinases to CKIip 
suggests that CKII may be regulated by phosphorylation. This has not been shown to 
be the case for Mos, RafA or p90Rsk, but the tyrosine kinase c-Abl has been reported 
to phosphorylate CKIIa in vitro and inhibit its activity (211). CKII may also be 
regulated by autophosphorylation (419). Clearly, there are a lot of potential 
mechanisms by which CKII may be regulated; however, the physiological relevance 
of these and their relative contributions to the overall regulation of CKII have yet to 
be fully elucidated. Nevertheless, the accumulating evidence is strongly supportive 
of CKII being regulated but suggest that its control may be complicated.
Another reason for uncertainty as to whether CKII can regulate pol III 
transcription is that CKII was found to be saturating for pol III transcription in 
actively proliferating human osteosarcoma cells and asynchronous HeLa extracts. 
Although there is evidence that CKII activity and levels of expression vary, for 
example between quiescent and actively proliferating cells, the variation is not
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dramatic. It may be that the range within which CKII activity is altered under 
different physiological conditions is insufficient for it to become limiting for pol III 
transcription. Hence, although CKII seems to have a stimulatory role in pol III 
transcription, both in yeast and in mammals, it is possible that it exerts no regulatory 
influence. However, it should be noted that we have only overexpressed CKII in two 
tumour cell lines; osteosarcoma cells in vivo and in extracts from HeLa cells in vitro. 
Since CKII activity is known to be higher in many tumour cells, it is very possible 
that if we overexpressed CKII in untransformed cells pol III transcription would be 
stimulated.
Regardless, the demonstration that CKII has an activating influence on pol III 
transcription in mammals is highly significant since only a handful of kinases have 
so far been shown to modulate the levels of pol III transcription (568). This is 
surprising since pol III transcription is tightly regulated and protein phosphorylation 
is a major control mechanism of protein function. However, although it is well 
established that pol III transcription is strongly regulated, the molecular mechanisms 
involved largely have still to be fully elucidated. Pol III transcription is regulated in 
response to a variety of extracellular stimuli (568), which suggests several protein 
kinase signalling cascades may impinge on the pol III transcription apparatus. It is 
likely that protein phosphorylation has a fundamental role in the control of pol III 
transcription. In support of this, the pocket proteins RB, p i07 and p i30, which are 
strongly implicated in the regulation of pol III transcription in response to growth 
conditions and the cell cycle, are negatively regulated by phosphorylation by the 
cyclin-dependent kinases. In addition to the regulation of pol III transcription by the 
phosphorylation of upstream regulators, transcription is also regulated by the direct 
phosphorylation of the pol III transcriptional apparatus (163, 164, 169, 217, 572). 
Metabolic labelling with P-orthophosphate has previously shown that TFIIIC and 
pol III are phosphorylated in vivo (481, 568), providing further support for the 
contention that direct phosphorylation of pol III factors has an important role in the 
physiological regulation of pol III activity. Recently, the BRF subunit of hTFIIIB 
has also been shown to be phosphorylated in vivo (470). Significantly, the CKII 
inhibitors quercetin and DRB were found to reduce the in vivo phosphorylation of 
BRF (470), consistent with in vitro evidence suggesting that CKII can phosphorylate 
BRF and the contention that TFIIIB is the CKII-responsive target. However, clearly 
there are multiple kinases in addition to CKII that may be responsible for the in vivo
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phosphorylation of TFIIIB. It also remains to be demonstrated that the 
phosphorylation of TFIIIB by CKII stimulates TFIIIB transcriptional activity.
6.3.4 CKII, pol III transcription and cancer
Recent data show that pol III products are overexpressed in a variety of 
human and rodent tumours (87, 88, 586), consistent with the negative regulation of 
pol III transcription by two key tumour suppressors, p53 and RB, that are frequently 
dysregulated in mammalian tumours (70, 579). Additionally, Ras, which is 
frequently mutationally activated in human tumours (344), has been shown to 
increase TFIIIB activity in Drosophila (548). Furthermore, several viral 
oncoproteins have been shown to activate pol III transcription and pol III 
transcription is elevated in a broad range of transformed cell types (569). The 
demonstration that CKII, a putative oncogene (600), can activate mammalian pol III 
transcription suggests a novel mechanism by which pol III transcription may be 
dysregulated in cancers.
6.3.5 GSK-3p may negatively regulate pol III transcription
The titration of increasing amounts of recombinant GSK-3 p into pol III 
transcription reactions reconstituted in vitro caused a dose-dependent decrease in the 
levels of pol III transcript produced, suggesting that pol III transcription may be 
negatively regulated by GSK-3 p. To investigate this further the effect of inhibiting 
endogenous GSK-3 p on pol III transcription was tested. As a specific and potent 
inhibitor of GSK-3, low doses of lithium ions were used. In support of an inhibitory 
role for GSK-3 p in pol III transcription, lithium ions were found to specifically 
stimulate pol III transcription both in vitro and in vivo. However, although GSK-3 
seems to be the dominant physiological target of lithium ions, similar doses of 
lithium ions to those that were used have previously also been shown to potently 
inhibit the inositol phosphatases IMPase and IPPase (34). It is also plausible that 
there may be other unidentified targets of lithium ions that could be responsible for
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the observed stimulatory effect of lithium ions on pol III transcription. Thus, the 
data demonstrate that low doses of lithium ions can specifically activate pol III 
transcription both in vitro and in vivo. The mechanism responsible clearly warrants 
investigation. The demonstration that the stimulation is due to the inhibition of 
GSK-3 would strongly indicate a physiological inhibitory role for GSK-3 in pol III 
transcription; as it is, the stimulatory effect of lithium ions can only be regarded as 
weakly suggestive of an in vivo role for GSK-3 in pol III transcription. On the other 
hand, the discovery that a GSK-3 independent mechanism is responsible for the 
stimulation may actually help identify a novel regulator of pol III transcription.
As a more direct investigation as to whether GSK-3 can influence pol III 
transcription in vivo, attempts were made to overexpress GSK-3 p by transiently 
transfecting cells with an expression vector encoding GSK-3 p. However, expression 
from the transfected gene was very poor and no effect on pol III transcription was 
observed. Therefore, at present the only in vivo evidence in support of a role for 
GSK-3 in modulating the levels of pol III transcription is circumstantial, being based 
on the stimulatory effect of lithium ions. As an alternative approach to investigating 
whether GSK-3 P has any influence on pol III transcription in vivo, the effect of 
depleting endogenous GSK-3 p using antisense oligonucleotides could be 
investigated with more time available. The levels of pol III transcription in GSK-3 p' 
A murine fibroblasts and corresponding wild-type cells could also be compared; 
GSK-3p-knockout cells have recently successfully been generated by Hoeflich et al. 
and used to demonstrate a novel function for GSK-3p in cell survival (219). Since 
the only genetic difference between GSK-3 P+/+ and GSK-3 p'A fibroblasts is the 
presence of the GSK-3 P gene, the levels of pol III transcription in these cells should 
provide a definitive answer as to whether endogenous GSK-3 p truly does have a role 
in the repression of pol III transcription. However, it is possible that the effect of the 
loss of GSK-3 p may be functionally compensated for by GSK-3 a , which may 
explain the lack of any notable effect of loss of GSK-3 p on Wnt signalling, cyclin 
D l levels or P-catenin accumulation observed by Hoefflich et al. (219). Thus, the 
generation of GSK-3 a  and GSK-3 P double knockouts may be necessary to 
investigate the physiological role of GSK-3 P in pol III transcription by this approach. 
The GSK-3 p'A fibroblasts would also enable it to be directly tested whether the 
stimulatory effect of low doses of lithium ions on pol III transcription in vivo is
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dependent on GSK-3 p. Both the knockout and antisense approaches reduce
endogenous levels of GSK-3 p and thus represent more physiological tests of the in 
vivo role of GSK-3 P than overexpression by transient transfection, since the 
overexpression of proteins can sometimes induce artefactual interactions. One 
disadvantage of these approaches is that they provide no information as to whether 
the endogenous protein is usually saturating, as seems to be the case for CKII, at 
least in some cells. However, the inhibitory effect on pol III transcription in vitro of 
artifically raising the levels of GSK-3p in cell extracts using recombinant GSK-3P 
suggests that endogenous GSK-3P is not usually in excess, consistent with its 
inactivation by mitogenic signalling.
Although the evidence for a physiological role for GSK-3p is currently weak, 
it is expected that GSK-3P can inhibit pol III transcription in vivo, since it negatively 
regulates cyclin D1 protein levels (124, 435). However, the demonstration that 
recombinant GSK-3p inhibits pol III transcription reconstituted in vitro with 
fractionated factors suggests a more direct influence of GSK-3p upon pol III 
transcription. GSK-3P does not seem to stably associate either with TFIIIB or 
TFIIIC2; however, it has yet to be tested whether it can interact with pol III or 
TFIIIC1. Potential GSK-3 phosphoacceptor sites have been identified in numerous 
components of the pol III transcriptional apparatus including four of the five subunits 
of TFIIIC2, BRF and TBP. It is possible that GSK-3 p transiently associates with and 
phosphorylates one or more of these components. Alternatively, perhaps GSK-3 P 
phosphorylates an upstream regulator of pol III transcription, altering its ability to 
transrepress or transactivate pol III transcription. The inhibitory effect of 
recombinant GSK-3 p on pol III transcription in vitro is supported by the stimulatory 
effect of inhibiting endogenous GSK-3p using low doses of lithium ions. 
Confirmation that reducing the levels of endogenous GSK-3 p increases pol III 
transcription in vitro awaits the development of novel GSK-3 p inhibitors or a 





Mammalian pol III transcription is subject to considerable physiological 
regulation. The two basal factors TFIIIB and TFIIIC have both been shown to be 
limiting for pol III transcription at different stages of the cell cycle (571) and are thus 
obvious targets for exerting regulatory control upon the transcriptional process. 
Despite this and the essential roles of TFIIIB and TFIIIC in mammalian pol III 
transcription, the composition of both factors have yet to be fully elucidated. 
Nevertheless, several components of both factors have been cloned. This provided 
me with the opportunity to develop effective immunoaffinity steps for the separate 
purification of TFIIIB and TFIIIC. In our laboratory, we have tended to rely on 
TFIIIB and TFIIIC purified by conventional chromatography. However, affinity 
chromatography offers the potential to achieve a much higher level of purity in fewer 
steps (468). Unfortunately, this potential was not fully realised because of problems 
of loss of activity that were encountered when attempting to wash the 
immunoisolated complexes with salt concentrations above lOOmM NaCl. 
Nonetheless, the extent of purification of active TFIIIB and TFIIIC was still 
significantly greater than that of TFIIIB and TFIIIC commonly used in regulatory 
studies. There are a number of possible causes for the loss of activity that 
accompanied more stringent washing of the immunoisolated complexes and these 
require further investigation. The most likely explanation is that the TFIIIB and 
TFIIIC complexes are disrupted. The TFIIIC 1 and TFIIIC2 components of hTFIIIC 
are relatively easily dissociated (118, 607). Recent work from the laboratory of 
Hernandez suggests that mammalian TFIIIB resembles the yeast factor, with B" only 
very loosely associated with TBP and BRF (463).
Using this immunoaffinity approach, a complex containing TFIIIB, TFIIIC 
and pol III was isolated, lending support to the possible existence of a pol III 
holoenzyme in vivo. This complex was used to show that recombinant RB is capable 
of disrupting the interaction between TFIIIB and TFIIIC2, providing a possible 
explanation as to how RB represses transcription of TFIIIC2-dependent class III 
genes. Using an immunoprecipitation approach, recombinant RB has also been
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shown to reduce the association between pol III and TFIIIB, suggesting that multiple 
mechanisms may contribute to the repressive effects of RB (503). However, in both 
approaches RB was overexpressed. It is clearly important to determine whether RB 
can also impair these interactions when present at physiological concentrations. This 
could be tested by carrying out immunoprecipitations using extracts from Rb'1' and 
Rb+I+ fibroblasts and comparing the level of TFIIIB that can be 
coimmunoprecipitated with TFIIIC or pol III in the presence or absence of 
endogenous RB.
The pocket proteins p i07 and p i30, which share -30-35% identity with RB, 
also repress pol III transcription, both in vitro and in vivo (504). As previously 
shown for RB, I have found that a population of endogenous p i07 and p i30 
molecules consistently cofractionate and coimmunoprecipitate with endogenous 
TFIIIB, demonstrating that all three pocket proteins can associate stably with TFIIIB 
at physiological concentrations. Since the three pocket proteins are structurally so 
similar and they target the same pol III factor, TFIIIB, this suggests that the 
mechanism(s) of repression of pol III transcription by p i07 and p i30 may be the 
same as for RB. However, it remains to be tested whether p i07 and p i30 are able to 
diminish the interaction of TFIIIB with TFIIIC2 or pol III, as has been demonstrated 
for RB. Alternatively, pl07 and p i30 may inhibit pol III transcription by different 
mechanisms to RB. All three pocket proteins have previously been found to 
associate with histone deacetylase activity and this appears to be actively involved in 
the repression by the pocket proteins of some E2F-responsive genes transcribed by 
pol II (53, 144, 346, 349). The histone deacetylase inhibitor trichostatin A (TSA) 
was found to have no effect on RB-mediated repression of pol III transcription. 
However, TSA has been shown to cause an increase in the levels of B2 RNA in vivo 
in a RB-independent manner (503). Perhaps p i07- or p i30- mediated repression of 
pol III activity involves histone deacetylase activity.
The stimulatory effect of TSA upon B2 RNA levels provides the first in vivo 
evidence that histone acetylation or deacetylation can affect the expression levels of 
pol III products. This is consistent with recent reports from the Roeder laboratory 
that human TFIIIC has histone acetyltransferase activity (230, 298). However, I 
have been unable to verify that this is actually the case. Although the B-block 
affinity-purified TFIIIC was enriched in HAT activity, immunoafflnity-purifled 
TFIIIC showed no increase in HAT activity compared with mock immunoaffinity-
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purified protein. Since the reported HAT activity of human TFIIIC is so weak, either 
of these results can be readily explained by the effect of small quantities of 
contaminants, in the one case producing a false positive and in the other case 
obscuring a real but weak activity. With more time available, to begin to resolve 
this, in-gel HAT assays could be performed to see if the HAT activity detected 
corresponds with polypeptides of approximately the same size as known subunits of 
human TFIIIC. Further purification of TFIIIC might also be required, because silver 
staining reveals that immuno- and DNA- affinity purified TFIIIC fractions contain a 
complex mixture of polypeptides.
The acetylation of histones at promoters is associated with the formation of a 
less compact chromatin structure and increased gene activity and has been shown to 
facilitate transcription factor access to chromatinised promoter sequences (321). 
Consistent with the reported HAT activity of hTFIIIC, increased concentrations of 
the factor have been shown to relieve chromatin-mediated repression of a tRNA gene 
assembled into chromatin in vitro (298). Yeast TFIIIC has also been shown to play a 
dominant role in relieving the repressive effects of chromatin, both in vitro and in 
vivo (67). However, preliminary results from the laboratory of Sentenac suggest that 
yeast TFIIIC lacks HAT activity (83). TFIIIC is poorly conserved between yeast and 
humans and none of the three subunits of human TFIIIC reported to possess HAT 
activity share any significant sequence homology with any of the yeast x subunits.
For pol II-transcribed genes, chromatin remodelling is an important 
mechanism of regulating gene expression. In recent years, a variety of 
transcriptional coactivators have been found to possess HAT activity and for several 
of these proteins the intrinsic HAT activity has been shown to be essential for their 
ability to function as a coactivator (303, 359, 500). Conversely, a number of 
transcriptional corepressors have been found associated with histone deacetylases (5, 
308). In addition, several ATP-dependent nucleosome remodelling factors have been 
shown to closely associate with particular pol II transcriptional coactivators, thereby 
targeting their activity to certain genes. Changes in chromatin structure have also 
been implicated in various aspects of the physiological regulation of pol III 
transcription, for example in the developmental regulation of 5S gene expression in 
Xenopus (568). However, it has yet to be studied in detail to what extent changes in 
chromatin structure are involved in regulating pol III transcription or how chromatin
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remodelling is achieved. The stimulatory effect of TSA in vivo and the reported 
HAT activity of hTFIIIC suggest that histone acetylation and deacetylation may be 
important. Perhaps some of the histone acetyltransferases and histone deacetylases 
involved in pol II transcription can also influence expression of class III genes, akin 
to the repressive effects of the pocket proteins upon both pol II and pol III 
transcription. The recruitment of particular chromatin remodelling factors, such as 
p300 for example, to class III genes could easily be tested by carrying out chromatin 
immunoprecipitations with antibodies to these components.
One area of pol III research that has been largely unexplored is its regulation 
by phosphorylation. The regulation of pol III transcription in response to a variety of 
different environmental stimuli suggests that multiple kinase signalling pathways 
may target the pol III machinery. All five subunits of TFIIIC2 have been shown to 
be phosphorylated in vivo, as well as several pol III subunits (83, 481). This has also 
recently extended to include the BRF subunit of TFIIIB (470). However, so far only 
a few kinases have been shown to affect the levels of pol III transcription. The 
identification of kinases that can modulate pol III activity is made more difficult by 
the vast number of different kinases that there are in a cell.
In this particular study, I have investigated the possible involvement of two 
different kinases, CKII and GSK-3 p, that I considered particularly strong candidates 
for a role in regulating pol III transcription. One of these, the ubiquitously expressed 
serine/threonine kinase CKII, had previously been shown to function in yeast pol III 
transcription (163, 164, 216). Since CKII has growth-promoting and oncogenic 
properties it was of particular interest to see whether it is also involved in 
mammalian pol III transcription. The competitive inhibition of endogenous CKII 
kinase activity in mammalian cell extracts and protein fractions potently inhibited pol 
III transcription, suggesting a stimulatory role for CKII as previously demonstrated 
in yeast. This was confirmed by the addition of recombinant CKII, which was able 
to restore pol III transcription to depleted extracts. The reduction of endogenous 
CKII levels in human fibroblasts using antisense oligonucleotides also caused a 
significant decrease in pol III transcription, demonstrating that CKII is required for 
efficient transcription in a physiological context (257).
The inhibitory effect of CKII inhibitors upon mammalian pol III transcription 
reconstituted with fractionated factors suggested that CKII might directly associate
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with one of the components of the basal pol III transcriptional machinery. Further 
investigation revealed that endogenous CKII and TFIIIB stably interact, as shown by 
their consistent cofractionation and coimmunoprecipitation. Very recently, CKII has 
also been shown to phosphorylate recombinant human BRF and B" in vitro (257). 
Furthermore, in vivo phosphorylation of BRF is reduced by chemical CKII inhibitors 
(470). A mechanism by which the phosphorylation of human TFIIIB by CKII 
stimulates pol III transcription has also been proposed. Coimmunoprecipitation 
experiments showed that the level of TFIIIC2 that can be coimmunoprecipitated with 
TFIIIB is specifically reduced in the presence of chemical CKII inhibitors. It is 
therefore proposed that the phosphorylation of TFIIIB by CKII promotes its 
association with TFIIIC2. Significantly, the tumour suppressor RB disrupts this very 
same interaction. Perhaps the phosphorylation of TFIIIB by CKII inhibits RB from 
binding TFIIIB or disrupting the interaction between TFIIIB and TFIIIC2. 
Alternatively, the opposing effects of CKII and RB on this crucial interaction may be 
independent of each other. This could easily be tested by seeing if CKII kinase 
activity promotes the interaction between TFIIIB and TFIIIC2 in a RB-negative 
background. As for RB, there may be additional mechanisms yet to be discovered 
that also contribute to the stimulatory effect of CKII on pol III transcription.
The regulation of CKII remains something of an enigma, but CKII activity is 
found to be specifically elevated in a variety of transformed and tumour cells and 
rapidly proliferating cell types, suggesting that it may contribute to the increase in 
pol III transcript levels frequently observed in response to transformation (141, 160, 
387). In addition, CKII is a candidate for the cell cycle regulation of pol III 
transcription because CKII has been shown to be required for transition of particular 
stages of the cell cycle (413). CKII has yet to be shown to be limiting for pol III 
transcription except when its endogenous levels were artificially reduced. However, 
the lack of a stimulatory effect when overexpressed in HeLa extracts or human 
osteosarcoma cells is not so surprising since CKII is often abnormally elevated in 
tumour cells. Clearly, it is important to determine under what physiological 
conditions CKII can stimulate pol III transcription when overexpressed.
GSK-3 P negatively regulates protein synthesis by phosphorylating and 
inhibiting the translation initiation factor eIF2B (423, 562). Since tRNA and 5S 
rRNA are also required for protein synthesis, this raised the possibility that GSK-3 P
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may also inhibit pol III transcription as part of its repressive effects upon the 
translational machinery. Recently, GSK-3 p has also been shown to induce cyclin D1 
proteolysis (124). Cyclin D1 levels vary periodically and are the principal 
determinant as to the timing of RB inactivation each cell cycle. This suggested that 
GSK-3 P might repress pol III transcription indirectly through its effects on RB 
activity. Although some weak evidence was obtained to suggest that GSK-3 p might 
inhibit pol III transcription, most of this relied on the use of low doses of lithium ions 
as a specific inhibitor of GSK-3 activity. Although lithium is routinely used to 
investigate GSK-3p function and is considered a highly specific inhibitor of GSK-3, 
the possibility remains that the stimulation of pol III transcription by lithium that was 
consistently observed both in vitro and in vivo was not due to the inhibition of GSK- 
3p (280). The molecular basis for the stimulatory effects of lithium ions upon pol III 
transcription requires further investigation to see if the inhibition of GSK-3 is 
responsible. In support of this and a role for GSK-3p in regulating mammalian pol 
III transcription, the addition of recombinant GSK-3 P to in vitro transcription 
reactions caused a dose-dependent decrease in the levels of pol III transcript 
produced.
The bulk of a cell’s dry mass is protein, which is why the rate of protein 
synthesis is such a critical determinant of the rate of cellular growth. tRNA and 5S 
rRNA, as essential components of the translational apparatus, can therefore serve to 
restrain cellular growth when their levels are limiting. This might explain why pol 
III products are overexpressed in many transformed and tumour cell types; this may 
be necessary in order to sustain elevated levels of growth. The increase in pol III 
transcript levels in response to transformation has recently been extended to include 
actual tumours (87, 88, 586). Two key repressors of pol III transcription RB and p53 
are frequently inactivated in human tumours, suggesting two potential mechanisms 
by which pol III transcript levels may become abnormally elevated in cancers. 
Indeed, several naturally occurring mutations in RB found in tumours have been 
shown to prevent RB from repressing pol III transcription. Recent work from our 
laboratory has shown that pol III products are abnormally elevated in nine out of nine 
human ovarian tumour samples analysed, relative to normal healthy tissue from the 
same patients (586). Further analysis revealed that the specific DNA-binding 
activity of TFIIIC2 is specifically elevated in each of the tumour samples (586).
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Using purified factors, I show that TFIIIC can be limiting in normal ovarian cell 
extracts, suggesting that the increase in TFIIIC2 activity in ovarian tumours is at 
least partially responsible for the overexpression of pol III transcripts in these 
tumours.
The most common genetic alterations detected in human ovarian cancers are 
mutations in Ki-ras,p53 and erbB2/neu (159), suggesting that a change in the protein 
product of one of these genes may be responsible for the increase in TFIIIC2 activity 
in ovarian tumours. Roles for p53 (70, 90) and Ras (548) in pol III transcription 
have previously been reported. p53 specifically inhibits TFIIIB and Ras can cause 
an increase in the abundance of TBP. The erbB2/neu gene encodes a member of the 
epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTKs) 
and is activated in approximately one-third of human ovarian cancers (30, 159, 241, 
399, 491). The possibility that erbB2/neu might influence pol III transcription and be 
responsible for the increase in TFIIIC2 activity was investigated using a rodent 
ovarian epithelial cell line transformed by an activated neu oncogene (ROSE 199- 
neu) (115). ROSE 199-neu cells can induce tumorigenesis in vivo and are 
considered a good model of certain aspects of human ovarian cancer (115). 
Comparison with untransformed control cells, ROSE 199 cells retrovirally 
transduced with the p-galactosidase gene, revealed that extracts from ROSE 199-neu 
cells support higher levels of pol III transcription. This provides the first evidence 
that erbB2/neu has a role in pol III transcription. Electrophoretic mobility shift 
assays were also performed and showed that extracts from the ROSE 199-neu cells 
display increased B-block binding activity. This strongly suggests that erbB2/neu 
may be at least partially responsible for the increase in TFIIIC2 activity observed in 
human ovarian tumours. However, the neu status of these tumours was not examined 
and it is possible that the increase in TFIIIC2 activity was achieved by a different 
mechanism.
Neu (erbB2) is the first cell surface receptor for which a role in pol III 
transcription has been demonstrated. The mitogenic stimulation of pol III 
transcription is well established, but the identities of the mitogens that are capable of 
activating this response have not been deduced. Serum has invariably been used to 
induce the mitogenic response and contains a complex mix of mitogens, which can 
vary depending on the serum batch. The ability of activated neu to induce an
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increase in pol III transcription suggests that in a normal healthy cell, epidermal 
growth factor (EGF) and other ligands utilised by the EGFR family of RTKs can 
stimulate pol III transcription. Although a direct ligand for erbB2/neu has not been 
identified, it can dimerise with every other member of the EGFR family on their 
binding of ligand and can therefore be induced by a whole host of ligands (115, 399). 
Activated neu receptor has multiple downstream effectors and can influence a variety 
of intracellular signalling pathways (241, 323, 399). The mechanism by which the 
activation of neu tyrosine kinase activity at the cell surface results in an increase in 
TFIIIC2 B-block-binding activity has yet to be elucidated but likely involves a 
cascade of phosphorylation events that transmit the stimulatory signal from neu to 
TFIIIC2. Cell growth stimulation by EGF can be inhibited with CKII antisense 
oligonucleotides (414) suggesting that CKII might be a downstream effector of neu 
and might therefore be responsible for the increase in TFIIIC2 activity. Protein 
kinase B (PKB), which can phosphorylate and inactivate GSK-3 (3, is also implicated 
as a downstream target of erbB2/neu signalling (194). However, the preincubation 
of cell extracts with recombinant CKII or GSK-3 P in the presence of a suitable 
phosphate donor had no effect on TFIIIC2 B-block binding activity when assayed in 
an electrophoretic mobility shift assay. Perhaps a protein that has not yet been 
shown to have any role in the modulation of pol III activity is responsible for the 
stimulation of TFIIIC2 activity induced by neu. The direct cause of the increase in 
TFIIIC2 activity also remains to be determined and might provide valuable clues as 
to the identity of the factor(s) directly responsible. For example, the human ovarian 
tumour samples were found to express elevated levels of mRNAs encoding the five 
subunits of TFIIIC2, suggesting that the rise in TFIIIC2 B-block binding activity was 
caused by an increase in the expression of TFIIIC2 (586). Assuming that the rise in 
mRNA levels was due to increased transcription and not because of a change in the 
stability of mRNAs, this in turn suggests that a change in a transcription factor or a 
chromatin-remodelling factor might have been responsible for the increase in 
TFIIIC2 activity. Alternatively, a change in the phosphorylation pattern of TFIIIC2 
in response to activated neu would imply that a kinase or phosphatase directly targets 
TFIIIC2 and could be responsible for the change in activity.
Neu/erbB2 signalling may target multiple components of the basal pol III 
transcriptional apparatus. Cyclin D1 levels are also induced by neu signalling (323)
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suggesting that TFIIIB activity may also be increased in ROSE 199-neu cells 
because of the inactivation of RB by cyclin Dl-cdk4/6. Moreover, TFIIIB was found 
to be weakly limiting for transcription in extracts from untransformed control cells 
(ROSE 199-pgal) suggesting that an increase in TFIIIB activity in response to neu 
would also contribute to the increase in pol III transcription, albeit probably to a 
lesser extent than TFIIIC2.
The molecular basis for the physiological regulation of mammalian pol III 
transcription is slowly being elucidated. The list of proteins that are capable of 
modulating the levels of pol III transcription and are therefore potential regulators of 
the transcriptional process is steadily being extended. Here, I have identified a novel 
role in mammalian pol III transcription for two cellular proteins, CKII and neu, both 
of which have been shown for the first time to be capable of stimulating mammalian 
pol III activity. The mechanisms by which proteins exert their modulatory effects 
upon pol III transcription are also gradually being determined. I have shown that 
recombinant RB can disrupt the interaction between TFIIIB and TFIIIC2 whereas 
CKII kinase activity can promote this interaction. Activated neu was shown to 
stimulate TFIIIC2 activity, and p i07 and p i30 were both found to stably interact 
with TFIIIB, however, the mechanistic bases of the effects of these three proteins 
upon pol III transcriptional activity have not been further examined at present. For 
many of the proteins for which a role in modulating pol III transcriptional activity 
has been demonstrated, it remains to be determined under what physiological 
conditions they actually contribute to the regulation of pol III transcription. In some 
cases, this can be inferred from knowledge of the other functions of the protein and 
their own physiological regulation. However, it is clearly important to establish 
whether or not these inferences are indeed correct and to determine the relative 
contributions of proteins to the regulation of pol III transcription under particular 
physiological conditions.
The level of pol III transcription is tightly linked to the rate of cellular 
growth. It has been suggested that under certain physiological conditions the level of 
pol III transcription, by restricting the production of 5S rRNA and tRNA, can restrain 
cell growth and that this may constitute an important preventive barrier to 
tumorigenesis (313, 567). In support of this contention, the unrelated tumour 
suppressors RB and p53 both repress pol III transcription (70, 90, 93, 579). The
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basal pol III transcriptional apparatus is also targeted for activation by several 
cellular and viral oncoproteins (569). Furthermore, pol III products are frequently 
overexpressed in many transformed and tumour cells. Together, these results suggest 
that elevated levels of pol III transcription may actually contribute towards tumour 
development. Direct evidence for this has recently been provided by two rarely 
studied pol III transcripts that are encoded by the genome of the Epstein-Barr virus 
(EBV). These two transcripts, EBER1 and EBER2, have been shown to induce 
tumorigenicity in EBV- negative Burkitt lymphoma cells (278). This provides the 
first direct evidence that a pol III transcript can be oncogenic. The functions of 
EBER1 and EBER2 have yet to be fully defined; however, they can activate 
interleukin (IL)-IO expression in Burkitt’s lymphoma (278). The IL-10 induced acts 
as an autocrine growth factor allowing the cells to grow in low serum conditions 
(278). However, transfection of EBV-negative Burkitt lymphoma cells with IL-10 
reveal that this is not sufficient to account for the oncogenicity of EBER1 and 
EBER2 (EBERs) (278). The EBERs may also be involved in the subversion of the 
host cell’s translational apparatus, as has been reported for the adenovirus VA RNAs 
(35). Other pol III transcripts may also be capable of inducing tumorigenicity. 
There are quite a large number of pol III transcripts of unknown function. Among 
these are BC1 and BC200 RNA that are highly induced in a range of rodent and 
human tumours respectively and therefore particularly good candidates for being 
oncogenic (87, 88).
It remains to be determined whether tRNA and 5S rRNA are actually ever 
limiting for protein synthesis in mammalian cells and thus whether their 
overexpression can contribute to tumorigenesis by releasing a constraint imposed 
upon cell growth. However, a further indication that this might be the case is 
provided by pol I transcription. The output of pol I transcription is devoted solely to 
the production of large rRNA, which is required for protein synthesis. Significantly, 
like pol III, pol I transcription is repressed by RB and a range of transformed cells 
display an enlarged nucleolus suggesting that pol I activity is elevated in these cells 
(78). These observations suggest that large rRNA can be limiting for protein 
synthesis. Furthermore, there appears to be some coordination of transcription by 
pols I and III, with the activities of both polymerases increasing in parallel following 
serum stimulation and fluctuating together during passage through the cell cycle. 
Thus, tRNA and 5S rRNA may also become limiting when large rRNA does.
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In this particular study, two cellular oncoproteins CKII and neu have been 
identified as novel modulatory, and potentially regulatory, proteins of mammalian 
pol III transcription. The frequent overexpression of pol III products in response to 
transformation and evidence that a pol III transcript can actually promote tumour 
development suggests that other oncoproteins and tumour suppressors may also 
target tie pol III transcriptional machinery. Regardless, in light of the extensive 
physiolcgical regulation of mammalian pol III transcription it is likely that additional 
proteins to those already identified also contribute to regulation of pol III activity.
The subunit compositions of mammalian TFIIIB and TFIIIC have still to be 
fully defined. A lack of knowledge as to the precise composition of components of 
the basal pol III machinery and a lack of molecular reagents against individual 
subunits of these components severely restricts the extent to which the regulation of 
pol III transcription can be dissected at the molecular level. This is further 
complicated by recent evidence suggesting that a different form of TFIIIB functions 
at TATA-less and TATA-containing promoters (365, 463, 515). The relationship 
between these different forms of TFIIIB, which appear extremely labile (463), and 
the possibility of interchange of common subunits between the different forms and 
coregulation is rather unclear at present. The majority of regulatory studies have 
examined only a single TFIIIB activity and in many cases it will be necessary to 
readdress whether the particular modulatory protein or stimulus studied affects one 
or both forms of TFIIIB, and if the latter is true, whether the mechanistic basis is the 
same. For this study, I focused entirely on the regulation of pol III transcription of 
class III genes with TATA-less promoters, since these constitute the majority of class 
III templates, including the essential 5S rRNA and tRNA genes, and more was 
already known about their regulation. TFIIIB and TFIIIC were both purified on the 
basis of their ability to support transcription of the adenovirus VAi gene or a tRNA 
gene, both of which lack TATA boxes in their promoters. In the case of TFIIIB, the 
factor was immunopurified using antibody 128 or 330, raised against residues 533- 
547 and 664-677 respectively of BRF 1. BRF1 appears to be specific to the form of 
TFIIIB utilised by TATA-less promoters; moreover, the regions of BRF 1 that 128 
and 330 recognise are both absent from the homologous BRF2 and BRFU proteins 
reportedly involved in transcription from TATA-containing promoters (365, 463, 
515). The immunopurified TFIIIB is therefore likely to be specific for transcription 
of TATA-less class III promoters. I also obtained some evidence in support of the
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existence of a pol III holoenzyme as previously reported by the Roeder laboratory 
(551). The assembly of components into a functional complex prior to recruitment to 
the promoter has severe implications for the regulation of pol III transcription at a 
molecular level and this is a possibility that deserves further investigation. Clearly, a 
lot of unanswered questions remain concerning the regulation of the mammalian pol 
III transcriptional machinery and this regulation may be considerably more complex 
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